<SEC-DOCUMENT>0001213900-22-026516.txt : 20220513
<SEC-HEADER>0001213900-22-026516.hdr.sgml : 20220513
<ACCEPTANCE-DATETIME>20220513164855
ACCESSION NUMBER:		0001213900-22-026516
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		54
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220513
DATE AS OF CHANGE:		20220513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Blue Water Vaccines Inc.
		CENTRAL INDEX KEY:			0001782107
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41294
		FILM NUMBER:		22923579

	BUSINESS ADDRESS:	
		STREET 1:		2041 COURTLAND AVENUE
		CITY:			CINCINNATI
		STATE:			OH
		ZIP:			45212
		BUSINESS PHONE:		646-303-0737

	MAIL ADDRESS:	
		STREET 1:		2041 COURTLAND AVENUE
		CITY:			CINCINNATI
		STATE:			OH
		ZIP:			45212
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q0322_bluewatervac.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 13 19:17:58 UTC 2022 -->
<html xmlns:bwv="http://www.bluewatervaccines.com/20220331" xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pf0="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xml="http://www.w3.org/XML/1998/namespace"><head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType">10-Q</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Mark One)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric> <b>QUARTERLY REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the quarterly period ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate">March 31, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric> <b>TRANSITION REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Commission File Number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber">001-41294</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><b>Blue Water Vaccines Inc.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 50%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></span></ix:nonNumeric></td> <td style="width: 1%; text-align: center">&#160;</td> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>81-2262816</b></span></ix:nonNumeric></td></tr> <tr> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of<br/>
incorporation or organization)</span></td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer<br/>
Identification No.)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="vertical-align: bottom; width: 50%; border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.75pt 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1">201 E. Fifth Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2">Suite 1900</ix:nonNumeric></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.75pt 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">Cincinnati</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressStateOrProvince">OH</ix:nonNumeric></b></p></td> <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td> <td style="vertical-align: bottom; width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>45202</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number, including
area code: <ix:nonNumeric contextRef="c0" name="dei:CityAreaCode">(513)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber">620-4101</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered pursuant to Section 12(b)
of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 34%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</span></td> <td style="width: 1%; text-align: center">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol(s)</span></td> <td style="width: 1%; text-align: center">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of exchange on which registered</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common stock, $0.00001 par value</b></span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BWV</b></span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The <ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric> Stock Market LLC</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered pursuant to Section 12(g)
of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>None</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; No &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is not
required to file reports pursuant to Section 13 or 15(d) of the Act. Yes &#9744; No &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
<ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric> &#9746; No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric> &#9746; No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions
of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging
growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Large accelerated filer &#9744; Accelerated filer &#9744; <ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
filer</ix:nonNumeric> &#9746; Smaller reporting company <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric><br/>
Emerging growth company <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 726(b)) by the registered public accounting firm that prepared or
issued its audit report. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Act). Yes &#9744; No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of May 12, 2022, the registrant had
<ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">11,638,993</ix:nonFraction> shares of common stock, $0.00001 par value per share, outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 9%">&#160;</td>
    <td style="width: 84%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cautionary Note Regarding Forward-Looking Statements</span></a></td>
    <td style="text-align: center">ii</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART I.</span></a></td>
    <td style="vertical-align: top"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL INFORMATION</span></a></td>
    <td style="text-align: center; vertical-align: bottom">1</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></a></td>
    <td style="vertical-align: top; padding-left: 0.1in"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Financial Statements (unaudited).</span></a></td>
    <td style="text-align: center; vertical-align: bottom">1</td></tr>

<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 9%">&#160;</td>
    <td style="padding-left: 0.1in; vertical-align: top; width: 84%"><span style="font-size: 10pt"><a href="#b_001">Condensed Balance Sheets</a></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 7%">1</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="padding-left: 0.1in; vertical-align: top"><span style="font-size: 10pt"><a href="#b_002">Condensed Statements of Operations</a></span></td>
    <td style="vertical-align: bottom; text-align: center">2</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="padding-left: 0.1in; vertical-align: top"><span style="font-size: 10pt"><a href="#b_003">Condensed Statements of Stockholders&#8217; Equity</a></span></td>
    <td style="vertical-align: bottom; text-align: center">3</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="padding-left: 0.1in; vertical-align: top"><span style="font-size: 10pt"><a href="#b_004">Condensed Statements of Cash Flows</a></span></td>
    <td style="vertical-align: bottom; text-align: center">4</td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 9%"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></a></td>
    <td style="vertical-align: top; padding-left: 0.1in; width: 84%"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></a></td>
    <td style="text-align: center; vertical-align: bottom; width: 7%">21</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</span></a></td>
    <td style="vertical-align: top; padding-left: 0.1in"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">33</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></a></td>
    <td style="vertical-align: top; padding-left: 0.1in"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">33</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II.</span></a></td>
    <td style="vertical-align: top"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OTHER INFORMATION</span></a></td>
    <td style="text-align: center; vertical-align: bottom">35</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></a></td>
    <td style="vertical-align: top; padding-left: 0.1in"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">35</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</span></a></td>
    <td style="vertical-align: top; padding-left: 0.1in"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">35</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></a></td>
    <td style="vertical-align: top; padding-left: 0.1in"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unregistered Sales of Equity Securities and Use of Proceeds.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">35</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</span></a></td>
    <td style="vertical-align: top; padding-left: 0.1in"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defaults Upon Senior Securities.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">35</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></a></td>
    <td style="vertical-align: top; padding-left: 0.1in"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">35</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</span></a></td>
    <td style="vertical-align: top; padding-left: 0.1in"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">35</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</span></a></td>
    <td style="vertical-align: top; padding-left: 0.1in"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">36</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;</span></td>
    <td style="padding-left: 0.1in; vertical-align: top"><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signatures</span></a></td>
    <td style="text-align: center; vertical-align: bottom">37</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This Quarterly Report on Form 10-Q (this &#8220;Report&#8221;)
contains forward-looking statements that reflect our current expectations and views of future events. The forward-looking statements are
contained principally in the sections entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations.&#8221; Readers are cautioned that known and unknown risks, uncertainties and other factors, including
those over which we may have no control and others listed in the &#8220;Risk Factors&#8221; section of this Report, may cause our actual
results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In some cases, you can identify forward-looking
statements by the words &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221;
&#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;objective,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221;
&#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; and &#8220;ongoing,&#8221;
or the negative of these terms, or other comparable terminology intended to identify statements about the future, although not all forward-looking
statements contain these words. These statements relate to future events or our future financial performance or condition and involve
known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement
to differ materially from those expressed or implied by these forward-looking statements. These forward-looking statements include, but
are not limited to, statements about:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our projected financial position and estimated cash burn rate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our estimates regarding expenses, future revenues and capital requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to continue as a going concern;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our need to raise substantial additional capital to fund our operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the success, cost and timing of our clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain the necessary regulatory approvals to market and commercialize our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ultimate impact of the ongoing COVID-19 pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential that results of pre-clinical and clinical trials indicate our current product candidates or any future product candidates we may seek to develop are unsafe or ineffective;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the results of market research conducted by us or others;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and maintain intellectual property protection for our current product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to protect our intellectual property rights and the potential for us to incur substantial costs from lawsuits to enforce or protect our intellectual property rights;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the possibility that a third party may claim we or our third-party licensors have infringed, misappropriated or otherwise violated their intellectual property rights and that we may incur substantial costs and be required to devote substantial time defending against claims against us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reliance on third parties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the success of competing therapies and products that are or become available;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to expand our organization to accommodate potential growth and our ability to retain and attract key personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential for us to incur substantial costs resulting from product liability lawsuits against us and the potential for these product liability lawsuits to cause us to limit our commercialization of our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market acceptance of our product candidates, the size and growth of the potential markets for our current product candidates and any future product candidates we may seek to develop, and our ability to serve those markets; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the successful development of our commercialization capabilities, including sales and marketing capabilities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">These forward-looking statements involve numerous
risks and uncertainties. Although we believe that our expectations expressed in these forward-looking statements are reasonable, our expectations
may later be found to be incorrect. Our actual results of operations or the results of other matters that we anticipate herein could be
materially different from our expectations. Important risks and factors that could cause our actual results to be materially different
from our expectations are generally set forth in &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations,&#8221; and other sections in this Report. You should thoroughly read this Report and the documents
that we refer to with the understanding that our actual future results may be materially different from and worse than what we expect.
We qualify all of our forward-looking statements by these cautionary statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The forward-looking statements made in this Report
relate only to events or information as of the date on which the statements are made in this Report. Except as required by law, we undertake
no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise,
after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this Report and
the documents that we refer to in this Report and have filed as exhibits to this Report, completely and with the understanding that our
actual future results may be materially different from what we expect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 3; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>PART I &#8211; FINANCIAL
INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1. Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="b_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BLUE WATER VACCINES INC.<br/>
Condensed Balance Sheets</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31,<br/>
 2022</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2021</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>(Unaudited)</b></span></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current assets</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: -9pt; padding-left: 0.25in">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">18,609,249</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">1,928,474</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd">90,005</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd">234,551</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCostsCurrent" scale="0" unitRef="usd">238,804</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCostsCurrent" scale="0" unitRef="usd">757,646</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Receivable from related parties</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="0" unitRef="usd">164,515</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="0" unitRef="usd">152,524</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">19,102,573</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">3,073,195</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Prepaid expenses, long-term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="0" unitRef="usd">129,454</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">15,399</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">11,502</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Deposit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsNoncurrent" scale="0" unitRef="usd">87,638</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total assets</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">19,335,064</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">3,084,697</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd">907,538</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd">582,605</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd">1,893,438</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd">1,055,515</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">2,800,976</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">1,638,120</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Commitments and Contingencies (see Note&#160;7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Stockholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Preferred stock, $<ix:nonFraction contextRef="c2" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c3" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.00001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March 31, 2022 and December&#160;31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-7">Series&#160;Seed: <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="bwv:PreferredStockSharesDesignated" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="bwv:PreferredStockSharesDesignated" scale="0" unitRef="shares">1,150,000</ix:nonFraction> shares designated at March 31, 2022 and December 31, 2021, respectively; <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockLiquidationPreferenceValue" scale="0" unitRef="usd">0</ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares">1,146,138</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March 31, 2022 and December&#160;31, 2021, respectively; $0 and $15.4&#160;million aggregate liquidation preference at March 31, 2022 and December&#160;31, 2021, respectively</div></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="bwv:PreferredStockValue1" scale="0" unitRef="usd">11</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Common stock, $<ix:nonFraction contextRef="c2" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c3" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.00001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March 31, 2022 and December&#160;31, 2021; <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">11,048,587</ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">3,200,000</ix:nonFraction> shares outstanding at March 31, 2022 and December&#160;31, 2021, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">110</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">32</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Additional paid-in-capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">24,561,309</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">7,403,204</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">8,027,331</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">5,956,670</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">16,534,088</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">1,446,577</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total liabilities and stockholders&#8217; equity</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">19,335,064</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">3,084,697</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>The accompanying notes are an integral part
of these condensed financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>&#160;</b></p><div>

</div><div><a id="b_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>BLUE WATER VACCINES INC.<br/>
Condensed Statements of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended March&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended March&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating costs and expenses</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">General and administrative</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd">1,615,569</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd">237,544</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">455,092</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">88,237</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">2,070,661</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">325,781</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Loss from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">2,070,661</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">325,781</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">2,070,661</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">325,781</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cumulative preferred stock dividends</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="0" unitRef="usd">96,359</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="0" unitRef="usd">137,687</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Net loss applicable to common stockholders</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" sign="-" unitRef="usd">2,167,020</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" sign="-" unitRef="usd">463,468</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss per share attributable to common stockholders, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="bwv:NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare" scale="0" sign="-" unitRef="usdPershares">0.34</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="bwv:NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare" scale="0" sign="-" unitRef="usdPershares">0.14</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Weighted average number of common shares outstanding, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="bwv:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares" scale="0" unitRef="shares">6,339,435</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="bwv:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares" scale="0" unitRef="shares">3,200,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>The accompanying notes are an integral part
of these condensed financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="b_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BLUE WATER VACCINES INC.<br/>
Condensed Statements of Stockholders&#8217; Equity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Preferred Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Additional Paid-in</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Total Stockholders&#8217;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance at December&#160;31, 2021</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="width: 6%; border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">1,146,138</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="width: 6%; border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">11</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="width: 6%; border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">3,200,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="width: 6%; border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">32</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="width: 6%; border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">7,403,204</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="width: 6%; border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">5,956,670</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="width: 6%; border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">1,446,577</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of common stock in initial public offering, net of $<ix:nonFraction contextRef="c0" decimals="1" format="ixt:num-dot-decimal" name="bwv:OfferingCostsNet" scale="0" unitRef="usd">2.9</ix:nonFraction> million of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">2,222,222</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">22</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">17,138,818</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">17,138,840</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Conversion of convertible preferred stock to common stock upon initial public offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" sign="-" unitRef="shares">1,146,138</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" sign="-" unitRef="usd">11</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares">5,626,365</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd">56</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" sign="-" unitRef="usd">45</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd">19,332</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd">19,332</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">2,070,661</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">2,070,661</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance at March&#160;31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#8212;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">11,048,587</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">110</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">24,561,309</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">8,027,331</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">16,534,088</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Preferred Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Additional Paid-in</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Total Stockholders&#8217;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance at December&#160;31, 2020</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="width: 6%; border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c17" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">1,146,138</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="width: 6%; border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">11</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="width: 6%; border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c18" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">3,200,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="width: 6%; border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">32</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="width: 6%; border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">7,273,063</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="width: 6%; border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">2,539,336</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="width: 6%; border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">4,733,770</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd">41,721</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd">41,721</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">325,781</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">325,781</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance at March&#160;31, 2021</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c26" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">1,146,138</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">11</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c27" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">3,200,000</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">32</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">7,314,784</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">2,865,117</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">4,449,710</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>The accompanying notes are an integral part
of these condensed financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="b_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>BLUE WATER VACCINES INC.<br/>
Statements of Cash Flows</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Unaudited)</b>&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cash flows from operating activities</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">2,070,661</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">325,781</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Depreciation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">1,300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">1,232</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">19,332</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">41,721</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Changes in assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" sign="-" unitRef="usd">144,546</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" unitRef="usd">57,309</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Receivable from related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" scale="0" unitRef="usd">11,991</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" scale="0" unitRef="usd">5,056</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Prepaid expenses, long-term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" unitRef="usd">129,454</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" sign="-" unitRef="usd">46,233</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" scale="0" unitRef="usd">87,638</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" unitRef="usd">896,659</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" unitRef="usd">351,816</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" unitRef="usd">42,412</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">886,091</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">256,548</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash flows from investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Purchase of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">5,197</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">5,197</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash flows from financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Payment of deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="0" unitRef="usd">5,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Proceeds from issuance of common stock in initial public offering, net of underwriting discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="0" unitRef="usd">18,400,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Payments of initial public offering costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" unitRef="usd">822,937</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">17,572,063</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net increase (decrease) in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" unitRef="usd">16,680,775</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" sign="-" unitRef="usd">256,548</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cash, beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">1,928,474</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">4,308,821</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Cash, end of period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">18,609,249</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">4,052,273</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Noncash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Deferred offering costs included in accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="0" unitRef="usd">233,804</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Conversion of convertible preferred stock to common stock upon initial public offering</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd">45</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Initial public offering costs included in accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" scale="0" unitRef="usd">104,035</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>The accompanying notes are an integral part
of these condensed financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BLUE WATER VACCINES INC.<br/>
Notes to Condensed Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;1 &#8212;&#160;Organization and Basis of Presentation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_2" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Organization and Nature of Operations</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_3" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Blue Water Vaccines Inc. (the &#8220;Company&#8221;)
was formed on October&#160;26, 2018, to focus on the research and development of transformational vaccines to prevent infectious diseases
worldwide. The Company&#8217;s lead vaccine candidates, BWV-101 and BWV-102, are being investigated as a universal influenza vaccine with
the potential against all influenza strains and may provide a first-in-class long-term global vaccine that protects millions. The Company&#8217;s
proprietary, immunogenic, multi-purpose platform enables the Company to bioengineer viral nanoparticles to deliver antigens, enhancing
immunity, in an array of infectious disease agents, including influenza. All of the Company&#8217;s vaccine candidates are in the pre-clinical
developmental stage.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_4" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Initial Public Offering</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_5" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">On February 23, 2022, the Company completed its
initial public offering (&#8220;IPO&#8221;) in which the Company issued and sold <ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="bwv:InitialPublicOfferingShares" scale="0" unitRef="shares">2,222,222</ix:nonFraction> shares of its common stock, at a price to the
public of $<ix:nonFraction contextRef="c31" decimals="2" format="ixt:num-dot-decimal" name="bwv:PricePerShare" scale="0" unitRef="usdPershares">9.00</ix:nonFraction> per share. <ix:nonNumeric contextRef="c32" name="bwv:InitialPublicOffering">Proceeds from the IPO, net of underwriting discounts, commissions, and offering costs of $2.9 million, were
$17.1 million.</ix:nonNumeric> In connection with the completion of the IPO, all outstanding shares of convertible preferred stock were converted into
<ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesReservedForFutureIssuance" scale="0" unitRef="shares">5,626,365</ix:nonFraction> shares of common stock. See Note 6.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_6" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Stock Split</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_7" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On November&#160;24, 2021, the Company&#8217;s
board of directors approved a 4-for-1 (4:1) stock split (the &#8220;Stock Split&#8221;) of the Company&#8217;s common stock without any
change to its par value, which became effective on November&#160;24, 2021. All references to share and per share amounts for all periods
presented in these financial statements have been retrospectively restated to reflect the Stock Split and proportional adjustment of the
preferred stock conversion ratio. Par values were not adjusted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_8" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&#8217;s unaudited condensed financial
statements have been prepared in conformity with accounting principles generally accepted in the United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;).</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LiquidityAndFinancialConditionTextBlock-c0_cont_1" escape="true" name="bwv:LiquidityAndFinancialConditionTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;2 &#8212;&#160;Liquidity and Financial Condition</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_LiquidityAndFinancialConditionTextBlock-c0_cont_2" id="_LiquidityAndFinancialConditionTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company has had limited operating activities
to date, substantially all of which have been devoted to seeking licenses and engaging in research and development activities. The Company&#8217;s
product candidates currently under development will require significant additional research and development efforts prior to commercialization.
The Company has financed its operations since inception primarily using proceeds received from seed investors, and proceeds received upon
the completion of its IPO.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LiquidityAndFinancialConditionTextBlock-c0_cont_3" id="_LiquidityAndFinancialConditionTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company has incurred substantial operating
losses since inception and expects to continue to incur significant operating losses for the foreseeable future. As of March 31, 2022,
the Company had cash of approximately $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsAndCash" scale="6" unitRef="usd">18.6</ix:nonFraction>&#160;million, working capital of approximately $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherAdditionalCapital" scale="6" unitRef="usd">16.3</ix:nonFraction>&#160;million and an accumulated deficit
of approximately $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAppropriated" scale="6" unitRef="usd">8.0</ix:nonFraction> million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_LiquidityAndFinancialConditionTextBlock-c0_cont_4" id="_LiquidityAndFinancialConditionTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On April 19, 2022, the Company completed a private
placement in which it received approximately $<ix:nonFraction contextRef="c33" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" unitRef="usd">7.0</ix:nonFraction> million in net proceeds, after deducting placement agent fees and other initial offering
expenses, see Note 11.&#160;The Company believes the existing cash at March&#160;31, 2022, together with the net proceeds received upon
the close of the private placement, will be sufficient to continue operations, satisfy its obligations and fund the future expenditures
that will be required to conduct the clinical and regulatory work to develop its product candidates for at least&#160;<ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">one year</ix:nonNumeric>&#160;after
the date that these financial statements are available to be issued. As such, the Company determined that it is not probable based on
projected cash flows that substantial doubt about the Company&#8217;s ability to continue as a going concern exists for the one-year period
following the date that the financial statements for the three months ended March 31, 2022 were available to be issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_LiquidityAndFinancialConditionTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company will require significant additional
capital to make the investments it needs to execute its longer-term business plan. The Company expects a significant increase in cash
outflows as compared to its historical spend for its planned pre-clinical development and clinical trial activities, and as such, it will
need to raise additional capital to sustain operations and meet its <ix:nonNumeric contextRef="c0" name="us-gaap:LongTermDebtDescription">long-term operating requirements beyond the one year period</ix:nonNumeric> following
the issuance of these financial statements. The Company expects to seek additional funding through additional debt or equity financings;
however, there are currently no commitments in place for further financing nor is there any assurance that such financing will be available
to the Company on favorable terms, if at all. If the Company is unable to secure additional capital, it may be required to curtail any
clinical trials and development of products and take additional measures to reduce expenses in order to conserve its cash in amounts sufficient
to sustain operations and meet its obligations in the long-term.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BLUE WATER VACCINES INC.<br/>
Notes to Condensed Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;3 &#8212;&#160;Summary of Significant Accounting Policies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;&#160;</i></b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The preparation of financial statements in conformity
with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the
reporting periods. The most significant estimates in the Company&#8217;s financial statements relate to the valuation of common stock,
stock-based compensation, accrued research and development expenses and the valuation allowance of deferred tax assets resulting from
net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed
to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets
and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and
adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s
future results of operations will be affected.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Unaudited Interim Financial Statements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:continuation continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_2" id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The accompanying condensed balance sheet as of March&#160;31, 2022,
and the condensed statements of operations, the condensed statements of changes in stockholders&#8217; equity, and the condensed
statements of cash flows for the three months ended March&#160;31, 2022 and 2021 are unaudited. These unaudited interim financial
statements have been prepared on the same basis as the audited financial statements, and in management&#8217;s opinion, include all
adjustments, consisting of only normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial
position as of March&#160;31, 2022 and its results of operations and cash flows for the three months ended March&#160;31, 2022 and
2021. The financial data and the other financial information disclosed in the notes to these condensed financial statements related
to the three-month&#160;periods are also unaudited. Operating results for the three months ended March&#160;31, 2022 are not
necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022, <span>any
other interim periods, or any future year or period</span>. The unaudited condensed financial statements included in this Quarterly
Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the
Company&#8217;s annual report on Form 10-K for the year</p></ix:continuation></ix:continuation><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">ended December 31, 2021, which includes a broader discussion of the Company&#8217;s
business and the risks inherent therein.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Concentration of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_8" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Financial instruments that potentially subject
the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal
Depository Insurance Coverage limit of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashFDICInsuredAmount" scale="0" unitRef="usd">250,000</ix:nonFraction>. As of March 31, 2022 and December&#160;31, 2021, the Company has not experienced losses
on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_9" id="_SignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Property and Equipment</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_10" id="_SignificantAccountingPoliciesTextBlock-c0_cont_9"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Property and equipment consists of computers and
office furniture and fixtures, all of which are recorded at cost. Depreciation is recorded using the straight-line method over the respective
useful lives of the assets ranging from <span style="-sec-ix-hidden: hidden-fact-38">three</span> to <span style="-sec-ix-hidden: hidden-fact-39">seven</span>&#160;years. Long-lived assets are reviewed for impairment whenever events or circumstances
indicate that the carrying amount of these assets may not be recoverable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BLUE WATER VACCINES INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;3 &#8212;&#160;Summary of Significant Accounting Policies</b>
(cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_11" id="_SignificantAccountingPoliciesTextBlock-c0_cont_10"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Fair Value Measurements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_12" id="_SignificantAccountingPoliciesTextBlock-c0_cont_11"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Fair value is defined as the price that would
be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement
date. U.S.&#160;GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and
the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_13" id="_SignificantAccountingPoliciesTextBlock-c0_cont_12"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_14" id="_SignificantAccountingPoliciesTextBlock-c0_cont_13"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_15" id="_SignificantAccountingPoliciesTextBlock-c0_cont_14"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_16" id="_SignificantAccountingPoliciesTextBlock-c0_cont_15"><ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In some circumstances, the inputs used to measure
fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is
categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
Financial instruments, including cash, prepaid expenses, deferred offering costs, receivables from related parties, accounts payable and
accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.
<span>None of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a
non-recurring basis. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_17" id="_SignificantAccountingPoliciesTextBlock-c0_cont_16"><ix:nonNumeric contextRef="c0" continuedAt="_DeferredChargesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:DeferredChargesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Deferred Offering Costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_18" id="_SignificantAccountingPoliciesTextBlock-c0_cont_17"><ix:continuation id="_DeferredChargesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>The Company
capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings
as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded
in stockholders&#8217; equity as a reduction of proceeds generated as a result of the offering. Should the in-process equity financing
be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations.
As of March 31, 2022, all previously deferred offering costs related to the IPO, totaling approximately $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredCostsCurrentAndNoncurrent" scale="6" unitRef="usd">0.8</ix:nonFraction>&#160;million, and of which
$<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredCostsCurrentAndNoncurrent" scale="6" unitRef="usd">0.3</ix:nonFraction> million were paid during 2021, were netted against the proceeds received upon the closing of the IPO, which occurred on February
23, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_19" id="_SignificantAccountingPoliciesTextBlock-c0_cont_18"><ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and Development</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_20" id="_SignificantAccountingPoliciesTextBlock-c0_cont_19"><ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_2" id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company expenses the cost of research and
development as incurred. Research and development expenses include costs incurred in funding research and development activities, license
fees, and other external costs. Advance payments for goods and services that will be used in future research and development activities
are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and
milestone payments due to third parties that perform research and development services on the Company&#8217;s behalf will be expensed
as services are rendered or when the milestone is achieved. When billing terms under research and development contracts do not coincide
with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of period end to
those third parties. Accrual estimates are based on several factors, including the Company&#8217;s knowledge of the progress towards completion
of the research and development activities, invoicing to date under the contracts, communication from the research institution or other
companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant
judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ
from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the
actual costs. See Notes 5 and 7.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BLUE WATER VACCINES INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;3 &#8212;&#160;Summary of Significant Accounting Policies</b>
(cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_21" id="_SignificantAccountingPoliciesTextBlock-c0_cont_20"><ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In accordance with FASB ASC Topic&#160;730-10-25-1,&#160;<i>Research
and Development,</i> costs incurred in obtaining licenses and patent rights are charged to research and development expense if the technology
licensed has not reached commercial feasibility and has no alternative future use. The licenses purchased by the Company (see Note&#160;5)
require substantial completion of research and development, regulatory and marketing approval efforts to reach commercial feasibility
and have no alternative future use. Accordingly, the total purchase price for the licenses acquired is reflected as research and development
on the Company&#8217;s statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_22" id="_SignificantAccountingPoliciesTextBlock-c0_cont_21"><ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Stock-Based Compensation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_23" id="_SignificantAccountingPoliciesTextBlock-c0_cont_22"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company expenses stock-based compensation
to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. Stock-based
awards to employees with graded-vesting schedules are recognized, using the accelerated attribution method, on a straight-line basis over
the requisite service period for each separately vesting portion of the award.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_24" id="_SignificantAccountingPoliciesTextBlock-c0_cont_23"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company estimates the fair value of stock
option grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards
represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>&#160;</i></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_25" id="_SignificantAccountingPoliciesTextBlock-c0_cont_24"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_4" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>Expected Term</i>&#160;&#8212;&#160;The expected term
of options represents the period that the Company&#8217;s stock-based awards are expected to be outstanding based on the simplified method,
which is the half-life from vesting to the end of its contractual term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>&#160;</i></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_26" id="_SignificantAccountingPoliciesTextBlock-c0_cont_25"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_5" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><i>Expected Volatility</i>&#160;&#8212;Volatility is a measure
of the amount by which the Company&#8217;s share price has historically fluctuated or is expected to fluctuate (i.e., expected volatility)
during a period. &#160;<span>Due to the lack of an adequate history of a public market for the trading
of the Company&#8217;s common stock and a lack of adequate company-specific historical and implied volatility data, </span>the Company
computes stock price volatility over expected terms based on comparable companies&#8217; historical common stock trading prices. For these
analyses, the Company has selected companies with comparable characteristics, including enterprise value, risk profiles, and position
within the industry, and with historical share price information sufficient to meet the expected term of the stock-based awards.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>&#160;</i></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_27" id="_SignificantAccountingPoliciesTextBlock-c0_cont_26"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_6" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>Common Stock Fair Value</i>&#160;&#8212;&#160;<span>Due
to the absence of an active market for the Company&#8217;s common stock prior to the IPO, t</span>he fair value of the common stock underlying
the Company&#8217;s stock options was estimated at each grant date and was determined with the assistance of an independent third-party
valuation expert. The assumptions underlying these valuations represented management&#8217;s best estimates, which involved inherent uncertainties
and the application of significant levels of management judgment. <span>After the completion of the IPO,
the fair value of each share of common stock is based on the closing price of the Company&#8217;s common stock as reported by the Nasdaq
Capital Market.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>&#160;</i></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_28" id="_SignificantAccountingPoliciesTextBlock-c0_cont_27"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_7" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>Risk-Free Interest Rate</i>&#160;&#8212;&#160;The Company
bases the risk-free interest rate on the implied yield available on U.S.&#160;Treasury securities with a remaining term commensurate with
the estimated expected term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>&#160;</i></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_29" id="_SignificantAccountingPoliciesTextBlock-c0_cont_28"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_8" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>Expected Dividend</i>&#160;&#8212;&#160;The Company has
never declared or paid any cash dividends on its shares of common stock and does not plan to pay cash dividends in the foreseeable future,
and, therefore, uses an expected dividend yield of <ix:nonFraction contextRef="c0" decimals="0" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" scale="0" unitRef="usd">zero</ix:nonFraction> in its valuation models.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_30" id="_SignificantAccountingPoliciesTextBlock-c0_cont_29"><ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company recognizes forfeitures of equity awards
as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_31" id="_SignificantAccountingPoliciesTextBlock-c0_cont_30"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueOfCommonStockPolicyTextBlock-c0_cont_1" escape="true" name="bwv:FairValueOfCommonStockPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Fair Value of Common Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_32" id="_SignificantAccountingPoliciesTextBlock-c0_cont_31"><ix:continuation continuedAt="_FairValueOfCommonStockPolicyTextBlock-c0_cont_2" id="_FairValueOfCommonStockPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In order to determine the fair value of shares
of common stock of the Company when issuing stock options prior to the IPO, its board of directors considered with input from third party
valuations, among other things, contemporaneous valuations of the Company&#8217;s common stock. Given the absence of a public trading
market of the Company&#8217;s capital stock prior to its IPO, its board of directors has exercised reasonable judgment and considered
a number of objective and subjective factors to determine the best estimate of the fair value of the Company common and preferred stock,
including:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_33" id="_SignificantAccountingPoliciesTextBlock-c0_cont_32"><ix:continuation continuedAt="_FairValueOfCommonStockPolicyTextBlock-c0_cont_3" id="_FairValueOfCommonStockPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the prices, rights, preferences and privileges of the Company&#8217;s preferred stock relative to the Company&#8217;s common stock;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_34" id="_SignificantAccountingPoliciesTextBlock-c0_cont_33"><ix:continuation continuedAt="_FairValueOfCommonStockPolicyTextBlock-c0_cont_4" id="_FairValueOfCommonStockPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company&#8217;s business, financial condition and results of operations, including related industry trends affecting the Company&#8217;s operations;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p></ix:continuation></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BLUE WATER VACCINES INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;3 &#8212;&#160;Summary of Significant Accounting Policies</b>
(cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_35" id="_SignificantAccountingPoliciesTextBlock-c0_cont_34"><ix:continuation continuedAt="_FairValueOfCommonStockPolicyTextBlock-c0_cont_5" id="_FairValueOfCommonStockPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the likelihood of achieving a liquidity event, such as an IPO, or sale of the Company, given prevailing market conditions;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_36" id="_SignificantAccountingPoliciesTextBlock-c0_cont_35"><ix:continuation continuedAt="_FairValueOfCommonStockPolicyTextBlock-c0_cont_6" id="_FairValueOfCommonStockPolicyTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the lack of marketability of the Company&#8217;s common stock;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_37" id="_SignificantAccountingPoliciesTextBlock-c0_cont_36"><ix:continuation continuedAt="_FairValueOfCommonStockPolicyTextBlock-c0_cont_7" id="_FairValueOfCommonStockPolicyTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the market performance of comparable publicly traded companies;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_38" id="_SignificantAccountingPoliciesTextBlock-c0_cont_37"><ix:continuation continuedAt="_FairValueOfCommonStockPolicyTextBlock-c0_cont_8" id="_FairValueOfCommonStockPolicyTextBlock-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.&#160;and global economic and capital market conditions and outlook; and</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_39" id="_SignificantAccountingPoliciesTextBlock-c0_cont_38"><ix:continuation continuedAt="_FairValueOfCommonStockPolicyTextBlock-c0_cont_9" id="_FairValueOfCommonStockPolicyTextBlock-c0_cont_8"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">common stock valuation methodology.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_40" id="_SignificantAccountingPoliciesTextBlock-c0_cont_39"><ix:continuation continuedAt="_FairValueOfCommonStockPolicyTextBlock-c0_cont_10" id="_FairValueOfCommonStockPolicyTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In estimating the fair market value of common
stock of the Company, its board of directors first determined the equity value of its business using accepted valuation methods.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_41" id="_SignificantAccountingPoliciesTextBlock-c0_cont_40"><ix:continuation continuedAt="_FairValueOfCommonStockPolicyTextBlock-c0_cont_11" id="_FairValueOfCommonStockPolicyTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company engaged a third-party valuation specialist
to conduct a valuation, which used its most recent preferred stock financing as a starting point and determined the equity value of the
Company based on the Backsolve method using an Option Pricing Method (OPM) to calculate the implied value based on a market approach.
The Company&#8217;s equity value was allocated using OPM to estimate the fair market value of the Company&#8217;s classes of equity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_42" id="_SignificantAccountingPoliciesTextBlock-c0_cont_41"><ix:continuation id="_FairValueOfCommonStockPolicyTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>After the completion of the IPO,
the fair value of each share of common stock is based on the closing price of the Company&#8217;s common stock as reported by the Nasdaq
Capital Market.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_43" id="_SignificantAccountingPoliciesTextBlock-c0_cont_42"><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Income Taxes</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_44" id="_SignificantAccountingPoliciesTextBlock-c0_cont_43"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Income taxes are accounted for under the asset
and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between
the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax
credit carryforwards.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_45" id="_SignificantAccountingPoliciesTextBlock-c0_cont_44"><ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be
recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rate is recognized in operations in the period
that includes the enactment date. Deferred tax assets are reduced to estimated amounts expected to be realized by the use of a valuation
allowance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_46" id="_SignificantAccountingPoliciesTextBlock-c0_cont_45"><ix:nonNumeric contextRef="c0" continuedAt="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Comprehensive Income (Loss)</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_47" id="_SignificantAccountingPoliciesTextBlock-c0_cont_46"><ix:continuation id="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company is required to report all components
of comprehensive income (loss), including net income (loss), in the accompanying condensed financial statements in the period in which
they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events
and circumstances from non-owner sources, including unrealized gains and losses on investments and foreign currency translation adjustments.
Net loss and comprehensive loss were the same for all periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_48" id="_SignificantAccountingPoliciesTextBlock-c0_cont_47"><ix:nonNumeric contextRef="c0" continuedAt="_DerivativesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:DerivativesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span><b><i>Warrants</i></b></span></p><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></p></ix:nonNumeric></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_49" id="_SignificantAccountingPoliciesTextBlock-c0_cont_48"><ix:continuation continuedAt="_DerivativesPolicyTextBlock-c0_cont_2" id="_DerivativesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>The
Company determines the accounting classification of warrants that are issued, as either liability or equity, by first assessing whether
the warrants meet liability classification in accordance with ASC 480-10, <i>Accounting for Certain Financial Instruments with Characteristics
of both Liabilities and Equity</i>, (&#8220;ASC 480-10&#8221;), and then in accordance with ASC 815-40, <i>Derivatives and Hedging - Contracts
in Entity's Own Equity</i> (&#8220;ASC 815-40&#8221;). Under ASC 480-10, warrants are considered liability-classified if the warrants
are mandatorily redeemable, obligate the issuer to settle the warrants or the underlying shares by paying cash or other assets, or must
or may require settlement by issuing variable number of shares. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15.5pt 0pt 4.5pt; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_50" id="_SignificantAccountingPoliciesTextBlock-c0_cont_49"><ix:continuation id="_DerivativesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>If
the warrants do not meet liability classification under ASC 480-10, the Company assesses the requirements under ASC 815-40, which states
that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective
of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability
classification under ASC 815-40, in order to conclude equity classification, the Company assesses whether the warrants are indexed to
its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP. After all relevant assessments
are made, the Company concludes whether the warrants are classified as liability or equity. Liability-classified warrants are required
to be accounted for at fair value both on the date of issuance and on subsequent accounting period ending dates, with all changes in fair
value after the issuance date recorded as a component of other income (expense), net in the statements of operations. Equity-classified
warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date. As of
March 31, 2022, all of the Company&#8217;s outstanding warrants are equity-classified warrants.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15.5pt 0pt 4.5pt; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_51" id="_SignificantAccountingPoliciesTextBlock-c0_cont_50"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Net Loss Per Share</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_52" id="_SignificantAccountingPoliciesTextBlock-c0_cont_51"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Basic loss per share is computed by dividing the
net income or loss applicable to common shares by the weighted average number of common shares outstanding during the period. Diluted
earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding
during the period. Potential common shares consist of the Company&#8217;s preferred stock, warrants and options. Diluted loss per share
excludes the shares issuable upon the conversion of preferred stock, as well as common stock options and warrants, from the calculation
of net loss per share if their effect would be anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BLUE WATER VACCINES INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;3 &#8212;&#160;Summary of Significant Accounting Policies</b>
(cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_53" id="_SignificantAccountingPoliciesTextBlock-c0_cont_52"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_3" id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The two-class method is used to determine earnings
per share based on participation rights of participating securities in any undistributed earnings. Each preferred stock that includes
rights to participate in distributed earnings is considered a participating security and the Company uses the two-class method to calculate
net income available to the Company&#8217;s common stockholders per common share&#160;&#8212;&#160;basic and diluted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_54" id="_SignificantAccountingPoliciesTextBlock-c0_cont_53"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following securities were excluded from the
computation of diluted shares outstanding due to the losses incurred in the periods presented, as they would have had an anti-dilutive
impact on the Company&#8217;s net loss:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_55" id="_SignificantAccountingPoliciesTextBlock-c0_cont_54"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Options to purchase shares of common stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="bwv:OptionsToPurchaseSharesOfCommonStock" scale="0" unitRef="shares">780,640</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="bwv:OptionsToPurchaseSharesOfCommonStock" scale="0" unitRef="shares">780,640</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Series&#160;Seed Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="bwv:SeriesSeedPreferredStock" scale="0" unitRef="shares">4,584,552</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Warrants to purchase shares of common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="bwv:WarrantsToPurchaseSharesOfCommonStock" scale="0" unitRef="shares">111,111</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="bwv:TotalShares" scale="0" unitRef="shares">891,751</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="bwv:TotalShares" scale="0" unitRef="shares">5,365,192</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_56" id="_SignificantAccountingPoliciesTextBlock-c0_cont_55"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>New Accounting Pronouncement</i>s</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_57" id="_SignificantAccountingPoliciesTextBlock-c0_cont_56"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In April 2012, the Jump-Start Our Business Startups
Act (the &#8220;JOBS Act&#8221;) was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting
requirements for an emerging growth company. As an emerging growth company, the Company may elect to adopt new or revised accounting standards
when they become effective for non-public companies, which typically is later than when public companies must adopt the standards. The
Company has elected to take advantage of the extended transition period afforded by the JOBS Act and, as a result, unless the Company
elects early adoption of any standards, will adopt the new or revised accounting standards on the relevant dates on which adoption of
such standards is required for non-public companies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_58" id="_SignificantAccountingPoliciesTextBlock-c0_cont_57"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In August&#160;2020, the FASB issued ASU No.&#160;2020-06,&#160;<i>Debt&#160;&#8212;&#160;Debt
with Conversion and Other Options (Subtopic&#160;470-20) and Derivatives and Hedging&#160;&#8212;&#160;Contracts in Entity&#8217;s Own
Equity (Subtopic&#160;815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>, which simplifies
accounting for convertible instruments by removing major separation models required under current GAAP.&#160;The ASU also removes certain</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BLUE WATER VACCINES INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;3 &#8212;&#160;Summary of Significant Accounting Policies</b>
(cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_59" id="_SignificantAccountingPoliciesTextBlock-c0_cont_58"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">settlement conditions that are required for equity contracts to qualify
for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This guidance is
effective for public business entities except for smaller reporting companies for fiscal&#160;years, and interim periods within those
fiscal&#160;years, beginning after December&#160;15, 2021. For all other entities, the standard will be effective for fiscal&#160;years
beginning after December&#160;15, 2023, including interim periods within those fiscal&#160;years. Early adoption is permitted. The Company
adopted ASU&#160;2020-06 on January&#160;1, 2022, using the modified retrospective method, and the adoption of the ASU did not impact
the Company&#8217;s financial position, results of operations, cash flows or net loss per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_60" id="_SignificantAccountingPoliciesTextBlock-c0_cont_59"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In October 2020, the FASB issued&#160;ASU 2020-10,&#160;Codification
Improvements, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC&#8217;s
regulations. The Company&#160;adopted&#160;ASU&#160;2020-10&#160;as of the reporting period beginning January 1, 2022. The adoption of
this update did not have a material effect on the Company&#8217;s financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_61" id="_SignificantAccountingPoliciesTextBlock-c0_cont_60"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_6" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In May&#160;2021, the FASB issued ASU&#160;2021-04,
Earnings Per Share (Topic&#160;260), Debt&#160;&#8212;&#160;Modifications and Extinguishments (Subtopic&#160;470-50), Compensation&#160;&#8212;&#160;Stock
Compensation (Topic&#160;718), and Derivatives and Hedging&#160;&#8212;&#160;Contracts in Entity&#8217;s Own Equity (Subtopic&#160;815-40):
Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of
the FASB Emerging Issues Task Force). The ASU clarifies and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges
of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange.
The ASU provides guidance that will clarify whether an issuer should account for a modification or an exchange of a freestanding equity-classified
written call option that remains equity classified after modification or exchange as (1)&#160;an adjustment to equity and, if so, the
related earnings per share (EPS) effects, if any, or (2)&#160;an expense and, if so, the manner and pattern of recognition. The new guidance
is effective for all entities for annual and interim periods beginning after December&#160;15, 2021, and early adoption is permitted,
including adoption in an interim period. The Company adopted ASU&#160;2021-04 on January&#160;1, 2022, and the adoption of the ASU did
not impact the Company&#8217;s financial position, results of operations, cash flows, or net loss per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_61"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&#8217;s management does not believe
that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying
condensed financial statements.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SupplementalBalanceSheetDisclosuresTextBlock-c0_cont_1" escape="true" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;4 &#8212;&#160;Balance Sheet Details</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SupplementalBalanceSheetDisclosuresTextBlock-c0_cont_2" id="_SupplementalBalanceSheetDisclosuresTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Prepaid Expenses</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SupplementalBalanceSheetDisclosuresTextBlock-c0_cont_3" id="_SupplementalBalanceSheetDisclosuresTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Prepaid expenses consisted of the following as
of March 31, 2022 and December&#160;31, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SupplementalBalanceSheetDisclosuresTextBlock-c0_cont_4" id="_SupplementalBalanceSheetDisclosuresTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> March&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd">69,205</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd">203,910</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="0" unitRef="usd">4,842</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Prepaid other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" unitRef="usd">20,800</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" unitRef="usd">25,799</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd">90,005</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd">234,551</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BLUE WATER VACCINES INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;4 &#8212;&#160;Balance Sheet Details</b> (cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SupplementalBalanceSheetDisclosuresTextBlock-c0_cont_5" id="_SupplementalBalanceSheetDisclosuresTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Accrued Expenses</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SupplementalBalanceSheetDisclosuresTextBlock-c0_cont_6" id="_SupplementalBalanceSheetDisclosuresTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Accrued expenses consisted of the following as
of March 31, 2022 and December&#160;31, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SupplementalBalanceSheetDisclosuresTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> March&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued license fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLicenseFeesReceived" scale="0" unitRef="usd">227,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLicenseFeesReceived" scale="0" unitRef="usd">225,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="bwv:AccruedResearchAndDevelopment" scale="0" unitRef="usd">564,634</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="bwv:AccruedResearchAndDevelopment" scale="0" unitRef="usd">300,182</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="bwv:AccruedDeferredOfferingCosts" scale="0" unitRef="usd">187,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="bwv:AccruedDeferredOfferingCosts" scale="0" unitRef="usd">246,236</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CompensatedAbsencesLiability" scale="0" unitRef="usd">680,537</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CompensatedAbsencesLiability" scale="0" unitRef="usd">234,265</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued insurance expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesFairValueDisclosure" scale="0" unitRef="usd">118,988</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued board of directors&#8217; compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" scale="0" unitRef="usd">33,750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd">80,529</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd">49,832</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd">1,893,438</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd">1,055,515</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAgreementsTextBlock-c0_cont_1" escape="true" name="bwv:SignificantAgreementsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;5 &#8212;&#160;Significant Agreements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAgreementsTextBlock-c0_cont_2" id="_SignificantAgreementsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Oxford University Innovation Limited</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAgreementsTextBlock-c0_cont_3" id="_SignificantAgreementsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In December&#160;2018, the Company entered into
an option agreement Oxford University Innovation (&#8220;OUI&#8221;), which was a precursor to a license agreement (the &#8220;OUI Agreement&#8221;),
dated July&#160;16, 2019. Under the terms of the OUI Agreement, the Company holds an exclusive, worldwide license to certain specified
patent rights and biological materials relating to the use of epitopes of limited variability and virus-like particle products and practice
processes that are covered by the licensed patent rights and biological materials for the purpose of developing and commercializing a
vaccine product candidate for influenza. The Company is obligated to use its best efforts to develop and market Licensed Products, as
defined in the OUI Agreement, in accordance with its development plan, report to OUI on progress, achieve the following milestones and
must pay OUI nonrefundable milestone fees when it achieves them: initiation of first Phase&#160;I study; initiation of first Phase&#160;II
study; initiation of first Phase&#160;III/pivotal registration studies; first submission of application for regulatory approval (BLA/NDA);
marketing authorization in the United&#160;States; marketing authorization in any EU country; marketing authorization in Japan; first
marketing authorization in any other country; first commercial sale in Japan; first commercial sale in any ROW country; first year that
annual sales equal or exceed certain thresholds. See Note&#160;7 for additional information on the milestone payments as well as royalty
obligations required under the OUI Agreement. The OUI Agreement will expire upon <ix:nonNumeric contextRef="c0" continuedAt="_OUIAgreementExpiration-c0_cont_1" format="ixt-sec:durwordsen" name="bwv:OUIAgreementExpiration">ten</ix:nonNumeric> (10)&#160;years from the expiration of the last patent
contained in the licensed patent rights, unless terminated earlier. During the<ix:continuation id="_OUIAgreementExpiration-c0_cont_1"> year</ix:continuation> ended December&#160;31, 2021, the U.S.&#160;Patent
related to immunogenic composition was issued to OUI.&#160;This patent expires in August&#160;2037. No additional patents have been issued
during the three months ended March 31, 2022. Either party may terminate the OUI Agreement for an uncured material breach. The Company
may terminate the OUI Agreement for any reason at any time upon six&#160;months&#8217; written notice expiring after the third anniversary
of the OUI Agreement. OUI&#160;may terminate immediately if the Company has a petition presented for its winding-up or passes a resolution
for winding up other than for a bona fide amalgamation or reconstruction or compounds with its creditors or has a receiver or administrator
appointed. OUI may also terminate if the Company opposes or challenges the validity of any of the patents or applications in the Licensed
Technology, as defined in the OUI Agreement; raises the claim that the know-how of the Licensed Technology is not necessary to develop
and market Licensed Products; or in OUI&#8217;s reasonable opinion, is taking inadequate or insufficient steps to develop or market Licensed
Products and does not take any further steps that OUI&#160;requests by written notice within a reasonable time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAgreementsTextBlock-c0_cont_4" id="_SignificantAgreementsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the&#160;three months ended March 31, 2022
and 2021, the Company did not incur any licensing fee payments for intellectual property licenses. See Note&#160;7.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BLUE WATER VACCINES INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;5 &#8212;&#160;Significant Agreements</b> (cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAgreementsTextBlock-c0_cont_5" id="_SignificantAgreementsTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>St. Jude Children&#8217;s Hospital</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAgreementsTextBlock-c0_cont_6" id="_SignificantAgreementsTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The Company entered into a license agreement (the
&#8220;St. Jude Agreement&#8221;), dated January&#160;27, 2020, with St. Jude Children&#8217;s Research Hospital (&#8220;St. Jude&#8221;).
Under the terms of the St. Jude Agreement, the Company holds an exclusive, worldwide license to certain specified patent rights and biological
materials relating to the use of live attenuated streptococcus pneumoniae and practice processes that are covered by the licensed patent
rights and biological materials for the purpose of developing and commercializing a vaccine product candidate for streptococcus pneumoniae.
The St. Jude Agreement will expire upon the expiration of the last valid claim contained in the licensed patent rights, unless terminated
earlier. The Company is obligated to use commercially reasonable efforts to develop and commercialize the licensed product(s). The milestones
include the following events: (i)&#160;complete IND enabling study; (ii)&#160;initiate animal toxicology study; (iii)&#160;file IND; (iv)&#160;complete
Phase&#160;I Clinical Trial; (v)&#160;commence Phase&#160;II Clinical Trial; (vi)&#160;commence Phase&#160;III Clinical Trial; and, (vii)&#160;regulatory
approval, U.S.&#160;or foreign equivalent. If the Company fails to achieve the development milestones contained in the St. Jude Agreement,
and if the Company and St. Jude fail to agree upon a mutually satisfactory revised timeline, St. Jude will have the right to terminate
the St. Jude Agreement. Either party may terminate the St. Jude Agreement in the event the other party (a)&#160;files or has filed against
it a petition under the Bankruptcy Act (among other things) or (b)&#160;fails to perform or otherwise breaches its obligations under the
St. Jude Agreement, and has not cured such failure or breach within sixty (60)&#160;days. The Company may terminate for any reason on
thirty (30)&#160;days written notice. On May 11, 2022, the Company entered into an amendment to the St.
Jude Agreement, whereby the royalty terms, milestones payments and licensing fees were amended. See Note 11 for more information on this
amendment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAgreementsTextBlock-c0_cont_7" id="_SignificantAgreementsTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the&#160;three months ended March&#160;31,
2022, the Company recognized approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesAndLicenses" scale="0" unitRef="usd">3,000</ix:nonFraction> for intellectual property licenses, which is recorded as research and development expenses.
For the three months ended March 31, 2021, the Company did not incur any licensing fee payments for intellectual property licenses. See
Note&#160;7 for additional information on the milestone payments as well as royalty obligations required under the St. Jude Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAgreementsTextBlock-c0_cont_8" id="_SignificantAgreementsTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cincinnati Children&#8217;s Hospital Medical Center</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAgreementsTextBlock-c0_cont_9" id="_SignificantAgreementsTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company entered into a license agreement (the
&#8220;CHMC Agreement&#8221;), dated June&#160;1, 2021, with Children&#8217;s Hospital Medical Center, d/b/a Cincinnati Children&#8217;s
Hospital Medical Center (&#8220;CHMC&#8221;). Under the terms of the CHMC Agreement, the Company holds an exclusive, worldwide license
(other than the excluded field of immunization against, and prevention, control, or reduction in the severity of gastroenteritis caused
by rotavirus and norovirus in China and Hong&#160;Kong) to certain specified patent and biological materials relating to the use of norovirus
nanoparticles and practice processes that are covered by the licensed patent rights and biological materials for the purpose of developing
and commercializing CHMC patents and related technology directed to a virus-like particle vaccine platform that utilizes nanoparticle
delivery technology that may have potential broad application to develop vaccines for multiple infectious diseases. The term of the CHMC
Agreement begins on the effective date and extends on a jurisdiction by jurisdiction and product by product basis until the later of:
(i)&#160;the last to expire licensed patent; (ii)&#160;ten (10)&#160;years after the first commercial sale; or, (iii)&#160;entrance onto
the market of a biosimilar or interchangeable product. The Company is obligated to use commercially reasonable efforts to bring licensed
products to market through diligent research and development, testing, manufacturing and commercialization, to use best efforts to make
all necessary regulatory filings and obtain all necessary regulatory approvals, to achieve milestones relating to development and sales,
and report to CHMC on progress. The Company will also be obligated to pay the agreed upon development milestone payments to CHMC, as well
as royalty payments, see Note&#160;7 for additional information. The Company may terminate the CHMC Agreement for convenience, at any
time prior to first commercial sale of a product or process by providing one hundred and eighty (180)&#160;days&#8217; written notice
to CHMC.&#160;It may also terminate for a CHMC uncured material breach. CHMC may terminate the CHMC Agreement for an uncured Company material
breach or insolvency or bankruptcy. Pursuant to the terms of the CHMC Agreement, if the Company fails to achieve the milestones, and cannot
mutually agree with CHMC on an amendment to the milestones, then CHMC will have the option of converting any and all of such exclusive
licenses to nonexclusive licenses, to continue developing indications that have already entered development at any stage or in which the
Company has invested in developing. CHMC may also terminate the CHMC Agreement to the fullest extent permitted by law in the countries
of the worldwide territory, in the event the Company or its affiliates challenge or induce others set up challenges to the validity or
enforceability of any of the Licensed Patents, as defined in the CHMC Agreement, and the Company will be obligated reimburse CHMC for
its costs, including reasonable attorneys&#8217; fees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BLUE WATER VACCINES INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;5 &#8212;&#160;Significant Agreements</b> (cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAgreementsTextBlock-c0_cont_10" id="_SignificantAgreementsTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the&#160;three months ended March 31, 2022
and 2021, the Company did not incur any licensing fee payments for intellectual property licenses. See Note 7.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAgreementsTextBlock-c0_cont_11" id="_SignificantAgreementsTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Ology Bioservices, Inc. (which was later acquired by National Resilience,
Inc.)</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SignificantAgreementsTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The Company entered into a Master Services Agreement
(&#8220;Ology MSA&#8221;), dated July&#160;19, 2019, with Ology, Inc. (&#8220;Ology&#8221;) to provide services from time to time, including
but not limited to technology transfer, process development, analytical method optimization, cGMP manufacture, regulatory affairs, and
stability studies of biologic products. Pursuant to the Ology MSA, the Company and Ology&#160;shall&#160;enter into a&#160;Project Addendum
for&#160;each&#160;project&#160;to be governed by the terms and conditions of the Ology MSA.&#160;The Company has entered into two Project
Addendums as of March 31, 2022 and December&#160;31, 2021.&#160;The initial Project Addendum&#160;was executed on October&#160;18, 2019&#160;and&#160;the
Company&#160;was&#160;required to pay Ology an aggregate of approximately $<ix:nonFraction contextRef="c37" decimals="-6" format="ixt:num-dot-decimal" name="bwv:AggregateAgreementAmountInitialAgreement" scale="6" unitRef="usd">4</ix:nonFraction>&#160;million.&#160;Due to unforeseen delays associated with
COVID-19, the Company and Ology entered into a letter agreement dated January&#160;9, 2020 to stop work on the project. The Company paid
Ology $<ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="bwv:PrepaidExpensesToRemainingPrepaidExpenses" scale="0" unitRef="usd">100,000</ix:nonFraction> for services, of which $<ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="bwv:PrepaidExpenseRemaining" scale="0" unitRef="usd">48,600</ix:nonFraction> remained as a prepaid expense as of December&#160;31, 2020.&#160;The second Project Addendum&#160;was
executed on May&#160;21, 2021&#160;and&#160;the Company is obligated to pay Ology an aggregate amount of approximately $<ix:nonFraction contextRef="c39" decimals="-5" format="ixt:num-dot-decimal" name="bwv:AggregateAmount" scale="6" unitRef="usd">2.8</ix:nonFraction>&#160;million,
plus reimbursement for materials and outsourced testing, which will be billed at cost plus <ix:nonFraction contextRef="c39" decimals="2" format="ixt:num-dot-decimal" name="bwv:CostPlusPercentage" scale="-2" unitRef="pure">15</ix:nonFraction>%. This project began during
2021, and the Company recorded approximately $<ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="0" unitRef="usd">164,000</ix:nonFraction> and $<ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="bwv:AccuredExpenses" scale="0" unitRef="usd">115,000</ix:nonFraction> as related accounts payable and accrued expenses, respectively, at
December 31, 2021. During the three months ended March 31, 2022, the Company incurred related research and development expenses of approximately
$217,000, and had approximately $<ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="bwv:AccuredExpenses" scale="0" unitRef="usd">332,000</ix:nonFraction> recorded as related accrued expenses at March&#160;31, 2022. See Note&#160;4. There were no such
expenses incurred during the three months ended March 31, 2021. On April 20, 2022, the Company entered into an amendment to the Ology
MSA, whereby the Company&#8217;s obligations increased by $<ix:nonFraction contextRef="c42" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities" scale="6" unitRef="usd">0.3</ix:nonFraction> million, specifically related to regulatory support on the project. See
Note 11.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;6 &#8212;&#160;Stockholders&#8217; Equity</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Authorized Capital and Stock Split</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On February&#160;23, 2022, the Company filed with
the Secretary of State of the State of Delaware an amended and restated certificate of incorporation (the &#8220;A&amp;R COI&#8221;),
which became effective immediately. The Company&#8217;s board of directors and stockholders approved the A&amp;R COI to be effective upon
the closing of the IPO.&#160;There was no change to the Company&#8217;s authorized shares of common stock and preferred stock of <ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="bwv:CommonStockShareAuthorized" scale="0" unitRef="shares">250,000,000</ix:nonFraction>
shares and <ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesAuthorized" scale="0" unitRef="shares">10,000,000</ix:nonFraction> shares, respectively, or the par value, which is $<ix:nonFraction contextRef="c43" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockNoParValue" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c44" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockNoParValue" scale="0" unitRef="usdPershares">0.00001</ix:nonFraction></ix:nonFraction> for both common and preferred stock. Prior to this amendment,
the Company had designated <ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" unitRef="shares">1,150,000</ix:nonFraction> shares of preferred stock, with par value $<ix:nonFraction contextRef="c31" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockNoParValue" scale="0" unitRef="usdPershares">0.00001</ix:nonFraction> per share. In addition, on February&#160;23, 2022
and in connection with the closing of the IPO, the Company&#8217;s board of directors adopted Amended and Restated Bylaws.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Common Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of March 31, 2022 and December&#160;31, 2021,
there were <ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">11,048,587</ix:nonFraction> and <ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">3,200,000</ix:nonFraction> shares of common stock issued and outstanding, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Holders of the Company&#8217;s common stock are
entitled to one vote for each share held of record, and are entitled upon liquidation of the Company to share ratably in the net assets
of the Company available for distribution after payment of all obligations of the Company and after provision has been made with respect
to each class of stock, if any, having preference over the common stock, currently including the Company&#8217;s preferred stock. The
shares of common stock are not redeemable and have no preemptive or similar rights.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On February&#160;17, 2022, the Company entered
into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Boustead Securities, LLC, acting as representative of the
underwriters (&#8220;Boustead&#8221;), in relation to the Company&#8217;s IPO, pursuant to which the Company agreed to sell to the underwriters
an aggregate of <ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="bwv:AggregatePurchaseShares" scale="0" unitRef="shares">2,222,222</ix:nonFraction> shares of the Company&#8217;s common stock, at a price of $<ix:nonFraction contextRef="c47" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares">9.00</ix:nonFraction> per share. The IPO closed on February&#160;23,
2022, and resulted in net proceeds to the Company, after deducting the <ix:nonFraction contextRef="c31" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LongDurationContractsAssumptionsByProductAndGuaranteeDiscountRate" scale="-2" unitRef="pure">8</ix:nonFraction>% underwriting discount, and other offering costs, of approximately
$<ix:nonFraction contextRef="c31" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherOwnershipInterestsOfferingCosts" scale="6" unitRef="usd">17.1</ix:nonFraction>&#160;million. Pursuant to the Underwriting Agreement, the Company issued to Boustead warrants to purchase <ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" scale="0" unitRef="shares">111,111</ix:nonFraction> shares of common
stock. The warrants are exercisable, at the option of the holder, at a per share exercise price equal to $<ix:nonFraction contextRef="c31" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" unitRef="usdPershares">10.35</ix:nonFraction> and are exercisable at
any time and from time to time, in whole or in part, starting on February 23, 2022 and terminating on February&#160;11, 2027.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company evaluated the terms of the warrants
issued at the IPO and determined that they should be classified as equity instruments based upon accounting guidance provided in ASC 480
and ASC 815-40. Since the Company determined that the warrants were equity-classified, the Company recorded the proceeds from the IPO,
net of issuance costs, within common stock at par value and the balance of the net proceeds to additional paid in capital. As of March
31, 2022, the outstanding warrants are exercisable into&#160;<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">111,111</ix:nonFraction>&#160;shares of common stock whose fair value was $<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ForwardContractIndexedToEquitySettlementShareFairValuePerShare" scale="0" unitRef="usdPershares">56.50</ix:nonFraction>&#160;per
share, based on the closing trading price on that day.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BLUE WATER VACCINES INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;6 &#8212;&#160;Stockholders&#8217; Equity</b> (cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Preferred Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Prior to the close of the IPO, the Company had
designated <ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" unitRef="shares">1,150,000</ix:nonFraction> shares of preferred stock as Series&#160;Seed Preferred Stock (&#8220;Series&#160;Seed&#8221;), with an original
issue price of $<ix:nonFraction contextRef="c49" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" unitRef="usdPershares">6.09</ix:nonFraction> per share (the &#8220;Original Issue Price&#8221;). As of March 31, 2022 and December&#160;31, 2021, there were <ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesOutstanding" scale="0" unitRef="shares">0</ix:nonFraction></ix:nonFraction>
and <ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesOutstanding" scale="0" unitRef="shares">1,146,138</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Conversion</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Each share of the Series&#160;Seed was convertible,
at the option of the holder, at any time and from time to time, and without the payment of additional consideration by the holder, at
a conversion price of $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="bwv:ConversionPricePerShares" scale="0" unitRef="usdPershares">1.52</ix:nonFraction> per share, subject to certain adjustments for stock splits, stock dividends, recapitalizations, and similar
corporate transactions, into fully paid and non-assessable shares of the Company&#8217;s common stock. Each Series&#160;Seed share was
automatically convertible into common stock of the Company, at the then-effective conversion price, upon the closing of a firmly underwritten
public offering netting proceeds of at least $<ix:nonFraction contextRef="c0" decimals="-6" format="ixt:num-dot-decimal" name="bwv:UnderwrittenPublicOfferingNettingProceeds" scale="6" unitRef="usd">50</ix:nonFraction>&#160;million with an offering price of at least three hundred percent (<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="bwv:OfferingPricePercentage" scale="-2" unitRef="pure">300</ix:nonFraction>%) of the Original
Issue Price of the Series&#160;Seed. On October&#160;7, 2021, the majority of the holders of the Series&#160;Seed approved the automatic
conversion of the outstanding shares of the Series&#160;Seed and all related accrued and unpaid dividends, upon the close of the IPO.&#160;The
number of conversion shares to be issued upon the close of the IPO were to be calculated in accordance with the original conversion terms
provided by the Company&#8217;s Amended and Restated Certificate of Incorporation (&#8220;COI&#8221;) dated July&#160;1, 2019. This conversion
occurred on February&#160;23, 2022, upon the close of the Company&#8217;s IPO.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Dividends</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Holders of the Series&#160;Seed were entitled
to receive cumulative dividends at a per share rate of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="bwv:CumulativeDividendsPerShare" scale="-2" unitRef="pure">8</ix:nonFraction>% per annum, compounded annually, on the initial investment amount commencing
on the date of issue. Dividends were payable only when, as, and if declared by the Board of Directors or upon a Liquidation Event, as
described below. Dividends on Series&#160;Seed were in preference to any dividend on the Company&#8217;s common stock. Upon the close
of the IPO, aggregate cumulative dividends of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CumulativeDividends" scale="0" unitRef="usd">1,586,162</ix:nonFraction> or $<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DividendsPayableAmountPerShare" scale="0" unitRef="usdPershares">1.38</ix:nonFraction> per Series&#160;Seed share were automatically converted into shares
of common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Liquidation Preference</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the event of certain voluntary or involuntary
acquisition or sale transactions or upon the liquidation, dissolution or winding up of the Company (each, a &#8220;Liquidation Event&#8221;),
the holders of Series&#160;Seed were entitled to receive out of the proceeds or assets of the Company legally available for distribution
to its stockholders (the&#160;&#8220;Proceeds&#8221;), prior and in preference to any distribution of the Proceeds of such Liquidation
Event to the holders of shares of common stock by reason of their ownership thereof, an amount (&#8220;the Liquidation Preference Amount&#8221;)
determined based on the provisions of the Company&#8217;s COI.&#160;The COI provided that the Liquidation Preference Amount be calculated
upon the occurrence of a Liquidation Event, based on the Company&#8217;s achievement of a Pre-Clinical Milestone and a Qualified Financing,
both as defined in the COI.&#160;Per the provisions of the COI, if a Liquidation Event occurred before a Pre-Clinical Milestone was achieved,
the Liquidation Preference Amount would be equal to two times the Series&#160;Seed Original Issue price per share, plus unpaid cumulative
dividends. If a Liquidation Event occurred after a Pre-Clinical Milestone was achieved, and after a Qualified Financing was completed,
then the Liquidation Preference Amount would be equal to one times the Series&#160;Seed Original Issue price, plus unpaid cumulative dividends.
If a Liquidation Event occurred after a Pre-Clinical Milestone was achieved and before a Qualified Financing was completed, the Liquidation
Preference Amount would be equal to the greater of (a)&#160;such amount per share as such holder would have been entitled to receive after
a Qualified Financing or (b)&#160;two times the Series&#160;Seed Original Issue price, plus unpaid cumulative dividends.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_17" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c36" name="us-gaap:PreferredStockDividendPreferenceOrRestrictions">As of December&#160;31, 2021, and all other prior
historical periods, the Liquidation Preference Amount was equal to two times the Series&#160;Seed Original Issue Price per share, plus
unpaid cumulative dividends.</ix:nonNumeric> In the event that the Proceeds were insufficient to enable the distribution in full of the Liquidation Preference
Amount to the holders of the Series&#160;Seed for all of the preferred shares held by them, all of the Proceeds were to be distributed
among the</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BLUE WATER VACCINES INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;6 &#8212;&#160;Stockholders&#8217; Equity</b> (cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_18" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">holders of Series&#160;Seed on a pro rata basis. Upon completion of
the distribution required to the holders of Series&#160;Seed, all of the remaining Proceeds available for distribution to stockholders
were to be distributed among the holders of common shares and preferred shares, on an as-converted basis, pro rata based on the number
of common shares held by each such holder. However, if upon the occurrence of a Liquidation Event, the Liquidation Preference Amount the
Series&#160;Seed stockholders were entitled to receive is two times the Original Issue Price per share, plus unpaid cumulative dividends,
after such distribution is made, then the remaining Proceeds available for distribution to stockholders were to be distributed among the
holders of common shares, pro rata based on the number of common shares held by each such holder.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_19" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Voting</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_20" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On any matter presented to the stockholders of
the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in
lieu of meeting), each holder of outstanding shares of Series&#160;Seed were entitled to cast the number of votes equal to the number
of whole shares of common stock into which the shares of Series&#160;Seed held by such holder were convertible as of the record date for
determining stockholders entitled to vote on such matter. Holders of Series&#160;Seed were entitled to vote together with the holder of
common stock as a single class. Holders of Series&#160;Seed were entitled to nominate two out of five of the Company&#8217;s directors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_21" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Equity Incentive Plans</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_22" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;The Company&#8217;s 2019 Equity Incentive
Plan (the &#8220;2019 Plan&#8221;) was adopted by its board of directors and by its stockholders on July&#160;1, 2019. The Company has
reserved <ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">1,400,000</ix:nonFraction> shares of common stock for issuance pursuant to the 2019 Plan. There were no share-based awards granted under the 2019
Plan during the three months ended March 31, 2022 and 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, on February&#160;23, 2022 and in
connection with the closing of the IPO, the Company&#8217;s board of directors adopted the Company&#8217;s 2022 Equity Incentive Plan
(the &#8220;2022 Plan&#8221;), which is the successor and continuation of the Company&#8217;s 2019 Plan. Under the 2022 Plan, the Company
may grant stock options, restricted stock, restricted stock units, stock appreciation rights, and other forms of awards to&#160;employees,
directors and consultants of the Company. Upon its effectiveness, a total of <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">1,600,000</ix:nonFraction> shares of common stock were reserved for issuance
under the 2022 Plan. As of March 31, 2022, there were no share-based awards granted under the 2022 Plan.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;7 &#8212;&#160;Commitments and Contingencies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Office lease</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The Company leased office space for approximately
$<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="0" unitRef="usd">5,500</ix:nonFraction> a month from a related party. The Company paid a $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="bwv:RentalDeposits" scale="0" unitRef="usd">15,000</ix:nonFraction> rental deposit and rent expense for the&#160;three months ended March
31, 2022 and 2021 was approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="0" unitRef="usd">0</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="0" unitRef="usd">20,000</ix:nonFraction>, respectively. The Company terminated the related party lease in May&#160;2021 and
entered into a new lease with an unrelated party in April&#160;2021. <ix:nonNumeric contextRef="c0" name="us-gaap:LesseeOperatingLeaseDescription">The Company is not a party to a lease with a term in excess of 12&#160;months
and has a month-to-month lease as of March&#160;31, 2022.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Litigation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">From time to time, the Company may be subject
to various legal proceedings and claims that arise in the ordinary course of its business activities. <ix:nonNumeric contextRef="c0" name="bwv:LitigationsDescription">As of March 31, 2022, the Company
is not a party to any material legal proceedings and is not aware of any pending or threatened claims.</ix:nonNumeric> See Note 11.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Significant agreements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Oxford University Innovation Limited</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the OUI Agreement, as disclosed in
Note&#160;5, the Company is obligated to pay certain milestone and royalty payments in the future, as the related contingent events occur.
Specifically, the Company is obligated to pay a <ix:nonFraction contextRef="c52" decimals="2" format="ixt:num-dot-decimal" name="bwv:PercentageOfRoyaltyOnSales" scale="-2" unitRef="pure">6</ix:nonFraction>% royalty on all net sales of licensed products, as defined in the OUI Agreement, with
an annual minimum royalty payment of $<ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="bwv:MinimumRoyaltyExpense" scale="0" unitRef="usd">250,000</ix:nonFraction> starting post-product launch, until the expiration of the OUI Agreement or revocation of
the last valid claim covering a licensed product, at which point a royalty rate of <ix:nonFraction contextRef="c53" decimals="2" format="ixt:num-dot-decimal" name="bwv:RoyaltyRatePercentage" scale="-2" unitRef="pure">3</ix:nonFraction>% will apply. An annual maintenance fee of <ix:nonNumeric contextRef="c54" name="us-gaap:DebtInstrumentFee">$10,000</ix:nonNumeric>
and <ix:nonNumeric contextRef="c55" name="us-gaap:DebtInstrumentFee">$20,000</ix:nonNumeric> is required in the pre-phase&#160;III year and Phase&#160;III year, respectively, and as defined in the OUI Agreement. The
Company is also obligated to pay a <ix:nonFraction contextRef="c53" decimals="2" format="ixt:num-dot-decimal" name="bwv:RoyaltyOnSumReceivedFromSublicenseePercentage" scale="-2" unitRef="pure">25</ix:nonFraction>% royalty on any sums received by the Company</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BLUE WATER VACCINES INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;7 &#8212;&#160;Commitments and Contingencies</b> (cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_9" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">from any sublicensee (including all up-front, milestone and other one-off
payments received by the Company from any sub-licenses or other contracts granted by the Company with respect to the licensed technology).
In addition, the Company is required to pay OUI milestone payments of up to an aggregate of $<ix:nonFraction contextRef="c53" decimals="-4" format="ixt:num-dot-decimal" name="bwv:AggregatePayments" scale="6" unitRef="usd">51.25</ix:nonFraction>&#160;million; specifically, upon the
achievement of specified development milestones of approximately $<ix:nonFraction contextRef="c53" decimals="-4" format="ixt:num-dot-decimal" name="bwv:SpecifiedMilestones" scale="6" unitRef="usd">2.25</ix:nonFraction>&#160;million, regulatory milestones of approximately $<ix:nonFraction contextRef="c53" decimals="-5" format="ixt:num-dot-decimal" name="bwv:RegulatoryMilestones" scale="6" unitRef="usd">9.5</ix:nonFraction>&#160;million,
and commercial milestones of approximately $<ix:nonFraction contextRef="c53" decimals="-5" format="ixt:num-dot-decimal" name="bwv:CommercialMilestones" scale="6" unitRef="usd">39.5</ix:nonFraction>&#160;million. The annual maintenance fee and milestone fees are indexed to the RPI (Retail
Prices index for all items which is published in the United Kingdom by the Office for National Statistics, or any replacement of it) and
will be increased or decreased as appropriate as set forth in the OUI Agreement. As of March&#160;31, 2022, the Company evaluated the
likelihood of the Company achieving the specified milestones and generating product sales, and determined the likelihood is not yet probable
and as such no accrual of these payments is required as of March&#160;31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_10" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Oxford University Research Agreement</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_11" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the terms of the OUI Agreement, as
disclosed in Note&#160;5, the Company entered into a sponsored research agreement dated December&#160;18, 2019 with Oxford University
for research related to the OUI Agreement for a period of <span style="-sec-ix-hidden: hidden-fact-43">three</span>&#160;years for a total of &#163;<ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PurchaseObligationDueInThirdYear" scale="0" unitRef="eur">420,000</ix:nonFraction>. The Company prepaid the full
amount to Oxford of $<ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="bwv:PrepaidAmount" scale="0" unitRef="usd">554,802</ix:nonFraction> for the services in January&#160;2020, of which approximately $<ix:nonFraction contextRef="c59" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" scale="6" unitRef="usd"><ix:nonFraction contextRef="c60" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" scale="6" unitRef="usd">0.2</ix:nonFraction></ix:nonFraction>&#160;million remains as a prepaid expense
as of March 31, 2022 and December&#160;31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_12" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>St. Jude Children&#8217;s Hospital</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_13" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the St. Jude Agreement, as disclosed
in Note&#160;5, the Company is obligated to pay certain milestone and royalty payments in the future, as the related contingent events
occur. Specifically, the Company is obligated to make <ix:nonFraction contextRef="c61" decimals="2" format="ixt:num-dot-decimal" name="bwv:RoyaltyPaymentsPercentage" scale="-2" unitRef="pure">4</ix:nonFraction>% royalty payments for each licensed product(s)&#160;sold by the Company or its
affiliates, based on the net sales for the duration of the St. Jude Agreement, and also pay <ix:nonFraction contextRef="c61" decimals="2" format="ixt:num-dot-decimal" name="bwv:RoyaltyOnSumReceivedFromSublicenseePercentage" scale="-2" unitRef="pure">15</ix:nonFraction>% of consideration received for any sublicenses.
The Company is required to pay an annual maintenance fee of $<ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="bwv:AnnualMaintenanceFee" scale="0" unitRef="usd">10,000</ix:nonFraction> beginning on the first anniversary of the Effective Date (which is
waived if all of the developmental milestones scheduled for completion before such annual fee is due have been achieved). In addition,
the Company is required to pay St. Jude milestone payments of up to an aggregate of $<ix:nonFraction contextRef="c61" decimals="-6" format="ixt:num-dot-decimal" name="bwv:AggregatePayments" scale="6" unitRef="usd">1</ix:nonFraction>&#160;million; specifically, upon the achievement
of specified development milestones of approximately $<ix:nonFraction contextRef="c61" decimals="-5" format="ixt:num-dot-decimal" name="bwv:SpecifiedMilestones" scale="6" unitRef="usd">0.2</ix:nonFraction>&#160;million, regulatory milestones of approximately $<ix:nonFraction contextRef="c61" decimals="-5" format="ixt:num-dot-decimal" name="bwv:RegulatoryMilestones" scale="6" unitRef="usd">0.3</ix:nonFraction>&#160;million, and
commercial milestones of approximately $<ix:nonFraction contextRef="c61" decimals="-5" format="ixt:num-dot-decimal" name="bwv:CommercialMilestones" scale="6" unitRef="usd">0.5</ix:nonFraction>&#160;million. On May 11, 2022, the Company entered into an amendment to the St. Jude Agreement,
whereby the royalty terms, milestones payments and licensing fees were amended. See Note 11 for more information on this amendment. As
of March&#160;31, 2022, the Company evaluated the likelihood of the Company achieving the specified milestones and generating product
sales, and determined the likelihood is not yet probable and as such no accrual of these payments is required as of March&#160;31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_14" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>St. Jude Children&#8217;s Sponsored Research Agreement</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_15" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition to the St. Jude Agreement, the Company
also entered into a sponsored research agreement dated May&#160;3, 2021 with St. Jude for research related to the St. Jude Agreement.
Pursuant to this research agreement, the Company is obligated to pay St. Jude an aggregate amount of $<ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="bwv:AggregateAmount" scale="0" unitRef="usd">73,073</ix:nonFraction> in two parts, Phase&#160;I
for $<ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="bwv:AggregateAmount" scale="0" unitRef="usd">57,624</ix:nonFraction> and Phase&#160;II for $<ix:nonFraction contextRef="c64" decimals="0" format="ixt:num-dot-decimal" name="bwv:AggregateAmount" scale="0" unitRef="usd">15,449</ix:nonFraction>. This sponsored research project began during 2021, and the Company recorded approximately $<ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="bwv:AccuredExpenses" scale="0" unitRef="usd">8,000</ix:nonFraction>
in related accrued expenses at December 31, 2021. During the three months ended March 31, 2022, the Company incurred related research
and development expenses of approximately $<ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="bwv:OtherResearchAndDevelopmentExpenses" scale="0" unitRef="usd">8,000</ix:nonFraction>, and had approximately $<ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="bwv:AccuredExpenses" scale="0" unitRef="usd">15,000</ix:nonFraction> recorded as related accrued expenses at March&#160;31,
2022. There were no such expenses incurred during the three months ended March 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_16" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cincinnati Children&#8217;s Hospital Medical Center</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_17" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the CHMC Agreement, as disclosed in
Note&#160;5, the Company is obligated to pay certain milestone and royalty payments in the future, as the related contingent events occur.
Specifically, the Company is obligated to pay CHMC a single-digit royalty on net sales, being <ix:nonFraction contextRef="c67" decimals="2" format="ixt:num-dot-decimal" name="bwv:PercentageOfRoyaltyOnSales" scale="-2" unitRef="pure">5</ix:nonFraction>%, 4% or 2% depending on the product, until
the last valid claim covering a licensed product exists, at which point the royalty rates decrease by <ix:nonFraction contextRef="c68" decimals="2" format="ixt:num-dot-decimal" name="bwv:RoyaltyRateDecreasePostValidClaimExpiration" scale="-2" unitRef="pure">50</ix:nonFraction>%. The Company is also</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BLUE WATER VACCINES INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;7 &#8212;&#160;Commitments and Contingencies</b> (cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_18" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">obligated to pay up to a <ix:nonFraction contextRef="c68" decimals="2" format="ixt:num-dot-decimal" name="bwv:RoyaltyOnSumReceivedFromSublicenseePercentage" scale="-2" unitRef="pure">25</ix:nonFraction>% royalty on any non-royalty sublicense
revenue paid to the Company by any sublicensee. The CHMC Agreement also provides the Company with an option to license any CHMC or jointly
patented modification, alteration or improvement of any invention claimed in a Licensed Patent (&#8220;CHMC Improvement&#8221; and &#8220;Joint
Improvement, respectively&#8221;), with a $<ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="bwv:OptionFee" scale="0" unitRef="usd">50,000</ix:nonFraction> option fee for each Improvement that the Company elects to include in the license grant
of the CHMC Agreement. In addition, the Company is required to pay CHMC milestone payments of up to an aggregate of $<ix:nonFraction contextRef="c68" decimals="-4" format="ixt:num-dot-decimal" name="bwv:AggregatePayments" scale="6" unitRef="usd">59.75</ix:nonFraction>&#160;million;
specifically, upon the achievement of specified development milestones of approximately $<ix:nonFraction contextRef="c68" decimals="-5" format="ixt:num-dot-decimal" name="bwv:SpecifiedMilestones" scale="6" unitRef="usd">0.5</ix:nonFraction>&#160;million, regulatory milestones of approximately
$<ix:nonFraction contextRef="c68" decimals="-4" format="ixt:num-dot-decimal" name="bwv:RegulatoryMilestones" scale="6" unitRef="usd">1.25</ix:nonFraction>&#160;million, and commercial milestones of approximately $<ix:nonFraction contextRef="c68" decimals="-6" format="ixt:num-dot-decimal" name="bwv:CommercialMilestones" scale="6" unitRef="usd">58</ix:nonFraction>&#160;million. As of March&#160;31, 2022, the Company evaluated the
likelihood of the Company achieving the specified milestones and generating product sales, and determined the likelihood is not yet probable
and as such no accrual of these payments is required as of March&#160;31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_19" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Ology Bioservices, Inc. (which was later acquired by National Resilience,
Inc.)</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_20" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the Ology MSA and the second Project
Addendum, as disclosed in Note&#160;5, the Company is obligated to pay Ology an aggregate amount of approximately $<ix:nonFraction contextRef="c69" decimals="-5" format="ixt:num-dot-decimal" name="bwv:AggregateAmount" scale="6" unitRef="usd">2.8</ix:nonFraction>&#160;million,
plus reimbursement for materials and outsourced testing which will be billed at cost plus <ix:nonFraction contextRef="c69" decimals="2" format="ixt:num-dot-decimal" name="bwv:CostPlusPercentage" scale="-2" unitRef="pure">15</ix:nonFraction>%. This project began during 2021, and the
Company recorded approximately $<ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="0" unitRef="usd">164,000</ix:nonFraction> and $<ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="bwv:AccuredExpenses" scale="0" unitRef="usd">115,000</ix:nonFraction> as related accounts payable and accrued expenses, respectively, at December 31,
2021. During the three months ended March 31, 2022, the Company incurred related research and development expenses of approximately $<ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="bwv:OtherResearchAndDevelopmentExpenses" scale="0" unitRef="usd">217,000</ix:nonFraction>,
and had approximately $<ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="bwv:AccuredExpenses" scale="0" unitRef="usd">332,000</ix:nonFraction> recorded as related accrued expenses at March&#160;31, 2022. See Note&#160;4. There were no such expenses
incurred during the three months ended March 31, 2021. This project is currently expected to be performed through the fourth quarter
of 2023. On April 20, 2022, the Company entered into an amendment to the Ology MSA, whereby the Company&#8217;s obligations increased
by $<ix:nonFraction contextRef="c72" decimals="-5" format="ixt:num-dot-decimal" name="bwv:TerminationFee" scale="6" unitRef="usd">0.3</ix:nonFraction> million, specifically related to regulatory support on the project. See Note 11.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_21" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Underwriter Termination Agreement</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_22" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On February&#160;7, 2022, the Company and its
former underwriter, Maxim Group (&#8220;Maxim&#8221;), entered into a termination agreement, whereby the parties agreed to terminate their
engagement of Maxim as the Company&#8217;s lead managing underwriter and book runner in connection with the Company&#8217;s IPO.&#160;Per
the terms of the termination agreement, the Company agreed to pay Maxim a termination fee of $<ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="bwv:TerminationFee" scale="0" unitRef="usd">300,000</ix:nonFraction>, due upon the close of the Company&#8217;s
IPO. The termination fee was recorded as general and administrative expense during the three months ended March 31, 2022, and is included
in accounts payable in the accompanying condensed balance sheet at March 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_23" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Indemnification</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_24" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_23"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the normal course of business, the Company
enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications.
The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the
future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification
obligations. However, the Company may incur charges in the future as a result of these indemnification obligations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_25" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_24"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Risks and Uncertainties&#160;&#8212;&#160;COVID-19</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_25"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Management continues to evaluate the impact of
the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect
on the Company&#8217;s financial position, results of its operations and/or search for drug candidates, the specific impact is not readily
determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from
the outcome of this uncertainty.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;8 &#8212;&#160;Related Party Transactions</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company originally engaged the Chief Executive
Officer, who is also the Board Chairman and prior to the close of the IPO, sole common stockholder of the Company, pursuant to a consulting
agreement commencing October&#160;22, 2018, which calls for the Company to pay for consulting services performed on a monthly basis. During
the&#160;three months ended March&#160;31, 2022 and 2021, the Company incurred approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" scale="0" unitRef="usd">63,000</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" scale="0" unitRef="usd">105,000</ix:nonFraction> in fees under the consulting
agreement, respectively, which are recognized in general and administrative expenses in the accompanying statements of operations. Upon
the close of the Company&#8217;s IPO, the consulting agreement was terminated and the CEO&#8217;s employment agreement became effective.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BLUE WATER VACCINES INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;8 &#8212;&#160;Related Party Transactions</b> (cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_3" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company also leased office space from a related
party, through common ownership. The lease is further described in Note&#160;7 of these financial statements. The lease was terminated
in May&#160;2021, and the related deposit was reclassified to the receivable from related parties balance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_4" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of March 31, 2022 and December&#160;31, 2021,
the Company has a receivable from related parties of approximately $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromRelatedParties" scale="0" unitRef="usd">165,000</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromRelatedParties" scale="0" unitRef="usd">153,000</ix:nonFraction>, respectively. The balance consists primarily
of consulting fee prepayments to the Company&#8217;s CEO, in the amount of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="0" unitRef="usd">140,000</ix:nonFraction> as of March 31, 2022 and December&#160;31, 2021. These
consulting fee prepayments were repaid to the Company in lieu of a bonus payout due to the CEO during May 2022. The remaining balance
as of March 31, 2022 consists of approximately $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsMiscellaneousCurrent" scale="0" unitRef="usd">18,000</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" scale="0" unitRef="usd">7,000</ix:nonFraction> of miscellaneous payments made by the Company on the behalf of the CEO
and Chief Business Officer, respectively.&#160; The balance due from the Chief Business Officer was repaid to the Company in April 2022.
The remaining balance as of December&#160;31, 2021 consists of miscellaneous payments made by the Company on the behalf of the CEO.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">One of the Company&#8217;s directors serves on
the Advisory Board for the Cincinnati Children&#8217;s Hospital Medical Center Innovation Fund, which is affiliated with CHMC.&#160;The
Company has an exclusive license agreement with CHMC as disclosed in Note&#160;5. This director resigned from the Company&#8217;s board
upon the close of its IPO.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;9 &#8212;&#160;Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">No provision for federal, state or foreign income
taxes has been recorded for the three months ended March 31, 2022 and 2021. The Company has incurred net operating losses for all of the
periods presented and has not reflected any benefit of such net operating loss carryforwards in the accompanying financial statements
due to uncertainty around utilizing these tax attributes within their respective carryforward periods. The Company has recorded a full
valuation allowance against all of its deferred tax assets as it is not more likely than not that such assets will be realized in the
near future. The Company&#8217;s policy is to recognize interest expense and penalties related to income tax matters as income tax expense.
For the three months ended March 31, 2022 and 2021, the Company has not recognized any interest or penalties related to income taxes.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;10 &#8212;&#160;Retirement Plan</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Effective January&#160;1, 2022, the Company adopted
a defined contribution savings plan pursuant to Section&#160;401(k)&#160;of the Internal Revenue Code (&#8220;the 401(k) Plan&#8221;).
The 401(k) Plan is for the benefit of all qualifying employees and permits voluntary contributions by employees of up to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% of eligible
compensation, subject to the maximum limits imposed by the Internal Revenue Service. The terms of the 401(k) Plan allow for discretionary
employer contributions. Enrollment in the 401(k) Plan will become available during the second quarter of 2022. No expenses were incurred
related to the 401(k) Plan during the three months ended March 31, 2022.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BLUE WATER VACCINES INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note&#160;11
&#8212;&#160;Subsequent Events</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_2" id="_SubsequentEventsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;On April 19, 2022, the Company consummated
the closing of a private placement (the &#8220;Private Placement&#8221;), pursuant to the terms and conditions of a securities purchase
agreement, dated as of April 13, 2022. At the closing of the Private Placement, the Company issued <ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares">590,406</ix:nonFraction> shares of common stock (the
&#8220;Shares&#8221;), pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase an aggregate of <ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="bwv:AggregatesPurchaseShares" scale="0" unitRef="shares">590,406</ix:nonFraction> shares of common
stock and preferred investment options (the &#8220;Preferred Investment Options&#8221;) to purchase up to an aggregate of <ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="bwv:AggregatesPurchaseShares" scale="0" unitRef="shares">1,180,812</ix:nonFraction> shares
of common stock. The purchase price of each Share together with the associated Preferred Investment Option was $<ix:nonFraction contextRef="c76" decimals="3" format="ixt:num-dot-decimal" name="bwv:PurchasePricePerShare" scale="0" unitRef="usd">6.775</ix:nonFraction>, and the purchase
price of each Pre-Funded Warrant together with the associated Preferred Investment Option was $<ix:nonFraction contextRef="c75" decimals="3" format="ixt:num-dot-decimal" name="bwv:PurchasePricePerShare" scale="0" unitRef="usd">6.774</ix:nonFraction>. The aggregate net proceeds to the
Company from the Private Placement were approximately $<ix:nonFraction contextRef="c74" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfDebt" scale="6" unitRef="usd">7.0</ix:nonFraction> million, after deducting placement agent fees and other initial offering expenses.
H.C. Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;) acted as the exclusive placement agent for the Private Placement. The Pre-Funded
Warrants have an exercise price of $<ix:nonFraction contextRef="c77" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">0.001</ix:nonFraction> per share, are exercisable on or after April 19, 2022, and are exercisable until the Pre-Funded
Warrants are exercised in full. The Preferred Investment Options are exercisable at any time on or after April 19, 2022 at an exercise
price of $<ix:nonFraction contextRef="c78" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">6.65</ix:nonFraction> per share, subject to certain adjustments as defined in the agreement. The Company agreed to pay Wainwright a placement
agent fee and management fee equal to <ix:nonFraction contextRef="c33" decimals="3" format="ixt:num-dot-decimal" name="bwv:AgentFee" scale="-2" unitRef="pure">7.5</ix:nonFraction>% and <ix:nonFraction contextRef="c33" decimals="3" format="ixt:num-dot-decimal" name="bwv:ManagementFee" scale="-2" unitRef="pure">1.0</ix:nonFraction>%, respectively, of the aggregate gross proceeds from the Private Placement and reimburse
certain out-of-pocket expenses up to an aggregate of $<ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="bwv:AggregateOutofPocketExpensesToPlacementAgent" scale="0" unitRef="usd">85,000</ix:nonFraction>. In addition, the Company issued warrants to Wainwright (the &#8220;Wainwright
Warrants&#8221;) to purchase up to <ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">70,849</ix:nonFraction> shares of common stock. The Wainwright Warrants are in substantially the same form as the Preferred
Investment Options, except that the exercise price is $<ix:nonFraction contextRef="c79" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">8.46875</ix:nonFraction>. Further, upon any exercise for cash of any Preferred Investment Options,
the Company agreed to issue to Wainwright warrants to purchase the number of Shares equal to <ix:nonFraction contextRef="c80" decimals="3" format="ixt:num-dot-decimal" name="bwv:SharesPercentage" scale="-2" unitRef="pure">6.0</ix:nonFraction>% of the aggregate number of Shares underlying
the Preferred Investment Options that have been exercised, also with an exercise price of $<ix:nonFraction contextRef="c80" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">8.46875</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_3" id="_SubsequentEventsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In connection with the Private Placement, the
Company entered into a Registration Rights Agreement with the purchasers, dated as of April 13, 2022 (the &#8220;Registration Rights Agreement&#8221;).
The Registration Rights Agreement provides that the Company shall file a registration statement covering the resale of all of the registrable
securities (as defined in the Registration Rights Agreement) with the Securities and Exchange Commission (the &#8220;SEC&#8221;) no later
than the 20th calendar day following the date of the Registration Rights Agreement and have the registration statement declared effective
by the SEC as promptly as possible after the filing thereof, but in any event no later than the 45th calendar day following April 13,
2022 or, in the event of a full review by the SEC, the 75th day following April 13, 2022. The registration statement on Form S-1 required
under the Registration Rights Agreement was filed with the SEC on May 3, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_4" id="_SubsequentEventsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Upon the occurrence of any Event (as defined in
the Registration Rights Agreement), which, among others, prohibits the Purchasers from reselling the securities for more than ten consecutive
calendar days or more than an aggregate of fifteen calendar days during any 12-month period, the Company is obligated to pay to each purchaser,
on each monthly anniversary of each such Event, an amount in cash, as partial liquidated damages and not as a penalty, equal to the product
of <ix:nonFraction contextRef="c33" decimals="3" format="ixt:num-dot-decimal" name="bwv:AggregateSubscriptionAmountPaidPercentage" scale="-2" unitRef="pure">2.0</ix:nonFraction>% multiplied by the aggregate subscription amount paid by such purchaser in the Private Placement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_5" id="_SubsequentEventsTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On April 15, 2022, the Company received a demand
letter (the &#8220;Demand Letter&#8221;) from Boustead. The Demand Letter alleges that the Company breached the Underwriting Agreement
entered into between Boustead and the Company, dated February 17, 2022 in connection with the Company&#8217;s initial public offering.
The Demand Letter alleges that, by engaging Wainwright as placement agent in the Private Placement, the Company breached the right of
first refusal to act as placement agent granted to Boustead under the Underwriting Agreement and, as a result of selling securities in
the Private Placement, breached the 12-month lock-up obligation following the consummation of the initial public offering under the Underwriting
Agreement. The Demand Letter requested that the Company rescind the Private Placement. The Company has not responded to the Demand Letter
and no legal action has been brought by Boustead to date. There can be no assurance as to whether any litigation will be commenced against
the Company with respect to the demand letter or that, if any such litigation is commenced, the Company will not incur material losses
due to damages, penalties, costs and/or expenses as a result of such litigation or that any such losses will not have a material impact
on the Company&#8217;s financial condition or results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_6" id="_SubsequentEventsTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">On April 20, 2022, <ix:nonNumeric contextRef="c81" name="us-gaap:SubsequentEventDescription">the Company and Ology entered into
a first amendment to the second Project Addendum (the &#8220;Ology Amendment&#8221;), see Notes 5 and 7. The Ology Amendment provides
for an increase to the Company&#8217;s obligation of $0.3 million, specifically related to regulatory support on the project.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_7" id="_SubsequentEventsTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On May 4, 2022, <ix:nonNumeric contextRef="c82" escape="true" name="us-gaap:ScheduleOfSubsequentEventsTextBlock">the Company&#8217;s compensation
committee approved stock option grants <span>under the Company&#8217;s 2022 Equity Incentive Plan</span>
to the Company&#8217;s executive officers, board members, employees and certain consultants. The stock options granted totaled 694,540
options, of which 500,000 were granted to the Company&#8217;s executive officers, and all of which have an exercise price of $6.45.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:continuation><div>


</div><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On May 11, 2022, the Company and St. Jude entered
into a first amendment to the St. Jude Agreement (the &#8220;St. Jude Amendment&#8221;), see Notes 5 and 7. <ix:nonNumeric contextRef="c83" name="us-gaap:SubsequentEventDescription">The St. Jude Amendment provides
for a revised development milestone timeline, a one-time license fee of $<ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLicenseFeesReceived" scale="0" unitRef="usd">5,000</ix:nonFraction>, and an increase to the royalty rate from <ix:nonFraction contextRef="c85" decimals="2" format="ixt:num-dot-decimal" name="bwv:RoyaltyRatePercentage" scale="-2" unitRef="pure">4</ix:nonFraction>% to <ix:nonFraction contextRef="c86" decimals="2" format="ixt:num-dot-decimal" name="bwv:RoyaltyRatePercentage" scale="-2" unitRef="pure">5</ix:nonFraction>%. The
St. Jude Amendment also provides for an increase to the contingent milestone payments, from $1.0 million to $1.9 million in the aggregate;
specifically, development milestones of $0.3&#160;million, regulatory milestones of $0.6&#160;million, and commercial milestones of $1.0&#160;million.</ix:nonNumeric></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 2. Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><i>The following discussion
and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the
related notes to those statements included elsewhere in this Quarterly Report on Form 10-Q and with the audited financial statements and
the related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC, on March
31, 2022. . In addition to historical financial information, the following discussion and analysis contains forward-looking statements
that involve risks, uncertainties, and assumptions. Some of the numbers included herein have been rounded for the convenience of presentation.
Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors. See &#8220;Cautionary
Note Regarding Forward-Looking Statements.&#8221;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a biotechnology company focused on the
research and development of transformational vaccines to prevent infectious diseases worldwide. Our versatile vaccine platform has unique
molecular properties that enables delivery of various antigens, which can be utilized to develop singular or multi-targeted vaccines.
Our lead influenza (flu) vaccine program uses proprietary technology to identify specific epitopes, or proteins of antigens, with cross-reactive
properties, that enable the potential development of a universal flu vaccine. We are focused on developing novel vaccines that induce
durable and long-term immunity. We believe that our pipeline and vaccine platform are synergistic for developing next generation preventive
vaccines to improve both health outcomes and quality of life globally.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;<img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Since our inception in October&#160;2018, we have
devoted substantially all of our resources to performing research and development, undertaking preclinical studies and enabling manufacturing
activities in support of our product development efforts, hiring personnel, acquiring and developing our technology and vaccine candidates,
organizing and staffing our company, performing business planning, establishing our intellectual property portfolio and raising capital
to support and expand such activities. We do not have any products approved for sale and have not generated any revenue from product sales.
To date, we have financed our operations primarily with proceeds from our sale of preferred securities to seed investors, the close of
our initial public offering, and the close of a private placement. We will continue to require additional capital to develop our vaccine
candidates and fund operations in the long-term. Accordingly, until such time as we can generate significant revenue from sales of our
vaccine candidates, if ever, we expect to finance our cash needs through public or private equity or debt financings, third-party (including
government) funding and marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements,
or any combination of these approaches.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have incurred net losses since inception and
expect to continue to incur net losses in the foreseeable future. Our net losses may fluctuate significantly from quarter-to-quarter and
year-to-year, depending in large part on the timing of our preclinical studies, clinical trials and manufacturing activities, and our
expenditures on other research and development activities. As of March 31, 2022, the Company had working capital of approximately $16.4&#160;million
and an accumulated deficit of approximately $7.9&#160;million. We will need to raise additional capital to sustain operations and meet
our long-term operating requirements beyond the one year period following the issuance of the accompanying financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">While we believe that we can raise additional
capital to fund our planned operations, until we generate revenue sufficient to support self-sustaining cash flows, if ever, we will need
to raise additional capital to fund our continued operations to execute our long-term business plan, including our product development
and commercialization activities related to our current and future products. There can be no assurance that additional capital will be
available to us on acceptable terms, or at all, or that we will ever generate revenue sufficient to provide for self-sustaining cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We do not expect to generate any revenue from
commercial product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our vaccine
candidates, which we expect will take a number of&#160;years. We expect our expenses will increase substantially in connection with our
ongoing activities, as we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance vaccine candidates through preclinical studies and clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require the manufacture of supplies for our preclinical studies and clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pursue regulatory approval of vaccine candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire additional personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operate as a public company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquire, discover, validate and develop additional vaccine candidates; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain, maintain, expand and protect our intellectual property portfolio.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We rely and will continue to rely on third parties
in the conduct of our preclinical studies and clinical trials and for manufacturing and supply of our vaccine candidates. We have no internal
manufacturing capabilities, and we will continue to rely on third parties, of which the main suppliers are single-source suppliers, for
our preclinical and clinical trial materials. Given our stage of development, we do not yet have a marketing or sales organization or
commercial infrastructure. Accordingly, if we obtain regulatory approval for any of our vaccine candidates, we also expect to incur significant
commercialization expenses related to product sales, marketing, manufacturing and distribution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Because of the numerous risks and uncertainties
associated with vaccine development, we are unable to predict the timing or amount of increased expenses or when or if we will be able
to achieve or maintain profitability. Even if we are able to generate revenue from the sale of our vaccines, we may not become profitable.
If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations
at planned levels and may be forced to reduce our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Certain
Significant Relationships</i></b></span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have entered into grant, license and collaboration
arrangements with various third parties as summarized below. For further details regarding these and other agreements, see Note&#160;5
to each of our audited financial statements included in the Form 10-K and unaudited financial statements included elsewhere in this Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Ology Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In July&#160;2019, we entered into a development
and manufacturing master services agreement with Ology Bioservices (which was later acquired by National Resilience, Inc.) (&#8220;Ology&#8221;),
as amended, which we refer to as the Ology Agreement, pursuant to which Ology is obligated to perform manufacturing process development
and clinical manufacture and supply of components.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the Ology Agreement, we will pay Ology agreed
upon fees for Ology&#8217;s performance of manufacturing services and regulatory support, and we will reimburse Ology for its out-of-pocket
costs associated with purchasing raw materials, plus a customary handling fee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On April 20, 2022, the Company and Ology entered
into a first amendment to the second Project Addendum (the &#8220;Ology Amendment&#8221;). The Ology Amendment provides for an increase
to the Company&#8217;s obligation of $0.3 million, specifically related to regulatory support on the project.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For additional details regarding our relationship
with Ology, see Notes&#160;5, 7 and 11 to our financial statements included elsewhere in this Report.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Cincinnati Children&#8217;s Hospital Medical
Center Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On June&#160;1, 2021, we entered into an exclusive,
worldwide license agreement with Children&#8217;s Hospital Medical Center, d/b/a Cincinnati Children&#8217;s Hospital Medical Center,
or CHMC, which we refer to as the CHMC Agreement, pursuant to which we obtained the right to develop and commercialize certain CHMC patents
and related technology directed at a virus-like particle (VLP) vaccine platform that utilizes nanoparticle delivery technology, which
may have potential broad application to develop vaccines for multiple infectious diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the CHMC Agreement, we agreed to pay CHMC
certain license fees, deferred license fees, development milestone fees, and running royalties beginning on the first net sale (among
others). For additional details regarding our relationship with CHMC, see Note&#160;5 to our financial statements included elsewhere in
this Report. The CHMC license includes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 21%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.&#160;Patent<br/>
Application No.</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.&#160;Patent No.</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Granted Claim Type</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.&#160;Expiration</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 15%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Foreign <br/>
Counterparts</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/797,396</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,486,421</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions of the vaccine/vaccine platform</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2031</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CN107043408B <br/>
EP2440582B1 <br/>
JP5894528B2</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13/924,906</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,096,644</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method of treatment</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/20/2030</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CN107043408B <br/>
EP2440582B1 <br/>
JP5894528B2</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13/803,057</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,562,077</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions of the vaccine platform</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/10/2034</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">none</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/489,095</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[3/15/2038]*</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending applications <br/>
in Canada, China, <br/>
EU and Japan</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63/149,742 <br/>
(filed 2/16/2021)</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[February&#160;2042]<sup>#</sup></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TBD</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63/162,369 <br/>
(filed 3/17/2021)</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[March&#160;2042]<sup>#</sup></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TBD</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Projected expiration if patent issues: 20&#160;years from earliest non-provisional application filing date.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-provisional application not yet filed. Expiration projected 21&#160;years from provisional application filing date. Dependent on timely conversion to non-provisional application and issuance of patent.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This is a pending application. Claim type will be determined after U.S.&#160;prosecution is complete. The claim type sought includes compositions of the vaccine and vaccine platform.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Oxford University Innovation Limited Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On July&#160;16, 2019, we entered into an exclusive,
worldwide license agreement with Oxford University Innovation Limited, which we refer to as the OUI Agreement, pursuant to which we obtained
the right to develop and commercialize certain licensed technology entitled &#8220;Immunogenic Composition.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the OUI Agreement, we agreed to fund three&#160;years&#8217;
worth of salaries for Dr.&#160;Craig Thompson in the University&#8217; Department of Zoology through a sponsored research agreement with
Oxford University, as well as royalties on all net sales of licensed products, along with certain development and milestone payments (among
others). For additional details regarding our relationship with OUI, see Note&#160;5 to our financial statements included elsewhere in
this Report. The OUI license includes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 21%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.&#160;Patent <br/>
Application No.</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.&#160;Patent No.</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Granted Claim Type</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.&#160;Expiration</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 15%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Foreign <br/>
Counterparts</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/326,749</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,123,422</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and method of treatment</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/25/2037</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending applications in Australia, Canada, China, EU and Japan</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/458,712</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[8/25/2037]*</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Projected expiration if patent issues: 20&#160;years from earliest non-provisional application filing date.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This is a pending application. Claim type will be determined after U.S.&#160;prosecution is complete. The claim type sought includes compositions of the compositions and method of treatment.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><i>St. Jude Children&#8217;s Research Hospital, Inc. Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On January&#160;27, 2020, we entered into an exclusive,
worldwide license agreement with St. Jude Children&#8217;s Research Hospital, Inc., as amended, which we refer to as the St. Jude Agreement,
pursuant to which we acquired the right to develop certain licensed products and produce vaccines for use in humans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the St. Jude Agreement, we agreed to pay
an initial license fee, an annual maintenance fee, milestone payments, patent reimbursement, and running royalties based on the net sales
of licensed products. On May 11, 2022, the Company and St. Jude entered into a first amendment to the St. Jude Agreement (the &#8220;St.
Jude Amendment&#8221;). The St. Jude Amendment provides for a revised development milestone timeline, a one-time license fee of $5,000,
and an increase to the royalty rate from 4% to 5%. The St. Jude Amendment also provides for an increase to the contingent milestone payments,
from $1.0 million to $1.9 million in the aggregate; specifically, development milestones of $0.3&#160;million, regulatory milestones of
$0.6&#160;million, and commercial milestones of $1.0&#160;million. For additional details regarding our relationship with St. Jude, see
Notes&#160;5, 7 and 11 to our financial statements included elsewhere in this Report. The St. Jude license includes:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 18%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.&#160;Patent Application No.</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 18%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.&#160;Patent No.</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 18%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Granted Claim Type</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 18%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.&#160;Expiration</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 24%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Foreign <br/>
Counterparts</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14/345,988</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,265,819</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and method of treatment</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/19/2032</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">none</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/602,414<sup>#</sup></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[3/12/2040]*</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending Applications in: Australia, Brazil, Canada, China, Europe, Hong&#160;Kong, Japan and Korea</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Projected expiration if patent issues: 20&#160;years from earliest non-provisional application filing date.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.&#160;National stage entry of WO 2020/183420 (PCT/IB2020/052250).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This is a pending application. Claim type will be determined after U.S.&#160;prosecution is complete. The claim type sought includes compositions of the compositions and method of treatment.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>COVID-19 Impacts</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are continuing to closely monitor the impact
of the global COVID-19 pandemic on our business and are taking proactive efforts designed to protect the health and safety of our employees
and to maintain business continuity. We believe that the measures we are implementing are appropriate, and we will continue to monitor
and seek to comply with guidance from governmental authorities and adjust our activities as appropriate. Based on guidance issued by federal,
state and local authorities, we transitioned to a remote work model for a vast majority of our employees in March&#160;2020. The COVID-19
pandemic has resulted in an impact to our development timelines, as the pandemic continues, we could continue to see an impact on our
ability to advance our programs, obtain supplies from our contract manufacturer or interact with regulators, ethics committees or other
important agencies due to limitations in regulatory authority, employee resources or otherwise. In any event, if the COVID-19 pandemic
continues and persists for an extended period of time, we could experience significant disruptions to our development timelines, which
would adversely affect our business, financial condition, results of operations and growth prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, while the potential economic impact
brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, the pandemic could result in significant
and prolonged disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect
our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business
and the potential value of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The extent of the impact of the COVID-19 pandemic
on our development and regulatory efforts, our ability to raise sufficient additional capital on acceptable terms, if at all, and the
future value of and market for our common stock will depend on future developments that are highly uncertain and cannot be predicted with
confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business
closure requirements in the U.S.&#160;and in other countries, and the effectiveness of actions taken globally to contain and treat COVID-19.
For additional information about risks and uncertainties related to the COVID-19 pandemic that may impact our business, financial condition
and results of operations, see the section titled &#8220;Risk Factors.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Components of Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Research and Development Expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Substantially all of our research and development
expenses consist of expenses incurred in connection with the development of our product candidates. These expenses include fees paid to
third parties to conduct certain research and development activities on our behalf, consulting costs, costs for laboratory supplies, product
acquisition and license costs, certain payroll and personnel-related expenses, including salaries and bonuses, employee benefit costs
and stock-based compensation expenses for our research and product development employees and allocated overheads, including information
technology costs and utilities. We expense both internal and external research and development expenses as they are incurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We do not allocate our costs by product candidate,
as a significant amount of research and development expenses include internal costs, such as payroll and other personnel expenses, laboratory
supplies and allocated overhead, and external costs, such as fees paid to third parties to conduct research and development activities
on our behalf, are not tracked by product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We expect our research and development expenses
to increase substantially for at least the next few&#160;years, as we seek to initiate additional clinical trials for our product candidates,
complete our clinical programs, pursue regulatory approval of our product candidates and prepare for the possible commercialization of
such product candidates. Predicting the timing or cost to complete our clinical programs or validation of our commercial manufacturing
and supply processes is difficult and delays may occur because of many factors, including factors outside of our control. For example,
if the FDA or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, we
could be required to expend significant additional financial resources and time on the completion of clinical development. Furthermore,
we are unable to predict when or if our product candidates will receive regulatory approval with any certainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>General and Administrative Expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">General and administrative expenses consist principally
of payroll and personnel expenses, including salaries and bonuses, benefits and stock-based compensation expenses, professional fees for
legal, consulting, accounting and tax services, including information technology costs, and other general operating expenses not otherwise
classified as research and development expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We anticipate that our general and administrative
expenses will increase as a result of increased personnel costs, expanded infrastructure and higher consulting, legal and accounting
services costs associated with complying with the applicable stock exchange and the SEC requirements, investor relations costs and director
and officer insurance premiums associated with being a public company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Comparison of the&#160;Three Months Ended March&#160;31, 2022
and 2021</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table summarizes our statements
of operations for the periods indicated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">$ Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating costs and expenses</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 20pt">General and administrative</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,615,569</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">237,544</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,378,025</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">580.1</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">455,092</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">88,237</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">366,855</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">415.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 30pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,070,661</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">325,781</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,744,880</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">535.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Loss from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,070,661</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(325,781</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,744,880</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">535.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,070,661</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(325,781</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,744,880</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">535.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  </table><div>


</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>General and Administrative Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the three months ended March&#160;31,
2022, general and administrative expenses increased by $1.4&#160;million compared to the same period in 2021. The increase was
mainly due to an increase in employee and director compensation, including annual bonus compensation, of approximately
$0.5&#160;million, an increase in audit, accounting, and legal services of $0.3&#160;million, and increases in other business
activities related to now being a public company of $0.2&#160;million. In addition, during the three months ended March 31, 2022,
the Company incurred $0.3 million for a non-recurring termination penalty to the Company&#8217;s former underwriter, to early
terminate the agreement with that underwriter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and Development Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the three months ended March&#160;31, 2022,
research and development expenses increased by approximately $0.4&#160;million compared to the same period in 2021. The increase was primarily
attributable to an increase in preclinical development activities of approximately $0.3&#160;million mainly related to BWV-201, and an
increase in research and development personnel costs of approximately $0.1&#160;million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><b><i>Liquidity and Capital Resources</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Since inception, we have devoted substantially
all of our efforts to research and development, undertaking preclinical studies and enabling manufacturing activities in support of our
product development efforts, hiring personnel, acquiring and developing our technology and vaccine candidates, organizing and staffing
our company, performing business planning, establishing our intellectual property portfolio and raising capital to support and expand
such activities. We do not have any products approved for sale and have not generated any revenue from product sales. We have incurred
net losses in each year since inception and expect to continue to incur net losses in the foreseeable future. Our net loss was $2.1&#160;million
for the three months ended March&#160;31, 2022. As of March&#160;31, 2022, we had an accumulated deficit of $8.0&#160;million. We also
generated negative operating cash flows of $0.9&#160;million for the three months ended March&#160;31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On February&#160;23, 2022, we completed our IPO
in which we received approximately $17.1&#160;million in net proceeds, after deducting the underwriting discount, and offering expenses.
In addition, on April 19, 2022, we completed a private placement in which we received approximately $7.0 million in net proceeds, after
deducting placement agent fees and other initial offering expenses.&#160;The Company believes the existing cash at March&#160;31, 2022,
together with the net proceeds received upon the close of the private placement, will be sufficient to continue operations, satisfy its
obligations and fund the future expenditures that will be required to conduct the clinical and regulatory work to develop its product
candidates for&#160;at least&#160;one year&#160;after the date that the accompanying financial statements were issued.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">However, we will require significant amounts of
additional capital to continue to fund our operations in the long term and complete our research and development activities. We will continue
seeking additional financing sources to meet our working capital requirements, make continued investment in research and development and
make capital expenditures needed for us to maintain and expand our business. We may not be able to obtain additional financing on terms
favorable to us, if at all. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it,
or if we expend capital on projects that are not successful, our ability to continue to support our business growth and to respond to
business challenges could be significantly limited, or we may even have to cease our operations. If we raise additional funds through
further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity
securities we issue could have rights, preferences and privileges superior to those of holders of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Future Funding Requirements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our primary uses of cash are to fund our operations,
which consist primarily of research and development expenditures related to our programs and general and administrative expenditures.
We anticipate that we will continue to incur significant expenses for the foreseeable future as we continue to advance our vaccine candidates,
expand our corporate infrastructure, including the costs associated with being a public company and further our research and development
initiatives for our vaccine candidates. We are subject to all of the risks typically related to the development of new drug candidates,
and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our
business. We anticipate that we will need substantial additional funding in connection with our continuing operations in order to execute
our long-term business plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We estimate that, based on our existing cash as
of March 31, 2022, together with the net proceeds received from the private placement, we have cash on hand sufficient to fund our operations
for at least the next 12 months. We will need to raise additional capital prior to commencing additional pivotal trials for certain of
our vaccine candidates. Until we can generate a sufficient amount of revenue from the commercialization of our vaccine candidates or from
collaboration agreements with third parties, if ever, we expect to finance our future cash needs through public or private equity or debt
financings, third-party (including government) funding and marketing and distribution arrangements, as well as other collaborations, strategic
alliances and licensing arrangements, or any combination of these approaches. The future sale of equity or convertible debt securities
may result in dilution to our stockholders and, in the case of preferred equity securities or convertible debt, those securities could
provide for rights, preferences or privileges senior to those of our common stock. Debt financings may subject us to covenant limitations
or restrictions on our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.
Our ability to raise additional funds may be adversely impacted by deteriorating global economic conditions and the recent disruptions
to and volatility in the credit and financial markets in the United&#160;States and worldwide resulting from the ongoing COVID-19 pandemic.
There can be no assurance that we will be successful in acquiring additional funding at levels sufficient to fund our operations or on
terms favorable or acceptable to us. If we are unable to obtain adequate financing when needed or on terms favorable or acceptable to
us, we may be forced to delay, reduce the scope of or eliminate one or more of our research and development programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our future capital requirements will depend on
many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing, scope, progress, results and costs of research and development, testing, screening, manufacturing, preclinical and non-clinical studies and clinical trials, including any impacts related to the COVID-19 pandemic;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA and comparable foreign regulatory authorities, including the potential for such authorities to require that we perform field efficacy studies for our vaccine candidates, require more studies than those that we currently expect or change their requirements regarding the data required to support a marketing application;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of building a sales force in anticipation of any product commercialization;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of future commercialization activities, including product manufacturing, marketing, sales, royalties and distribution, for any of our vaccine candidates for which we receive marketing approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any product liability or other lawsuits related to our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the expenses needed to attract, hire and retain skilled personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the revenue, if any, received from commercial sales, or sales to foreign governments, of our vaccine candidates for which we may receive marketing approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs to establish, maintain, expand, enforce and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending and enforcing our patents or other intellectual property rights;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses needed to attract, hire and retain skilled personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of operating as a public company; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of the COVID-19 pandemic, which may exacerbate the magnitude of the factors discussed above.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A change in the outcome of any of these or other
variables could significantly change the costs and timing associated with the development of our vaccine candidates. Furthermore, our
operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated
with such change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Cash Flows</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table summarizes our cash flows
for the periods indicated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Net cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(886,091</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(256,548</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,197</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,572,063</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Net increase (decrease) in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,680,775</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(256,548</td><td style="text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cash Flows from Operating Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Net cash used in operating activities for the
three months ended&#160;March 31, 2022 was $0.9&#160;million, which primarily resulted from a net loss of $2.1&#160;million, and was partially
offset by a net change in our operating assets and liabilities of $1.2&#160;million.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Net cash used in operating activities for the
three months ended&#160;March 31, 2021 was $0.3&#160;million, which primarily resulted from a net loss of $0.3 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cash Flows from Investing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Net cash used in investing activities for the&#160;three
months ended&#160;March 31, 2022 was $5,000, which resulted from purchases of property and equipment. There were no such purchases, or
other investing activities during the three months ended March 31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cash Flows from Financing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Net cash provided by financing activities for
the three months ended&#160;March 31, 2022 was $17.6 million, and resulted primarily from the close of our IPO. No financing activities
took place during the three months ended March 31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Legal Contingencies</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">From time to time, we may become involved in legal
proceedings arising from the ordinary course of business. We record a liability for such matters when it is probable that future losses
will be incurred and that such losses can be reasonably estimated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Off-Balance Sheet Arrangements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During the periods presented we did not have,
nor do we currently have, any off-balance sheet arrangements as defined in the rules and regulations of the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recent Accounting Pronouncements Not Yet Adopted</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">See Note&#160;3 to our financial statements included
elsewhere in this Report for more information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Accounting Policies and Estimates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Our financial statements have been prepared in accordance
with U.S.&#160;generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;). The preparation of these financial statements
requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of
contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including
those related to accrued research and development expenses, fair value of common stock, and stock-based compensation. We base our estimates
on historical experience, known trends and events and various other factors that are believed to be reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">While our significant accounting policies are
described in more detail in Note&#160;3 to our financial statements included elsewhere in this Report, we believe the following accounting
policies and estimates to be most critical to the judgments and estimates used in the preparation of our financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Accrued Research and Development Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have entered into various agreements with contract
manufacturing organizations, or CMOs, and may enter into contracts with clinical research organizations, or CROs, in the future. As part
of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses as of
each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel and third
parties to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost
incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our accrued
research and development expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically
confirm the accuracy of our estimates with the service providers and make adjustments, if necessary. The significant estimates in our
accrued research and development expenses include the costs incurred for services performed by our vendors in connection with research
and development activities for which we have not yet been invoiced.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We accrue for costs related to research and development activities
based on our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors, including CMOs, that
conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract
to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level
of services provided and result in a prepayment of the research and development expense. Advance payments for goods and services that
will be used in future research and development activities are expensed when the activity has been performed or when the goods have been
received. We make significant judgments and estimates in determining accrued research and development liabilities as of each reporting
period based on the estimated time period over which services will be performed and the level of effort to be expended. If the actual
timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid expense accordingly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Although we do not expect our estimates to be
materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the
actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular
period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span><b><i>Warrants</i></b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15.5pt 0pt 67.5pt; text-align: justify; text-indent: -63pt"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>The
Company determines the accounting classification of warrants that are issued, as either liability or equity, by first assessing whether
the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics
of both Liabilities and Equity, (&#8220;ASC 480-10&#8221;), and then in accordance with ASC 815-40, Derivatives and Hedging - Contracts
in Entity's Own Equity (&#8220;ASC 815-40&#8221;). Under ASC 480-10, warrants are considered liability-classified if the warrants are
mandatorily redeemable, obligate the issuer to settle the warrants or the underlying shares by paying cash or other assets, or must or
may require settlement by issuing variable number of shares. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15.5pt 0pt 4.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>If
the warrants do not meet liability classification under ASC 480-10, the Company assesses the requirements under ASC 815-40, which states
that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective
of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability
classification under ASC 815-40, in order to conclude equity classification, the Company assesses whether the warrants are indexed to
its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP. After all relevant assessments
are made, the Company concludes whether the warrants are classified as liability or equity. Liability-classified warrants are required
to be accounted for at fair value both on the date of issuance and on subsequent accounting period ending dates, with all changes in fair
value after the issuance date recorded as a component of other income (expense), net in the statements of operations. Equity-classified
warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Stock-Based Compensation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company expensed stock-based compensation
to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. Stock-based
awards to employees with graded-vesting schedules are recognized, using the accelerated attribution method, on a straight-line basis over
the requisite service period for each separately vesting portion of the award.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company estimates the fair value of stock
option grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards
represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected Term</i>&#160;&#8212;&#160;The expected term of options represents the period that the Company&#8217;s stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt"><i>Expected Volatility&#160;</i>&#8212;&#160;Volatility is a measure of the amount by which the Company&#8217;s share price has historically fluctuated or is expected to fluctuate (i.e., expected volatility) during a period. &#160;<span>Due to the lack of an adequate history of a public market for the trading of the Company&#8217;s common stock and a lack of adequate company-specific historical and implied volatility data, </span>the Company computes stock price volatility over expected terms based on comparable companies&#8217; historical common stock trading prices.&#160;&#160;For these analyses, the Company has selected companies with comparable characteristics, including enterprise value, risk profiles, and position within the industry, and with historical share price information sufficient to meet the expected term of the stock-based awards.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common Stock Fair Value</i>&#160;&#8212;&#160;<span>Due to the absence of an active market for the Company&#8217;s common stock prior to the IPO, t</span>he fair value of the common stock underlying the Company&#8217;s stock options was estimated at each grant date and was determined with the assistance of an independent third-party valuation expert. The assumptions underlying these valuations represented management&#8217;s best estimates, which involved inherent uncertainties and the application of significant levels of management judgment.&#160;&#160;<span>After the completion of the IPO, the fair value of each share of common stock is based on the closing price of the Company&#8217;s common stock as reported by the Nasdaq Capital Market.</span></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-Free Interest Rate</i>&#160;&#8212;&#160;The Company bases the risk-free interest rate on the implied yield available on U.S.&#160;Treasury securities with a remaining term commensurate with the estimated expected term.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected Dividend</i>&#160;&#8212;&#160;The Company has never declared or paid any cash dividends on its shares of common stock and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company recognizes forfeitures of equity awards
as they occur.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Fair value of common stock</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In order to determine the fair value of shares
of common stock of the Company when issuing stock options prior to the IPO, and computing their estimated stock-based compensation expense,
its board of directors considered with input from third party valuations, among other things, contemporaneous valuations of the Company&#8217;s
common stock. Given the absence of a public trading market of the Company&#8217;s capital stock prior to the IPO, its board of directors
has exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair
value of our common and preferred stock, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the prices, rights, preferences and privileges of our preferred stock relative to our common stock;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our business, financial condition and results of operations, including related industry trends affecting our operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the likelihood of achieving a liquidity event, such as an initial public offering, or IPO, or sale of our company, given prevailing market conditions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the lack of marketability of our common stock;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the market performance of comparable publicly traded companies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.&#160;and global economic and capital market conditions and outlook; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock valuation methodology.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In estimating the fair market value of common
stock of the Company, its board of directors first determined the equity value of its business using accepted valuation methods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company engaged a third party valuation specialist
to conduct a valuation, which used its recent preferred stock financing as a starting point and determined the equity value of the company
based on the Backsolve method using an Option Pricing Method (OPM) to calculate the implied value based on a market approach. The Company&#8217;s
equity value was allocated using OPM to estimate the fair market value of the Company&#8217;s classes of equity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>After the
completion of the IPO, the fair value of each share of common stock is based on the closing price of the Company&#8217;s common stock
as reported by the Nasdaq Capital Market.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Quantitative and Qualitative Disclosures About Market Risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a smaller reporting company as defined
by Rule&#160;12b-2 of the Exchange&#160;Act and are not required to provide the information otherwise required under this item.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>JOBS Act</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Section&#160;107 of the JOBS Act also provides
that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B)&#160;of
the Securities Act for complying with new or revised accounting standards. In other words, an &#8220;emerging growth company&#8221; can
delay the adoption of new or revised accounting standards until those standards would otherwise apply to private companies. We have elected
to avail ourselves of this extended transition period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For as long as we remain an &#8220;emerging growth
company&#8221; under the recently enacted JOBS Act, we will, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be exempt from the provisions of Section&#160;404(b)&#160;of the Sarbanes-Oxley Act, which requires that our independent registered public accounting firm provide an attestation report on the effectiveness of our internal control over financial reporting;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be permitted to omit the detailed compensation discussion and analysis from proxy statements and reports filed under the Exchange&#160;Act and instead provide a reduced level of disclosure concerning executive compensation; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be exempt from any rules that may be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation or a supplement to the auditor&#8217;s report on the financial statements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Although we are still evaluating the JOBS Act,
we currently intend to take advantage of some or all of the reduced regulatory and reporting requirements that will be available to us
so long as we qualify as an &#8220;emerging growth company,&#8221; including the extension of time to comply with new or revised financial
accounting standards available under Section&#160;102(b)&#160;of the JOBS Act. Among other things, this means that our independent registered
public accounting firm will not be required to provide an attestation report on the effectiveness of our internal control over financial
reporting so long as we qualify as an emerging growth company, which may increase the risk that weaknesses or deficiencies in our internal
control over financial reporting go undetected. Likewise, so long as we qualify as an emerging growth company, we may elect not to provide
you with certain information, including certain financial information and certain information regarding compensation of our executive
officers, that we would otherwise have been required to provide in filings we make with the SEC, which may make it more difficult for
investors and securities analysts to evaluate our company. As a result, investor confidence in our company and the market price of our
common stock may be materially and adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Related Party Transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock Options</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>On May 4,
2022, the Company&#8217;s compensation committee approved stock option grants under the Company&#8217;s 2022 Equity Incentive Plan to
certain of the Company&#8217;s executive officers, board members, employees and certain consultants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>One-Time Bonuses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><b><i>Joe Hernandez, Chairman
and CEO</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On May 6, 2022, the Company&#8217;s
compensation committee approved a one-time&#160;bonus&#160;award of $140,000 to Mr. Hernandez in recognition of Mr. Hernandez&#8217;s
efforts in connection with the Company&#8217;s IPO.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><b><i>Erin Henderson, Chief
Business Officer and Secretary</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On April 4, 2022, the Company&#8217;s
compensation committee approved a one-time&#160;bonus&#160;award of $100,000 to Ms. Henderson in recognition of Ms. Henderson&#8217;s
efforts in connection with the Company&#8217;s IPO.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 3. Quantitative and Qualitative Disclosures About Market Risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a smaller reporting company, we are not required
to provide the information required by this item.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 4. Controls and Procedures. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Evaluation of Disclosure Controls and Procedures</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Sarbanes-Oxley Act requires, among other things,
that we maintain effective disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) that are designed to ensure
that information required to be disclosed by us in reports we file or submit under the Securities Exchange Act of 1934, as amended, is
recorded, processed, summarized and reported within the appropriate time periods, and that such information is accumulated and communicated
to the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely discussions regarding required disclosure.
We, under the supervision of and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer,
have evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2022. Based on that evaluation, our Chief Executive
Officer and Chief Financial Officer concluded that the design and operation of our disclosure controls and procedures were not effective
because of material weaknesses in our internal control over financial reporting, which are further described below in <i>Material Weaknesses
in Internal Control Over Financial Reporting</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Material Weaknesses in Internal Control Over Financial Reporting</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A material weakness is a deficiency, or a combination
of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement
of our annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses identified
as of March 31, 2022 are as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">We failed to employ a sufficient number of staff to maintain optimal segregation of duties and to provide optimal levels of oversight in order to process financial information in a timely manner,&#160;analyze and account for complex, non-routine transactions,&#160;and prepare financial statements.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We do not yet have adequate internal controls in place for the timely identification, approval or reporting of related party transactions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>The above
material weaknesses did not result in a material misstatement of our previously issued financial statements, however, it could result
in a misstatement of our account balances or disclosures that would result in a material misstatement of our annual or interim financial
statements that would not be prevented or detected. </span>We have developed a remediation plan for these material weaknesses which is
described below in <i>Remediation of Material Weaknesses</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Remediation of Material Weaknesses </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are committed to maintaining a strong internal
control environment and implementing measures designed to help ensure that the material weaknesses are remediated as soon as possible.
We believe we have made progress towards remediation and continue to implement our remediation plan for the material weaknesses, which
includes steps to increase dedicated qualified personnel including financial consultants, improve reporting processes, and design and
implement new controls. Further, we have designed an approval policy and certain controls surrounding the identification, approval and
reporting of related party transactions, that we expect to implement during 2022. We will consider the material weaknesses remediated
after the applicable controls operate for a sufficient period of time, and management has concluded, through testing, that the controls
are operating effectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The process of designing and implementing an effective
accounting and financial reporting system is a continuous effort that requires us to anticipate and react to changes in our business and
the economic and regulatory environments and to expend significant resources to maintain an accounting and financial reporting system
that is adequate to satisfy our reporting obligations. As we continue to evaluate and take actions to improve our internal control over
financial reporting, we may determine to take additional actions to address control deficiencies or determine to modify certain of the
remediation measures described above. We cannot assure you that the measures we have taken to date, or any measures we may take in the
future, will be sufficient to remediate the material weakness we have identified or avoid potential future material weaknesses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><i>Inherent Limitation
on the Effectiveness of Internal Control Processes</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b>&#160;</b>Our management, including our Chief
Executive Officer and Chief Financial Officer, does not expect that our disclosure controls or our internal control over financial reporting
will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute,
assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation
of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent
limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error
or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by
management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood
of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future
conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures
may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur
and not be detected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><i>Changes in Internal Control over Financial
Reporting</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; ">During the fiscal quarter
ended March 31, 2022, there were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f)
and 15d-15(f) of the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control
over financial reporting.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; "></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; ">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II &#8211; OTHER INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1. Legal Proceedings </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 51.75pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are not currently subject to any material legal
proceedings, nor, to our knowledge, is any material legal proceeding threatened against us or any of our officers or directors in their
corporate capacity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1A. Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">For the complete list of risks
relating to our operations, see the section titled &#8220;Risk Factors&#8221; contained in our Registration Statement on Form S-1, filed
with the SEC on May 3, 2022. Any of these factors could result in a significant or material adverse effect on our results of operations
or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business
or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 2. Unregistered Sales of Equity Securities
and Use of Proceeds</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; ">There are no transactions
that have not been previously included in a Current Report on Form 8-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 3. Default Upon Senior Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 4. Mine Safety Disclosures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 5. Other Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 6. Exhibits, Financial Statement Schedules.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following documents are
filed as exhibits to this Quarterly Report on Form 10-Q.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXHIBIT INDEX </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit <br/>
Number</b></span></td>
    <td style="padding-bottom: 1.5pt; vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description of Document</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.1</td>
    <td>&#160;</td>
    <td><a href="f10q0322ex10-1_bluewater.htm">Amendment <span style="font-family: Times New Roman, Times, Serif">No. 1 to Project Addendum
2 to Master Services Agreement, dated as of April 20, 2022, by and between the Registrant and Ology Bioservices, Inc.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>10.2</td>
    <td>&#160;</td>
    <td><a href="f10q0322ex10-2_bluewater.htm">Amendment #1 to Exclusive License Agreement, dated as of May 11, 2022,
by and between the Registrant and St. Jude Children&#8217;s Research Hospital, Inc.</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td>&#160;</td>
    <td><a href="f10q0322ex31-1_bluewater.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td>&#160;</td>
    <td><a href="f10q0322ex31-2_bluewater.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*</span></td>
    <td>&#160;</td>
    <td><a href="f10q0322ex32-1_bluewater.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2*</span></td>
    <td>&#160;</td>
    <td><a href="f10q0322ex32-2_bluewater.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td>
    <td>&#160;</td>
    <td><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Inline XBRL Instance Document.</p></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
    <td>&#160;</td>
    <td><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Inline XBRL Taxonomy Extension Schema Document.</p></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
    <td>&#160;</td>
    <td><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
    <td>&#160;</td>
    <td><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Inline XBRL Taxonomy Extension Definition Linkbase Document.</p></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
    <td>&#160;</td>
    <td><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Inline XBRL Taxonomy Extension Label Linkbase Document.</p></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
    <td>&#160;</td>
    <td><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</p></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>104</td>
    <td>&#160;</td>
    <td>Cover Page Interactive Data File (formatted as Inline XBRL and contained
in Exhibit 101).</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished
herewith..</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Blue Water Vaccines Inc.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 13, 2022 &#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Joseph Hernandez</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph Hernandez</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board and Chief Executive Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal executive officer)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 13, 2022</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jon Garfield</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jon Garfield </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal financial and accounting officer)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 40; Options: Last --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


















































































</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c3" id="hidden-fact-0" name="us-gaap:PrepaidExpenseNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-1" name="us-gaap:DepositsAssetsNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-2" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-3" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-4" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-5" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-6" name="bwv:PreferredStockValue1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" decimals="0" id="hidden-fact-7" name="us-gaap:PreferredStockLiquidationPreferenceValue" unitRef="usd">15400000</ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-8" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-9" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-10" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-11" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-12" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-13" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-14" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-15" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-16" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-17" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-18" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-19" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-20" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-21" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-22" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-23" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-24" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-25" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-26" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-27" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-28" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-29" name="us-gaap:PaymentsOfDebtIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-30" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-31" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-32" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-33" name="us-gaap:DeferredOfferingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-34" name="us-gaap:DebtConversionConvertedInstrumentAmount1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-35" name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-36" name="bwv:SeriesSeedPreferredStock" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-37" name="bwv:WarrantsToPurchaseSharesOfCommonStock" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c34" id="hidden-fact-38" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P3Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c35" id="hidden-fact-39" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P7Y</ix:nonNumeric>
<ix:nonFraction contextRef="c2" id="hidden-fact-40" name="us-gaap:PrepaidInsurance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-41" name="us-gaap:AccountsPayableAndAccruedLiabilitiesFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-42" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c56" id="hidden-fact-43" name="bwv:PurchaseObligationDueInThirdYearperiod">P3Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001782107</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="bwv-20220331.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-02-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-02-01</xbrli:startDate>
    <xbrli:endDate>2022-02-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-04-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bwv:OlogyBioservicesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bwv:OlogyBioservicesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bwv:OlogyBioservicesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-01</xbrli:startDate>
    <xbrli:endDate>2021-05-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bwv:OlogyBioservicesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bwv:OlogyBioservicesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bwv:OlogyBioservicesIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-04-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwr9eJsDhBsVZfVtlP9aR4miPG9aL6mOS58KqaHVgLidMi2z82g/tcsacBQzQtHbKODQ/VLlSZXvcdklLkgAYbkbMy97AZwaH6tfqzDj871fqnq7Wqc/uzYF3hiM1Xm0+bx8P64VLx0p+9x2jakJvUXFyZahdnN8LgH/EKlrl6Cv2yT3qYwjnQizoBL7VNI8S//Cc+qkLLc1yrKkGSD9yzlNpM/owYy7M=] CSR-->
  <xbrli:period>
    <xbrli:instant>2022-02-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-02-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bwv:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-02-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-02-01</xbrli:startDate>
    <xbrli:endDate>2022-02-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-02-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bwv:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bwv:OriginalIssuePriceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bwv:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bwv:TwoThousandNinteenEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:OUIAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:OUIAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:OUIAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bwv:PrephaseIIIYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:OUIAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bwv:PhaseIIIYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:OxfordResearchMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-12-01</xbrli:startDate>
    <xbrli:endDate>2019-12-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:OxfordResearchMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:OxfordResearchMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:OxfordResearchMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:OxfordResearchMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:StJudeAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:StJudeResearchAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-01</xbrli:startDate>
    <xbrli:endDate>2021-05-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:StJudeAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bwv:PhaseIMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-01</xbrli:startDate>
    <xbrli:endDate>2021-05-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:StJudeAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bwv:PhaseIIMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-01</xbrli:startDate>
    <xbrli:endDate>2021-05-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:StJudeAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:StJudeResearchAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:CHMCAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:CHMCAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:OlogyAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:CHMCAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:CHMCAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:UnderwriterTerminationAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-04-20</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:UnderwriterTerminationAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-02-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-04-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bwv:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-04-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bwv:PreferredInvestmentOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-04-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bwv:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-04-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bwv:PreferredInvestmentOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-04-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bwv:WainwrightWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-04-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bwv:WainwrightWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-04-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bwv:OlogyAmendmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-04-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-01</xbrli:startDate>
    <xbrli:endDate>2022-05-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bwv:StJudeAmendmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782107</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="eur">
  <xbrli:measure>iso4217:EUR</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>f10q0322ex10-1_bluewater.htm
<DESCRIPTION>AMENDMENT NO. 1 TO PROJECT ADDENDUM 2 TO MASTER SERVICES AGREEMENT, DATED AS OF APRIL 20, 2022, BY AND BETWEEN THE REGISTRANT AND OLOGY BIOSERVICES, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0; margin-left: 0"><B>Exhibit 10.1</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex10-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>AMENDMENT 1 TO PROJECT ADDENDUM 2 TO MASTER SERVICES
AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">This Amendment 1 (the &ldquo;Amendment&rdquo;) is effectively
dated as of January 11, 2022 (the &ldquo;Effective Date&rdquo;) by and between Blue Water Vaccines, Inc., a Delaware corporation having
a principal place of business at 15 East Putnam Avenue, Suite 363, Greenwich, CT 06830 (&ldquo;Blue Water&rdquo; or &ldquo;Client&rdquo;),
and Ology Bioservices, Inc., a Delaware corporation having a principal place of business at 13200 NW Nano Court, Alachua, Florida 32615
(&ldquo;Ology Bio&rdquo;). Blue Water and Ology Bio are sometimes referred to herein individually as a &ldquo;Party&rdquo; and collectively
as the &ldquo;Parties.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">WHEREAS, Blue Water and Ology Bio entered into a Master
Services Agreement effectively dated as of July 19, 2019 (the &ldquo;MSA&rdquo;) whereby Ology Bio agreed to provide, from time to time,
services and deliverables associated therewith to Client pursuant to the terms and conditions set forth in the MSA and any Project Addendum;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">WHEREAS, Blue Water and Ology Bio entered into Project Addendum
II dated May 21, 2021 (&ldquo;PA II&rdquo;); and WHEREAS, the Parties desire to amend PA II in the manner described herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">NOW, THEREFORE, in consideration of the foregoing and the mutual
promises, covenants and agreements set forth below, and for other good and valuable consideration, the receipt and sufficiency of which
the parties hereby acknowledge, the Parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>Amendment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">The Parties agree to Amend PA II by adding Task 9, as set forth
below, to provide additional regulatory support to Blue Water .</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>Task 9: Regulatory Support</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Ology Bio Regulatory will provide CMC support to Client,
including preparing all CMC documents for submission in a regulatory application to the US FDA (i.e., Module 2 and Module 3 Quality Information).
The CMC information will be prepared for Client according to FDA and ICH guidance using templates that provide consistent granularity
for products in clinical development. Regulatory will provide CMC sections in CTD format in Microsoft Word documents along with a letter
of authorization (cross reference) to the ADM Alachua Florida Type 5 Site Master File to support the facility section (3.2.A). CMC writing
to support pre-submission briefing packages is included. The CMC information will support a Master File or IND submission as desired by
Client. If the application is for non-US dossiers, a facility section will be provided in the CMC to support regulatory filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Ology Bio Tier 2 Support shall include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 25pt"></TD><TD STYLE="width: 18pt">&#9679;</TD><TD STYLE="text-align: left; padding-right: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Review of key CMC documents to determine if
supportive of product intended use, including specifications/batch analysis, DS and DP release and stability protocols/reports. For clarification,
this does not include manufacturing operations documentation (i.e. batch production records, sampling plans, raw material specifications,
media prep documents).</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left; padding-right: 11.5pt">&nbsp;</TD></TR>
                                       </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 24.95pt"></TD><TD STYLE="text-align: left; width: 18.05pt">&#9679;</TD><TD STYLE="text-align: left; padding-right: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Review of applicable change controls related to the facility and program
for regulatory impact.</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
                                       </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 25pt"></TD><TD STYLE="text-align: left; width: 18pt">&#9679;</TD><TD STYLE="text-align: left; padding-right: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Module 2 and Module 3 Quality CMC technical
writing resulting in WORD CTD deliverables, supporting two complete rounds of review per document.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">CMC consultation and guidance shall be limited to products
manufactured in ADM Facility or by ADM subcontractors specific to this project.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-left: 1pt; font-size: 10pt">Regulatory Support</TD>
    <TD STYLE="text-align: right; width: 50%; padding-top: 0.55pt; padding-left: 1pt; font-size: 10pt">November 17,2021</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>Section 3-Project Schedule:</B> Section 3 of PAII shall
be amended to include Task 9, listed below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #006666">
    <TD STYLE="border-bottom: Black 1.5pt solid; background-color: White; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Task</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; background-color: White; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; background-color: White; width: 62%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Description</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; background-color: White; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; background-color: White; width: 15%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Start</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; background-color: White; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; background-color: White; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>End</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">9</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Regulatory Support</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">November 2021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">TBD</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>Section 4, Project Budget:</B> Section 4 of PA II
shall be amended to include the budget for Task 9, by adding the following language:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">The budget for Task 9 is <B>$300,000.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>Section 5, Payment Schedule:</B> Section 5 of PA II shall
be amended to include the Payment Schedule for Task 9 by adding the following language:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Milestone</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Description</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 9%; text-align: center">23</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 76%; text-align: left">Initiation of Task 9: Regulatory Support (50%)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">150,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">24</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Completion of Task 9: Regulatory Support (50%)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>Payment Terms</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Ology Bio will invoice Client in the amounts and as provided
in the Payment Schedule above. Payment is due in accordance with Section 6.4 of the MSA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>Section 9, General Assumptions: Section 9 of PA II shall
be amended to include the following language:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">13. The schedules, estimates and costs contained within
this Project Addendum are subject to the General Assumptions set forth in PA II.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>PA II Terms:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">This Amendment 1 is intended to supplement the scope of work
set forth in PA II. Except as expressly provided in this Amendment, all of the terms, conditions and general assumptions set forth in
PA II remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0.55pt; padding-left: 1pt; width: 34%">Ology Bioservices, Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0.55pt; padding-left: 1pt; width: 33%">CONFIDENTIAL</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0.55pt; padding-left: 1pt; width: 33%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 1pt; font-size: 10pt; width: 50%">Regulatory Support</TD>
    <TD STYLE="text-align: right; padding-top: 0.55pt; padding-left: 1pt; font-size: 10pt; width: 50%">November 17,2021</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">IN WITNESS WHEREOF, the Parties have caused this Amendment
to be executed by their duly authorized representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ology Bioservices, Inc.</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Blue Water Vaccines, Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Todd Ranheim</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Joe Hernandez</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Todd Ranheim</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joe Hernandez</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Head, Analytical Science &amp; Technology</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/26/2022</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/19/2022</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; padding-top: 0.55pt; font-size: 10pt; width: 34%">Ology Bioservices, Inc.</TD>
    <TD STYLE="text-align: center; padding-top: 0.55pt; padding-left: 1pt; font-size: 10pt; width: 33%">CONFIDENTIAL</TD>
    <TD STYLE="text-align: right; padding-top: 0.55pt; padding-left: 1pt; font-size: 10pt; width: 33%">3</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>f10q0322ex10-2_bluewater.htm
<DESCRIPTION>AMENDMENT #1 TO EXCLUSIVE LICENSE AGREEMENT, DATED AS OF MAY 11, 2022, BY AND BETWEEN THE REGISTRANT AND ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: right; text-indent: -0.5in"><B>Exhibit 10.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"><B>EXCLUSIVE LICENSE
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"><B>AMENDMENT #1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Amendment (&ldquo;Amendment&rdquo;), effective
as of May 11, 2022 (Effective Date), amends that certain Exclusive License Agreement of January 27, 2020 by and between <B>Blue Water
Vaccines, Inc. </B>(Company) and <B>St. Jude Children&rsquo;s Research Hospital, Inc. </B>(St. Jude) (the &ldquo;License Agreement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS the parties wish to revise the term of
the License Agreement to include the inventions disclosed in provisional patent application number 63/329,083, filed April 8, 2022, titled
&ldquo;Vaccine Compositions and Methods for Reducing Transmission of Pathogens&rdquo; (St. Jude File No. SJ-22-0020), developed by St.
Jude;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW THEREFORE, in consideration
of the above, the Parties agree that the following terms will apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 1.9 shall be revised to read:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.9 &ldquo;PATENT RIGHTS&rdquo;
shall mean U.S. provisional patent application no. 61/537,290, titled &ldquo;Live, Attenuated Streptococcus Pneumoniae Strain and Vaccine
for Protection Against Pneumococcal Disease&rdquo; filed on September 21, 2011, which issued as US patent number 9,265,819 on February
23, 2016 and U.S. provisional patent application no. 62/817,748 filed March 13, 2019 and U.S. provisional patent application no. 63/329,083
titled &ldquo;Vaccine Compositions and Methods for Reducing Transmission of Pathogens&rdquo; filed April 8, 2022 owned by LICENSOR and
all invention(s) disclosed and claimed therein (&ldquo;INVENTION&rdquo;), and any issued patents, divisions, continuations, continuations-in-part
to the extent that the claims are directed to subject matter described in the above-referenced patent applications and are entitled to
the priority date of the existing PATENT RIGHTS, reexaminations, substitutions, renewals, restorations, additions or registrations thereof,
as well as non-United States counterparts thereof and extensions and supplementary protection certificates thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>EXHIBIT A shall be revised to read:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>LICENSE FEE &amp; ROYALTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>1.</B></TD><TD STYLE="text-align: justify"><B>License Fee: </B>The initial license fee due under Paragraph
3.1 within thirty (30) days of the EFFECTIVE DATE is fifteen thousand US dollars ($15,000). A first amendment fee of five thousand US
dollars ($5,000) is due within thirty (30) days of the Effective Date of this Amendment #1.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>2.</B></TD><TD STYLE="text-align: justify"><B>Annual Maintenance Fee: </B>The annual maintenance fee
pursuant to Paragraph 3.2 is ten thousand US dollars ($10,000) per year, beginning on the first anniversary of the effective date of
the license.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>3.</B></TD><TD STYLE="text-align: justify"><B>Royalties: </B>The running royalty rate payable under Paragraph
3.3 is five percent (5%).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">In the event COMPANY is required to enter into one or more
third party license agreements to practice Patent Rights, the royalty payments due LICENSOR may be reduced by a percentage equal to half
of that paid to such third party. However, in no event shall the milestone payments due to LICENSOR be reduced by more than one half of
the original royalty percentage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SUBLICENSE CONSIDERATION: </B>COMPANY shall pay LICENSOR Fifteen
percent (15%) of any SUBLICENSE CONSIDERATION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>EXHIBIT B shall be revised to read:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">EXHIBIT B</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>DEVELOPMENTAL MILESTONES &amp; MILESTONE PAYMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>1.</B></TD><TD STYLE="text-align: justify"><B>Developmental Milestones: </B> Developmental Milestones
by COMPANY for a LICENSED PRODUCT in accord with Paragraph 5.3 are as follows:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 51%"><FONT STYLE="font-size: 10pt">Complete IND enabling study</FONT></TD>
    <TD STYLE="padding-left: 0.75in; width: 49%"><FONT STYLE="font-size: 10pt">2022/2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Initiate animal toxicology study</FONT></TD>
    <TD STYLE="padding-left: 0.75in"><FONT STYLE="font-size: 10pt">last half 2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">File IND</FONT></TD>
    <TD STYLE="padding-left: 0.75in"><FONT STYLE="font-size: 10pt">last half 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Complete PHASE I CLINICAL TRIAL</FONT></TD>
    <TD STYLE="padding-left: 0.75in"><FONT STYLE="font-size: 10pt">last half of 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Commence PHASE II CLINICAL TRIAL</FONT></TD>
    <TD STYLE="padding-left: 0.75in"><FONT STYLE="font-size: 10pt">2025</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Commence PHASE III CLINICAL TRIAL</FONT></TD>
    <TD STYLE="padding-left: 0.75in"><FONT STYLE="font-size: 10pt">2027</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Regulatory approval, US or foreign equivalent</FONT></TD>
    <TD STYLE="padding-left: 0.75in"><FONT STYLE="font-size: 10pt">2030-2032</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>2.</B></TD><TD STYLE="text-align: justify"><B>Milestone Payments: </B>The Milestone Payments payable
under Paragraph 3.5 are as follows:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 130.5pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Upon Commencement of PHASE III CLINICAL TRIAL</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">300,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Upon regulatory approval, US or foreign equivalent</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">600,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Upon FIRST COMMERCIAL SALE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 130.5pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;Commence&rdquo; or &ldquo;Commencement&rdquo; of either a PHASE
I, PHASE II or PHASE III CLINCIAL TRIAL shall mean the dosing of the first patient in such PHASE I, PHASE II, or PHASE III CLINICAL TRIAL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All other terms and conditions of the original
Exclusive License Agreement shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties have caused this
Amendment to be duly executed as of the date first set forth above by their respective duly authorized offices.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4"><B>BLUE WATER VACCINES, INC.</B></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Joseph Hernandez</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Date 5/10/2022</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name:</FONT>&nbsp;</TD>
    <TD STYLE="width: 35%"> <FONT STYLE="font-size: 10pt">Joseph Hernandez</FONT></TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4"><FONT STYLE="font-size: 10pt"><B>ST. JUDE CHILDREN&rsquo;S RESEARCH HOSPITAL, INC.</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ J. Scott Elmer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Date</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">J. Scott Elmer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Director, Technology Licensing</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>f10q0322ex31-1_bluewater.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRINCIPAL EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RULE 13a-14(a) AND RULE 15d-14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Joseph Hernandez, hereby certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 of Blue Water Vaccines Inc.</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors:</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 13, 2022</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Joseph Hernandez</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph Hernandez</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>f10q0322ex31-2_bluewater.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRINCIPAL FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RULE 13a-14(a) AND RULE 15d-14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Jon Garfield, hereby certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 of Blue Water Vaccines Inc.</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.55pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.55pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.55pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.55pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors:</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.55pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.55pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 13, 2022</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jon Garfield </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jon Garfield </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>f10q0322ex32-1_bluewater.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;906 of the Sarbanes-Oxley
Act of 2002 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(18 U.S.C. 1350) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Pursuant to Section&nbsp;906 of the Sarbanes-Oxley
Act of (18 U.S.C. 1350), the undersigned officer of Blue Water Vaccines Inc., a Delaware corporation (the &ldquo;Company&rdquo;), does
hereby certify, to the best of such officer&rsquo;s knowledge and belief, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">(1) The Quarterly Report on Form 10-Q for the
period ended March 31, 2022 (the &ldquo;Form 10-Q&rdquo;) of the Company fully complies with the requirements of Section&nbsp;13(a) or
15(d) of the Securities Exchange Act of 1934, as amended; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">(2) The information contained in the Form 10-Q
fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 13, 2022</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Joseph Hernandez</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph Hernandez, </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>f10q0322ex32-2_bluewater.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;906 of the Sarbanes-Oxley
Act of 2002 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(18 U.S.C. 1350) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Pursuant to Section&nbsp;906 of the Sarbanes-Oxley
Act of 2002 (18 U.S.C. 1350), the undersigned officer of Blue Water Vaccines Inc., a Delaware corporation (the &ldquo;Company&rdquo;),
does hereby certify, to the best of such officer&rsquo;s knowledge and belief, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">(1) The Quarterly Report on Form 10-Q for the
period ended March 31, 2022 (the &ldquo;Form 10-Q&rdquo;) of the Company fully complies with the requirements of Section&nbsp;13(a) or
15(d) of the Securities Exchange Act of 1934, as amended; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">(2) The information contained in the Form 10-Q
fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 13, 2022</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jon Garfield</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jon Garfield,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #P E@# 2(  A$! Q$!_\0
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M2"4%HY%*, Q&0>#R.10!(9$!4%ERW09Z_2D5U895@PR1P<\^E>4:5I6LC2?
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M/8R#VB/HJBOG*#XJ?$2YSY$=F^&9>+=>JYS_ !=!@\]*I?\ "[/&G_/>R_\
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M_?\ _':,)_?_ /':;118+F;XD6)O#.I!YBB& Y;83CD=N]>0_9M/_P"@D_\
MX"M_C7K7BC_D5=4_Z]S_ #%>,5VX5>Z]2)O8N_9M/_Z"3_\ @*W^-'V;3_\
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MING-Q9ZE.:G%-#=S_P!S]::I;S'^7T[U+3!_K'_"LRPW/_<_6C<_]S]:?10
MS<_]S]:-S_W/UI]% #-S_P!S]:-S_P!S]:?10 S<_P#<_6FL6ROR=_7VJ6F'
M[R?7^E !N?\ N?K1N?\ N?K3Z* &;G_N?K1N?^Y^M/HH 9N?^Y^M&Y_[GZT^
MB@!FY_[GZT%GP?D_6GTAZ&@!B%MB_)V]:7<_]S]:5/N+]!3J &;G_N?K1N?^
MY^M/HH 9N?\ N?K1N?\ N?K3Z* &;G_N?K1N?^Y^M/HH ^==;D"?&;7QYD<<
MK1XC:3H#L4G]/T!K3DN]-A\'.'CU-;@6S6()5QEV7=P<\@N,[N@'?%<Y\1=
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M<S&$B$2F(2A-_3)0Y_"J<WP]TJYAF6>ZOI99Q<":=I%WRF>,1,3\N.$50N
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MX$G_  H_UAP7=_<']@XSLOO1R%%=?_8^C_\ /E-_X$G_  I?['T?_GRF_P#
MD_X4?ZPX+N_N#^P<9V7WHX^KVM?\AR^_Z[M_.NA_L?1_^?*;_P "3_A5K4-)
MTF74KEWLY2S2,21<$9.?I1_;^#OS7?W!_8>+VLOO1PU%=?\ V/H__/E-_P"!
M)_PI?['T?_GRF_\  D_X4?ZPX+N_N#^P<9V7WHX^BNO_ +'T?_GRF_\  D_X
M4'1M'(_X\IO_  )/^%'^L."[O[@_L'&=E]Z.I^$OAS9%+X@N4^9\Q6N1T7^)
MOQ/'X&O5<5YI:>-;FQM(;6VL+6."% B*"W  P*F_X6#J'_/G;_FU>56S6A5F
MY-_@=M/*,3"-K+[T>B]:8O\ K'_"LG0-7_MK3%N?E20$K(@YVL/_ *V#6HH;
MS&^?T[5M":G%2CLSCG"4).$MT344S:_]_P#2C:_]_P#2K)'T4S:_]_\ 2C:_
M]_\ 2@!]%,VO_?\ THVO_?\ TH ?3#]Y/K_2C:_]_P#2FE7ROS]_3VH EHIF
MU_[_ .E&U_[_ .E #Z*9M?\ O_I1M?\ O_I0 ^BF;7_O_I1M?^_^E #Z0]#3
M=K_W_P!*"KX/S_I0 J?<7Z"G5&BOL7Y^WI2[7_O_ *4 /HIFU_[_ .E&U_[_
M .E #Z*9M?\ O_I1M?\ O_I0 ^BF;7_O_I1M?^_^E  GW?Q/\Z?4<?W.?4_S
MJ2@ HHHH **** "BBB@!C?>7_>_I3Z8_.W!QS44\T=M"TT\ZQ1(,N[L%51ZD
MGI0!0\1V+:GX=O[%%N"T\13%O*(Y.?[K'@'Z\=J\]?P)K=PLTDMA817EUH#V
M'G0,$$$P=RO _O*R@E> 0>V*]+2_M9+B*W2\B,LL1GC0.I+Q@@;QZKR.?<5'
M!K&FW!MA#J=K(;E-\ 65295]5'<?2@#S^X\->(]0U>?5+S2(GMI)[1Y-,-\#
MYRQQ2(06Z?*[*^#P<>M4[7P)XFM]#ELX/+MI#8R0J%N-RY-\TQ3/^U$=N3ZX
M->I07MI<S30V][#-+"<2I'(K,A]& Z?C5G:W]\_D* /-;+PGK-M)H<\5O(TE
MM>22/%=21>1;Q.ZE@J(3A@%)0J>,D'@UZ;4,3K-$LL4PDC895D(((]C222)$
M%,DP0,P4%B!DG@#ZF@"5_P#5M]#13'5O+;YST/:B@#AYO^/B3_?/\Z@FFCMX
M]\K;5S@<9R?05/-_KY?]\_SJI>0&XM_+58V.01O)&/<$<@UX4]V>_#97)D<.
M@=?ND9&1BG9'J*J"*X2T>)W$N(=N[!W,V#5&WTJ0Q1&01J,QEHAG!"@YS[G-
M1=]BTEW-FC(]163'I,JO;EI0PB &,D8PQ/%-&DS["C21E0A1<9SC>&YI7?8?
M+'N;%-DD6.,R-DJ/[HS67_9#+N\N18]PD&5ST;[H_"I/[.D^Q74(:-#-C:J9
MV)C'\\4[OL%H]S2J-)HY)9(U;+1X#?B,BLYM*D,CNLBHSF3++G.&& /P-)'I
MDT:EE,"N)(Y%50=ORC%*[[!:/<ULCUZTC,%4L3P!DFLN+2Y8P@+QMB,IN(.4
M)).Y??FF+I$JPJNZ)B&R58DJ?EQGV/>B[[!RQ[FB;R!;073/B$@$,1V/M227
M]M#MWR@;EW# )^7U..@JN;"1K*TMC*%$6-[ 9S@<8S[U%'IUU#&Z)-$?,B\I
MBX/ &<$?@>E%Y!:/<O->VZ/(C2@-&F]O9?6I8Y$FB61#E&&0?45FMI),JD2#
M8-JD=V0*!@_B!5VSA:WLX87(+(NTD=#33=]1-1MH%]_R#KK_ *Y&N2KK;[_D
M'77_ %R-<E7-B=T=N"^&7K^@45HZ3IJ:B;C>T@\H*0$*@G+8ZL<5;_X1Y664
MI.S!(Y0IVXW2HQ 7';(&:SCAZDUS11I/%4X2<9/8PZ*VCH<1F4)<.8XY6CN'
M('[O:F\D?^/#GTJG9:>+JX\B9I8)'4LFZ+(VX)W,<C XZT.A--(:Q--IM/;^
MOZ\BC16E+I2PVPE>Y.Y/*,P$>0@D&1CGGWZ54OK86=[-;A]XC;:&(QG\*F5.
M45=E0KPF[19!5B__ .0A<?\ 70U7JQ?_ /(0N/\ KH:7V/F4_C7I^I7HHHJ#
M0**** "BBB@#H_!NJ?8-8$$AQ!<X0YZ!_P"$_P!/QKTQ1\[?A7B )4AE)# Y
M!'8UZYX>U(:KI,5R?]9@)(/]L=?\?QKW,KKWBZ3Z:H^=SC#VDJRZZ,V****]
M<\4**** "BBB@ IA^\GU_I3Z8?O)]?Z4 /HHHH **** "BBB@ I#T-+2'H:
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M#^T_#&J60MTN))K618XF4$,^T[>O&<XK5/5?K_2O,M9U[Q$NH7<.EW9:>+Q
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M^5/HH 9A_P"\/RH(?!^9?RI](>AH 8@?8OS#IZ4N'_O#\J5/N+]!3J &8?\
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M_P"S=.EDFD2+$%A,PN?G/SH$X/XLI''K5+2K"&XO/(N4602)E#%(3@X)VY'
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M^L?\*?3!_K'_  H ?1110 4444 %%%% !3#]Y/K_ $I],/WD^O\ 2@!]%%%
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M$,&+.<'&T KC:%P!5;Q1X5M+V[U"\O=52PM=0MC82"./897D 1#(2V'*G[O
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9K4R\R&&)4WGWP.:*M/(GEM\Z]#WHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>bwv-20220331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 13 19:17:58 UTC 2022 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" targetNamespace="http://www.bluewatervaccines.com/20220331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:bwv="http://www.bluewatervaccines.com/20220331" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="bwv-20220331_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="bwv-20220331_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="bwv-20220331_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="bwv-20220331_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet" id="bwv_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals" id="bwv_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Condensed Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement" id="bwv_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Condensed Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3" id="bwv_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Condensed Statements of Stockholders&#8217; Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3_Parentheticals" id="bwv_r_ShareholdersEquityType2or3_Parentheticals">
        <link:definition>005 - Statement - Condensed Statements of Stockholders&#8217; Equity (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ConsolidatedCashFlow" id="bwv_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentation" id="bwv_r_OrganizationandBasisofPresentation">
        <link:definition>007 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/LiquidityandFinancialCondition" id="bwv_r_LiquidityandFinancialCondition">
        <link:definition>008 - Disclosure - Liquidity and Financial Condition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPolicies" id="bwv_r_SummaryofSignificantAccountingPolicies">
        <link:definition>009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/BalanceSheetDetails" id="bwv_r_BalanceSheetDetails">
        <link:definition>010 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/SignificantAgreements" id="bwv_r_SignificantAgreements">
        <link:definition>011 - Disclosure - Significant Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/StockholdersEquity" id="bwv_r_StockholdersEquity">
        <link:definition>012 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/CommitmentsandContingencies" id="bwv_r_CommitmentsandContingencies">
        <link:definition>013 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/RelatedPartyTransactions" id="bwv_r_RelatedPartyTransactions">
        <link:definition>014 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/IncomeTaxes" id="bwv_r_IncomeTaxes">
        <link:definition>015 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/RetirementPlan" id="bwv_r_RetirementPlan">
        <link:definition>016 - Disclosure - Retirement Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/SubsequentEvents" id="bwv_r_SubsequentEvents">
        <link:definition>017 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy" id="bwv_r_AccountingPoliciesByPolicy">
        <link:definition>018 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables" id="bwv_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>019 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables" id="bwv_r_BalanceSheetDetailsTables">
        <link:definition>020 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails" id="bwv_r_OrganizationandBasisofPresentationDetails">
        <link:definition>021 - Disclosure - Organization and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/LiquidityandFinancialConditionDetails" id="bwv_r_LiquidityandFinancialConditionDetails">
        <link:definition>022 - Disclosure - Liquidity and Financial Condition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails" id="bwv_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>023 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofcomputationofdilutedsharesoutstandingTable" id="bwv_r_ScheduleofcomputationofdilutedsharesoutstandingTable">
        <link:definition>024 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of computation of diluted shares outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwr9eJsDhBsVZfVtlP9aR4miPG9aL6mOS58KqaHVgLidMi2z82g/tcsacBQzQtHbKODQ/VLlSZXvcdklLkgAYbkbMy97AZwaH6tfqzDj871fqnq7Wqc/uzYF3hiM1Xm0+bx8P64VLx0p+9x2jakJvUXFyZahdnN8LgH/EKlrl6Cv2yT3qYwjnQizoBL7VNI8TrjB2A8Em8Cw/SczOTBCsyA/29Z3OaP5U=] CSR-->
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofprepaidexpensesTable" id="bwv_r_ScheduleofprepaidexpensesTable">
        <link:definition>025 - Disclosure - Balance Sheet Details (Details) - Schedule of prepaid expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/ScheduleofaccruedexpensesTable" id="bwv_r_ScheduleofaccruedexpensesTable">
        <link:definition>026 - Disclosure - Balance Sheet Details (Details) - Schedule of accrued expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/SignificantAgreementsDetails" id="bwv_r_SignificantAgreementsDetails">
        <link:definition>027 - Disclosure - Significant Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/StockholdersEquityDetails" id="bwv_r_StockholdersEquityDetails">
        <link:definition>028 - Disclosure - Stockholders&#8217; Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails" id="bwv_r_CommitmentsandContingenciesDetails">
        <link:definition>029 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails" id="bwv_r_RelatedPartyTransactionsDetails">
        <link:definition>030 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/RetirementPlanDetails" id="bwv_r_RetirementPlanDetails">
        <link:definition>031 - Disclosure - Retirement Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/SubsequentEventsDetails" id="bwv_r_SubsequentEventsDetails">
        <link:definition>032 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bluewatervaccines.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xs:element name="LiquidityAndFinancialConditionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_LiquidityAndFinancialConditionAbstract"/>
  <xs:element name="ScheduleOfComputationOfDilutedSharesOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_ScheduleOfComputationOfDilutedSharesOutstandingAbstract"/>
  <xs:element name="ScheduleOfPrepaidExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_ScheduleOfPrepaidExpensesAbstract"/>
  <xs:element name="ScheduleOfAccruedExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_ScheduleOfAccruedExpensesAbstract"/>
  <xs:element name="SignificantAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_SignificantAgreementsAbstract"/>
  <xs:element name="CashFlowsFromOperatingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_CashFlowsFromOperatingActivitiesAbstract"/>
  <xs:element name="PreferredStockValue1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bwv_PreferredStockValue1"/>
  <xs:element name="PreferredStockSharesDesignated" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="bwv_PreferredStockSharesDesignated"/>
  <xs:element name="NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare"/>
  <xs:element name="WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares"/>
  <xs:element name="OfferingCostsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bwv_OfferingCostsNet"/>
  <xs:element name="LiquidityAndFinancialConditionTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_LiquidityAndFinancialConditionTextBlock"/>
  <xs:element name="SignificantAgreementsTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_SignificantAgreementsTextBlock"/>
  <xs:element name="FairValueOfCommonStockPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_FairValueOfCommonStockPolicyTextBlock"/>
  <xs:element name="OptionsToPurchaseSharesOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_OptionsToPurchaseSharesOfCommonStock"/>
  <xs:element name="SeriesSeedPreferredStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_SeriesSeedPreferredStock"/>
  <xs:element name="WarrantsToPurchaseSharesOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_WarrantsToPurchaseSharesOfCommonStock"/>
  <xs:element name="TotalShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_TotalShares"/>
  <xs:element name="AccruedResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bwv_AccruedResearchAndDevelopment"/>
  <xs:element name="AccruedDeferredOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bwv_AccruedDeferredOfferingCosts"/>
  <xs:element name="InitialPublicOfferingShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="bwv_InitialPublicOfferingShares"/>
  <xs:element name="PricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="bwv_PricePerShare"/>
  <xs:element name="InitialPublicOffering" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_InitialPublicOffering"/>
  <xs:element name="LiquidityandFinancialConditionDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bwv_LiquidityandFinancialConditionDetailsTable"/>
  <xs:element name="LiquidityandFinancialConditionDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_LiquidityandFinancialConditionDetailsLineItems"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bwv_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
  <xs:element name="SignificantAgreementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bwv_SignificantAgreementsDetailsTable"/>
  <xs:element name="SignificantAgreementsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_SignificantAgreementsDetailsLineItems"/>
  <xs:element name="OUIAgreementExpiration" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_OUIAgreementExpiration"/>
  <xs:element name="AggregateAgreementAmountInitialAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bwv_AggregateAgreementAmountInitialAgreement"/>
  <xs:element name="PrepaidExpensesToRemainingPrepaidExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bwv_PrepaidExpensesToRemainingPrepaidExpenses"/>
  <xs:element name="PrepaidExpenseRemaining" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bwv_PrepaidExpenseRemaining"/>
  <xs:element name="AggregateAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bwv_AggregateAmount"/>
  <xs:element name="CostPlusPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_CostPlusPercentage"/>
  <xs:element name="AccuredExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bwv_AccuredExpenses"/>
  <xs:element name="StockholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bwv_StockholdersEquityDetailsTable"/>
  <xs:element name="StockholdersEquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_StockholdersEquityDetailsLineItems"/>
  <xs:element name="CommonStockShareAuthorized" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="bwv_CommonStockShareAuthorized"/>
  <xs:element name="AggregatePurchaseShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_AggregatePurchaseShares"/>
  <xs:element name="ConversionPricePerShares" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_ConversionPricePerShares"/>
  <xs:element name="UnderwrittenPublicOfferingNettingProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bwv_UnderwrittenPublicOfferingNettingProceeds"/>
  <xs:element name="OfferingPricePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_OfferingPricePercentage"/>
  <xs:element name="CumulativeDividendsPerShare" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_CumulativeDividendsPerShare"/>
  <xs:element name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bwv_CommitmentsandContingenciesDetailsTable"/>
  <xs:element name="CommitmentsandContingenciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_CommitmentsandContingenciesDetailsLineItems"/>
  <xs:element name="RentalDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bwv_RentalDeposits"/>
  <xs:element name="LitigationsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_LitigationsDescription"/>
  <xs:element name="PercentageOfRoyaltyOnSales" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="bwv_PercentageOfRoyaltyOnSales"/>
  <xs:element name="MinimumRoyaltyExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bwv_MinimumRoyaltyExpense"/>
  <xs:element name="RoyaltyRatePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_RoyaltyRatePercentage"/>
  <xs:element name="RoyaltyOnSumReceivedFromSublicenseePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_RoyaltyOnSumReceivedFromSublicenseePercentage"/>
  <xs:element name="AggregatePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bwv_AggregatePayments"/>
  <xs:element name="SpecifiedMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bwv_SpecifiedMilestones"/>
  <xs:element name="RegulatoryMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bwv_RegulatoryMilestones"/>
  <xs:element name="CommercialMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bwv_CommercialMilestones"/>
  <xs:element name="PurchaseObligationDueInThirdYearperiod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_PurchaseObligationDueInThirdYearperiod"/>
  <xs:element name="PrepaidAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bwv_PrepaidAmount"/>
  <xs:element name="RoyaltyPaymentsPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_RoyaltyPaymentsPercentage"/>
  <xs:element name="AnnualMaintenanceFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bwv_AnnualMaintenanceFee"/>
  <xs:element name="OtherResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bwv_OtherResearchAndDevelopmentExpenses"/>
  <xs:element name="RoyaltyRateDecreasePostValidClaimExpiration" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_RoyaltyRateDecreasePostValidClaimExpiration"/>
  <xs:element name="OptionFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bwv_OptionFee"/>
  <xs:element name="TerminationFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bwv_TerminationFee"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bwv_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_SubsequentEventsDetailsLineItems"/>
  <xs:element name="AggregatesPurchaseShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_AggregatesPurchaseShares"/>
  <xs:element name="PurchasePricePerShare" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bwv_PurchasePricePerShare"/>
  <xs:element name="AgentFee" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_AgentFee"/>
  <xs:element name="ManagementFee" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_ManagementFee"/>
  <xs:element name="AggregateOutofPocketExpensesToPlacementAgent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bwv_AggregateOutofPocketExpensesToPlacementAgent"/>
  <xs:element name="SharesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_SharesPercentage"/>
  <xs:element name="AggregateSubscriptionAmountPaidPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_AggregateSubscriptionAmountPaidPercentage"/>
  <xs:element name="CHMCAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_CHMCAgreementMember"/>
  <xs:element name="OUIAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_OUIAgreementMember"/>
  <xs:element name="OlogyAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_OlogyAgreementMember"/>
  <xs:element name="OlogyAmendmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_OlogyAmendmentMember"/>
  <xs:element name="OlogyBioservicesIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_OlogyBioservicesIncMember"/>
  <xs:element name="OriginalIssuePriceMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_OriginalIssuePriceMember"/>
  <xs:element name="OxfordResearchMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_OxfordResearchMember"/>
  <xs:element name="PhaseIIIYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_PhaseIIIYearMember"/>
  <xs:element name="PhaseIIMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_PhaseIIMember"/>
  <xs:element name="PhaseIMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_PhaseIMember"/>
  <xs:element name="PreFundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_PreFundedWarrantsMember"/>
  <xs:element name="PreferredInvestmentOptionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_PreferredInvestmentOptionsMember"/>
  <xs:element name="PrephaseIIIYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_PrephaseIIIYearMember"/>
  <xs:element name="SeriesSeedPreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_SeriesSeedPreferredStockMember"/>
  <xs:element name="StJudeAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_StJudeAgreementMember"/>
  <xs:element name="StJudeAmendmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_StJudeAmendmentMember"/>
  <xs:element name="StJudeResearchAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_StJudeResearchAgreementMember"/>
  <xs:element name="TwoThousandNinteenEquityIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_TwoThousandNinteenEquityIncentivePlanMember"/>
  <xs:element name="UnderwriterTerminationAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_UnderwriterTerminationAgreementMember"/>
  <xs:element name="WainwrightWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_WainwrightWarrantsMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bwv_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>bwv-20220331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 13 19:17:58 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_ConsolidatedBalanceSheet" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_ConsolidatedIncomeStatement" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_ConsolidatedCashFlow" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DeferredCostsCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="bwv_PreferredStockValue1" xlink:href="bwv-20220331.xsd#bwv_PreferredStockValue1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="bwv_PreferredStockValue1" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwr9eJsDhBsVZfVtlP9aR4miPG9aL6mOS58KqaHVgLidMi2z82g/tcsacBQzQtHbKODQ/VLlSZXvcdklLkgAYbkbMy97AZwaH6tfqzDj871fqnq7Wqc/uzYF3hiM1Xm0+bx8P64VLx0p+9x2jakJvUXFyZahdnN8LgH/EKlrl6Cv2yT3qYwjnQizoBL7VNI8SFhlLlD4bai0KrLhZQ2OOdFxu+hljnAoc=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>bwv-20220331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 13 19:17:58 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_ConsolidatedBalanceSheet" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_ConsolidatedIncomeStatement" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_ShareholdersEquityType2or3" roleURI="http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_ConsolidatedCashFlow" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_OrganizationandBasisofPresentation" roleURI="http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentation"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_LiquidityandFinancialCondition" roleURI="http://www.bluewatervaccines.com/role/LiquidityandFinancialCondition"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_BalanceSheetDetails" roleURI="http://www.bluewatervaccines.com/role/BalanceSheetDetails"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_SignificantAgreements" roleURI="http://www.bluewatervaccines.com/role/SignificantAgreements"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_StockholdersEquity" roleURI="http://www.bluewatervaccines.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_CommitmentsandContingencies" roleURI="http://www.bluewatervaccines.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_RelatedPartyTransactions" roleURI="http://www.bluewatervaccines.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_IncomeTaxes" roleURI="http://www.bluewatervaccines.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_RetirementPlan" roleURI="http://www.bluewatervaccines.com/role/RetirementPlan"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_SubsequentEvents" roleURI="http://www.bluewatervaccines.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_AccountingPoliciesByPolicy" roleURI="http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_BalanceSheetDetailsTables" roleURI="http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_ScheduleofcomputationofdilutedsharesoutstandingTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofcomputationofdilutedsharesoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_ScheduleofprepaidexpensesTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofprepaidexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_ScheduleofaccruedexpensesTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofaccruedexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_OrganizationandBasisofPresentationDetails" roleURI="http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_LiquidityandFinancialConditionDetails" roleURI="http://www.bluewatervaccines.com/role/LiquidityandFinancialConditionDetails"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_SignificantAgreementsDetails" roleURI="http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_StockholdersEquityDetails" roleURI="http://www.bluewatervaccines.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_CommitmentsandContingenciesDetails" roleURI="http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_RelatedPartyTransactionsDetails" roleURI="http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_RetirementPlanDetails" roleURI="http://www.bluewatervaccines.com/role/RetirementPlanDetails"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_SubsequentEventsDetails" roleURI="http://www.bluewatervaccines.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#DocumentAndEntityInformation" roleURI="http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DeferredCostsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_AssetsCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_Assets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_StockholdersEquityAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_PreferredStockValue1" xlink:href="bwv-20220331.xsd#bwv_PreferredStockValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="bwv_PreferredStockValue1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_PreferredStockSharesDesignated" xlink:href="bwv-20220331.xsd#bwv_PreferredStockSharesDesignated"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="bwv_PreferredStockSharesDesignated" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OperatingExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OperatingIncomeLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_NetIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare" xlink:href="bwv-20220331.xsd#bwv_NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLoss" xlink:to="bwv_NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares" xlink:href="bwv-20220331.xsd#bwv_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLoss" xlink:to="bwv_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="bwv_OfferingCostsNet" xlink:href="bwv-20220331.xsd#bwv_OfferingCostsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="bwv_OfferingCostsNet" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="bwv_CashFlowsFromOperatingActivitiesAbstract" xlink:href="bwv-20220331.xsd#bwv_CashFlowsFromOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="bwv_CashFlowsFromOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CashFlowsFromOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DeferredOfferingCosts" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentation">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/LiquidityandFinancialCondition">
    <loc xlink:type="locator" xlink:label="bwv_LiquidityAndFinancialConditionAbstract" xlink:href="bwv-20220331.xsd#bwv_LiquidityAndFinancialConditionAbstract"/>
    <loc xlink:type="locator" xlink:label="bwv_LiquidityAndFinancialConditionTextBlock" xlink:href="bwv-20220331.xsd#bwv_LiquidityAndFinancialConditionTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_LiquidityAndFinancialConditionAbstract" xlink:to="bwv_LiquidityAndFinancialConditionTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/BalanceSheetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SignificantAgreements">
    <loc xlink:type="locator" xlink:label="bwv_SignificantAgreementsAbstract" xlink:href="bwv-20220331.xsd#bwv_SignificantAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="bwv_SignificantAgreementsTextBlock" xlink:href="bwv-20220331.xsd#bwv_SignificantAgreementsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SignificantAgreementsAbstract" xlink:to="bwv_SignificantAgreementsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/RetirementPlan">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_FairValueOfCommonStockPolicyTextBlock" xlink:href="bwv-20220331.xsd#bwv_FairValueOfCommonStockPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bwv_FairValueOfCommonStockPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofcomputationofdilutedsharesoutstandingTable">
    <loc xlink:type="locator" xlink:label="bwv_ScheduleOfComputationOfDilutedSharesOutstandingAbstract" xlink:href="bwv-20220331.xsd#bwv_ScheduleOfComputationOfDilutedSharesOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="bwv_OptionsToPurchaseSharesOfCommonStock" xlink:href="bwv-20220331.xsd#bwv_OptionsToPurchaseSharesOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_ScheduleOfComputationOfDilutedSharesOutstandingAbstract" xlink:to="bwv_OptionsToPurchaseSharesOfCommonStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_SeriesSeedPreferredStock" xlink:href="bwv-20220331.xsd#bwv_SeriesSeedPreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_ScheduleOfComputationOfDilutedSharesOutstandingAbstract" xlink:to="bwv_SeriesSeedPreferredStock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_WarrantsToPurchaseSharesOfCommonStock" xlink:href="bwv-20220331.xsd#bwv_WarrantsToPurchaseSharesOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_ScheduleOfComputationOfDilutedSharesOutstandingAbstract" xlink:to="bwv_WarrantsToPurchaseSharesOfCommonStock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_TotalShares" xlink:href="bwv-20220331.xsd#bwv_TotalShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_WarrantsToPurchaseSharesOfCommonStock" xlink:to="bwv_TotalShares" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofprepaidexpensesTable">
    <loc xlink:type="locator" xlink:label="bwv_ScheduleOfPrepaidExpensesAbstract" xlink:href="bwv-20220331.xsd#bwv_ScheduleOfPrepaidExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_ScheduleOfPrepaidExpensesAbstract" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_ScheduleOfPrepaidExpensesAbstract" xlink:to="us-gaap_PrepaidInsurance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_ScheduleOfPrepaidExpensesAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_ScheduleOfPrepaidExpensesAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofaccruedexpensesTable">
    <loc xlink:type="locator" xlink:label="bwv_ScheduleOfAccruedExpensesAbstract" xlink:href="bwv-20220331.xsd#bwv_ScheduleOfAccruedExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_ScheduleOfAccruedExpensesAbstract" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_AccruedResearchAndDevelopment" xlink:href="bwv-20220331.xsd#bwv_AccruedResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_ScheduleOfAccruedExpensesAbstract" xlink:to="bwv_AccruedResearchAndDevelopment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_AccruedDeferredOfferingCosts" xlink:href="bwv-20220331.xsd#bwv_AccruedDeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_ScheduleOfAccruedExpensesAbstract" xlink:to="bwv_AccruedDeferredOfferingCosts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensatedAbsencesLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensatedAbsencesLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_ScheduleOfAccruedExpensesAbstract" xlink:to="us-gaap_CompensatedAbsencesLiability" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_ScheduleOfAccruedExpensesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_ScheduleOfAccruedExpensesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_ScheduleOfAccruedExpensesAbstract" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_ScheduleOfAccruedExpensesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="bwv_InitialPublicOfferingShares" xlink:href="bwv-20220331.xsd#bwv_InitialPublicOfferingShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bwv_InitialPublicOfferingShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_PricePerShare" xlink:href="bwv-20220331.xsd#bwv_PricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bwv_PricePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_InitialPublicOffering" xlink:href="bwv-20220331.xsd#bwv_InitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bwv_InitialPublicOffering" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/LiquidityandFinancialConditionDetails">
    <loc xlink:type="locator" xlink:label="bwv_LiquidityandFinancialConditionDetailsLineItems" xlink:href="bwv-20220331.xsd#bwv_LiquidityandFinancialConditionDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bwv_LiquidityandFinancialConditionDetailsTable" xlink:href="bwv-20220331.xsd#bwv_LiquidityandFinancialConditionDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bwv_LiquidityandFinancialConditionDetailsLineItems" xlink:to="bwv_LiquidityandFinancialConditionDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bwv_LiquidityandFinancialConditionDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_LiquidityandFinancialConditionDetailsLineItems" xlink:to="us-gaap_InvestmentsAndCash" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAdditionalCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAdditionalCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_LiquidityandFinancialConditionDetailsLineItems" xlink:to="us-gaap_OtherAdditionalCapital" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAppropriated" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAppropriated"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_LiquidityandFinancialConditionDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAppropriated" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_LiquidityandFinancialConditionDetailsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_LiquidityandFinancialConditionDetailsLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="5" xbrldt:closed="true"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwr9eJsDhBsVZfVtlP9aR4miPG9aL6mOS58KqaHVgLidMi2z82g/tcsacBQzQtHbKODQ/VLlSZXvcdklLkgAYbkbMy97AZwaH6tfqzDj871fqnq7Wqc/uzYF3hiM1Xm0+bx8P64VLx0p+9x2jakJvUXFyZahdnN8LgH/EKlrl6Cv2yT3qYwjnQizoBL7VNI8QxJ+HuNlpxrzgSeOIHcAHWlT9J694d+K0=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_LiquidityandFinancialConditionDetailsLineItems" xlink:to="us-gaap_LongTermDebtDescription" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="bwv_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="bwv-20220331.xsd#bwv_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bwv_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="bwv-20220331.xsd#bwv_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bwv_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="bwv_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bwv_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredCostsCurrentAndNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SignificantAgreementsDetails">
    <loc xlink:type="locator" xlink:label="bwv_SignificantAgreementsDetailsLineItems" xlink:href="bwv-20220331.xsd#bwv_SignificantAgreementsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bwv_SignificantAgreementsDetailsTable" xlink:href="bwv-20220331.xsd#bwv_SignificantAgreementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bwv_SignificantAgreementsDetailsLineItems" xlink:to="bwv_SignificantAgreementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bwv_SignificantAgreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bwv_SignificantAgreementsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_OlogyBioservicesIncMember" xlink:href="bwv-20220331.xsd#bwv_OlogyBioservicesIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bwv_OlogyBioservicesIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_OUIAgreementExpiration" xlink:href="bwv-20220331.xsd#bwv_OUIAgreementExpiration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SignificantAgreementsDetailsLineItems" xlink:to="bwv_OUIAgreementExpiration" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesAndLicenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesAndLicenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SignificantAgreementsDetailsLineItems" xlink:to="us-gaap_TaxesAndLicenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_AggregateAgreementAmountInitialAgreement" xlink:href="bwv-20220331.xsd#bwv_AggregateAgreementAmountInitialAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SignificantAgreementsDetailsLineItems" xlink:to="bwv_AggregateAgreementAmountInitialAgreement" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_PrepaidExpensesToRemainingPrepaidExpenses" xlink:href="bwv-20220331.xsd#bwv_PrepaidExpensesToRemainingPrepaidExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SignificantAgreementsDetailsLineItems" xlink:to="bwv_PrepaidExpensesToRemainingPrepaidExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_PrepaidExpenseRemaining" xlink:href="bwv-20220331.xsd#bwv_PrepaidExpenseRemaining"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SignificantAgreementsDetailsLineItems" xlink:to="bwv_PrepaidExpenseRemaining" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_AggregateAmount" xlink:href="bwv-20220331.xsd#bwv_AggregateAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SignificantAgreementsDetailsLineItems" xlink:to="bwv_AggregateAmount" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_CostPlusPercentage" xlink:href="bwv-20220331.xsd#bwv_CostPlusPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SignificantAgreementsDetailsLineItems" xlink:to="bwv_CostPlusPercentage" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SignificantAgreementsDetailsLineItems" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_AccuredExpenses" xlink:href="bwv-20220331.xsd#bwv_AccuredExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SignificantAgreementsDetailsLineItems" xlink:to="bwv_AccuredExpenses" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SignificantAgreementsDetailsLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="bwv_StockholdersEquityDetailsLineItems" xlink:href="bwv-20220331.xsd#bwv_StockholdersEquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bwv_StockholdersEquityDetailsTable" xlink:href="bwv-20220331.xsd#bwv_StockholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="bwv_StockholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bwv_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bwv_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_TwoThousandNinteenEquityIncentivePlanMember" xlink:href="bwv-20220331.xsd#bwv_TwoThousandNinteenEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="bwv_TwoThousandNinteenEquityIncentivePlanMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_SeriesSeedPreferredStockMember" xlink:href="bwv-20220331.xsd#bwv_SeriesSeedPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bwv_SeriesSeedPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_OriginalIssuePriceMember" xlink:href="bwv-20220331.xsd#bwv_OriginalIssuePriceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bwv_OriginalIssuePriceMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_CommonStockShareAuthorized" xlink:href="bwv-20220331.xsd#bwv_CommonStockShareAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="bwv_CommonStockShareAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNoParValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockNoParValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockNoParValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_AggregatePurchaseShares" xlink:href="bwv-20220331.xsd#bwv_AggregatePurchaseShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="bwv_AggregatePurchaseShares" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongDurationContractsAssumptionsByProductAndGuaranteeDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongDurationContractsAssumptionsByProductAndGuaranteeDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_LongDurationContractsAssumptionsByProductAndGuaranteeDiscountRate" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOwnershipInterestsOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherOwnershipInterestsOfferingCosts" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockRedemptionPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesOutstanding" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_ConversionPricePerShares" xlink:href="bwv-20220331.xsd#bwv_ConversionPricePerShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="bwv_ConversionPricePerShares" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_UnderwrittenPublicOfferingNettingProceeds" xlink:href="bwv-20220331.xsd#bwv_UnderwrittenPublicOfferingNettingProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="bwv_UnderwrittenPublicOfferingNettingProceeds" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_OfferingPricePercentage" xlink:href="bwv-20220331.xsd#bwv_OfferingPricePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="bwv_OfferingPricePercentage" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_CumulativeDividendsPerShare" xlink:href="bwv-20220331.xsd#bwv_CumulativeDividendsPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="bwv_CumulativeDividendsPerShare" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CumulativeDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CumulativeDividends"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CumulativeDividends" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPayableAmountPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_DividendsPayableAmountPerShare" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendPreferenceOrRestrictions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendPreferenceOrRestrictions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockDividendPreferenceOrRestrictions" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="25" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:href="bwv-20220331.xsd#bwv_CommitmentsandContingenciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bwv_CommitmentsandContingenciesDetailsTable" xlink:href="bwv-20220331.xsd#bwv_CommitmentsandContingenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="bwv_CommitmentsandContingenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bwv_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bwv_CommitmentsandContingenciesDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_OUIAgreementMember" xlink:href="bwv-20220331.xsd#bwv_OUIAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bwv_OUIAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_OxfordResearchMember" xlink:href="bwv-20220331.xsd#bwv_OxfordResearchMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bwv_OxfordResearchMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_StJudeAgreementMember" xlink:href="bwv-20220331.xsd#bwv_StJudeAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bwv_StJudeAgreementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_StJudeResearchAgreementMember" xlink:href="bwv-20220331.xsd#bwv_StJudeResearchAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bwv_StJudeResearchAgreementMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_CHMCAgreementMember" xlink:href="bwv-20220331.xsd#bwv_CHMCAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bwv_CHMCAgreementMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_OlogyAgreementMember" xlink:href="bwv-20220331.xsd#bwv_OlogyAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bwv_OlogyAgreementMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_UnderwriterTerminationAgreementMember" xlink:href="bwv-20220331.xsd#bwv_UnderwriterTerminationAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bwv_UnderwriterTerminationAgreementMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_PrephaseIIIYearMember" xlink:href="bwv-20220331.xsd#bwv_PrephaseIIIYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bwv_PrephaseIIIYearMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_PhaseIIIYearMember" xlink:href="bwv-20220331.xsd#bwv_PhaseIIIYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bwv_PhaseIIIYearMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_PhaseIMember" xlink:href="bwv-20220331.xsd#bwv_PhaseIMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bwv_PhaseIMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_PhaseIIMember" xlink:href="bwv-20220331.xsd#bwv_PhaseIIMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bwv_PhaseIIMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LeaseCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_RentalDeposits" xlink:href="bwv-20220331.xsd#bwv_RentalDeposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="bwv_RentalDeposits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_PaymentsForRent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_LitigationsDescription" xlink:href="bwv-20220331.xsd#bwv_LitigationsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="bwv_LitigationsDescription" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_PercentageOfRoyaltyOnSales" xlink:href="bwv-20220331.xsd#bwv_PercentageOfRoyaltyOnSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="bwv_PercentageOfRoyaltyOnSales" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_MinimumRoyaltyExpense" xlink:href="bwv-20220331.xsd#bwv_MinimumRoyaltyExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="bwv_MinimumRoyaltyExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_RoyaltyRatePercentage" xlink:href="bwv-20220331.xsd#bwv_RoyaltyRatePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="bwv_RoyaltyRatePercentage" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFee" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_RoyaltyOnSumReceivedFromSublicenseePercentage" xlink:href="bwv-20220331.xsd#bwv_RoyaltyOnSumReceivedFromSublicenseePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="bwv_RoyaltyOnSumReceivedFromSublicenseePercentage" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_AggregatePayments" xlink:href="bwv-20220331.xsd#bwv_AggregatePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="bwv_AggregatePayments" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_SpecifiedMilestones" xlink:href="bwv-20220331.xsd#bwv_SpecifiedMilestones"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="bwv_SpecifiedMilestones" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_RegulatoryMilestones" xlink:href="bwv-20220331.xsd#bwv_RegulatoryMilestones"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="bwv_RegulatoryMilestones" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_CommercialMilestones" xlink:href="bwv-20220331.xsd#bwv_CommercialMilestones"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="bwv_CommercialMilestones" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_PurchaseObligationDueInThirdYearperiod" xlink:href="bwv-20220331.xsd#bwv_PurchaseObligationDueInThirdYearperiod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="bwv_PurchaseObligationDueInThirdYearperiod" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PurchaseObligationDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_PurchaseObligationDueInThirdYear" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_PrepaidAmount" xlink:href="bwv-20220331.xsd#bwv_PrepaidAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="bwv_PrepaidAmount" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_RoyaltyPaymentsPercentage" xlink:href="bwv-20220331.xsd#bwv_RoyaltyPaymentsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="bwv_RoyaltyPaymentsPercentage" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_AnnualMaintenanceFee" xlink:href="bwv-20220331.xsd#bwv_AnnualMaintenanceFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="bwv_AnnualMaintenanceFee" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_AggregateAmount" xlink:href="bwv-20220331.xsd#bwv_AggregateAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="bwv_AggregateAmount" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_AccuredExpenses" xlink:href="bwv-20220331.xsd#bwv_AccuredExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="bwv_AccuredExpenses" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_OtherResearchAndDevelopmentExpenses" xlink:href="bwv-20220331.xsd#bwv_OtherResearchAndDevelopmentExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="bwv_OtherResearchAndDevelopmentExpenses" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_RoyaltyRateDecreasePostValidClaimExpiration" xlink:href="bwv-20220331.xsd#bwv_RoyaltyRateDecreasePostValidClaimExpiration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="bwv_RoyaltyRateDecreasePostValidClaimExpiration" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_OptionFee" xlink:href="bwv-20220331.xsd#bwv_OptionFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="bwv_OptionFee" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_CostPlusPercentage" xlink:href="bwv-20220331.xsd#bwv_CostPlusPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="bwv_CostPlusPercentage" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_TerminationFee" xlink:href="bwv-20220331.xsd#bwv_TerminationFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="bwv_TerminationFee" order="28" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_DueFromRelatedParties" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsMiscellaneousCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_OtherAssetsMiscellaneousCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_OtherAssetsMiscellaneousNoncurrent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/RetirementPlanDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="bwv_SubsequentEventsDetailsLineItems" xlink:href="bwv-20220331.xsd#bwv_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bwv_SubsequentEventsDetailsTable" xlink:href="bwv-20220331.xsd#bwv_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bwv_SubsequentEventsDetailsLineItems" xlink:to="bwv_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bwv_SubsequentEventsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bwv_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bwv_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bwv_SubsequentEventsDetailsTable" xlink:to="srt_RangeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_PreFundedWarrantsMember" xlink:href="bwv-20220331.xsd#bwv_PreFundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bwv_PreFundedWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_PreferredInvestmentOptionsMember" xlink:href="bwv-20220331.xsd#bwv_PreferredInvestmentOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bwv_PreferredInvestmentOptionsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_WainwrightWarrantsMember" xlink:href="bwv-20220331.xsd#bwv_WainwrightWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bwv_WainwrightWarrantsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_OlogyAmendmentMember" xlink:href="bwv-20220331.xsd#bwv_OlogyAmendmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bwv_OlogyAmendmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_StJudeAmendmentMember" xlink:href="bwv-20220331.xsd#bwv_StJudeAmendmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bwv_StJudeAmendmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_AggregatesPurchaseShares" xlink:href="bwv-20220331.xsd#bwv_AggregatesPurchaseShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SubsequentEventsDetailsLineItems" xlink:to="bwv_AggregatesPurchaseShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_PurchasePricePerShare" xlink:href="bwv-20220331.xsd#bwv_PurchasePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SubsequentEventsDetailsLineItems" xlink:to="bwv_PurchasePricePerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ProceedsFromRepaymentsOfDebt" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_AgentFee" xlink:href="bwv-20220331.xsd#bwv_AgentFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SubsequentEventsDetailsLineItems" xlink:to="bwv_AgentFee" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_ManagementFee" xlink:href="bwv-20220331.xsd#bwv_ManagementFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SubsequentEventsDetailsLineItems" xlink:to="bwv_ManagementFee" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_AggregateOutofPocketExpensesToPlacementAgent" xlink:href="bwv-20220331.xsd#bwv_AggregateOutofPocketExpensesToPlacementAgent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SubsequentEventsDetailsLineItems" xlink:to="bwv_AggregateOutofPocketExpensesToPlacementAgent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_SharesPercentage" xlink:href="bwv-20220331.xsd#bwv_SharesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SubsequentEventsDetailsLineItems" xlink:to="bwv_SharesPercentage" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_AggregateSubscriptionAmountPaidPercentage" xlink:href="bwv-20220331.xsd#bwv_AggregateSubscriptionAmountPaidPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SubsequentEventsDetailsLineItems" xlink:to="bwv_AggregateSubscriptionAmountPaidPercentage" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SubsequentEventDescription" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ScheduleOfSubsequentEventsTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bwv_RoyaltyRatePercentage" xlink:href="bwv-20220331.xsd#bwv_RoyaltyRatePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bwv_SubsequentEventsDetailsLineItems" xlink:to="bwv_RoyaltyRatePercentage" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="31" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>bwv-20220331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 13 19:17:58 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss applicable to common stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash, end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_LiquidityAndFinancialConditionAbstract" xlink:href="bwv-20220331.xsd#bwv_LiquidityAndFinancialConditionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_LiquidityAndFinancialConditionAbstract_lbl" xml:lang="en-US">Liquidity and Financial Condition [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_LiquidityAndFinancialConditionAbstract" xlink:to="bwv_LiquidityAndFinancialConditionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_ScheduleOfComputationOfDilutedSharesOutstandingAbstract" xlink:href="bwv-20220331.xsd#bwv_ScheduleOfComputationOfDilutedSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_ScheduleOfComputationOfDilutedSharesOutstandingAbstract_lbl" xml:lang="en-US">Schedule of computation of diluted shares outstanding [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_ScheduleOfComputationOfDilutedSharesOutstandingAbstract" xlink:to="bwv_ScheduleOfComputationOfDilutedSharesOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_ScheduleOfPrepaidExpensesAbstract" xlink:href="bwv-20220331.xsd#bwv_ScheduleOfPrepaidExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_ScheduleOfPrepaidExpensesAbstract_lbl" xml:lang="en-US">Schedule of prepaid expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_ScheduleOfPrepaidExpensesAbstract" xlink:to="bwv_ScheduleOfPrepaidExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_ScheduleOfAccruedExpensesAbstract" xlink:href="bwv-20220331.xsd#bwv_ScheduleOfAccruedExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_ScheduleOfAccruedExpensesAbstract_lbl" xml:lang="en-US">Schedule of accrued expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_ScheduleOfAccruedExpensesAbstract" xlink:to="bwv_ScheduleOfAccruedExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_SignificantAgreementsAbstract" xlink:href="bwv-20220331.xsd#bwv_SignificantAgreementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_SignificantAgreementsAbstract_lbl" xml:lang="en-US">Significant Agreements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_SignificantAgreementsAbstract" xlink:to="bwv_SignificantAgreementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US">Deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xml:lang="en-US">Receivable from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid expenses, long-term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (see Note 7)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.00001 par value, 10,000,000 shares authorized at March 31, 2022 and December 31, 2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_PreferredStockValue1" xlink:href="bwv-20220331.xsd#bwv_PreferredStockValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_PreferredStockValue1_lbl" xml:lang="en-US">Series Seed: 0 and 1,150,000 shares designated at March 31, 2022 and December 31, 2021, respectively; 0 and 1,146,138 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively; $0 and $15.4 million aggregate liquidation preference at March 31, 2022 and December 31, 2021, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PreferredStockValue1" xlink:to="bwv_PreferredStockValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_PreferredStockSharesDesignated" xlink:href="bwv-20220331.xsd#bwv_PreferredStockSharesDesignated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_PreferredStockSharesDesignated_lbl" xml:lang="en-US">Preferred stock, shares designated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PreferredStockSharesDesignated" xlink:to="bwv_PreferredStockSharesDesignated_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xml:lang="en-US">Aggregate liquidation preference shares (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.00001 par value, 250,000,000 shares authorized at March 31, 2022 and December 31, 2021; 11,048,587 and 3,200,000 shares outstanding at March 31, 2022 and December 31, 2021, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in-capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xml:lang="en-US">Operating costs and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xml:lang="en-US">Cumulative preferred stock dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare" xlink:href="bwv-20220331.xsd#bwv_NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare_lbl" xml:lang="en-US">Net loss per share attributable to common stockholders, basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare" xlink:to="bwv_NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares" xlink:href="bwv-20220331.xsd#bwv_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares_lbl" xml:lang="en-US">Weighted average number of common shares outstanding, basic and diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares" xlink:to="bwv_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock in initial public offering, net of $2.9 million of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock in initial public offering, net of $2.9 million of offering costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_OfferingCostsNet" xlink:href="bwv-20220331.xsd#bwv_OfferingCostsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_OfferingCostsNet_lbl" xml:lang="en-US">Offering costs, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OfferingCostsNet" xlink:to="bwv_OfferingCostsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of convertible preferred stock to common stock upon initial public offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of convertible preferred stock to common stock upon initial public offering (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_CashFlowsFromOperatingActivitiesAbstract" xlink:href="bwv-20220331.xsd#bwv_CashFlowsFromOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_CashFlowsFromOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_CashFlowsFromOperatingActivitiesAbstract" xlink:to="bwv_CashFlowsFromOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from issuance of common stock in initial public offering, net of underwriting discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Noncash investing and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs included in accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Conversion of convertible preferred stock to common stock upon initial public offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl" xml:lang="en-US">Initial public offering costs included in accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" xml:lang="en-US">Receivable from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses, long-term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xml:lang="en-US">Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Payment of deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments of initial public offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockMember_lbl0" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Organization and Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_LiquidityAndFinancialConditionTextBlock" xlink:href="bwv-20220331.xsd#bwv_LiquidityAndFinancialConditionTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_LiquidityAndFinancialConditionTextBlock_lbl" xml:lang="en-US">Liquidity and Financial Condition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_LiquidityAndFinancialConditionTextBlock" xlink:to="bwv_LiquidityAndFinancialConditionTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of computation of diluted shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_OptionsToPurchaseSharesOfCommonStock" xlink:href="bwv-20220331.xsd#bwv_OptionsToPurchaseSharesOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_OptionsToPurchaseSharesOfCommonStock_lbl" xml:lang="en-US">Options to purchase shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OptionsToPurchaseSharesOfCommonStock" xlink:to="bwv_OptionsToPurchaseSharesOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_SeriesSeedPreferredStock" xlink:href="bwv-20220331.xsd#bwv_SeriesSeedPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_SeriesSeedPreferredStock_lbl" xml:lang="en-US">Series Seed Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_SeriesSeedPreferredStock" xlink:to="bwv_SeriesSeedPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_WarrantsToPurchaseSharesOfCommonStock" xlink:href="bwv-20220331.xsd#bwv_WarrantsToPurchaseSharesOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_WarrantsToPurchaseSharesOfCommonStock_lbl" xml:lang="en-US">Warrants to purchase shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_WarrantsToPurchaseSharesOfCommonStock" xlink:to="bwv_WarrantsToPurchaseSharesOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_TotalShares" xlink:href="bwv-20220331.xsd#bwv_TotalShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_TotalShares_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_TotalShares" xlink:to="bwv_TotalShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US">Balance Sheet Details</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Prepaid research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xml:lang="en-US">Accrued license fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl0" xml:lang="en-US">License fee (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl0"/>
    <loc xlink:type="locator" xlink:label="bwv_AccruedResearchAndDevelopment" xlink:href="bwv-20220331.xsd#bwv_AccruedResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_AccruedResearchAndDevelopment_lbl" xml:lang="en-US">Accrued research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AccruedResearchAndDevelopment" xlink:to="bwv_AccruedResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_AccruedDeferredOfferingCosts" xlink:href="bwv-20220331.xsd#bwv_AccruedDeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_AccruedDeferredOfferingCosts_lbl" xml:lang="en-US">Accrued deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AccruedDeferredOfferingCosts" xlink:to="bwv_AccruedDeferredOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensatedAbsencesLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensatedAbsencesLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensatedAbsencesLiability_lbl" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensatedAbsencesLiability" xlink:to="us-gaap_CompensatedAbsencesLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Accrued insurance expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_lbl" xml:lang="en-US">Accrued board of directors&#8217; compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_SignificantAgreementsTextBlock" xlink:href="bwv-20220331.xsd#bwv_SignificantAgreementsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_SignificantAgreementsTextBlock_lbl" xml:lang="en-US">Significant Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_SignificantAgreementsTextBlock" xlink:to="bwv_SignificantAgreementsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Retirement Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_InitialPublicOfferingShares" xlink:href="bwv-20220331.xsd#bwv_InitialPublicOfferingShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_InitialPublicOfferingShares_lbl" xml:lang="en-US">Initial public offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_InitialPublicOfferingShares" xlink:to="bwv_InitialPublicOfferingShares_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_PricePerShare" xlink:href="bwv-20220331.xsd#bwv_PricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_PricePerShare_lbl" xml:lang="en-US">Initial public offering price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PricePerShare" xlink:to="bwv_PricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_InitialPublicOffering" xlink:href="bwv-20220331.xsd#bwv_InitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_InitialPublicOffering_lbl" xml:lang="en-US">Initial public offering, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_InitialPublicOffering" xlink:to="bwv_InitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Convertible preferred stock shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" xlink:to="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsAndCash_lbl" xml:lang="en-US">Company cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_InvestmentsAndCash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAdditionalCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAdditionalCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAdditionalCapital_lbl" xml:lang="en-US">Working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAdditionalCapital" xlink:to="us-gaap_OtherAdditionalCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAppropriated" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAppropriated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAppropriated_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAppropriated" xlink:to="us-gaap_RetainedEarningsAppropriated_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Least term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtDescription_lbl" xml:lang="en-US">Long-term operating description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtDescription" xlink:to="us-gaap_LongTermDebtDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Federal depository insurance coverage limit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl" xml:lang="en-US">Deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:to="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xml:lang="en-US">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_OUIAgreementExpiration" xlink:href="bwv-20220331.xsd#bwv_OUIAgreementExpiration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_OUIAgreementExpiration_lbl" xml:lang="en-US">OUI Agreement Expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OUIAgreementExpiration" xlink:to="bwv_OUIAgreementExpiration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesAndLicenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesAndLicenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesAndLicenses_lbl" xml:lang="en-US">Intellectual property licenses is recorded as research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesAndLicenses" xlink:to="us-gaap_TaxesAndLicenses_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_AggregateAgreementAmountInitialAgreement" xlink:href="bwv-20220331.xsd#bwv_AggregateAgreementAmountInitialAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_AggregateAgreementAmountInitialAgreement_lbl" xml:lang="en-US">Aggregate agreement amount initial agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AggregateAgreementAmountInitialAgreement" xlink:to="bwv_AggregateAgreementAmountInitialAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_PrepaidExpensesToRemainingPrepaidExpenses" xlink:href="bwv-20220331.xsd#bwv_PrepaidExpensesToRemainingPrepaidExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_PrepaidExpensesToRemainingPrepaidExpenses_lbl" xml:lang="en-US">Prepaid expenses to remaining prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PrepaidExpensesToRemainingPrepaidExpenses" xlink:to="bwv_PrepaidExpensesToRemainingPrepaidExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_PrepaidExpenseRemaining" xlink:href="bwv-20220331.xsd#bwv_PrepaidExpenseRemaining"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_PrepaidExpenseRemaining_lbl" xml:lang="en-US">Prepaid expense remaining</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PrepaidExpenseRemaining" xlink:to="bwv_PrepaidExpenseRemaining_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_AggregateAmount" xlink:href="bwv-20220331.xsd#bwv_AggregateAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_AggregateAmount_lbl" xml:lang="en-US">Aggregate amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AggregateAmount" xlink:to="bwv_AggregateAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_CostPlusPercentage" xlink:href="bwv-20220331.xsd#bwv_CostPlusPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_CostPlusPercentage_lbl" xml:lang="en-US">Cost plus, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_CostPlusPercentage" xlink:to="bwv_CostPlusPercentage_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bwv_CostPlusPercentage_lbl0" xml:lang="en-US">Cost plus percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_CostPlusPercentage" xlink:to="bwv_CostPlusPercentage_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_AccuredExpenses" xlink:href="bwv-20220331.xsd#bwv_AccuredExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_AccuredExpenses_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AccuredExpenses" xlink:to="bwv_AccuredExpenses_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bwv_AccuredExpenses_lbl0" xml:lang="en-US">Accured expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AccuredExpenses" xlink:to="bwv_AccuredExpenses_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl" xml:lang="en-US">Increased in obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:to="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_CommonStockShareAuthorized" xlink:href="bwv-20220331.xsd#bwv_CommonStockShareAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_CommonStockShareAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_CommonStockShareAuthorized" xlink:to="bwv_CommonStockShareAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesAuthorized" xlink:to="us-gaap_ExcessStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNoParValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockNoParValue_lbl" xml:lang="en-US">Preferred stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNoParValue" xlink:to="us-gaap_PreferredStockNoParValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockNoParValue_lbl" xml:lang="en-US">Common stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Preferred stock, shares designated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_AggregatePurchaseShares" xlink:href="bwv-20220331.xsd#bwv_AggregatePurchaseShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_AggregatePurchaseShares_lbl" xml:lang="en-US">Aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AggregatePurchaseShares" xlink:to="bwv_AggregatePurchaseShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Common stock price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongDurationContractsAssumptionsByProductAndGuaranteeDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongDurationContractsAssumptionsByProductAndGuaranteeDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongDurationContractsAssumptionsByProductAndGuaranteeDiscountRate_lbl" xml:lang="en-US">Underwriting discount percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongDurationContractsAssumptionsByProductAndGuaranteeDiscountRate" xlink:to="us-gaap_LongDurationContractsAssumptionsByProductAndGuaranteeDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOwnershipInterestsOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherOwnershipInterestsOfferingCosts_lbl" xml:lang="en-US">Other offering costs (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:to="us-gaap_OtherOwnershipInterestsOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xml:lang="en-US">Warrants to purchase shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl" xml:lang="en-US">Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare_lbl" xml:lang="en-US">Fair value price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare" xlink:to="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockRedemptionPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xml:lang="en-US">Original issue price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionPricePerShare" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesOutstanding" xlink:to="us-gaap_ExcessStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_ConversionPricePerShares" xlink:href="bwv-20220331.xsd#bwv_ConversionPricePerShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_ConversionPricePerShares_lbl" xml:lang="en-US">Conversion price, per shares (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_ConversionPricePerShares" xlink:to="bwv_ConversionPricePerShares_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_UnderwrittenPublicOfferingNettingProceeds" xlink:href="bwv-20220331.xsd#bwv_UnderwrittenPublicOfferingNettingProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_UnderwrittenPublicOfferingNettingProceeds_lbl" xml:lang="en-US">Underwritten public offering netting proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_UnderwrittenPublicOfferingNettingProceeds" xlink:to="bwv_UnderwrittenPublicOfferingNettingProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_OfferingPricePercentage" xlink:href="bwv-20220331.xsd#bwv_OfferingPricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_OfferingPricePercentage_lbl" xml:lang="en-US">Offering price percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OfferingPricePercentage" xlink:to="bwv_OfferingPricePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_CumulativeDividendsPerShare" xlink:href="bwv-20220331.xsd#bwv_CumulativeDividendsPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_CumulativeDividendsPerShare_lbl" xml:lang="en-US">Cumulative dividends, per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_CumulativeDividendsPerShare" xlink:to="bwv_CumulativeDividendsPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CumulativeDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CumulativeDividends"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CumulativeDividends_lbl" xml:lang="en-US">Cumulative dividends (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeDividends" xlink:to="us-gaap_CumulativeDividends_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPayableAmountPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsPayableAmountPerShare_lbl" xml:lang="en-US">Cumulative dividends per series seed share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableAmountPerShare" xlink:to="us-gaap_DividendsPayableAmountPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendPreferenceOrRestrictions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendPreferenceOrRestrictions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendPreferenceOrRestrictions_lbl" xml:lang="en-US">Description of liquidation preference</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendPreferenceOrRestrictions" xlink:to="us-gaap_PreferredStockDividendPreferenceOrRestrictions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Reserved shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Company leased office space</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_RentalDeposits" xlink:href="bwv-20220331.xsd#bwv_RentalDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_RentalDeposits_lbl" xml:lang="en-US">Rental deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_RentalDeposits" xlink:to="bwv_RentalDeposits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rent expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Office lease term, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_LitigationsDescription" xlink:href="bwv-20220331.xsd#bwv_LitigationsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_LitigationsDescription_lbl" xml:lang="en-US">Litigations description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_LitigationsDescription" xlink:to="bwv_LitigationsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_PercentageOfRoyaltyOnSales" xlink:href="bwv-20220331.xsd#bwv_PercentageOfRoyaltyOnSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_PercentageOfRoyaltyOnSales_lbl" xml:lang="en-US">Percentage of royalty on net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PercentageOfRoyaltyOnSales" xlink:to="bwv_PercentageOfRoyaltyOnSales_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_MinimumRoyaltyExpense" xlink:href="bwv-20220331.xsd#bwv_MinimumRoyaltyExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_MinimumRoyaltyExpense_lbl" xml:lang="en-US">Minimum Royalty Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_MinimumRoyaltyExpense" xlink:to="bwv_MinimumRoyaltyExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_RoyaltyRatePercentage" xlink:href="bwv-20220331.xsd#bwv_RoyaltyRatePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_RoyaltyRatePercentage_lbl" xml:lang="en-US">Royalty rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_RoyaltyRatePercentage" xlink:to="bwv_RoyaltyRatePercentage_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bwv_RoyaltyRatePercentage_lbl0" xml:lang="en-US">Royalty rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_RoyaltyRatePercentage" xlink:to="bwv_RoyaltyRatePercentage_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFee_lbl" xml:lang="en-US">Annual maintenance fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFee" xlink:to="us-gaap_DebtInstrumentFee_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_RoyaltyOnSumReceivedFromSublicenseePercentage" xlink:href="bwv-20220331.xsd#bwv_RoyaltyOnSumReceivedFromSublicenseePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_RoyaltyOnSumReceivedFromSublicenseePercentage_lbl" xml:lang="en-US">Royalty on sum received from sublicensee, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_RoyaltyOnSumReceivedFromSublicenseePercentage" xlink:to="bwv_RoyaltyOnSumReceivedFromSublicenseePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_AggregatePayments" xlink:href="bwv-20220331.xsd#bwv_AggregatePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_AggregatePayments_lbl" xml:lang="en-US">Aggregate payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AggregatePayments" xlink:to="bwv_AggregatePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_SpecifiedMilestones" xlink:href="bwv-20220331.xsd#bwv_SpecifiedMilestones"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_SpecifiedMilestones_lbl" xml:lang="en-US">Specified milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_SpecifiedMilestones" xlink:to="bwv_SpecifiedMilestones_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_RegulatoryMilestones" xlink:href="bwv-20220331.xsd#bwv_RegulatoryMilestones"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_RegulatoryMilestones_lbl" xml:lang="en-US">Regulatory milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_RegulatoryMilestones" xlink:to="bwv_RegulatoryMilestones_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_CommercialMilestones" xlink:href="bwv-20220331.xsd#bwv_CommercialMilestones"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_CommercialMilestones_lbl" xml:lang="en-US">Commercial milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_CommercialMilestones" xlink:to="bwv_CommercialMilestones_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_PurchaseObligationDueInThirdYearperiod" xlink:href="bwv-20220331.xsd#bwv_PurchaseObligationDueInThirdYearperiod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_PurchaseObligationDueInThirdYearperiod_lbl" xml:lang="en-US">Agreement period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PurchaseObligationDueInThirdYearperiod" xlink:to="bwv_PurchaseObligationDueInThirdYearperiod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PurchaseObligationDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseObligationDueInThirdYear_lbl" xml:lang="en-US">Total (in Euro)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInThirdYear" xlink:to="us-gaap_PurchaseObligationDueInThirdYear_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_PrepaidAmount" xlink:href="bwv-20220331.xsd#bwv_PrepaidAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_PrepaidAmount_lbl" xml:lang="en-US">Prepaid amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PrepaidAmount" xlink:to="bwv_PrepaidAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xml:lang="en-US">Prepaid expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_RoyaltyPaymentsPercentage" xlink:href="bwv-20220331.xsd#bwv_RoyaltyPaymentsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_RoyaltyPaymentsPercentage_lbl" xml:lang="en-US">Royalty payments percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_RoyaltyPaymentsPercentage" xlink:to="bwv_RoyaltyPaymentsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_AnnualMaintenanceFee" xlink:href="bwv-20220331.xsd#bwv_AnnualMaintenanceFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_AnnualMaintenanceFee_lbl" xml:lang="en-US">Annual maintenance fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AnnualMaintenanceFee" xlink:to="bwv_AnnualMaintenanceFee_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_OtherResearchAndDevelopmentExpenses" xlink:href="bwv-20220331.xsd#bwv_OtherResearchAndDevelopmentExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_OtherResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OtherResearchAndDevelopmentExpenses" xlink:to="bwv_OtherResearchAndDevelopmentExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_RoyaltyRateDecreasePostValidClaimExpiration" xlink:href="bwv-20220331.xsd#bwv_RoyaltyRateDecreasePostValidClaimExpiration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_RoyaltyRateDecreasePostValidClaimExpiration_lbl" xml:lang="en-US">Royalty rate decrease, post valid claim expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_RoyaltyRateDecreasePostValidClaimExpiration" xlink:to="bwv_RoyaltyRateDecreasePostValidClaimExpiration_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_OptionFee" xlink:href="bwv-20220331.xsd#bwv_OptionFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_OptionFee_lbl" xml:lang="en-US">Option fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OptionFee" xlink:to="bwv_OptionFee_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_TerminationFee" xlink:href="bwv-20220331.xsd#bwv_TerminationFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_TerminationFee_lbl" xml:lang="en-US">Termination fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_TerminationFee" xlink:to="bwv_TerminationFee_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Fees under consulting agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromRelatedParties_lbl" xml:lang="en-US">Receivable from related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedParties" xlink:to="us-gaap_DueFromRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Related party transactions amounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsMiscellaneousCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsMiscellaneousCurrent_lbl" xml:lang="en-US">Remaining balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMiscellaneousCurrent" xlink:to="us-gaap_OtherAssetsMiscellaneousCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent_lbl" xml:lang="en-US">Miscellaneous payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:to="us-gaap_OtherAssetsMiscellaneousNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_lbl" xml:lang="en-US">Employees compensation percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_AggregatesPurchaseShares" xlink:href="bwv-20220331.xsd#bwv_AggregatesPurchaseShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_AggregatesPurchaseShares_lbl" xml:lang="en-US">Aggregates purchase shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AggregatesPurchaseShares" xlink:to="bwv_AggregatesPurchaseShares_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_PurchasePricePerShare" xlink:href="bwv-20220331.xsd#bwv_PurchasePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_PurchasePricePerShare_lbl" xml:lang="en-US">Purchase price, per share (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PurchasePricePerShare" xlink:to="bwv_PurchasePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt_lbl" xml:lang="en-US">Aggregate net proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Excerise price, per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_AgentFee" xlink:href="bwv-20220331.xsd#bwv_AgentFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_AgentFee_lbl" xml:lang="en-US">Agent fee, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AgentFee" xlink:to="bwv_AgentFee_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_ManagementFee" xlink:href="bwv-20220331.xsd#bwv_ManagementFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_ManagementFee_lbl" xml:lang="en-US">Management fee, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_ManagementFee" xlink:to="bwv_ManagementFee_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_AggregateOutofPocketExpensesToPlacementAgent" xlink:href="bwv-20220331.xsd#bwv_AggregateOutofPocketExpensesToPlacementAgent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_AggregateOutofPocketExpensesToPlacementAgent_lbl" xml:lang="en-US">Aggregate out-of pocket expenses to placement agent (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AggregateOutofPocketExpensesToPlacementAgent" xlink:to="bwv_AggregateOutofPocketExpensesToPlacementAgent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Issued warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_SharesPercentage" xlink:href="bwv-20220331.xsd#bwv_SharesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_SharesPercentage_lbl" xml:lang="en-US">Shares percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_SharesPercentage" xlink:to="bwv_SharesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_AggregateSubscriptionAmountPaidPercentage" xlink:href="bwv-20220331.xsd#bwv_AggregateSubscriptionAmountPaidPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_AggregateSubscriptionAmountPaidPercentage_lbl" xml:lang="en-US">Aggregate subscription amount paid percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AggregateSubscriptionAmountPaidPercentage" xlink:to="bwv_AggregateSubscriptionAmountPaidPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventDescription_lbl" xml:lang="en-US">Subsequent event, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventDescription" xlink:to="us-gaap_SubsequentEventDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent event, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsequentEventsTextBlock" xlink:to="us-gaap_ScheduleOfSubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Unaudited Interim Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</label>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwr9eJsDhBsVZfVtlP9aR4miPG9aL6mOS58KqaHVgLidMi2z82g/tcsacBQzQtHbKODQ/VLlSZXvcdklLkgAYbkbMy97AZwaH6tfqzDj871fqnq7Wqc/uzYF3hiM1Xm0+bx8P64VLx0p+9x2jakJvUXFyZahdnN8LgH/EKlrl6Cv2yT3qYwjnQizoBL7VNI8THKUWZktN1RcSBxbrMydUXapDB2ymJFe0=] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_FairValueOfCommonStockPolicyTextBlock" xlink:href="bwv-20220331.xsd#bwv_FairValueOfCommonStockPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_FairValueOfCommonStockPolicyTextBlock_lbl" xml:lang="en-US">Fair Value of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_FairValueOfCommonStockPolicyTextBlock" xlink:to="bwv_FairValueOfCommonStockPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_OlogyBioservicesIncMember" xlink:href="bwv-20220331.xsd#bwv_OlogyBioservicesIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_OlogyBioservicesIncMember_lbl" xml:lang="en-US">Ology Bioservices, Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OlogyBioservicesIncMember" xlink:to="bwv_OlogyBioservicesIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_SeriesSeedPreferredStockMember" xlink:href="bwv-20220331.xsd#bwv_SeriesSeedPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_SeriesSeedPreferredStockMember_lbl" xml:lang="en-US">Preferred Stock Series Seed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_SeriesSeedPreferredStockMember" xlink:to="bwv_SeriesSeedPreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bwv_SeriesSeedPreferredStockMember_lbl0" xml:lang="en-US">Series Seed Preferred Stock.[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_SeriesSeedPreferredStockMember" xlink:to="bwv_SeriesSeedPreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="bwv_OriginalIssuePriceMember" xlink:href="bwv-20220331.xsd#bwv_OriginalIssuePriceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_OriginalIssuePriceMember_lbl" xml:lang="en-US">Original Issue Price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OriginalIssuePriceMember" xlink:to="bwv_OriginalIssuePriceMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_TwoThousandNinteenEquityIncentivePlanMember" xlink:href="bwv-20220331.xsd#bwv_TwoThousandNinteenEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_TwoThousandNinteenEquityIncentivePlanMember_lbl" xml:lang="en-US">2019 Equity Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_TwoThousandNinteenEquityIncentivePlanMember" xlink:to="bwv_TwoThousandNinteenEquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_OUIAgreementMember" xlink:href="bwv-20220331.xsd#bwv_OUIAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_OUIAgreementMember_lbl" xml:lang="en-US">OUI Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OUIAgreementMember" xlink:to="bwv_OUIAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_PrephaseIIIYearMember" xlink:href="bwv-20220331.xsd#bwv_PrephaseIIIYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_PrephaseIIIYearMember_lbl" xml:lang="en-US">Pre-phase III year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PrephaseIIIYearMember" xlink:to="bwv_PrephaseIIIYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_PhaseIIIYearMember" xlink:href="bwv-20220331.xsd#bwv_PhaseIIIYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_PhaseIIIYearMember_lbl" xml:lang="en-US">Phase III year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PhaseIIIYearMember" xlink:to="bwv_PhaseIIIYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_OxfordResearchMember" xlink:href="bwv-20220331.xsd#bwv_OxfordResearchMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_OxfordResearchMember_lbl" xml:lang="en-US">Oxford Research [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OxfordResearchMember" xlink:to="bwv_OxfordResearchMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_StJudeAgreementMember" xlink:href="bwv-20220331.xsd#bwv_StJudeAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_StJudeAgreementMember_lbl" xml:lang="en-US">St. Jude Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_StJudeAgreementMember" xlink:to="bwv_StJudeAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_StJudeResearchAgreementMember" xlink:href="bwv-20220331.xsd#bwv_StJudeResearchAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_StJudeResearchAgreementMember_lbl" xml:lang="en-US">St. Jude Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_StJudeResearchAgreementMember" xlink:to="bwv_StJudeResearchAgreementMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bwv_StJudeResearchAgreementMember_lbl0" xml:lang="en-US">St Jude Research Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_StJudeResearchAgreementMember" xlink:to="bwv_StJudeResearchAgreementMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="bwv_PhaseIMember" xlink:href="bwv-20220331.xsd#bwv_PhaseIMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_PhaseIMember_lbl" xml:lang="en-US">Phase I [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PhaseIMember" xlink:to="bwv_PhaseIMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_PhaseIIMember" xlink:href="bwv-20220331.xsd#bwv_PhaseIIMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_PhaseIIMember_lbl" xml:lang="en-US">Phase II [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PhaseIIMember" xlink:to="bwv_PhaseIIMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_CHMCAgreementMember" xlink:href="bwv-20220331.xsd#bwv_CHMCAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_CHMCAgreementMember_lbl" xml:lang="en-US">CHMC Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_CHMCAgreementMember" xlink:to="bwv_CHMCAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_OlogyAgreementMember" xlink:href="bwv-20220331.xsd#bwv_OlogyAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_OlogyAgreementMember_lbl" xml:lang="en-US">Ology Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OlogyAgreementMember" xlink:to="bwv_OlogyAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_UnderwriterTerminationAgreementMember" xlink:href="bwv-20220331.xsd#bwv_UnderwriterTerminationAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_UnderwriterTerminationAgreementMember_lbl" xml:lang="en-US">Underwriter Termination Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_UnderwriterTerminationAgreementMember" xlink:to="bwv_UnderwriterTerminationAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_PreFundedWarrantsMember" xlink:href="bwv-20220331.xsd#bwv_PreFundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre-Funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PreFundedWarrantsMember" xlink:to="bwv_PreFundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_PreferredInvestmentOptionsMember" xlink:href="bwv-20220331.xsd#bwv_PreferredInvestmentOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_PreferredInvestmentOptionsMember_lbl" xml:lang="en-US">Preferred Investment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PreferredInvestmentOptionsMember" xlink:to="bwv_PreferredInvestmentOptionsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bwv_PreferredInvestmentOptionsMember_lbl0" xml:lang="en-US">Preferred Investment Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PreferredInvestmentOptionsMember" xlink:to="bwv_PreferredInvestmentOptionsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="bwv_WainwrightWarrantsMember" xlink:href="bwv-20220331.xsd#bwv_WainwrightWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_WainwrightWarrantsMember_lbl" xml:lang="en-US">Wainwright Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_WainwrightWarrantsMember" xlink:to="bwv_WainwrightWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_OlogyAmendmentMember" xlink:href="bwv-20220331.xsd#bwv_OlogyAmendmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_OlogyAmendmentMember_lbl" xml:lang="en-US">Ology Amendment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OlogyAmendmentMember" xlink:to="bwv_OlogyAmendmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_StJudeAmendmentMember" xlink:href="bwv-20220331.xsd#bwv_StJudeAmendmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bwv_StJudeAmendmentMember_lbl" xml:lang="en-US">St. Jude Amendment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_StJudeAmendmentMember" xlink:to="bwv_StJudeAmendmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_LiquidityandFinancialConditionDetailsTable" xlink:href="bwv-20220331.xsd#bwv_LiquidityandFinancialConditionDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_LiquidityandFinancialConditionDetailsTable_lbl" xml:lang="en-US">Liquidity and Financial Condition (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_LiquidityandFinancialConditionDetailsTable" xlink:to="bwv_LiquidityandFinancialConditionDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_LiquidityandFinancialConditionDetailsLineItems" xlink:href="bwv-20220331.xsd#bwv_LiquidityandFinancialConditionDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_LiquidityandFinancialConditionDetailsLineItems_lbl" xml:lang="en-US">Liquidity and Financial Condition (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_LiquidityandFinancialConditionDetailsLineItems" xlink:to="bwv_LiquidityandFinancialConditionDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="bwv-20220331.xsd#bwv_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="bwv_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="bwv-20220331.xsd#bwv_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="bwv_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_SignificantAgreementsDetailsTable" xlink:href="bwv-20220331.xsd#bwv_SignificantAgreementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_SignificantAgreementsDetailsTable_lbl" xml:lang="en-US">Significant Agreements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_SignificantAgreementsDetailsTable" xlink:to="bwv_SignificantAgreementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_SignificantAgreementsDetailsLineItems" xlink:href="bwv-20220331.xsd#bwv_SignificantAgreementsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_SignificantAgreementsDetailsLineItems_lbl" xml:lang="en-US">Significant Agreements (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_SignificantAgreementsDetailsLineItems" xlink:to="bwv_SignificantAgreementsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_StockholdersEquityDetailsTable" xlink:href="bwv-20220331.xsd#bwv_StockholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_StockholdersEquityDetailsTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_StockholdersEquityDetailsTable" xlink:to="bwv_StockholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_StockholdersEquityDetailsLineItems" xlink:href="bwv-20220331.xsd#bwv_StockholdersEquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_StockholdersEquityDetailsLineItems_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_StockholdersEquityDetailsLineItems" xlink:to="bwv_StockholdersEquityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_CommitmentsandContingenciesDetailsTable" xlink:href="bwv-20220331.xsd#bwv_CommitmentsandContingenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_CommitmentsandContingenciesDetailsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_CommitmentsandContingenciesDetailsTable" xlink:to="bwv_CommitmentsandContingenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:href="bwv-20220331.xsd#bwv_CommitmentsandContingenciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_CommitmentsandContingenciesDetailsLineItems_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_CommitmentsandContingenciesDetailsLineItems" xlink:to="bwv_CommitmentsandContingenciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_SubsequentEventsDetailsTable" xlink:href="bwv-20220331.xsd#bwv_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_SubsequentEventsDetailsTable" xlink:to="bwv_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bwv_SubsequentEventsDetailsLineItems" xlink:href="bwv-20220331.xsd#bwv_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_SubsequentEventsDetailsLineItems" xlink:to="bwv_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_AccruedDeferredOfferingCosts_lbl0" xml:lang="en-US">Accrued deferred offering costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AccruedDeferredOfferingCosts" xlink:to="bwv_AccruedDeferredOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_AccruedResearchAndDevelopment_lbl0" xml:lang="en-US">Accrued research and development.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AccruedResearchAndDevelopment" xlink:to="bwv_AccruedResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_AccuredExpenses_lbl1" xml:lang="en-US">Accured expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AccuredExpenses" xlink:to="bwv_AccuredExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_AgentFee_lbl0" xml:lang="en-US">Agent fee percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AgentFee" xlink:to="bwv_AgentFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_AggregateAgreementAmountInitialAgreement_lbl0" xml:lang="en-US">Amount of aggregate Agreement amount initial agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AggregateAgreementAmountInitialAgreement" xlink:to="bwv_AggregateAgreementAmountInitialAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_AggregateAmount_lbl0" xml:lang="en-US">Aggregate amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AggregateAmount" xlink:to="bwv_AggregateAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_AggregateOutofPocketExpensesToPlacementAgent_lbl0" xml:lang="en-US">It represents of aggregate out-of pocket expenses to placement agent.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AggregateOutofPocketExpensesToPlacementAgent" xlink:to="bwv_AggregateOutofPocketExpensesToPlacementAgent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_AggregatePayments_lbl0" xml:lang="en-US">Aggregate payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AggregatePayments" xlink:to="bwv_AggregatePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_AggregatePurchaseShares_lbl0" xml:lang="en-US">Number of aggregate purchase shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AggregatePurchaseShares" xlink:to="bwv_AggregatePurchaseShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_AggregateSubscriptionAmountPaidPercentage_lbl0" xml:lang="en-US">Aggregate subscription amount paid, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AggregateSubscriptionAmountPaidPercentage" xlink:to="bwv_AggregateSubscriptionAmountPaidPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_AggregatesPurchaseShares_lbl0" xml:lang="en-US">Number of aggregates purchase shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AggregatesPurchaseShares" xlink:to="bwv_AggregatesPurchaseShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_AnnualMaintenanceFee_lbl0" xml:lang="en-US">Annual maintenance fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AnnualMaintenanceFee" xlink:to="bwv_AnnualMaintenanceFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_CommonStockShareAuthorized_lbl0" xml:lang="en-US">Maximum number of excess stock shares permitted to be issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_CommonStockShareAuthorized" xlink:to="bwv_CommonStockShareAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_ConversionPricePerShares_lbl0" xml:lang="en-US">Conversion price, per shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_ConversionPricePerShares" xlink:to="bwv_ConversionPricePerShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_CostPlusPercentage_lbl1" xml:lang="en-US">Cost plus, percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_CostPlusPercentage" xlink:to="bwv_CostPlusPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_CumulativeDividendsPerShare_lbl0" xml:lang="en-US">Cumulative dividends per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_CumulativeDividendsPerShare" xlink:to="bwv_CumulativeDividendsPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_InitialPublicOffering_lbl0" xml:lang="en-US">Initial public offering description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_InitialPublicOffering" xlink:to="bwv_InitialPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_InitialPublicOfferingShares_lbl0" xml:lang="en-US">Number of shares issued initial public offering of shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_InitialPublicOfferingShares" xlink:to="bwv_InitialPublicOfferingShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_LitigationsDescription_lbl0" xml:lang="en-US">Litigations description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_LitigationsDescription" xlink:to="bwv_LitigationsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_ManagementFee_lbl0" xml:lang="en-US">Management fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_ManagementFee" xlink:to="bwv_ManagementFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_MinimumRoyaltyExpense_lbl0" xml:lang="en-US">It represents of minimum royalty expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_MinimumRoyaltyExpense" xlink:to="bwv_MinimumRoyaltyExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare_lbl0" xml:lang="en-US">Net loss per share attributable to common stockholder, basic and diluted (in Dollars per share).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare" xlink:to="bwv_NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_OfferingPricePercentage_lbl0" xml:lang="en-US">Offering price percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OfferingPricePercentage" xlink:to="bwv_OfferingPricePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_OptionFee_lbl0" xml:lang="en-US">Option fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OptionFee" xlink:to="bwv_OptionFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_OptionsToPurchaseSharesOfCommonStock_lbl0" xml:lang="en-US">Options to purchase shares of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OptionsToPurchaseSharesOfCommonStock" xlink:to="bwv_OptionsToPurchaseSharesOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_OtherResearchAndDevelopmentExpenses_lbl0" xml:lang="en-US">Other Research and Development Expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OtherResearchAndDevelopmentExpenses" xlink:to="bwv_OtherResearchAndDevelopmentExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_PreferredStockSharesDesignated_lbl0" xml:lang="en-US">Preferred stock, shares designated.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PreferredStockSharesDesignated" xlink:to="bwv_PreferredStockSharesDesignated_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_PreferredStockValue1_lbl0" xml:lang="en-US">Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders&apos; equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PreferredStockValue1" xlink:to="bwv_PreferredStockValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_PrepaidAmount_lbl0" xml:lang="en-US">prepaid amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PrepaidAmount" xlink:to="bwv_PrepaidAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_PrepaidExpenseRemaining_lbl0" xml:lang="en-US">Amount of prepaid expense remaining.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PrepaidExpenseRemaining" xlink:to="bwv_PrepaidExpenseRemaining_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_PrepaidExpensesToRemainingPrepaidExpenses_lbl0" xml:lang="en-US">It represents of prepaid expenses to remaining prepaid expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PrepaidExpensesToRemainingPrepaidExpenses" xlink:to="bwv_PrepaidExpensesToRemainingPrepaidExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_PricePerShare_lbl0" xml:lang="en-US">Price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PricePerShare" xlink:to="bwv_PricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_PurchasePricePerShare_lbl0" xml:lang="en-US">Purchase price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PurchasePricePerShare" xlink:to="bwv_PurchasePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_RoyaltyOnSumReceivedFromSublicenseePercentage_lbl0" xml:lang="en-US">Royalty on sum received from sublicensee of percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_RoyaltyOnSumReceivedFromSublicenseePercentage" xlink:to="bwv_RoyaltyOnSumReceivedFromSublicenseePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_RoyaltyPaymentsPercentage_lbl0" xml:lang="en-US">Royalty payments percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_RoyaltyPaymentsPercentage" xlink:to="bwv_RoyaltyPaymentsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_RoyaltyRateDecreasePostValidClaimExpiration_lbl0" xml:lang="en-US">Percentage of royalty rate decrease post valid claim expiration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_RoyaltyRateDecreasePostValidClaimExpiration" xlink:to="bwv_RoyaltyRateDecreasePostValidClaimExpiration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_RoyaltyRatePercentage_lbl1" xml:lang="en-US">Royalty rate percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_RoyaltyRatePercentage" xlink:to="bwv_RoyaltyRatePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_SeriesSeedPreferredStock_lbl0" xml:lang="en-US">Series Seed Preferred Stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_SeriesSeedPreferredStock" xlink:to="bwv_SeriesSeedPreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_SharesPercentage_lbl0" xml:lang="en-US">Shares percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_SharesPercentage" xlink:to="bwv_SharesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_SpecifiedMilestones_lbl0" xml:lang="en-US">It represents of specified milestones.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_SpecifiedMilestones" xlink:to="bwv_SpecifiedMilestones_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_TerminationFee_lbl0" xml:lang="en-US">Definite liabilities to third parties under a termination loan agreement, whether or not guaranteed in whole or in part by the government.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_TerminationFee" xlink:to="bwv_TerminationFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_TotalShares_lbl0" xml:lang="en-US">Total shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_TotalShares" xlink:to="bwv_TotalShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_UnderwrittenPublicOfferingNettingProceeds_lbl0" xml:lang="en-US">Underwritten public offering netting proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_UnderwrittenPublicOfferingNettingProceeds" xlink:to="bwv_UnderwrittenPublicOfferingNettingProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_WarrantsToPurchaseSharesOfCommonStock_lbl0" xml:lang="en-US">Warrants to purchase shares of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_WarrantsToPurchaseSharesOfCommonStock" xlink:to="bwv_WarrantsToPurchaseSharesOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bwv_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares_lbl0" xml:lang="en-US">Weighted average number of common shares outstanding, basic and diluted (in Shares).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares" xlink:to="bwv_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_SharesPercentage_lbl1" xml:lang="en-US">SharesPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_SharesPercentage" xlink:to="bwv_SharesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_UnderwriterTerminationAgreementMember_lbl0" xml:lang="en-US">UnderwriterTerminationAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_UnderwriterTerminationAgreementMember" xlink:to="bwv_UnderwriterTerminationAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_UnderwrittenPublicOfferingNettingProceeds_lbl1" xml:lang="en-US">UnderwrittenPublicOfferingNettingProceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_UnderwrittenPublicOfferingNettingProceeds" xlink:to="bwv_UnderwrittenPublicOfferingNettingProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_AggregateAgreementAmountInitialAgreement_lbl1" xml:lang="en-US">AggregateAgreementAmountInitialAgreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AggregateAgreementAmountInitialAgreement" xlink:to="bwv_AggregateAgreementAmountInitialAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_FairValueOfCommonStockPolicyTextBlock_lbl0" xml:lang="en-US">FairValueOfCommonStockPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_FairValueOfCommonStockPolicyTextBlock" xlink:to="bwv_FairValueOfCommonStockPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_PreferredStockSharesDesignated_lbl1" xml:lang="en-US">PreferredStockSharesDesignated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PreferredStockSharesDesignated" xlink:to="bwv_PreferredStockSharesDesignated_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_CumulativeDividendsPerShare_lbl1" xml:lang="en-US">CumulativeDividendsPerShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_CumulativeDividendsPerShare" xlink:to="bwv_CumulativeDividendsPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_PrepaidAmount_lbl1" xml:lang="en-US">PrepaidAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PrepaidAmount" xlink:to="bwv_PrepaidAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_OptionFee_lbl1" xml:lang="en-US">OptionFee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OptionFee" xlink:to="bwv_OptionFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_PrepaidExpenseRemaining_lbl1" xml:lang="en-US">PrepaidExpenseRemaining</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PrepaidExpenseRemaining" xlink:to="bwv_PrepaidExpenseRemaining_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_SignificantAgreementsTextBlock_lbl0" xml:lang="en-US">SignificantAgreementsTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_SignificantAgreementsTextBlock" xlink:to="bwv_SignificantAgreementsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_AggregateOutofPocketExpensesToPlacementAgent_lbl1" xml:lang="en-US">AggregateOutofPocketExpensesToPlacementAgent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AggregateOutofPocketExpensesToPlacementAgent" xlink:to="bwv_AggregateOutofPocketExpensesToPlacementAgent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_PrepaidExpensesToRemainingPrepaidExpenses_lbl1" xml:lang="en-US">PrepaidExpensesToRemainingPrepaidExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PrepaidExpensesToRemainingPrepaidExpenses" xlink:to="bwv_PrepaidExpensesToRemainingPrepaidExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_RoyaltyRatePercentage_lbl2" xml:lang="en-US">RoyaltyRatePercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_RoyaltyRatePercentage" xlink:to="bwv_RoyaltyRatePercentage_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_AnnualMaintenanceFee_lbl1" xml:lang="en-US">AnnualMaintenanceFee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AnnualMaintenanceFee" xlink:to="bwv_AnnualMaintenanceFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_OUIAgreementExpiration_lbl0" xml:lang="en-US">OUIAgreementExpiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OUIAgreementExpiration" xlink:to="bwv_OUIAgreementExpiration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_TotalShares_lbl1" xml:lang="en-US">TotalShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_TotalShares" xlink:to="bwv_TotalShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_OlogyAgreementMember_lbl0" xml:lang="en-US">OlogyAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OlogyAgreementMember" xlink:to="bwv_OlogyAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_StJudeAmendmentMember_lbl0" xml:lang="en-US">StJudeAmendmentMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_StJudeAmendmentMember" xlink:to="bwv_StJudeAmendmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_PercentageOfRoyaltyOnSales_lbl0" xml:lang="en-US">PercentageOfRoyaltyOnSales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PercentageOfRoyaltyOnSales" xlink:to="bwv_PercentageOfRoyaltyOnSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_AggregatePayments_lbl1" xml:lang="en-US">AggregatePayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AggregatePayments" xlink:to="bwv_AggregatePayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_OtherResearchAndDevelopmentExpenses_lbl1" xml:lang="en-US">OtherResearchAndDevelopmentExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OtherResearchAndDevelopmentExpenses" xlink:to="bwv_OtherResearchAndDevelopmentExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_CashFlowsFromOperatingActivitiesAbstract_lbl0" xml:lang="en-US">CashFlowsFromOperatingActivitiesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_CashFlowsFromOperatingActivitiesAbstract" xlink:to="bwv_CashFlowsFromOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_LiquidityAndFinancialConditionTextBlock_lbl0" xml:lang="en-US">LiquidityAndFinancialConditionTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_LiquidityAndFinancialConditionTextBlock" xlink:to="bwv_LiquidityAndFinancialConditionTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_OxfordResearchMember_lbl0" xml:lang="en-US">OxfordResearchMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OxfordResearchMember" xlink:to="bwv_OxfordResearchMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_PrephaseIIIYearMember_lbl0" xml:lang="en-US">PrephaseIIIYearMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PrephaseIIIYearMember" xlink:to="bwv_PrephaseIIIYearMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_SpecifiedMilestones_lbl1" xml:lang="en-US">SpecifiedMilestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_SpecifiedMilestones" xlink:to="bwv_SpecifiedMilestones_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_SeriesSeedPreferredStockMember_lbl1" xml:lang="en-US">SeriesSeedPreferredStockMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_SeriesSeedPreferredStockMember" xlink:to="bwv_SeriesSeedPreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_LitigationsDescription_lbl1" xml:lang="en-US">LitigationsDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_LitigationsDescription" xlink:to="bwv_LitigationsDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_AccuredExpenses_lbl2" xml:lang="en-US">AccuredExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AccuredExpenses" xlink:to="bwv_AccuredExpenses_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_PreferredInvestmentOptionsMember_lbl1" xml:lang="en-US">PreferredInvestmentOptionsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PreferredInvestmentOptionsMember" xlink:to="bwv_PreferredInvestmentOptionsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_SeriesSeedPreferredStock_lbl1" xml:lang="en-US">SeriesSeedPreferredStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_SeriesSeedPreferredStock" xlink:to="bwv_SeriesSeedPreferredStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_ManagementFee_lbl1" xml:lang="en-US">ManagementFee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_ManagementFee" xlink:to="bwv_ManagementFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_PhaseIIIYearMember_lbl0" xml:lang="en-US">PhaseIIIYearMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PhaseIIIYearMember" xlink:to="bwv_PhaseIIIYearMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_ConversionPricePerShares_lbl1" xml:lang="en-US">ConversionPricePerShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_ConversionPricePerShares" xlink:to="bwv_ConversionPricePerShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_PhaseIIMember_lbl0" xml:lang="en-US">PhaseIIMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PhaseIIMember" xlink:to="bwv_PhaseIIMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_CommonStockShareAuthorized_lbl1" xml:lang="en-US">CommonStockShareAuthorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_CommonStockShareAuthorized" xlink:to="bwv_CommonStockShareAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_AccruedDeferredOfferingCosts_lbl1" xml:lang="en-US">AccruedDeferredOfferingCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AccruedDeferredOfferingCosts" xlink:to="bwv_AccruedDeferredOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_CHMCAgreementMember_lbl0" xml:lang="en-US">CHMCAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_CHMCAgreementMember" xlink:to="bwv_CHMCAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_PreferredStockValue1_lbl1" xml:lang="en-US">PreferredStockValue1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PreferredStockValue1" xlink:to="bwv_PreferredStockValue1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_WainwrightWarrantsMember_lbl0" xml:lang="en-US">WainwrightWarrantsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_WainwrightWarrantsMember" xlink:to="bwv_WainwrightWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_CostPlusPercentage_lbl2" xml:lang="en-US">CostPlusPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_CostPlusPercentage" xlink:to="bwv_CostPlusPercentage_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_StJudeAgreementMember_lbl0" xml:lang="en-US">StJudeAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_StJudeAgreementMember" xlink:to="bwv_StJudeAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_AgentFee_lbl1" xml:lang="en-US">AgentFee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AgentFee" xlink:to="bwv_AgentFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_OlogyBioservicesIncMember_lbl0" xml:lang="en-US">OlogyBioservicesIncMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OlogyBioservicesIncMember" xlink:to="bwv_OlogyBioservicesIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_CommercialMilestones_lbl0" xml:lang="en-US">CommercialMilestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_CommercialMilestones" xlink:to="bwv_CommercialMilestones_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_OUIAgreementMember_lbl0" xml:lang="en-US">OUIAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OUIAgreementMember" xlink:to="bwv_OUIAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_RentalDeposits_lbl0" xml:lang="en-US">RentalDeposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_RentalDeposits" xlink:to="bwv_RentalDeposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_OfferingPricePercentage_lbl1" xml:lang="en-US">OfferingPricePercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OfferingPricePercentage" xlink:to="bwv_OfferingPricePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_TerminationFee_lbl1" xml:lang="en-US">TerminationFee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_TerminationFee" xlink:to="bwv_TerminationFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_OptionsToPurchaseSharesOfCommonStock_lbl1" xml:lang="en-US">OptionsToPurchaseSharesOfCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OptionsToPurchaseSharesOfCommonStock" xlink:to="bwv_OptionsToPurchaseSharesOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_StJudeResearchAgreementMember_lbl1" xml:lang="en-US">StJudeResearchAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_StJudeResearchAgreementMember" xlink:to="bwv_StJudeResearchAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare_lbl1" xml:lang="en-US">NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare" xlink:to="bwv_NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_MinimumRoyaltyExpense_lbl1" xml:lang="en-US">MinimumRoyaltyExpense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_MinimumRoyaltyExpense" xlink:to="bwv_MinimumRoyaltyExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_RoyaltyOnSumReceivedFromSublicenseePercentage_lbl1" xml:lang="en-US">RoyaltyOnSumReceivedFromSublicenseePercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_RoyaltyOnSumReceivedFromSublicenseePercentage" xlink:to="bwv_RoyaltyOnSumReceivedFromSublicenseePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_RoyaltyPaymentsPercentage_lbl1" xml:lang="en-US">RoyaltyPaymentsPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_RoyaltyPaymentsPercentage" xlink:to="bwv_RoyaltyPaymentsPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_InitialPublicOfferingShares_lbl1" xml:lang="en-US">InitialPublicOfferingShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_InitialPublicOfferingShares" xlink:to="bwv_InitialPublicOfferingShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_PurchaseObligationDueInThirdYearperiod_lbl0" xml:lang="en-US">PurchaseObligationDueInThirdYearperiod</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PurchaseObligationDueInThirdYearperiod" xlink:to="bwv_PurchaseObligationDueInThirdYearperiod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_AggregatePurchaseShares_lbl1" xml:lang="en-US">AggregatePurchaseShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AggregatePurchaseShares" xlink:to="bwv_AggregatePurchaseShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_PurchasePricePerShare_lbl1" xml:lang="en-US">PurchasePricePerShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PurchasePricePerShare" xlink:to="bwv_PurchasePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_RoyaltyRateDecreasePostValidClaimExpiration_lbl1" xml:lang="en-US">RoyaltyRateDecreasePostValidClaimExpiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_RoyaltyRateDecreasePostValidClaimExpiration" xlink:to="bwv_RoyaltyRateDecreasePostValidClaimExpiration_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_PhaseIMember_lbl0" xml:lang="en-US">PhaseIMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PhaseIMember" xlink:to="bwv_PhaseIMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares_lbl1" xml:lang="en-US">WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares" xlink:to="bwv_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_OfferingCostsNet_lbl0" xml:lang="en-US">OfferingCostsNet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OfferingCostsNet" xlink:to="bwv_OfferingCostsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_InitialPublicOffering_lbl1" xml:lang="en-US">InitialPublicOffering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_InitialPublicOffering" xlink:to="bwv_InitialPublicOffering_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_AccruedResearchAndDevelopment_lbl1" xml:lang="en-US">AccruedResearchAndDevelopment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AccruedResearchAndDevelopment" xlink:to="bwv_AccruedResearchAndDevelopment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_AggregateAmount_lbl1" xml:lang="en-US">AggregateAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AggregateAmount" xlink:to="bwv_AggregateAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_OlogyAmendmentMember_lbl0" xml:lang="en-US">OlogyAmendmentMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OlogyAmendmentMember" xlink:to="bwv_OlogyAmendmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_WarrantsToPurchaseSharesOfCommonStock_lbl1" xml:lang="en-US">WarrantsToPurchaseSharesOfCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_WarrantsToPurchaseSharesOfCommonStock" xlink:to="bwv_WarrantsToPurchaseSharesOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_RegulatoryMilestones_lbl0" xml:lang="en-US">RegulatoryMilestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_RegulatoryMilestones" xlink:to="bwv_RegulatoryMilestones_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_AggregatesPurchaseShares_lbl1" xml:lang="en-US">AggregatesPurchaseShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AggregatesPurchaseShares" xlink:to="bwv_AggregatesPurchaseShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_AggregateSubscriptionAmountPaidPercentage_lbl1" xml:lang="en-US">AggregateSubscriptionAmountPaidPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_AggregateSubscriptionAmountPaidPercentage" xlink:to="bwv_AggregateSubscriptionAmountPaidPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_OriginalIssuePriceMember_lbl0" xml:lang="en-US">OriginalIssuePriceMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_OriginalIssuePriceMember" xlink:to="bwv_OriginalIssuePriceMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_PricePerShare_lbl1" xml:lang="en-US">PricePerShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PricePerShare" xlink:to="bwv_PricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_TwoThousandNinteenEquityIncentivePlanMember_lbl0" xml:lang="en-US">TwoThousandNinteenEquityIncentivePlanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_TwoThousandNinteenEquityIncentivePlanMember" xlink:to="bwv_TwoThousandNinteenEquityIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bwv_PreFundedWarrantsMember_lbl0" xml:lang="en-US">PreFundedWarrantsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bwv_PreFundedWarrantsMember" xlink:to="bwv_PreFundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CumulativeDividends_lbl0" xml:lang="en-US">Cumulative Dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeDividends" xlink:to="us-gaap_CumulativeDividends_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOwnershipInterestsOfferingCosts_lbl0" xml:lang="en-US">Other Ownership Interests, Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:to="us-gaap_OtherOwnershipInterestsOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockNoParValue_lbl0" xml:lang="en-US">Preferred Stock, No Par Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNoParValue" xlink:to="us-gaap_PreferredStockNoParValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl0" xml:lang="en-US">Preferred Stock Dividends and Other Adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Other Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl0" xml:lang="en-US">Lessee, Operating Lease, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl0" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl0" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesAndLicenses_lbl0" xml:lang="en-US">Taxes and Licenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesAndLicenses" xlink:to="us-gaap_TaxesAndLicenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl0" xml:lang="en-US">Due from Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsequentEventsTextBlock_lbl0" xml:lang="en-US">Schedule of Subsequent Events [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsequentEventsTextBlock" xlink:to="us-gaap_ScheduleOfSubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventDescription_lbl0" xml:lang="en-US">Subsequent Event, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventDescription" xlink:to="us-gaap_SubsequentEventDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFee_lbl0" xml:lang="en-US">Debt Instrument, Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFee" xlink:to="us-gaap_DebtInstrumentFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl0" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl1" xml:lang="en-US">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl0" xml:lang="en-US">Operating Costs and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedParties_lbl0" xml:lang="en-US">Due from Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedParties" xlink:to="us-gaap_DueFromRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl0" xml:lang="en-US">Prepaid Expense, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl0" xml:lang="en-US">Stock Option, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrent_lbl0" xml:lang="en-US">Deferred Costs, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl1" xml:lang="en-US">Proceeds from License Fees Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsMiscellaneousCurrent_lbl0" xml:lang="en-US">Other Assets, Miscellaneous, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMiscellaneousCurrent" xlink:to="us-gaap_OtherAssetsMiscellaneousCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesOutstanding_lbl0" xml:lang="en-US">Excess Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesOutstanding" xlink:to="us-gaap_ExcessStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl0" xml:lang="en-US">Payments for Repurchase of Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable, Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesAuthorized_lbl0" xml:lang="en-US">Excess Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesAuthorized" xlink:to="us-gaap_ExcessStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl0" xml:lang="en-US">Payments for Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAdditionalCapital_lbl0" xml:lang="en-US">Other Additional Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAdditionalCapital" xlink:to="us-gaap_OtherAdditionalCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl0" xml:lang="en-US">Prepaid Insurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl1" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl0" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Convertible Preferred Stock, Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" xlink:to="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent_lbl0" xml:lang="en-US">Other Assets, Miscellaneous, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:to="us-gaap_OtherAssetsMiscellaneousNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl0" xml:lang="en-US">Prepaid Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl0" xml:lang="en-US">Payments of Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl0" xml:lang="en-US">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl0" xml:lang="en-US">Deferred Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:to="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare_lbl0" xml:lang="en-US">Preferred Stock, Redemption Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionPricePerShare" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl0" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtDescription_lbl0" xml:lang="en-US">Long-Term Debt, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtDescription" xlink:to="us-gaap_LongTermDebtDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl0" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendPreferenceOrRestrictions_lbl0" xml:lang="en-US">Preferred Stock, Dividend Preference or Restrictions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendPreferenceOrRestrictions" xlink:to="us-gaap_PreferredStockDividendPreferenceOrRestrictions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableAmountPerShare_lbl0" xml:lang="en-US">Dividends Payable, Amount Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableAmountPerShare" xlink:to="us-gaap_DividendsPayableAmountPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl0" xml:lang="en-US">Repayment of Long-Term Debt, Long-Term Lease Obligation, and Capital Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:to="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare_lbl0" xml:lang="en-US">Forward Contract Indexed to Equity, Settlement, Share, Fair Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare" xlink:to="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationDueInThirdYear_lbl0" xml:lang="en-US">Purchase Obligation, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInThirdYear" xlink:to="us-gaap_PurchaseObligationDueInThirdYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensatedAbsencesLiability_lbl0" xml:lang="en-US">Compensated Absences Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensatedAbsencesLiability" xlink:to="us-gaap_CompensatedAbsencesLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_lbl0" xml:lang="en-US">Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl0" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongDurationContractsAssumptionsByProductAndGuaranteeDiscountRate_lbl0" xml:lang="en-US">Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongDurationContractsAssumptionsByProductAndGuaranteeDiscountRate" xlink:to="us-gaap_LongDurationContractsAssumptionsByProductAndGuaranteeDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_lbl0" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl0" xml:lang="en-US">Deposits Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl0" xml:lang="en-US">Retirement Benefits [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl0" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl0" xml:lang="en-US">Cash, FDIC Insured Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockNoParValue_lbl0" xml:lang="en-US">Common Stock, No Par Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl0" xml:lang="en-US">Preferred Stock, Liquidation Preference, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Deposit Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl0" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl0" xml:lang="en-US">Document Quarterly Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesIssued_lbl0" xml:lang="en-US">Excess Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt_lbl0" xml:lang="en-US">Proceeds from (Repayments of) Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl1" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl0" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl0" xml:lang="en-US">Debt Instrument, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAppropriated_lbl0" xml:lang="en-US">Retained Earnings, Appropriated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAppropriated" xlink:to="us-gaap_RetainedEarningsAppropriated_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAndCash_lbl0" xml:lang="en-US">Investments and Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_InvestmentsAndCash_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>bwv-20220331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 13 19:17:58 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_ConsolidatedBalanceSheet" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_ConsolidatedIncomeStatement" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_ShareholdersEquityType2or3" roleURI="http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_ConsolidatedCashFlow" roleURI="http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_OrganizationandBasisofPresentation" roleURI="http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentation"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_LiquidityandFinancialCondition" roleURI="http://www.bluewatervaccines.com/role/LiquidityandFinancialCondition"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_BalanceSheetDetails" roleURI="http://www.bluewatervaccines.com/role/BalanceSheetDetails"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_SignificantAgreements" roleURI="http://www.bluewatervaccines.com/role/SignificantAgreements"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_StockholdersEquity" roleURI="http://www.bluewatervaccines.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_CommitmentsandContingencies" roleURI="http://www.bluewatervaccines.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_RelatedPartyTransactions" roleURI="http://www.bluewatervaccines.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_IncomeTaxes" roleURI="http://www.bluewatervaccines.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_RetirementPlan" roleURI="http://www.bluewatervaccines.com/role/RetirementPlan"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_SubsequentEvents" roleURI="http://www.bluewatervaccines.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_AccountingPoliciesByPolicy" roleURI="http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_BalanceSheetDetailsTables" roleURI="http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_ScheduleofcomputationofdilutedsharesoutstandingTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofcomputationofdilutedsharesoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_ScheduleofprepaidexpensesTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofprepaidexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_ScheduleofaccruedexpensesTable" roleURI="http://www.bluewatervaccines.com/role/ScheduleofaccruedexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_OrganizationandBasisofPresentationDetails" roleURI="http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_LiquidityandFinancialConditionDetails" roleURI="http://www.bluewatervaccines.com/role/LiquidityandFinancialConditionDetails"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_SignificantAgreementsDetails" roleURI="http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_StockholdersEquityDetails" roleURI="http://www.bluewatervaccines.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_CommitmentsandContingenciesDetails" roleURI="http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_RelatedPartyTransactionsDetails" roleURI="http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_RetirementPlanDetails" roleURI="http://www.bluewatervaccines.com/role/RetirementPlanDetails"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#bwv_r_SubsequentEventsDetails" roleURI="http://www.bluewatervaccines.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="bwv-20220331.xsd#DocumentAndEntityInformation" roleURI="http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DeferredCostsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_AssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_Assets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_StockholdersEquityAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredStockValue1" xlink:href="bwv-20220331.xsd#bwv_PreferredStockValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="PreferredStockValue1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredStockSharesDesignated" xlink:href="bwv-20220331.xsd#bwv_PreferredStockSharesDesignated"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="PreferredStockSharesDesignated" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OperatingExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_NetIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare" xlink:href="bwv-20220331.xsd#bwv_NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLoss" xlink:to="NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares" xlink:href="bwv-20220331.xsd#bwv_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLoss" xlink:to="WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="OfferingCostsNet" xlink:href="bwv-20220331.xsd#bwv_OfferingCostsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="OfferingCostsNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="CashFlowsFromOperatingActivitiesAbstract" xlink:href="bwv-20220331.xsd#bwv_CashFlowsFromOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="CashFlowsFromOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DeferredOfferingCosts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentation">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/LiquidityandFinancialCondition">
    <loc xlink:type="locator" xlink:label="LiquidityAndFinancialConditionAbstract" xlink:href="bwv-20220331.xsd#bwv_LiquidityAndFinancialConditionAbstract"/>
    <loc xlink:type="locator" xlink:label="LiquidityAndFinancialConditionTextBlock" xlink:href="bwv-20220331.xsd#bwv_LiquidityAndFinancialConditionTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndFinancialConditionAbstract" xlink:to="LiquidityAndFinancialConditionTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/BalanceSheetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SignificantAgreements">
    <loc xlink:type="locator" xlink:label="SignificantAgreementsAbstract" xlink:href="bwv-20220331.xsd#bwv_SignificantAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAgreementsTextBlock" xlink:href="bwv-20220331.xsd#bwv_SignificantAgreementsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAgreementsAbstract" xlink:to="SignificantAgreementsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/RetirementPlan">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfCommonStockPolicyTextBlock" xlink:href="bwv-20220331.xsd#bwv_FairValueOfCommonStockPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="FairValueOfCommonStockPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofcomputationofdilutedsharesoutstandingTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfComputationOfDilutedSharesOutstandingAbstract" xlink:href="bwv-20220331.xsd#bwv_ScheduleOfComputationOfDilutedSharesOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="OptionsToPurchaseSharesOfCommonStock" xlink:href="bwv-20220331.xsd#bwv_OptionsToPurchaseSharesOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComputationOfDilutedSharesOutstandingAbstract" xlink:to="OptionsToPurchaseSharesOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesSeedPreferredStock" xlink:href="bwv-20220331.xsd#bwv_SeriesSeedPreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComputationOfDilutedSharesOutstandingAbstract" xlink:to="SeriesSeedPreferredStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchaseSharesOfCommonStock" xlink:href="bwv-20220331.xsd#bwv_WarrantsToPurchaseSharesOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComputationOfDilutedSharesOutstandingAbstract" xlink:to="WarrantsToPurchaseSharesOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalShares" xlink:href="bwv-20220331.xsd#bwv_TotalShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsToPurchaseSharesOfCommonStock" xlink:to="TotalShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofprepaidexpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPrepaidExpensesAbstract" xlink:href="bwv-20220331.xsd#bwv_ScheduleOfPrepaidExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAbstract" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAbstract" xlink:to="us-gaap_PrepaidInsurance" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/ScheduleofaccruedexpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccruedExpensesAbstract" xlink:href="bwv-20220331.xsd#bwv_ScheduleOfAccruedExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedExpensesAbstract" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedResearchAndDevelopment" xlink:href="bwv-20220331.xsd#bwv_AccruedResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedExpensesAbstract" xlink:to="AccruedResearchAndDevelopment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedDeferredOfferingCosts" xlink:href="bwv-20220331.xsd#bwv_AccruedDeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedExpensesAbstract" xlink:to="AccruedDeferredOfferingCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensatedAbsencesLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensatedAbsencesLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedExpensesAbstract" xlink:to="us-gaap_CompensatedAbsencesLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedExpensesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedExpensesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedExpensesAbstract" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedExpensesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="InitialPublicOfferingShares" xlink:href="bwv-20220331.xsd#bwv_InitialPublicOfferingShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="InitialPublicOfferingShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PricePerShare" xlink:href="bwv-20220331.xsd#bwv_PricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PricePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialPublicOffering" xlink:href="bwv-20220331.xsd#bwv_InitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="InitialPublicOffering" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/LiquidityandFinancialConditionDetails">
    <loc xlink:type="locator" xlink:label="LiquidityAndFinancialConditionAbstract" xlink:href="bwv-20220331.xsd#bwv_LiquidityAndFinancialConditionAbstract"/>
    <loc xlink:type="locator" xlink:label="LiquidityandFinancialConditionDetailsTable" xlink:href="bwv-20220331.xsd#bwv_LiquidityandFinancialConditionDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LiquidityandFinancialConditionDetailsLineItems" xlink:href="bwv-20220331.xsd#bwv_LiquidityandFinancialConditionDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndFinancialConditionAbstract" xlink:to="LiquidityandFinancialConditionDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityandFinancialConditionDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityandFinancialConditionDetailsTable" xlink:to="LiquidityandFinancialConditionDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityandFinancialConditionDetailsLineItems" xlink:to="us-gaap_InvestmentsAndCash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAdditionalCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAdditionalCapital"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwr9eJsDhBsVZfVtlP9aR4miPG9aL6mOS58KqaHVgLidMi2z82g/tcsacBQzQtHbKODQ/VLlSZXvcdklLkgAYbkbMy97AZwaH6tfqzDj871fqnq7Wqc/uzYF3hiM1Xm0+bx8P64VLx0p+9x2jakJvUXFyZahdnN8LgH/EKlrl6Cv2yT3qYwjnQizoBL7VNI8SPBD/AXSV29OrFEJ4J6jdhl8QQZ6chhA8=] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityandFinancialConditionDetailsLineItems" xlink:to="us-gaap_OtherAdditionalCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAppropriated" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAppropriated"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityandFinancialConditionDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAppropriated" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityandFinancialConditionDetailsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityandFinancialConditionDetailsLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityandFinancialConditionDetailsLineItems" xlink:to="us-gaap_LongTermDebtDescription" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="bwv-20220331.xsd#bwv_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="bwv-20220331.xsd#bwv_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredCostsCurrentAndNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SignificantAgreementsDetails">
    <loc xlink:type="locator" xlink:label="SignificantAgreementsAbstract" xlink:href="bwv-20220331.xsd#bwv_SignificantAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAgreementsDetailsTable" xlink:href="bwv-20220331.xsd#bwv_SignificantAgreementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SignificantAgreementsDetailsLineItems" xlink:href="bwv-20220331.xsd#bwv_SignificantAgreementsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAgreementsAbstract" xlink:to="SignificantAgreementsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAgreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OlogyBioservicesIncMember" xlink:href="bwv-20220331.xsd#bwv_OlogyBioservicesIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="OlogyBioservicesIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAgreementsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAgreementsDetailsTable" xlink:to="SignificantAgreementsDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="OUIAgreementExpiration" xlink:href="bwv-20220331.xsd#bwv_OUIAgreementExpiration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAgreementsDetailsLineItems" xlink:to="OUIAgreementExpiration" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesAndLicenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesAndLicenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAgreementsDetailsLineItems" xlink:to="us-gaap_TaxesAndLicenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateAgreementAmountInitialAgreement" xlink:href="bwv-20220331.xsd#bwv_AggregateAgreementAmountInitialAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAgreementsDetailsLineItems" xlink:to="AggregateAgreementAmountInitialAgreement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidExpensesToRemainingPrepaidExpenses" xlink:href="bwv-20220331.xsd#bwv_PrepaidExpensesToRemainingPrepaidExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAgreementsDetailsLineItems" xlink:to="PrepaidExpensesToRemainingPrepaidExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidExpenseRemaining" xlink:href="bwv-20220331.xsd#bwv_PrepaidExpenseRemaining"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAgreementsDetailsLineItems" xlink:to="PrepaidExpenseRemaining" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateAmount" xlink:href="bwv-20220331.xsd#bwv_AggregateAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAgreementsDetailsLineItems" xlink:to="AggregateAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CostPlusPercentage" xlink:href="bwv-20220331.xsd#bwv_CostPlusPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAgreementsDetailsLineItems" xlink:to="CostPlusPercentage" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAgreementsDetailsLineItems" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccuredExpenses" xlink:href="bwv-20220331.xsd#bwv_AccuredExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAgreementsDetailsLineItems" xlink:to="AccuredExpenses" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAgreementsDetailsLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsTable" xlink:href="bwv-20220331.xsd#bwv_StockholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsLineItems" xlink:href="bwv-20220331.xsd#bwv_StockholdersEquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="StockholdersEquityDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesSeedPreferredStockMember" xlink:href="bwv-20220331.xsd#bwv_SeriesSeedPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesSeedPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginalIssuePriceMember" xlink:href="bwv-20220331.xsd#bwv_OriginalIssuePriceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="OriginalIssuePriceMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandNinteenEquityIncentivePlanMember" xlink:href="bwv-20220331.xsd#bwv_TwoThousandNinteenEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="TwoThousandNinteenEquityIncentivePlanMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="StockholdersEquityDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="CommonStockShareAuthorized" xlink:href="bwv-20220331.xsd#bwv_CommonStockShareAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="CommonStockShareAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNoParValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockNoParValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockNoParValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregatePurchaseShares" xlink:href="bwv-20220331.xsd#bwv_AggregatePurchaseShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="AggregatePurchaseShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongDurationContractsAssumptionsByProductAndGuaranteeDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongDurationContractsAssumptionsByProductAndGuaranteeDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_LongDurationContractsAssumptionsByProductAndGuaranteeDiscountRate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOwnershipInterestsOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherOwnershipInterestsOfferingCosts" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockRedemptionPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesOutstanding" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionPricePerShares" xlink:href="bwv-20220331.xsd#bwv_ConversionPricePerShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="ConversionPricePerShares" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnderwrittenPublicOfferingNettingProceeds" xlink:href="bwv-20220331.xsd#bwv_UnderwrittenPublicOfferingNettingProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="UnderwrittenPublicOfferingNettingProceeds" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfferingPricePercentage" xlink:href="bwv-20220331.xsd#bwv_OfferingPricePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="OfferingPricePercentage" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CumulativeDividendsPerShare" xlink:href="bwv-20220331.xsd#bwv_CumulativeDividendsPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="CumulativeDividendsPerShare" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CumulativeDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CumulativeDividends"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CumulativeDividends" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPayableAmountPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_DividendsPayableAmountPerShare" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendPreferenceOrRestrictions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendPreferenceOrRestrictions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockDividendPreferenceOrRestrictions" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsTable" xlink:href="bwv-20220331.xsd#bwv_CommitmentsandContingenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsLineItems" xlink:href="bwv-20220331.xsd#bwv_CommitmentsandContingenciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsandContingenciesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrephaseIIIYearMember" xlink:href="bwv-20220331.xsd#bwv_PrephaseIIIYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PrephaseIIIYearMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PhaseIIIYearMember" xlink:href="bwv-20220331.xsd#bwv_PhaseIIIYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PhaseIIIYearMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PhaseIMember" xlink:href="bwv-20220331.xsd#bwv_PhaseIMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PhaseIMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PhaseIIMember" xlink:href="bwv-20220331.xsd#bwv_PhaseIIMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PhaseIIMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OUIAgreementMember" xlink:href="bwv-20220331.xsd#bwv_OUIAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="OUIAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OxfordResearchMember" xlink:href="bwv-20220331.xsd#bwv_OxfordResearchMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="OxfordResearchMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StJudeAgreementMember" xlink:href="bwv-20220331.xsd#bwv_StJudeAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="StJudeAgreementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StJudeResearchAgreementMember" xlink:href="bwv-20220331.xsd#bwv_StJudeResearchAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="StJudeResearchAgreementMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CHMCAgreementMember" xlink:href="bwv-20220331.xsd#bwv_CHMCAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="CHMCAgreementMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OlogyAgreementMember" xlink:href="bwv-20220331.xsd#bwv_OlogyAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="OlogyAgreementMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnderwriterTerminationAgreementMember" xlink:href="bwv-20220331.xsd#bwv_UnderwriterTerminationAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="UnderwriterTerminationAgreementMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="CommitmentsandContingenciesDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RentalDeposits" xlink:href="bwv-20220331.xsd#bwv_RentalDeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="RentalDeposits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_PaymentsForRent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LitigationsDescription" xlink:href="bwv-20220331.xsd#bwv_LitigationsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="LitigationsDescription" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfRoyaltyOnSales" xlink:href="bwv-20220331.xsd#bwv_PercentageOfRoyaltyOnSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="PercentageOfRoyaltyOnSales" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MinimumRoyaltyExpense" xlink:href="bwv-20220331.xsd#bwv_MinimumRoyaltyExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="MinimumRoyaltyExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyRatePercentage" xlink:href="bwv-20220331.xsd#bwv_RoyaltyRatePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="RoyaltyRatePercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFee" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyOnSumReceivedFromSublicenseePercentage" xlink:href="bwv-20220331.xsd#bwv_RoyaltyOnSumReceivedFromSublicenseePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="RoyaltyOnSumReceivedFromSublicenseePercentage" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregatePayments" xlink:href="bwv-20220331.xsd#bwv_AggregatePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="AggregatePayments" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SpecifiedMilestones" xlink:href="bwv-20220331.xsd#bwv_SpecifiedMilestones"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="SpecifiedMilestones" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegulatoryMilestones" xlink:href="bwv-20220331.xsd#bwv_RegulatoryMilestones"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="RegulatoryMilestones" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommercialMilestones" xlink:href="bwv-20220331.xsd#bwv_CommercialMilestones"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="CommercialMilestones" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseObligationDueInThirdYearperiod" xlink:href="bwv-20220331.xsd#bwv_PurchaseObligationDueInThirdYearperiod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="PurchaseObligationDueInThirdYearperiod" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PurchaseObligationDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_PurchaseObligationDueInThirdYear" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidAmount" xlink:href="bwv-20220331.xsd#bwv_PrepaidAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="PrepaidAmount" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyPaymentsPercentage" xlink:href="bwv-20220331.xsd#bwv_RoyaltyPaymentsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="RoyaltyPaymentsPercentage" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AnnualMaintenanceFee" xlink:href="bwv-20220331.xsd#bwv_AnnualMaintenanceFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="AnnualMaintenanceFee" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateAmount" xlink:href="bwv-20220331.xsd#bwv_AggregateAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="AggregateAmount" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccuredExpenses" xlink:href="bwv-20220331.xsd#bwv_AccuredExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="AccuredExpenses" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherResearchAndDevelopmentExpenses" xlink:href="bwv-20220331.xsd#bwv_OtherResearchAndDevelopmentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="OtherResearchAndDevelopmentExpenses" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyRateDecreasePostValidClaimExpiration" xlink:href="bwv-20220331.xsd#bwv_RoyaltyRateDecreasePostValidClaimExpiration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="RoyaltyRateDecreasePostValidClaimExpiration" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionFee" xlink:href="bwv-20220331.xsd#bwv_OptionFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="OptionFee" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CostPlusPercentage" xlink:href="bwv-20220331.xsd#bwv_CostPlusPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="CostPlusPercentage" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TerminationFee" xlink:href="bwv-20220331.xsd#bwv_TerminationFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="TerminationFee" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_DueFromRelatedParties" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsMiscellaneousCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_OtherAssetsMiscellaneousCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_OtherAssetsMiscellaneousNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/RetirementPlanDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="bwv-20220331.xsd#bwv_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="bwv-20220331.xsd#bwv_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OlogyAmendmentMember" xlink:href="bwv-20220331.xsd#bwv_OlogyAmendmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="OlogyAmendmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StJudeAmendmentMember" xlink:href="bwv-20220331.xsd#bwv_StJudeAmendmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="StJudeAmendmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreFundedWarrantsMember" xlink:href="bwv-20220331.xsd#bwv_PreFundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="PreFundedWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredInvestmentOptionsMember" xlink:href="bwv-20220331.xsd#bwv_PreferredInvestmentOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="PreferredInvestmentOptionsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="WainwrightWarrantsMember" xlink:href="bwv-20220331.xsd#bwv_WainwrightWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="WainwrightWarrantsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="5.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregatesPurchaseShares" xlink:href="bwv-20220331.xsd#bwv_AggregatesPurchaseShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="AggregatesPurchaseShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasePricePerShare" xlink:href="bwv-20220331.xsd#bwv_PurchasePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="PurchasePricePerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ProceedsFromRepaymentsOfDebt" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgentFee" xlink:href="bwv-20220331.xsd#bwv_AgentFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="AgentFee" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ManagementFee" xlink:href="bwv-20220331.xsd#bwv_ManagementFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ManagementFee" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateOutofPocketExpensesToPlacementAgent" xlink:href="bwv-20220331.xsd#bwv_AggregateOutofPocketExpensesToPlacementAgent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="AggregateOutofPocketExpensesToPlacementAgent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesPercentage" xlink:href="bwv-20220331.xsd#bwv_SharesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="SharesPercentage" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateSubscriptionAmountPaidPercentage" xlink:href="bwv-20220331.xsd#bwv_AggregateSubscriptionAmountPaidPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="AggregateSubscriptionAmountPaidPercentage" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SubsequentEventDescription" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ScheduleOfSubsequentEventsTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyRatePercentage" xlink:href="bwv-20220331.xsd#bwv_RoyaltyRatePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="RoyaltyRatePercentage" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.bluewatervaccines.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="bwv-20220331.xsd#bwv_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ex10-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !6 5D# 2(  A$! Q$!_\0
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M55& !Z5I.M'V:IQ-:F(C[%4H?,?1117,<84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !BBBB@ HQ110 48HHH **** "BBB
M@ HHHH QO$'AC3?$MH(+^'++_JY4X=/H?Z5YKJ/PCOK1S)8:K"R9X\T,C ?5
M<YHHK:E6G#1/0Z*->I#W8O0@LOA1JU[(#<ZG:J@_B7>[?J!7HOAGP1I7AD>9
M AFNR,&XEY;Z#T%%%.K6G+W6]!UL14E[K>ATM%%%8',%%%% !1110 4444 %
2%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583741443992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 12, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Blue Water Vaccines Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BWV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,638,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001782107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-2262816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">201 E. Fifth Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cincinnati<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">OH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">45202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(513)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">620-4101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.00001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583741204248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 18,609,249<span></span>
</td>
<td class="nump">$ 1,928,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">90,005<span></span>
</td>
<td class="nump">234,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred offering costs</a></td>
<td class="nump">238,804<span></span>
</td>
<td class="nump">757,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Receivable from related parties</a></td>
<td class="nump">164,515<span></span>
</td>
<td class="nump">152,524<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">19,102,573<span></span>
</td>
<td class="nump">3,073,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expenses, long-term</a></td>
<td class="nump">129,454<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">15,399<span></span>
</td>
<td class="nump">11,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposit</a></td>
<td class="nump">87,638<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">19,335,064<span></span>
</td>
<td class="nump">3,084,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">907,538<span></span>
</td>
<td class="nump">582,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,893,438<span></span>
</td>
<td class="nump">1,055,515<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,800,976<span></span>
</td>
<td class="nump">1,638,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (see Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.00001 par value, 10,000,000 shares authorized at March 31, 2022 and December 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_PreferredStockValue1', window );">Series Seed: 0 and 1,150,000 shares designated at March 31, 2022 and December 31, 2021, respectively; 0 and 1,146,138 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively; $0 and $15.4 million aggregate liquidation preference at March 31, 2022 and December 31, 2021, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.00001 par value, 250,000,000 shares authorized at March 31, 2022 and December 31, 2021; 11,048,587 and 3,200,000 shares outstanding at March 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="nump">24,561,309<span></span>
</td>
<td class="nump">7,403,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(8,027,331)<span></span>
</td>
<td class="num">(5,956,670)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">16,534,088<span></span>
</td>
<td class="nump">1,446,577<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 19,335,064<span></span>
</td>
<td class="nump">$ 3,084,697<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_PreferredStockValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_PreferredStockValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583735855784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_PreferredStockSharesDesignated', window );">Preferred stock, shares designated</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,146,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,146,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Aggregate liquidation preference shares (in Dollars)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">11,048,587<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_PreferredStockSharesDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock, shares designated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_PreferredStockSharesDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583741416296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating costs and expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 1,615,569<span></span>
</td>
<td class="nump">$ 237,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">455,092<span></span>
</td>
<td class="nump">88,237<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,070,661<span></span>
</td>
<td class="nump">325,781<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,070,661)<span></span>
</td>
<td class="num">(325,781)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,070,661)<span></span>
</td>
<td class="num">(325,781)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Cumulative preferred stock dividends</a></td>
<td class="nump">96,359<span></span>
</td>
<td class="nump">137,687<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss applicable to common stockholders</a></td>
<td class="num">$ (2,167,020)<span></span>
</td>
<td class="num">$ (463,468)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare', window );">Net loss per share attributable to common stockholders, basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares', window );">Weighted average number of common shares outstanding, basic and diluted (in Shares)</a></td>
<td class="nump">6,339,435<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net loss per share attributable to common stockholder, basic and diluted (in Dollars per share).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average number of common shares outstanding, basic and diluted (in Shares).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583741262024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Stockholders&#8217; Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 7,273,063<span></span>
</td>
<td class="num">$ (2,539,336)<span></span>
</td>
<td class="nump">$ 4,733,770<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="nump">1,146,138<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">41,721<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">41,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(325,781)<span></span>
</td>
<td class="num">(325,781)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">7,314,784<span></span>
</td>
<td class="num">(2,865,117)<span></span>
</td>
<td class="nump">4,449,710<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2021</a></td>
<td class="nump">1,146,138<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">7,403,204<span></span>
</td>
<td class="num">(5,956,670)<span></span>
</td>
<td class="nump">1,446,577<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">1,146,138<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in initial public offering, net of $2.9 million of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">17,138,818<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,138,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in initial public offering, net of $2.9 million of offering costs (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,222,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock upon initial public offering</a></td>
<td class="num">$ (11)<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock upon initial public offering (in Shares)</a></td>
<td class="num">(1,146,138)<span></span>
</td>
<td class="nump">5,626,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">19,332<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">19,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,070,661)<span></span>
</td>
<td class="num">(2,070,661)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">$ 24,561,309<span></span>
</td>
<td class="num">$ (8,027,331)<span></span>
</td>
<td class="nump">$ 16,534,088<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,048,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583737857288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Stockholders&#8217; Equity (Unaudited) (Parentheticals)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_OfferingCostsNet', window );">Offering costs, net</a></td>
<td class="nump">$ 2.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_OfferingCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_OfferingCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583735779864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_CashFlowsFromOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,070,661)<span></span>
</td>
<td class="num">$ (325,781)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">1,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">19,332<span></span>
</td>
<td class="nump">41,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">144,546<span></span>
</td>
<td class="num">(57,309)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties', window );">Receivable from related parties</a></td>
<td class="num">(11,991)<span></span>
</td>
<td class="num">(5,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, long-term</a></td>
<td class="num">(129,454)<span></span>
</td>
<td class="nump">46,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Deposit</a></td>
<td class="num">(87,638)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">896,659<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">351,816<span></span>
</td>
<td class="nump">42,412<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(886,091)<span></span>
</td>
<td class="num">(256,548)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(5,197)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(5,197)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of deferred offering costs</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock in initial public offering, net of underwriting discount</a></td>
<td class="nump">18,400,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of initial public offering costs</a></td>
<td class="num">(822,937)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">17,572,063<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash</a></td>
<td class="nump">16,680,775<span></span>
</td>
<td class="num">(256,548)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, beginning of period</a></td>
<td class="nump">1,928,474<span></span>
</td>
<td class="nump">4,308,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, end of period</a></td>
<td class="nump">18,609,249<span></span>
</td>
<td class="nump">4,052,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs included in accounts payable and accrued expenses</a></td>
<td class="nump">233,804<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible preferred stock to common stock upon initial public offering</a></td>
<td class="nump">45<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering', window );">Initial public offering costs included in accounts payable</a></td>
<td class="nump">$ 104,035<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_CashFlowsFromOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_CashFlowsFromOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583737823496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;1 &#8212;&#160;Organization and Basis of Presentation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Organization and Nature of Operations</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Blue Water Vaccines Inc. (the &#8220;Company&#8221;)
was formed on October&#160;26, 2018, to focus on the research and development of transformational vaccines to prevent infectious diseases
worldwide. The Company&#8217;s lead vaccine candidates, BWV-101 and BWV-102, are being investigated as a universal influenza vaccine with
the potential against all influenza strains and may provide a first-in-class long-term global vaccine that protects millions. The Company&#8217;s
proprietary, immunogenic, multi-purpose platform enables the Company to bioengineer viral nanoparticles to deliver antigens, enhancing
immunity, in an array of infectious disease agents, including influenza. All of the Company&#8217;s vaccine candidates are in the pre-clinical
developmental stage.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Initial Public Offering</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">On February 23, 2022, the Company completed its
initial public offering (&#8220;IPO&#8221;) in which the Company issued and sold 2,222,222 shares of its common stock, at a price to the
public of $9.00 per share. Proceeds from the IPO, net of underwriting discounts, commissions, and offering costs of $2.9 million, were
$17.1 million. In connection with the completion of the IPO, all outstanding shares of convertible preferred stock were converted into
5,626,365 shares of common stock. See Note 6.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Stock Split</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On November&#160;24, 2021, the Company&#8217;s
board of directors approved a 4-for-1 (4:1) stock split (the &#8220;Stock Split&#8221;) of the Company&#8217;s common stock without any
change to its par value, which became effective on November&#160;24, 2021. All references to share and per share amounts for all periods
presented in these financial statements have been retrospectively restated to reflect the Stock Split and proportional adjustment of the
preferred stock conversion ratio. Par values were not adjusted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&#8217;s unaudited condensed financial
statements have been prepared in conformity with accounting principles generally accepted in the United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583737842520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Financial Condition<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_LiquidityAndFinancialConditionAbstract', window );"><strong>Liquidity and Financial Condition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_LiquidityAndFinancialConditionTextBlock', window );">Liquidity and Financial Condition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;2 &#8212;&#160;Liquidity and Financial Condition</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company has had limited operating activities
to date, substantially all of which have been devoted to seeking licenses and engaging in research and development activities. The Company&#8217;s
product candidates currently under development will require significant additional research and development efforts prior to commercialization.
The Company has financed its operations since inception primarily using proceeds received from seed investors, and proceeds received upon
the completion of its IPO.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company has incurred substantial operating
losses since inception and expects to continue to incur significant operating losses for the foreseeable future. As of March 31, 2022,
the Company had cash of approximately $18.6&#160;million, working capital of approximately $16.3&#160;million and an accumulated deficit
of approximately $8.0 million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On April 19, 2022, the Company completed a private
placement in which it received approximately $7.0 million in net proceeds, after deducting placement agent fees and other initial offering
expenses, see Note 11.&#160;The Company believes the existing cash at March&#160;31, 2022, together with the net proceeds received upon
the close of the private placement, will be sufficient to continue operations, satisfy its obligations and fund the future expenditures
that will be required to conduct the clinical and regulatory work to develop its product candidates for at least&#160;one year&#160;after
the date that these financial statements are available to be issued. As such, the Company determined that it is not probable based on
projected cash flows that substantial doubt about the Company&#8217;s ability to continue as a going concern exists for the one-year period
following the date that the financial statements for the three months ended March 31, 2022 were available to be issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company will require significant additional
capital to make the investments it needs to execute its longer-term business plan. The Company expects a significant increase in cash
outflows as compared to its historical spend for its planned pre-clinical development and clinical trial activities, and as such, it will
need to raise additional capital to sustain operations and meet its long-term operating requirements beyond the one year period following
the issuance of these financial statements. The Company expects to seek additional funding through additional debt or equity financings;
however, there are currently no commitments in place for further financing nor is there any assurance that such financing will be available
to the Company on favorable terms, if at all. If the Company is unable to secure additional capital, it may be required to curtail any
clinical trials and development of products and take additional measures to reduce expenses in order to conserve its cash in amounts sufficient
to sustain operations and meet its obligations in the long-term.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_LiquidityAndFinancialConditionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_LiquidityAndFinancialConditionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_LiquidityAndFinancialConditionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_LiquidityAndFinancialConditionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583737726312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;3 &#8212;&#160;Summary of Significant Accounting Policies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The preparation of financial statements in conformity
with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the
reporting periods. The most significant estimates in the Company&#8217;s financial statements relate to the valuation of common stock,
stock-based compensation, accrued research and development expenses and the valuation allowance of deferred tax assets resulting from
net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed
to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets
and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and
adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s
future results of operations will be affected.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Unaudited Interim Financial Statements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The accompanying condensed balance sheet as of March&#160;31, 2022,
and the condensed statements of operations, the condensed statements of changes in stockholders&#8217; equity, and the condensed
statements of cash flows for the three months ended March&#160;31, 2022 and 2021 are unaudited. These unaudited interim financial
statements have been prepared on the same basis as the audited financial statements, and in management&#8217;s opinion, include all
adjustments, consisting of only normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial
position as of March&#160;31, 2022 and its results of operations and cash flows for the three months ended March&#160;31, 2022 and
2021. The financial data and the other financial information disclosed in the notes to these condensed financial statements related
to the three-month&#160;periods are also unaudited. Operating results for the three months ended March&#160;31, 2022 are not
necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022, <span>any
other interim periods, or any future year or period</span>. The unaudited condensed financial statements included in this Quarterly
Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the
Company&#8217;s annual report on Form 10-K for the year</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">ended December 31, 2021, which includes a broader discussion of the Company&#8217;s
business and the risks inherent therein.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Concentration of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Financial instruments that potentially subject
the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal
Depository Insurance Coverage limit of $250,000. As of March 31, 2022 and December&#160;31, 2021, the Company has not experienced losses
on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Property and Equipment</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Property and equipment consists of computers and
office furniture and fixtures, all of which are recorded at cost. Depreciation is recorded using the straight-line method over the respective
useful lives of the assets ranging from <span style="-sec-ix-hidden: hidden-fact-38">three</span> to <span style="-sec-ix-hidden: hidden-fact-39">seven</span>&#160;years. Long-lived assets are reviewed for impairment whenever events or circumstances
indicate that the carrying amount of these assets may not be recoverable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Fair Value Measurements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Fair value is defined as the price that would
be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement
date. U.S.&#160;GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and
the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In some circumstances, the inputs used to measure
fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is
categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
Financial instruments, including cash, prepaid expenses, deferred offering costs, receivables from related parties, accounts payable and
accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.
<span>None of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a
non-recurring basis. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Deferred Offering Costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>The Company
capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings
as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded
in stockholders&#8217; equity as a reduction of proceeds generated as a result of the offering. Should the in-process equity financing
be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations.
As of March 31, 2022, all previously deferred offering costs related to the IPO, totaling approximately $0.8&#160;million, and of which
$0.3 million were paid during 2021, were netted against the proceeds received upon the closing of the IPO, which occurred on February
23, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and Development</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company expenses the cost of research and
development as incurred. Research and development expenses include costs incurred in funding research and development activities, license
fees, and other external costs. Advance payments for goods and services that will be used in future research and development activities
are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and
milestone payments due to third parties that perform research and development services on the Company&#8217;s behalf will be expensed
as services are rendered or when the milestone is achieved. When billing terms under research and development contracts do not coincide
with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of period end to
those third parties. Accrual estimates are based on several factors, including the Company&#8217;s knowledge of the progress towards completion
of the research and development activities, invoicing to date under the contracts, communication from the research institution or other
companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant
judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ
from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the
actual costs. See Notes 5 and 7.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In accordance with FASB ASC Topic&#160;730-10-25-1,&#160;<i>Research
and Development,</i> costs incurred in obtaining licenses and patent rights are charged to research and development expense if the technology
licensed has not reached commercial feasibility and has no alternative future use. The licenses purchased by the Company (see Note&#160;5)
require substantial completion of research and development, regulatory and marketing approval efforts to reach commercial feasibility
and have no alternative future use. Accordingly, the total purchase price for the licenses acquired is reflected as research and development
on the Company&#8217;s statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Stock-Based Compensation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company expenses stock-based compensation
to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. Stock-based
awards to employees with graded-vesting schedules are recognized, using the accelerated attribution method, on a straight-line basis over
the requisite service period for each separately vesting portion of the award.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company estimates the fair value of stock
option grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards
represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>Expected Term</i>&#160;&#8212;&#160;The expected term
of options represents the period that the Company&#8217;s stock-based awards are expected to be outstanding based on the simplified method,
which is the half-life from vesting to the end of its contractual term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><i>Expected Volatility</i>&#160;&#8212;Volatility is a measure
of the amount by which the Company&#8217;s share price has historically fluctuated or is expected to fluctuate (i.e., expected volatility)
during a period. &#160;<span>Due to the lack of an adequate history of a public market for the trading
of the Company&#8217;s common stock and a lack of adequate company-specific historical and implied volatility data, </span>the Company
computes stock price volatility over expected terms based on comparable companies&#8217; historical common stock trading prices. For these
analyses, the Company has selected companies with comparable characteristics, including enterprise value, risk profiles, and position
within the industry, and with historical share price information sufficient to meet the expected term of the stock-based awards.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>Common Stock Fair Value</i>&#160;&#8212;&#160;<span>Due
to the absence of an active market for the Company&#8217;s common stock prior to the IPO, t</span>he fair value of the common stock underlying
the Company&#8217;s stock options was estimated at each grant date and was determined with the assistance of an independent third-party
valuation expert. The assumptions underlying these valuations represented management&#8217;s best estimates, which involved inherent uncertainties
and the application of significant levels of management judgment. <span>After the completion of the IPO,
the fair value of each share of common stock is based on the closing price of the Company&#8217;s common stock as reported by the Nasdaq
Capital Market.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>Risk-Free Interest Rate</i>&#160;&#8212;&#160;The Company
bases the risk-free interest rate on the implied yield available on U.S.&#160;Treasury securities with a remaining term commensurate with
the estimated expected term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>Expected Dividend</i>&#160;&#8212;&#160;The Company has
never declared or paid any cash dividends on its shares of common stock and does not plan to pay cash dividends in the foreseeable future,
and, therefore, uses an expected dividend yield of zero in its valuation models.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company recognizes forfeitures of equity awards
as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Fair Value of Common Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In order to determine the fair value of shares
of common stock of the Company when issuing stock options prior to the IPO, its board of directors considered with input from third party
valuations, among other things, contemporaneous valuations of the Company&#8217;s common stock. Given the absence of a public trading
market of the Company&#8217;s capital stock prior to its IPO, its board of directors has exercised reasonable judgment and considered
a number of objective and subjective factors to determine the best estimate of the fair value of the Company common and preferred stock,
including:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the prices, rights, preferences and privileges of the Company&#8217;s preferred stock relative to the Company&#8217;s common stock;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company&#8217;s business, financial condition and results of operations, including related industry trends affecting the Company&#8217;s operations;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the likelihood of achieving a liquidity event, such as an IPO, or sale of the Company, given prevailing market conditions;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the lack of marketability of the Company&#8217;s common stock;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the market performance of comparable publicly traded companies;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.&#160;and global economic and capital market conditions and outlook; and</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">common stock valuation methodology.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In estimating the fair market value of common
stock of the Company, its board of directors first determined the equity value of its business using accepted valuation methods.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company engaged a third-party valuation specialist
to conduct a valuation, which used its most recent preferred stock financing as a starting point and determined the equity value of the
Company based on the Backsolve method using an Option Pricing Method (OPM) to calculate the implied value based on a market approach.
The Company&#8217;s equity value was allocated using OPM to estimate the fair market value of the Company&#8217;s classes of equity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>After the completion of the IPO,
the fair value of each share of common stock is based on the closing price of the Company&#8217;s common stock as reported by the Nasdaq
Capital Market.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Income Taxes</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Income taxes are accounted for under the asset
and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between
the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax
credit carryforwards.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be
recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rate is recognized in operations in the period
that includes the enactment date. Deferred tax assets are reduced to estimated amounts expected to be realized by the use of a valuation
allowance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Comprehensive Income (Loss)</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company is required to report all components
of comprehensive income (loss), including net income (loss), in the accompanying condensed financial statements in the period in which
they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events
and circumstances from non-owner sources, including unrealized gains and losses on investments and foreign currency translation adjustments.
Net loss and comprehensive loss were the same for all periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span><b><i>Warrants</i></b></span></p><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>The
Company determines the accounting classification of warrants that are issued, as either liability or equity, by first assessing whether
the warrants meet liability classification in accordance with ASC 480-10, <i>Accounting for Certain Financial Instruments with Characteristics
of both Liabilities and Equity</i>, (&#8220;ASC 480-10&#8221;), and then in accordance with ASC 815-40, <i>Derivatives and Hedging - Contracts
in Entity's Own Equity</i> (&#8220;ASC 815-40&#8221;). Under ASC 480-10, warrants are considered liability-classified if the warrants
are mandatorily redeemable, obligate the issuer to settle the warrants or the underlying shares by paying cash or other assets, or must
or may require settlement by issuing variable number of shares. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15.5pt 0pt 4.5pt; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>If
the warrants do not meet liability classification under ASC 480-10, the Company assesses the requirements under ASC 815-40, which states
that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective
of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability
classification under ASC 815-40, in order to conclude equity classification, the Company assesses whether the warrants are indexed to
its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP. After all relevant assessments
are made, the Company concludes whether the warrants are classified as liability or equity. Liability-classified warrants are required
to be accounted for at fair value both on the date of issuance and on subsequent accounting period ending dates, with all changes in fair
value after the issuance date recorded as a component of other income (expense), net in the statements of operations. Equity-classified
warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date. As of
March 31, 2022, all of the Company&#8217;s outstanding warrants are equity-classified warrants.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15.5pt 0pt 4.5pt; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Net Loss Per Share</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Basic loss per share is computed by dividing the
net income or loss applicable to common shares by the weighted average number of common shares outstanding during the period. Diluted
earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding
during the period. Potential common shares consist of the Company&#8217;s preferred stock, warrants and options. Diluted loss per share
excludes the shares issuable upon the conversion of preferred stock, as well as common stock options and warrants, from the calculation
of net loss per share if their effect would be anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The two-class method is used to determine earnings
per share based on participation rights of participating securities in any undistributed earnings. Each preferred stock that includes
rights to participate in distributed earnings is considered a participating security and the Company uses the two-class method to calculate
net income available to the Company&#8217;s common stockholders per common share&#160;&#8212;&#160;basic and diluted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following securities were excluded from the
computation of diluted shares outstanding due to the losses incurred in the periods presented, as they would have had an anti-dilutive
impact on the Company&#8217;s net loss:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Options to purchase shares of common stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">780,640</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">780,640</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Series&#160;Seed Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,584,552</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Warrants to purchase shares of common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">111,111</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">891,751</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,365,192</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>New Accounting Pronouncement</i>s</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In April 2012, the Jump-Start Our Business Startups
Act (the &#8220;JOBS Act&#8221;) was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting
requirements for an emerging growth company. As an emerging growth company, the Company may elect to adopt new or revised accounting standards
when they become effective for non-public companies, which typically is later than when public companies must adopt the standards. The
Company has elected to take advantage of the extended transition period afforded by the JOBS Act and, as a result, unless the Company
elects early adoption of any standards, will adopt the new or revised accounting standards on the relevant dates on which adoption of
such standards is required for non-public companies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In August&#160;2020, the FASB issued ASU No.&#160;2020-06,&#160;<i>Debt&#160;&#8212;&#160;Debt
with Conversion and Other Options (Subtopic&#160;470-20) and Derivatives and Hedging&#160;&#8212;&#160;Contracts in Entity&#8217;s Own
Equity (Subtopic&#160;815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>, which simplifies
accounting for convertible instruments by removing major separation models required under current GAAP.&#160;The ASU also removes certain</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">settlement conditions that are required for equity contracts to qualify
for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This guidance is
effective for public business entities except for smaller reporting companies for fiscal&#160;years, and interim periods within those
fiscal&#160;years, beginning after December&#160;15, 2021. For all other entities, the standard will be effective for fiscal&#160;years
beginning after December&#160;15, 2023, including interim periods within those fiscal&#160;years. Early adoption is permitted. The Company
adopted ASU&#160;2020-06 on January&#160;1, 2022, using the modified retrospective method, and the adoption of the ASU did not impact
the Company&#8217;s financial position, results of operations, cash flows or net loss per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In October 2020, the FASB issued&#160;ASU 2020-10,&#160;Codification
Improvements, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC&#8217;s
regulations. The Company&#160;adopted&#160;ASU&#160;2020-10&#160;as of the reporting period beginning January 1, 2022. The adoption of
this update did not have a material effect on the Company&#8217;s financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In May&#160;2021, the FASB issued ASU&#160;2021-04,
Earnings Per Share (Topic&#160;260), Debt&#160;&#8212;&#160;Modifications and Extinguishments (Subtopic&#160;470-50), Compensation&#160;&#8212;&#160;Stock
Compensation (Topic&#160;718), and Derivatives and Hedging&#160;&#8212;&#160;Contracts in Entity&#8217;s Own Equity (Subtopic&#160;815-40):
Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of
the FASB Emerging Issues Task Force). The ASU clarifies and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges
of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange.
The ASU provides guidance that will clarify whether an issuer should account for a modification or an exchange of a freestanding equity-classified
written call option that remains equity classified after modification or exchange as (1)&#160;an adjustment to equity and, if so, the
related earnings per share (EPS) effects, if any, or (2)&#160;an expense and, if so, the manner and pattern of recognition. The new guidance
is effective for all entities for annual and interim periods beginning after December&#160;15, 2021, and early adoption is permitted,
including adoption in an interim period. The Company adopted ASU&#160;2021-04 on January&#160;1, 2022, and the adoption of the ASU did
not impact the Company&#8217;s financial position, results of operations, cash flows, or net loss per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&#8217;s management does not believe
that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying
condensed financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583737768328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Details</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;4 &#8212;&#160;Balance Sheet Details</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Prepaid Expenses</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Prepaid expenses consisted of the following as
of March 31, 2022 and December&#160;31, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> March&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">69,205</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">203,910</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,842</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Prepaid other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,799</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">90,005</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">234,551</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Accrued Expenses</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Accrued expenses consisted of the following as
of March 31, 2022 and December&#160;31, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> March&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued license fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">227,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">225,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">564,634</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,182</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">187,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">246,236</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">680,537</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">234,265</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued insurance expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118,988</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued board of directors&#8217; compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">80,529</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">49,832</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,893,438</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,055,515</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583737905064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_SignificantAgreementsAbstract', window );"><strong>Significant Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_SignificantAgreementsTextBlock', window );">Significant Agreements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;5 &#8212;&#160;Significant Agreements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Oxford University Innovation Limited</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In December&#160;2018, the Company entered into
an option agreement Oxford University Innovation (&#8220;OUI&#8221;), which was a precursor to a license agreement (the &#8220;OUI Agreement&#8221;),
dated July&#160;16, 2019. Under the terms of the OUI Agreement, the Company holds an exclusive, worldwide license to certain specified
patent rights and biological materials relating to the use of epitopes of limited variability and virus-like particle products and practice
processes that are covered by the licensed patent rights and biological materials for the purpose of developing and commercializing a
vaccine product candidate for influenza. The Company is obligated to use its best efforts to develop and market Licensed Products, as
defined in the OUI Agreement, in accordance with its development plan, report to OUI on progress, achieve the following milestones and
must pay OUI nonrefundable milestone fees when it achieves them: initiation of first Phase&#160;I study; initiation of first Phase&#160;II
study; initiation of first Phase&#160;III/pivotal registration studies; first submission of application for regulatory approval (BLA/NDA);
marketing authorization in the United&#160;States; marketing authorization in any EU country; marketing authorization in Japan; first
marketing authorization in any other country; first commercial sale in Japan; first commercial sale in any ROW country; first year that
annual sales equal or exceed certain thresholds. See Note&#160;7 for additional information on the milestone payments as well as royalty
obligations required under the OUI Agreement. The OUI Agreement will expire upon ten (10)&#160;years from the expiration of the last patent
contained in the licensed patent rights, unless terminated earlier. During the year ended December&#160;31, 2021, the U.S.&#160;Patent
related to immunogenic composition was issued to OUI.&#160;This patent expires in August&#160;2037. No additional patents have been issued
during the three months ended March 31, 2022. Either party may terminate the OUI Agreement for an uncured material breach. The Company
may terminate the OUI Agreement for any reason at any time upon six&#160;months&#8217; written notice expiring after the third anniversary
of the OUI Agreement. OUI&#160;may terminate immediately if the Company has a petition presented for its winding-up or passes a resolution
for winding up other than for a bona fide amalgamation or reconstruction or compounds with its creditors or has a receiver or administrator
appointed. OUI may also terminate if the Company opposes or challenges the validity of any of the patents or applications in the Licensed
Technology, as defined in the OUI Agreement; raises the claim that the know-how of the Licensed Technology is not necessary to develop
and market Licensed Products; or in OUI&#8217;s reasonable opinion, is taking inadequate or insufficient steps to develop or market Licensed
Products and does not take any further steps that OUI&#160;requests by written notice within a reasonable time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the&#160;three months ended March 31, 2022
and 2021, the Company did not incur any licensing fee payments for intellectual property licenses. See Note&#160;7.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>St. Jude Children&#8217;s Hospital</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The Company entered into a license agreement (the
&#8220;St. Jude Agreement&#8221;), dated January&#160;27, 2020, with St. Jude Children&#8217;s Research Hospital (&#8220;St. Jude&#8221;).
Under the terms of the St. Jude Agreement, the Company holds an exclusive, worldwide license to certain specified patent rights and biological
materials relating to the use of live attenuated streptococcus pneumoniae and practice processes that are covered by the licensed patent
rights and biological materials for the purpose of developing and commercializing a vaccine product candidate for streptococcus pneumoniae.
The St. Jude Agreement will expire upon the expiration of the last valid claim contained in the licensed patent rights, unless terminated
earlier. The Company is obligated to use commercially reasonable efforts to develop and commercialize the licensed product(s). The milestones
include the following events: (i)&#160;complete IND enabling study; (ii)&#160;initiate animal toxicology study; (iii)&#160;file IND; (iv)&#160;complete
Phase&#160;I Clinical Trial; (v)&#160;commence Phase&#160;II Clinical Trial; (vi)&#160;commence Phase&#160;III Clinical Trial; and, (vii)&#160;regulatory
approval, U.S.&#160;or foreign equivalent. If the Company fails to achieve the development milestones contained in the St. Jude Agreement,
and if the Company and St. Jude fail to agree upon a mutually satisfactory revised timeline, St. Jude will have the right to terminate
the St. Jude Agreement. Either party may terminate the St. Jude Agreement in the event the other party (a)&#160;files or has filed against
it a petition under the Bankruptcy Act (among other things) or (b)&#160;fails to perform or otherwise breaches its obligations under the
St. Jude Agreement, and has not cured such failure or breach within sixty (60)&#160;days. The Company may terminate for any reason on
thirty (30)&#160;days written notice. On May 11, 2022, the Company entered into an amendment to the St.
Jude Agreement, whereby the royalty terms, milestones payments and licensing fees were amended. See Note 11 for more information on this
amendment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the&#160;three months ended March&#160;31,
2022, the Company recognized approximately $3,000 for intellectual property licenses, which is recorded as research and development expenses.
For the three months ended March 31, 2021, the Company did not incur any licensing fee payments for intellectual property licenses. See
Note&#160;7 for additional information on the milestone payments as well as royalty obligations required under the St. Jude Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cincinnati Children&#8217;s Hospital Medical Center</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company entered into a license agreement (the
&#8220;CHMC Agreement&#8221;), dated June&#160;1, 2021, with Children&#8217;s Hospital Medical Center, d/b/a Cincinnati Children&#8217;s
Hospital Medical Center (&#8220;CHMC&#8221;). Under the terms of the CHMC Agreement, the Company holds an exclusive, worldwide license
(other than the excluded field of immunization against, and prevention, control, or reduction in the severity of gastroenteritis caused
by rotavirus and norovirus in China and Hong&#160;Kong) to certain specified patent and biological materials relating to the use of norovirus
nanoparticles and practice processes that are covered by the licensed patent rights and biological materials for the purpose of developing
and commercializing CHMC patents and related technology directed to a virus-like particle vaccine platform that utilizes nanoparticle
delivery technology that may have potential broad application to develop vaccines for multiple infectious diseases. The term of the CHMC
Agreement begins on the effective date and extends on a jurisdiction by jurisdiction and product by product basis until the later of:
(i)&#160;the last to expire licensed patent; (ii)&#160;ten (10)&#160;years after the first commercial sale; or, (iii)&#160;entrance onto
the market of a biosimilar or interchangeable product. The Company is obligated to use commercially reasonable efforts to bring licensed
products to market through diligent research and development, testing, manufacturing and commercialization, to use best efforts to make
all necessary regulatory filings and obtain all necessary regulatory approvals, to achieve milestones relating to development and sales,
and report to CHMC on progress. The Company will also be obligated to pay the agreed upon development milestone payments to CHMC, as well
as royalty payments, see Note&#160;7 for additional information. The Company may terminate the CHMC Agreement for convenience, at any
time prior to first commercial sale of a product or process by providing one hundred and eighty (180)&#160;days&#8217; written notice
to CHMC.&#160;It may also terminate for a CHMC uncured material breach. CHMC may terminate the CHMC Agreement for an uncured Company material
breach or insolvency or bankruptcy. Pursuant to the terms of the CHMC Agreement, if the Company fails to achieve the milestones, and cannot
mutually agree with CHMC on an amendment to the milestones, then CHMC will have the option of converting any and all of such exclusive
licenses to nonexclusive licenses, to continue developing indications that have already entered development at any stage or in which the
Company has invested in developing. CHMC may also terminate the CHMC Agreement to the fullest extent permitted by law in the countries
of the worldwide territory, in the event the Company or its affiliates challenge or induce others set up challenges to the validity or
enforceability of any of the Licensed Patents, as defined in the CHMC Agreement, and the Company will be obligated reimburse CHMC for
its costs, including reasonable attorneys&#8217; fees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the&#160;three months ended March 31, 2022
and 2021, the Company did not incur any licensing fee payments for intellectual property licenses. See Note 7.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Ology Bioservices, Inc. (which was later acquired by National Resilience,
Inc.)</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The Company entered into a Master Services Agreement
(&#8220;Ology MSA&#8221;), dated July&#160;19, 2019, with Ology, Inc. (&#8220;Ology&#8221;) to provide services from time to time, including
but not limited to technology transfer, process development, analytical method optimization, cGMP manufacture, regulatory affairs, and
stability studies of biologic products. Pursuant to the Ology MSA, the Company and Ology&#160;shall&#160;enter into a&#160;Project Addendum
for&#160;each&#160;project&#160;to be governed by the terms and conditions of the Ology MSA.&#160;The Company has entered into two Project
Addendums as of March 31, 2022 and December&#160;31, 2021.&#160;The initial Project Addendum&#160;was executed on October&#160;18, 2019&#160;and&#160;the
Company&#160;was&#160;required to pay Ology an aggregate of approximately $4&#160;million.&#160;Due to unforeseen delays associated with
COVID-19, the Company and Ology entered into a letter agreement dated January&#160;9, 2020 to stop work on the project. The Company paid
Ology $100,000 for services, of which $48,600 remained as a prepaid expense as of December&#160;31, 2020.&#160;The second Project Addendum&#160;was
executed on May&#160;21, 2021&#160;and&#160;the Company is obligated to pay Ology an aggregate amount of approximately $2.8&#160;million,
plus reimbursement for materials and outsourced testing, which will be billed at cost plus 15%. This project began during
2021, and the Company recorded approximately $164,000 and $115,000 as related accounts payable and accrued expenses, respectively, at
December 31, 2021. During the three months ended March 31, 2022, the Company incurred related research and development expenses of approximately
$217,000, and had approximately $332,000 recorded as related accrued expenses at March&#160;31, 2022. See Note&#160;4. There were no such
expenses incurred during the three months ended March 31, 2021. On April 20, 2022, the Company entered into an amendment to the Ology
MSA, whereby the Company&#8217;s obligations increased by $0.3 million, specifically related to regulatory support on the project. See
Note 11.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_SignificantAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_SignificantAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_SignificantAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_SignificantAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583737755048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;6 &#8212;&#160;Stockholders&#8217; Equity</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Authorized Capital and Stock Split</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On February&#160;23, 2022, the Company filed with
the Secretary of State of the State of Delaware an amended and restated certificate of incorporation (the &#8220;A&amp;R COI&#8221;),
which became effective immediately. The Company&#8217;s board of directors and stockholders approved the A&amp;R COI to be effective upon
the closing of the IPO.&#160;There was no change to the Company&#8217;s authorized shares of common stock and preferred stock of 250,000,000
shares and 10,000,000 shares, respectively, or the par value, which is $0.00001 for both common and preferred stock. Prior to this amendment,
the Company had designated 1,150,000 shares of preferred stock, with par value $0.00001 per share. In addition, on February&#160;23, 2022
and in connection with the closing of the IPO, the Company&#8217;s board of directors adopted Amended and Restated Bylaws.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Common Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of March 31, 2022 and December&#160;31, 2021,
there were 11,048,587 and 3,200,000 shares of common stock issued and outstanding, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Holders of the Company&#8217;s common stock are
entitled to one vote for each share held of record, and are entitled upon liquidation of the Company to share ratably in the net assets
of the Company available for distribution after payment of all obligations of the Company and after provision has been made with respect
to each class of stock, if any, having preference over the common stock, currently including the Company&#8217;s preferred stock. The
shares of common stock are not redeemable and have no preemptive or similar rights.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On February&#160;17, 2022, the Company entered
into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Boustead Securities, LLC, acting as representative of the
underwriters (&#8220;Boustead&#8221;), in relation to the Company&#8217;s IPO, pursuant to which the Company agreed to sell to the underwriters
an aggregate of 2,222,222 shares of the Company&#8217;s common stock, at a price of $9.00 per share. The IPO closed on February&#160;23,
2022, and resulted in net proceeds to the Company, after deducting the 8% underwriting discount, and other offering costs, of approximately
$17.1&#160;million. Pursuant to the Underwriting Agreement, the Company issued to Boustead warrants to purchase 111,111 shares of common
stock. The warrants are exercisable, at the option of the holder, at a per share exercise price equal to $10.35 and are exercisable at
any time and from time to time, in whole or in part, starting on February 23, 2022 and terminating on February&#160;11, 2027.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company evaluated the terms of the warrants
issued at the IPO and determined that they should be classified as equity instruments based upon accounting guidance provided in ASC 480
and ASC 815-40. Since the Company determined that the warrants were equity-classified, the Company recorded the proceeds from the IPO,
net of issuance costs, within common stock at par value and the balance of the net proceeds to additional paid in capital. As of March
31, 2022, the outstanding warrants are exercisable into&#160;111,111&#160;shares of common stock whose fair value was $56.50&#160;per
share, based on the closing trading price on that day.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Preferred Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Prior to the close of the IPO, the Company had
designated 1,150,000 shares of preferred stock as Series&#160;Seed Preferred Stock (&#8220;Series&#160;Seed&#8221;), with an original
issue price of $6.09 per share (the &#8220;Original Issue Price&#8221;). As of March 31, 2022 and December&#160;31, 2021, there were 0
and 1,146,138 shares issued and outstanding, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Conversion</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Each share of the Series&#160;Seed was convertible,
at the option of the holder, at any time and from time to time, and without the payment of additional consideration by the holder, at
a conversion price of $1.52 per share, subject to certain adjustments for stock splits, stock dividends, recapitalizations, and similar
corporate transactions, into fully paid and non-assessable shares of the Company&#8217;s common stock. Each Series&#160;Seed share was
automatically convertible into common stock of the Company, at the then-effective conversion price, upon the closing of a firmly underwritten
public offering netting proceeds of at least $50&#160;million with an offering price of at least three hundred percent (300%) of the Original
Issue Price of the Series&#160;Seed. On October&#160;7, 2021, the majority of the holders of the Series&#160;Seed approved the automatic
conversion of the outstanding shares of the Series&#160;Seed and all related accrued and unpaid dividends, upon the close of the IPO.&#160;The
number of conversion shares to be issued upon the close of the IPO were to be calculated in accordance with the original conversion terms
provided by the Company&#8217;s Amended and Restated Certificate of Incorporation (&#8220;COI&#8221;) dated July&#160;1, 2019. This conversion
occurred on February&#160;23, 2022, upon the close of the Company&#8217;s IPO.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Dividends</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Holders of the Series&#160;Seed were entitled
to receive cumulative dividends at a per share rate of 8% per annum, compounded annually, on the initial investment amount commencing
on the date of issue. Dividends were payable only when, as, and if declared by the Board of Directors or upon a Liquidation Event, as
described below. Dividends on Series&#160;Seed were in preference to any dividend on the Company&#8217;s common stock. Upon the close
of the IPO, aggregate cumulative dividends of $1,586,162 or $1.38 per Series&#160;Seed share were automatically converted into shares
of common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Liquidation Preference</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the event of certain voluntary or involuntary
acquisition or sale transactions or upon the liquidation, dissolution or winding up of the Company (each, a &#8220;Liquidation Event&#8221;),
the holders of Series&#160;Seed were entitled to receive out of the proceeds or assets of the Company legally available for distribution
to its stockholders (the&#160;&#8220;Proceeds&#8221;), prior and in preference to any distribution of the Proceeds of such Liquidation
Event to the holders of shares of common stock by reason of their ownership thereof, an amount (&#8220;the Liquidation Preference Amount&#8221;)
determined based on the provisions of the Company&#8217;s COI.&#160;The COI provided that the Liquidation Preference Amount be calculated
upon the occurrence of a Liquidation Event, based on the Company&#8217;s achievement of a Pre-Clinical Milestone and a Qualified Financing,
both as defined in the COI.&#160;Per the provisions of the COI, if a Liquidation Event occurred before a Pre-Clinical Milestone was achieved,
the Liquidation Preference Amount would be equal to two times the Series&#160;Seed Original Issue price per share, plus unpaid cumulative
dividends. If a Liquidation Event occurred after a Pre-Clinical Milestone was achieved, and after a Qualified Financing was completed,
then the Liquidation Preference Amount would be equal to one times the Series&#160;Seed Original Issue price, plus unpaid cumulative dividends.
If a Liquidation Event occurred after a Pre-Clinical Milestone was achieved and before a Qualified Financing was completed, the Liquidation
Preference Amount would be equal to the greater of (a)&#160;such amount per share as such holder would have been entitled to receive after
a Qualified Financing or (b)&#160;two times the Series&#160;Seed Original Issue price, plus unpaid cumulative dividends.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December&#160;31, 2021, and all other prior
historical periods, the Liquidation Preference Amount was equal to two times the Series&#160;Seed Original Issue Price per share, plus
unpaid cumulative dividends. In the event that the Proceeds were insufficient to enable the distribution in full of the Liquidation Preference
Amount to the holders of the Series&#160;Seed for all of the preferred shares held by them, all of the Proceeds were to be distributed
among the</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">holders of Series&#160;Seed on a pro rata basis. Upon completion of
the distribution required to the holders of Series&#160;Seed, all of the remaining Proceeds available for distribution to stockholders
were to be distributed among the holders of common shares and preferred shares, on an as-converted basis, pro rata based on the number
of common shares held by each such holder. However, if upon the occurrence of a Liquidation Event, the Liquidation Preference Amount the
Series&#160;Seed stockholders were entitled to receive is two times the Original Issue Price per share, plus unpaid cumulative dividends,
after such distribution is made, then the remaining Proceeds available for distribution to stockholders were to be distributed among the
holders of common shares, pro rata based on the number of common shares held by each such holder.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Voting</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On any matter presented to the stockholders of
the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in
lieu of meeting), each holder of outstanding shares of Series&#160;Seed were entitled to cast the number of votes equal to the number
of whole shares of common stock into which the shares of Series&#160;Seed held by such holder were convertible as of the record date for
determining stockholders entitled to vote on such matter. Holders of Series&#160;Seed were entitled to vote together with the holder of
common stock as a single class. Holders of Series&#160;Seed were entitled to nominate two out of five of the Company&#8217;s directors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Equity Incentive Plans</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;The Company&#8217;s 2019 Equity Incentive
Plan (the &#8220;2019 Plan&#8221;) was adopted by its board of directors and by its stockholders on July&#160;1, 2019. The Company has
reserved 1,400,000 shares of common stock for issuance pursuant to the 2019 Plan. There were no share-based awards granted under the 2019
Plan during the three months ended March 31, 2022 and 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, on February&#160;23, 2022 and in
connection with the closing of the IPO, the Company&#8217;s board of directors adopted the Company&#8217;s 2022 Equity Incentive Plan
(the &#8220;2022 Plan&#8221;), which is the successor and continuation of the Company&#8217;s 2019 Plan. Under the 2022 Plan, the Company
may grant stock options, restricted stock, restricted stock units, stock appreciation rights, and other forms of awards to&#160;employees,
directors and consultants of the Company. Upon its effectiveness, a total of 1,600,000 shares of common stock were reserved for issuance
under the 2022 Plan. As of March 31, 2022, there were no share-based awards granted under the 2022 Plan.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583737826296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;7 &#8212;&#160;Commitments and Contingencies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Office lease</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The Company leased office space for approximately
$5,500 a month from a related party. The Company paid a $15,000 rental deposit and rent expense for the&#160;three months ended March
31, 2022 and 2021 was approximately $0 and $20,000, respectively. The Company terminated the related party lease in May&#160;2021 and
entered into a new lease with an unrelated party in April&#160;2021. The Company is not a party to a lease with a term in excess of 12&#160;months
and has a month-to-month lease as of March&#160;31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Litigation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">From time to time, the Company may be subject
to various legal proceedings and claims that arise in the ordinary course of its business activities. As of March 31, 2022, the Company
is not a party to any material legal proceedings and is not aware of any pending or threatened claims. See Note 11.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Significant agreements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Oxford University Innovation Limited</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the OUI Agreement, as disclosed in
Note&#160;5, the Company is obligated to pay certain milestone and royalty payments in the future, as the related contingent events occur.
Specifically, the Company is obligated to pay a 6% royalty on all net sales of licensed products, as defined in the OUI Agreement, with
an annual minimum royalty payment of $250,000 starting post-product launch, until the expiration of the OUI Agreement or revocation of
the last valid claim covering a licensed product, at which point a royalty rate of 3% will apply. An annual maintenance fee of $10,000
and $20,000 is required in the pre-phase&#160;III year and Phase&#160;III year, respectively, and as defined in the OUI Agreement. The
Company is also obligated to pay a 25% royalty on any sums received by the Company</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">from any sublicensee (including all up-front, milestone and other one-off
payments received by the Company from any sub-licenses or other contracts granted by the Company with respect to the licensed technology).
In addition, the Company is required to pay OUI milestone payments of up to an aggregate of $51.25&#160;million; specifically, upon the
achievement of specified development milestones of approximately $2.25&#160;million, regulatory milestones of approximately $9.5&#160;million,
and commercial milestones of approximately $39.5&#160;million. The annual maintenance fee and milestone fees are indexed to the RPI (Retail
Prices index for all items which is published in the United Kingdom by the Office for National Statistics, or any replacement of it) and
will be increased or decreased as appropriate as set forth in the OUI Agreement. As of March&#160;31, 2022, the Company evaluated the
likelihood of the Company achieving the specified milestones and generating product sales, and determined the likelihood is not yet probable
and as such no accrual of these payments is required as of March&#160;31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Oxford University Research Agreement</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the terms of the OUI Agreement, as
disclosed in Note&#160;5, the Company entered into a sponsored research agreement dated December&#160;18, 2019 with Oxford University
for research related to the OUI Agreement for a period of <span style="-sec-ix-hidden: hidden-fact-43">three</span>&#160;years for a total of &#163;420,000. The Company prepaid the full
amount to Oxford of $554,802 for the services in January&#160;2020, of which approximately $0.2&#160;million remains as a prepaid expense
as of March 31, 2022 and December&#160;31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>St. Jude Children&#8217;s Hospital</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the St. Jude Agreement, as disclosed
in Note&#160;5, the Company is obligated to pay certain milestone and royalty payments in the future, as the related contingent events
occur. Specifically, the Company is obligated to make 4% royalty payments for each licensed product(s)&#160;sold by the Company or its
affiliates, based on the net sales for the duration of the St. Jude Agreement, and also pay 15% of consideration received for any sublicenses.
The Company is required to pay an annual maintenance fee of $10,000 beginning on the first anniversary of the Effective Date (which is
waived if all of the developmental milestones scheduled for completion before such annual fee is due have been achieved). In addition,
the Company is required to pay St. Jude milestone payments of up to an aggregate of $1&#160;million; specifically, upon the achievement
of specified development milestones of approximately $0.2&#160;million, regulatory milestones of approximately $0.3&#160;million, and
commercial milestones of approximately $0.5&#160;million. On May 11, 2022, the Company entered into an amendment to the St. Jude Agreement,
whereby the royalty terms, milestones payments and licensing fees were amended. See Note 11 for more information on this amendment. As
of March&#160;31, 2022, the Company evaluated the likelihood of the Company achieving the specified milestones and generating product
sales, and determined the likelihood is not yet probable and as such no accrual of these payments is required as of March&#160;31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>St. Jude Children&#8217;s Sponsored Research Agreement</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition to the St. Jude Agreement, the Company
also entered into a sponsored research agreement dated May&#160;3, 2021 with St. Jude for research related to the St. Jude Agreement.
Pursuant to this research agreement, the Company is obligated to pay St. Jude an aggregate amount of $73,073 in two parts, Phase&#160;I
for $57,624 and Phase&#160;II for $15,449. This sponsored research project began during 2021, and the Company recorded approximately $8,000
in related accrued expenses at December 31, 2021. During the three months ended March 31, 2022, the Company incurred related research
and development expenses of approximately $8,000, and had approximately $15,000 recorded as related accrued expenses at March&#160;31,
2022. There were no such expenses incurred during the three months ended March 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cincinnati Children&#8217;s Hospital Medical Center</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the CHMC Agreement, as disclosed in
Note&#160;5, the Company is obligated to pay certain milestone and royalty payments in the future, as the related contingent events occur.
Specifically, the Company is obligated to pay CHMC a single-digit royalty on net sales, being 5%, 4% or 2% depending on the product, until
the last valid claim covering a licensed product exists, at which point the royalty rates decrease by 50%. The Company is also</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">obligated to pay up to a 25% royalty on any non-royalty sublicense
revenue paid to the Company by any sublicensee. The CHMC Agreement also provides the Company with an option to license any CHMC or jointly
patented modification, alteration or improvement of any invention claimed in a Licensed Patent (&#8220;CHMC Improvement&#8221; and &#8220;Joint
Improvement, respectively&#8221;), with a $50,000 option fee for each Improvement that the Company elects to include in the license grant
of the CHMC Agreement. In addition, the Company is required to pay CHMC milestone payments of up to an aggregate of $59.75&#160;million;
specifically, upon the achievement of specified development milestones of approximately $0.5&#160;million, regulatory milestones of approximately
$1.25&#160;million, and commercial milestones of approximately $58&#160;million. As of March&#160;31, 2022, the Company evaluated the
likelihood of the Company achieving the specified milestones and generating product sales, and determined the likelihood is not yet probable
and as such no accrual of these payments is required as of March&#160;31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Ology Bioservices, Inc. (which was later acquired by National Resilience,
Inc.)</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the Ology MSA and the second Project
Addendum, as disclosed in Note&#160;5, the Company is obligated to pay Ology an aggregate amount of approximately $2.8&#160;million,
plus reimbursement for materials and outsourced testing which will be billed at cost plus 15%. This project began during 2021, and the
Company recorded approximately $164,000 and $115,000 as related accounts payable and accrued expenses, respectively, at December 31,
2021. During the three months ended March 31, 2022, the Company incurred related research and development expenses of approximately $217,000,
and had approximately $332,000 recorded as related accrued expenses at March&#160;31, 2022. See Note&#160;4. There were no such expenses
incurred during the three months ended March 31, 2021. This project is currently expected to be performed through the fourth quarter
of 2023. On April 20, 2022, the Company entered into an amendment to the Ology MSA, whereby the Company&#8217;s obligations increased
by $0.3 million, specifically related to regulatory support on the project. See Note 11.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Underwriter Termination Agreement</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On February&#160;7, 2022, the Company and its
former underwriter, Maxim Group (&#8220;Maxim&#8221;), entered into a termination agreement, whereby the parties agreed to terminate their
engagement of Maxim as the Company&#8217;s lead managing underwriter and book runner in connection with the Company&#8217;s IPO.&#160;Per
the terms of the termination agreement, the Company agreed to pay Maxim a termination fee of $300,000, due upon the close of the Company&#8217;s
IPO. The termination fee was recorded as general and administrative expense during the three months ended March 31, 2022, and is included
in accounts payable in the accompanying condensed balance sheet at March 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Indemnification</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the normal course of business, the Company
enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications.
The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the
future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification
obligations. However, the Company may incur charges in the future as a result of these indemnification obligations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Risks and Uncertainties&#160;&#8212;&#160;COVID-19</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Management continues to evaluate the impact of
the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect
on the Company&#8217;s financial position, results of its operations and/or search for drug candidates, the specific impact is not readily
determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from
the outcome of this uncertainty.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583737862344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;8 &#8212;&#160;Related Party Transactions</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company originally engaged the Chief Executive
Officer, who is also the Board Chairman and prior to the close of the IPO, sole common stockholder of the Company, pursuant to a consulting
agreement commencing October&#160;22, 2018, which calls for the Company to pay for consulting services performed on a monthly basis. During
the&#160;three months ended March&#160;31, 2022 and 2021, the Company incurred approximately $63,000 and $105,000 in fees under the consulting
agreement, respectively, which are recognized in general and administrative expenses in the accompanying statements of operations. Upon
the close of the Company&#8217;s IPO, the consulting agreement was terminated and the CEO&#8217;s employment agreement became effective.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company also leased office space from a related
party, through common ownership. The lease is further described in Note&#160;7 of these financial statements. The lease was terminated
in May&#160;2021, and the related deposit was reclassified to the receivable from related parties balance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of March 31, 2022 and December&#160;31, 2021,
the Company has a receivable from related parties of approximately $165,000 and $153,000, respectively. The balance consists primarily
of consulting fee prepayments to the Company&#8217;s CEO, in the amount of $140,000 as of March 31, 2022 and December&#160;31, 2021. These
consulting fee prepayments were repaid to the Company in lieu of a bonus payout due to the CEO during May 2022. The remaining balance
as of March 31, 2022 consists of approximately $18,000 and $7,000 of miscellaneous payments made by the Company on the behalf of the CEO
and Chief Business Officer, respectively.&#160; The balance due from the Chief Business Officer was repaid to the Company in April 2022.
The remaining balance as of December&#160;31, 2021 consists of miscellaneous payments made by the Company on the behalf of the CEO.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">One of the Company&#8217;s directors serves on
the Advisory Board for the Cincinnati Children&#8217;s Hospital Medical Center Innovation Fund, which is affiliated with CHMC.&#160;The
Company has an exclusive license agreement with CHMC as disclosed in Note&#160;5. This director resigned from the Company&#8217;s board
upon the close of its IPO.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583737860664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;9 &#8212;&#160;Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">No provision for federal, state or foreign income
taxes has been recorded for the three months ended March 31, 2022 and 2021. The Company has incurred net operating losses for all of the
periods presented and has not reflected any benefit of such net operating loss carryforwards in the accompanying financial statements
due to uncertainty around utilizing these tax attributes within their respective carryforward periods. The Company has recorded a full
valuation allowance against all of its deferred tax assets as it is not more likely than not that such assets will be realized in the
near future. The Company&#8217;s policy is to recognize interest expense and penalties related to income tax matters as income tax expense.
For the three months ended March 31, 2022 and 2021, the Company has not recognized any interest or penalties related to income taxes.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583740916840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Plan</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note&#160;10 &#8212;&#160;Retirement Plan</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Effective January&#160;1, 2022, the Company adopted
a defined contribution savings plan pursuant to Section&#160;401(k)&#160;of the Internal Revenue Code (&#8220;the 401(k) Plan&#8221;).
The 401(k) Plan is for the benefit of all qualifying employees and permits voluntary contributions by employees of up to 100% of eligible
compensation, subject to the maximum limits imposed by the Internal Revenue Service. The terms of the 401(k) Plan allow for discretionary
employer contributions. Enrollment in the 401(k) Plan will become available during the second quarter of 2022. No expenses were incurred
related to the 401(k) Plan during the three months ended March 31, 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583737881000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note&#160;11
&#8212;&#160;Subsequent Events</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;On April 19, 2022, the Company consummated
the closing of a private placement (the &#8220;Private Placement&#8221;), pursuant to the terms and conditions of a securities purchase
agreement, dated as of April 13, 2022. At the closing of the Private Placement, the Company issued 590,406 shares of common stock (the
&#8220;Shares&#8221;), pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase an aggregate of 590,406 shares of common
stock and preferred investment options (the &#8220;Preferred Investment Options&#8221;) to purchase up to an aggregate of 1,180,812 shares
of common stock. The purchase price of each Share together with the associated Preferred Investment Option was $6.775, and the purchase
price of each Pre-Funded Warrant together with the associated Preferred Investment Option was $6.774. The aggregate net proceeds to the
Company from the Private Placement were approximately $7.0 million, after deducting placement agent fees and other initial offering expenses.
H.C. Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;) acted as the exclusive placement agent for the Private Placement. The Pre-Funded
Warrants have an exercise price of $0.001 per share, are exercisable on or after April 19, 2022, and are exercisable until the Pre-Funded
Warrants are exercised in full. The Preferred Investment Options are exercisable at any time on or after April 19, 2022 at an exercise
price of $6.65 per share, subject to certain adjustments as defined in the agreement. The Company agreed to pay Wainwright a placement
agent fee and management fee equal to 7.5% and 1.0%, respectively, of the aggregate gross proceeds from the Private Placement and reimburse
certain out-of-pocket expenses up to an aggregate of $85,000. In addition, the Company issued warrants to Wainwright (the &#8220;Wainwright
Warrants&#8221;) to purchase up to 70,849 shares of common stock. The Wainwright Warrants are in substantially the same form as the Preferred
Investment Options, except that the exercise price is $8.46875. Further, upon any exercise for cash of any Preferred Investment Options,
the Company agreed to issue to Wainwright warrants to purchase the number of Shares equal to 6.0% of the aggregate number of Shares underlying
the Preferred Investment Options that have been exercised, also with an exercise price of $8.46875.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In connection with the Private Placement, the
Company entered into a Registration Rights Agreement with the purchasers, dated as of April 13, 2022 (the &#8220;Registration Rights Agreement&#8221;).
The Registration Rights Agreement provides that the Company shall file a registration statement covering the resale of all of the registrable
securities (as defined in the Registration Rights Agreement) with the Securities and Exchange Commission (the &#8220;SEC&#8221;) no later
than the 20th calendar day following the date of the Registration Rights Agreement and have the registration statement declared effective
by the SEC as promptly as possible after the filing thereof, but in any event no later than the 45th calendar day following April 13,
2022 or, in the event of a full review by the SEC, the 75th day following April 13, 2022. The registration statement on Form S-1 required
under the Registration Rights Agreement was filed with the SEC on May 3, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Upon the occurrence of any Event (as defined in
the Registration Rights Agreement), which, among others, prohibits the Purchasers from reselling the securities for more than ten consecutive
calendar days or more than an aggregate of fifteen calendar days during any 12-month period, the Company is obligated to pay to each purchaser,
on each monthly anniversary of each such Event, an amount in cash, as partial liquidated damages and not as a penalty, equal to the product
of 2.0% multiplied by the aggregate subscription amount paid by such purchaser in the Private Placement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On April 15, 2022, the Company received a demand
letter (the &#8220;Demand Letter&#8221;) from Boustead. The Demand Letter alleges that the Company breached the Underwriting Agreement
entered into between Boustead and the Company, dated February 17, 2022 in connection with the Company&#8217;s initial public offering.
The Demand Letter alleges that, by engaging Wainwright as placement agent in the Private Placement, the Company breached the right of
first refusal to act as placement agent granted to Boustead under the Underwriting Agreement and, as a result of selling securities in
the Private Placement, breached the 12-month lock-up obligation following the consummation of the initial public offering under the Underwriting
Agreement. The Demand Letter requested that the Company rescind the Private Placement. The Company has not responded to the Demand Letter
and no legal action has been brought by Boustead to date. There can be no assurance as to whether any litigation will be commenced against
the Company with respect to the demand letter or that, if any such litigation is commenced, the Company will not incur material losses
due to damages, penalties, costs and/or expenses as a result of such litigation or that any such losses will not have a material impact
on the Company&#8217;s financial condition or results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">On April 20, 2022, the Company and Ology entered into
a first amendment to the second Project Addendum (the &#8220;Ology Amendment&#8221;), see Notes 5 and 7. The Ology Amendment provides
for an increase to the Company&#8217;s obligation of $0.3 million, specifically related to regulatory support on the project.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On May 4, 2022, the Company&#8217;s compensation
committee approved stock option grants <span>under the Company&#8217;s 2022 Equity Incentive Plan</span>
to the Company&#8217;s executive officers, board members, employees and certain consultants. The stock options granted totaled 694,540
options, of which 500,000 were granted to the Company&#8217;s executive officers, and all of which have an exercise price of $6.45.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On May 11, 2022, the Company and St. Jude entered
into a first amendment to the St. Jude Agreement (the &#8220;St. Jude Amendment&#8221;), see Notes 5 and 7. The St. Jude Amendment provides
for a revised development milestone timeline, a one-time license fee of $5,000, and an increase to the royalty rate from 4% to 5%. The
St. Jude Amendment also provides for an increase to the contingent milestone payments, from $1.0 million to $1.9 million in the aggregate;
specifically, development milestones of $0.3&#160;million, regulatory milestones of $0.6&#160;million, and commercial milestones of $1.0&#160;million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583741295464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The preparation of financial statements in conformity
with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the
reporting periods. The most significant estimates in the Company&#8217;s financial statements relate to the valuation of common stock,
stock-based compensation, accrued research and development expenses and the valuation allowance of deferred tax assets resulting from
net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed
to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets
and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and
adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s
future results of operations will be affected.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Unaudited Interim Financial Statements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Unaudited Interim Financial Statements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The accompanying condensed balance sheet as of March&#160;31, 2022,
and the condensed statements of operations, the condensed statements of changes in stockholders&#8217; equity, and the condensed
statements of cash flows for the three months ended March&#160;31, 2022 and 2021 are unaudited. These unaudited interim financial
statements have been prepared on the same basis as the audited financial statements, and in management&#8217;s opinion, include all
adjustments, consisting of only normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial
position as of March&#160;31, 2022 and its results of operations and cash flows for the three months ended March&#160;31, 2022 and
2021. The financial data and the other financial information disclosed in the notes to these condensed financial statements related
to the three-month&#160;periods are also unaudited. Operating results for the three months ended March&#160;31, 2022 are not
necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022, <span>any
other interim periods, or any future year or period</span>. The unaudited condensed financial statements included in this Quarterly
Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the
Company&#8217;s annual report on Form 10-K for the year</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">ended December 31, 2021, which includes a broader discussion of the Company&#8217;s
business and the risks inherent therein.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Concentration of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Financial instruments that potentially subject
the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal
Depository Insurance Coverage limit of $250,000. As of March 31, 2022 and December&#160;31, 2021, the Company has not experienced losses
on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Property and Equipment</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Property and equipment consists of computers and
office furniture and fixtures, all of which are recorded at cost. Depreciation is recorded using the straight-line method over the respective
useful lives of the assets ranging from <span style="-sec-ix-hidden: hidden-fact-38">three</span> to <span style="-sec-ix-hidden: hidden-fact-39">seven</span>&#160;years. Long-lived assets are reviewed for impairment whenever events or circumstances
indicate that the carrying amount of these assets may not be recoverable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Fair Value Measurements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Fair value is defined as the price that would
be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement
date. U.S.&#160;GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and
the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In some circumstances, the inputs used to measure
fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is
categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
Financial instruments, including cash, prepaid expenses, deferred offering costs, receivables from related parties, accounts payable and
accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.
<span>None of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a
non-recurring basis. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Deferred Offering Costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>The Company
capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings
as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded
in stockholders&#8217; equity as a reduction of proceeds generated as a result of the offering. Should the in-process equity financing
be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations.
As of March 31, 2022, all previously deferred offering costs related to the IPO, totaling approximately $0.8&#160;million, and of which
$0.3 million were paid during 2021, were netted against the proceeds received upon the closing of the IPO, which occurred on February
23, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and Development</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company expenses the cost of research and
development as incurred. Research and development expenses include costs incurred in funding research and development activities, license
fees, and other external costs. Advance payments for goods and services that will be used in future research and development activities
are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and
milestone payments due to third parties that perform research and development services on the Company&#8217;s behalf will be expensed
as services are rendered or when the milestone is achieved. When billing terms under research and development contracts do not coincide
with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of period end to
those third parties. Accrual estimates are based on several factors, including the Company&#8217;s knowledge of the progress towards completion
of the research and development activities, invoicing to date under the contracts, communication from the research institution or other
companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant
judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ
from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the
actual costs. See Notes 5 and 7.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In accordance with FASB ASC Topic&#160;730-10-25-1,&#160;<i>Research
and Development,</i> costs incurred in obtaining licenses and patent rights are charged to research and development expense if the technology
licensed has not reached commercial feasibility and has no alternative future use. The licenses purchased by the Company (see Note&#160;5)
require substantial completion of research and development, regulatory and marketing approval efforts to reach commercial feasibility
and have no alternative future use. Accordingly, the total purchase price for the licenses acquired is reflected as research and development
on the Company&#8217;s statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Stock-Based Compensation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company expenses stock-based compensation
to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. Stock-based
awards to employees with graded-vesting schedules are recognized, using the accelerated attribution method, on a straight-line basis over
the requisite service period for each separately vesting portion of the award.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company estimates the fair value of stock
option grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards
represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>Expected Term</i>&#160;&#8212;&#160;The expected term
of options represents the period that the Company&#8217;s stock-based awards are expected to be outstanding based on the simplified method,
which is the half-life from vesting to the end of its contractual term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><i>Expected Volatility</i>&#160;&#8212;Volatility is a measure
of the amount by which the Company&#8217;s share price has historically fluctuated or is expected to fluctuate (i.e., expected volatility)
during a period. &#160;<span>Due to the lack of an adequate history of a public market for the trading
of the Company&#8217;s common stock and a lack of adequate company-specific historical and implied volatility data, </span>the Company
computes stock price volatility over expected terms based on comparable companies&#8217; historical common stock trading prices. For these
analyses, the Company has selected companies with comparable characteristics, including enterprise value, risk profiles, and position
within the industry, and with historical share price information sufficient to meet the expected term of the stock-based awards.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>Common Stock Fair Value</i>&#160;&#8212;&#160;<span>Due
to the absence of an active market for the Company&#8217;s common stock prior to the IPO, t</span>he fair value of the common stock underlying
the Company&#8217;s stock options was estimated at each grant date and was determined with the assistance of an independent third-party
valuation expert. The assumptions underlying these valuations represented management&#8217;s best estimates, which involved inherent uncertainties
and the application of significant levels of management judgment. <span>After the completion of the IPO,
the fair value of each share of common stock is based on the closing price of the Company&#8217;s common stock as reported by the Nasdaq
Capital Market.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>Risk-Free Interest Rate</i>&#160;&#8212;&#160;The Company
bases the risk-free interest rate on the implied yield available on U.S.&#160;Treasury securities with a remaining term commensurate with
the estimated expected term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><i>Expected Dividend</i>&#160;&#8212;&#160;The Company has
never declared or paid any cash dividends on its shares of common stock and does not plan to pay cash dividends in the foreseeable future,
and, therefore, uses an expected dividend yield of zero in its valuation models.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company recognizes forfeitures of equity awards
as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_FairValueOfCommonStockPolicyTextBlock', window );">Fair Value of Common Stock</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Fair Value of Common Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In order to determine the fair value of shares
of common stock of the Company when issuing stock options prior to the IPO, its board of directors considered with input from third party
valuations, among other things, contemporaneous valuations of the Company&#8217;s common stock. Given the absence of a public trading
market of the Company&#8217;s capital stock prior to its IPO, its board of directors has exercised reasonable judgment and considered
a number of objective and subjective factors to determine the best estimate of the fair value of the Company common and preferred stock,
including:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the prices, rights, preferences and privileges of the Company&#8217;s preferred stock relative to the Company&#8217;s common stock;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company&#8217;s business, financial condition and results of operations, including related industry trends affecting the Company&#8217;s operations;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the likelihood of achieving a liquidity event, such as an IPO, or sale of the Company, given prevailing market conditions;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the lack of marketability of the Company&#8217;s common stock;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the market performance of comparable publicly traded companies;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.&#160;and global economic and capital market conditions and outlook; and</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">common stock valuation methodology.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In estimating the fair market value of common
stock of the Company, its board of directors first determined the equity value of its business using accepted valuation methods.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company engaged a third-party valuation specialist
to conduct a valuation, which used its most recent preferred stock financing as a starting point and determined the equity value of the
Company based on the Backsolve method using an Option Pricing Method (OPM) to calculate the implied value based on a market approach.
The Company&#8217;s equity value was allocated using OPM to estimate the fair market value of the Company&#8217;s classes of equity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>After the completion of the IPO,
the fair value of each share of common stock is based on the closing price of the Company&#8217;s common stock as reported by the Nasdaq
Capital Market.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Income Taxes</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Income taxes are accounted for under the asset
and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between
the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax
credit carryforwards.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be
recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rate is recognized in operations in the period
that includes the enactment date. Deferred tax assets are reduced to estimated amounts expected to be realized by the use of a valuation
allowance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Comprehensive Income (Loss)</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company is required to report all components
of comprehensive income (loss), including net income (loss), in the accompanying condensed financial statements in the period in which
they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events
and circumstances from non-owner sources, including unrealized gains and losses on investments and foreign currency translation adjustments.
Net loss and comprehensive loss were the same for all periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span><b><i>Warrants</i></b></span></p><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>The
Company determines the accounting classification of warrants that are issued, as either liability or equity, by first assessing whether
the warrants meet liability classification in accordance with ASC 480-10, <i>Accounting for Certain Financial Instruments with Characteristics
of both Liabilities and Equity</i>, (&#8220;ASC 480-10&#8221;), and then in accordance with ASC 815-40, <i>Derivatives and Hedging - Contracts
in Entity's Own Equity</i> (&#8220;ASC 815-40&#8221;). Under ASC 480-10, warrants are considered liability-classified if the warrants
are mandatorily redeemable, obligate the issuer to settle the warrants or the underlying shares by paying cash or other assets, or must
or may require settlement by issuing variable number of shares. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15.5pt 0pt 4.5pt; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>If
the warrants do not meet liability classification under ASC 480-10, the Company assesses the requirements under ASC 815-40, which states
that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective
of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability
classification under ASC 815-40, in order to conclude equity classification, the Company assesses whether the warrants are indexed to
its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP. After all relevant assessments
are made, the Company concludes whether the warrants are classified as liability or equity. Liability-classified warrants are required
to be accounted for at fair value both on the date of issuance and on subsequent accounting period ending dates, with all changes in fair
value after the issuance date recorded as a component of other income (expense), net in the statements of operations. Equity-classified
warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date. As of
March 31, 2022, all of the Company&#8217;s outstanding warrants are equity-classified warrants.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15.5pt 0pt 4.5pt; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Net Loss Per Share</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Basic loss per share is computed by dividing the
net income or loss applicable to common shares by the weighted average number of common shares outstanding during the period. Diluted
earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding
during the period. Potential common shares consist of the Company&#8217;s preferred stock, warrants and options. Diluted loss per share
excludes the shares issuable upon the conversion of preferred stock, as well as common stock options and warrants, from the calculation
of net loss per share if their effect would be anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The two-class method is used to determine earnings
per share based on participation rights of participating securities in any undistributed earnings. Each preferred stock that includes
rights to participate in distributed earnings is considered a participating security and the Company uses the two-class method to calculate
net income available to the Company&#8217;s common stockholders per common share&#160;&#8212;&#160;basic and diluted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following securities were excluded from the
computation of diluted shares outstanding due to the losses incurred in the periods presented, as they would have had an anti-dilutive
impact on the Company&#8217;s net loss:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>New Accounting Pronouncement</i>s</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In April 2012, the Jump-Start Our Business Startups
Act (the &#8220;JOBS Act&#8221;) was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting
requirements for an emerging growth company. As an emerging growth company, the Company may elect to adopt new or revised accounting standards
when they become effective for non-public companies, which typically is later than when public companies must adopt the standards. The
Company has elected to take advantage of the extended transition period afforded by the JOBS Act and, as a result, unless the Company
elects early adoption of any standards, will adopt the new or revised accounting standards on the relevant dates on which adoption of
such standards is required for non-public companies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In August&#160;2020, the FASB issued ASU No.&#160;2020-06,&#160;<i>Debt&#160;&#8212;&#160;Debt
with Conversion and Other Options (Subtopic&#160;470-20) and Derivatives and Hedging&#160;&#8212;&#160;Contracts in Entity&#8217;s Own
Equity (Subtopic&#160;815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>, which simplifies
accounting for convertible instruments by removing major separation models required under current GAAP.&#160;The ASU also removes certain</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">settlement conditions that are required for equity contracts to qualify
for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This guidance is
effective for public business entities except for smaller reporting companies for fiscal&#160;years, and interim periods within those
fiscal&#160;years, beginning after December&#160;15, 2021. For all other entities, the standard will be effective for fiscal&#160;years
beginning after December&#160;15, 2023, including interim periods within those fiscal&#160;years. Early adoption is permitted. The Company
adopted ASU&#160;2020-06 on January&#160;1, 2022, using the modified retrospective method, and the adoption of the ASU did not impact
the Company&#8217;s financial position, results of operations, cash flows or net loss per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In October 2020, the FASB issued&#160;ASU 2020-10,&#160;Codification
Improvements, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC&#8217;s
regulations. The Company&#160;adopted&#160;ASU&#160;2020-10&#160;as of the reporting period beginning January 1, 2022. The adoption of
this update did not have a material effect on the Company&#8217;s financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In May&#160;2021, the FASB issued ASU&#160;2021-04,
Earnings Per Share (Topic&#160;260), Debt&#160;&#8212;&#160;Modifications and Extinguishments (Subtopic&#160;470-50), Compensation&#160;&#8212;&#160;Stock
Compensation (Topic&#160;718), and Derivatives and Hedging&#160;&#8212;&#160;Contracts in Entity&#8217;s Own Equity (Subtopic&#160;815-40):
Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of
the FASB Emerging Issues Task Force). The ASU clarifies and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges
of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange.
The ASU provides guidance that will clarify whether an issuer should account for a modification or an exchange of a freestanding equity-classified
written call option that remains equity classified after modification or exchange as (1)&#160;an adjustment to equity and, if so, the
related earnings per share (EPS) effects, if any, or (2)&#160;an expense and, if so, the manner and pattern of recognition. The new guidance
is effective for all entities for annual and interim periods beginning after December&#160;15, 2021, and early adoption is permitted,
including adoption in an interim period. The Company adopted ASU&#160;2021-04 on January&#160;1, 2022, and the adoption of the ASU did
not impact the Company&#8217;s financial position, results of operations, cash flows, or net loss per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&#8217;s management does not believe
that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying
condensed financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_FairValueOfCommonStockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_FairValueOfCommonStockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583737868168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of computation of diluted shares outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Options to purchase shares of common stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">780,640</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">780,640</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Series&#160;Seed Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,584,552</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Warrants to purchase shares of common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">111,111</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">891,751</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,365,192</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583739667352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of prepaid expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> March&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">69,205</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">203,910</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,842</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Prepaid other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,799</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">90,005</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">234,551</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> March&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued license fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">227,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">225,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">564,634</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,182</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">187,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">246,236</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">680,537</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">234,265</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued insurance expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118,988</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued board of directors&#8217; compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">80,529</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">49,832</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,893,438</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,055,515</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583735817688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Feb. 23, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_InitialPublicOfferingShares', window );">Initial public offering</a></td>
<td class="nump">2,222,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_PricePerShare', window );">Initial public offering price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_InitialPublicOffering', window );">Initial public offering, description</a></td>
<td class="text">Proceeds from the IPO, net of underwriting discounts, commissions, and offering costs of $2.9 million, were
$17.1 million.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance', window );">Convertible preferred stock shares</a></td>
<td class="nump">5,626,365<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_InitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial public offering description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_InitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_InitialPublicOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued initial public offering of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_InitialPublicOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_PricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price per share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_PricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of nonredeemable convertible preferred shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583735919496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Financial Condition (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 19, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_LiquidityandFinancialConditionDetailsLineItems', window );"><strong>Liquidity and Financial Condition (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Company cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAdditionalCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAppropriated', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Least term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtDescription', window );">Long-term operating description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">long-term operating requirements beyond the one year period<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_LiquidityandFinancialConditionDetailsLineItems', window );"><strong>Liquidity and Financial Condition (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds</a></td>
<td class="nump">$ 7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_LiquidityandFinancialConditionDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_LiquidityandFinancialConditionDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of long-term debt arrangements, which are debt arrangements that originally require full repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer, and disclosures pertaining to the underlying arrangements, including repayment terms, conversion features, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements. Types of long-term debt arrangements include borrowing under notes payable, bonds payable, debentures, term loans, and other contractual obligations for payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAdditionalCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of additional paid-in capital (APIC) classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 5.T)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868742-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAdditionalCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAppropriated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A segregation of retained earnings which is unavailable for dividend distribution. Includes also retained earnings appropriated for loss contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21346-112643<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21332-112643<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(23)(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(30)(a)(3)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAppropriated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583735842312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federal depository insurance coverage limit</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrentAndNoncurrent', window );">Deferred offering costs</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Expected dividend yield</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583741207800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of computation of diluted shares outstanding - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_ScheduleOfComputationOfDilutedSharesOutstandingAbstract', window );"><strong>Schedule of computation of diluted shares outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_OptionsToPurchaseSharesOfCommonStock', window );">Options to purchase shares of common stock</a></td>
<td class="nump">780,640<span></span>
</td>
<td class="nump">780,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_SeriesSeedPreferredStock', window );">Series Seed Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,584,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_WarrantsToPurchaseSharesOfCommonStock', window );">Warrants to purchase shares of common stock</a></td>
<td class="nump">111,111<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_TotalShares', window );">Total</a></td>
<td class="nump">891,751<span></span>
</td>
<td class="nump">5,365,192<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_OptionsToPurchaseSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options to purchase shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_OptionsToPurchaseSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_ScheduleOfComputationOfDilutedSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_ScheduleOfComputationOfDilutedSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_SeriesSeedPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Series Seed Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_SeriesSeedPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_TotalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_TotalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_WarrantsToPurchaseSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants to purchase shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_WarrantsToPurchaseSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583735831224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Details) - Schedule of prepaid expenses - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_ScheduleOfPrepaidExpensesAbstract', window );"><strong>Schedule of prepaid expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Prepaid research and development</a></td>
<td class="nump">$ 69,205<span></span>
</td>
<td class="nump">$ 203,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid other</a></td>
<td class="nump">20,800<span></span>
</td>
<td class="nump">25,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Total</a></td>
<td class="nump">$ 90,005<span></span>
</td>
<td class="nump">$ 234,551<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_ScheduleOfPrepaidExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_ScheduleOfPrepaidExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583735942056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Details) - Schedule of accrued expenses - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_ScheduleOfAccruedExpensesAbstract', window );"><strong>Schedule of accrued expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Accrued license fees</a></td>
<td class="nump">$ 227,500<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_AccruedResearchAndDevelopment', window );">Accrued research and development</a></td>
<td class="nump">564,634<span></span>
</td>
<td class="nump">300,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_AccruedDeferredOfferingCosts', window );">Accrued deferred offering costs</a></td>
<td class="nump">187,500<span></span>
</td>
<td class="nump">246,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensatedAbsencesLiability', window );">Accrued compensation</a></td>
<td class="nump">680,537<span></span>
</td>
<td class="nump">234,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure', window );">Accrued insurance expense</a></td>
<td class="nump">118,988<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits', window );">Accrued board of directors&#8217; compensation</a></td>
<td class="nump">33,750<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Accrued other</a></td>
<td class="nump">80,529<span></span>
</td>
<td class="nump">49,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,893,438<span></span>
</td>
<td class="nump">$ 1,055,515<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_AccruedDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_AccruedDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_ScheduleOfAccruedExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_ScheduleOfAccruedExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of trade and related party payables and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensatedAbsencesLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability accrued for the employer's obligation related to an employee's right to receive compensation for future absences that have been earned by employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19366-108361<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensatedAbsencesLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583735576888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 20, 2022</div></th>
<th class="th"><div>May 21, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_SignificantAgreementsDetailsLineItems', window );"><strong>Significant Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_OUIAgreementExpiration', window );">OUI Agreement Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesAndLicenses', window );">Intellectual property licenses is recorded as research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bwv_OlogyBioservicesIncMember', window );">Ology Bioservices, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_SignificantAgreementsDetailsLineItems', window );"><strong>Significant Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_AggregateAgreementAmountInitialAgreement', window );">Aggregate agreement amount initial agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_PrepaidExpensesToRemainingPrepaidExpenses', window );">Prepaid expenses to remaining prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_PrepaidExpenseRemaining', window );">Prepaid expense remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_AggregateAmount', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_CostPlusPercentage', window );">Cost plus, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_AccuredExpenses', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 332,000<span></span>
</td>
<td class="nump">$ 115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bwv_OlogyBioservicesIncMember', window );">Ology Bioservices, Inc [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_SignificantAgreementsDetailsLineItems', window );"><strong>Significant Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities', window );">Increased in obligation</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_AccuredExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accured expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_AccuredExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_AggregateAgreementAmountInitialAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of aggregate Agreement amount initial agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_AggregateAgreementAmountInitialAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_AggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_AggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_CostPlusPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost plus, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_CostPlusPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_OUIAgreementExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_OUIAgreementExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_PrepaidExpenseRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prepaid expense remaining.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_PrepaidExpenseRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_PrepaidExpensesToRemainingPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents of prepaid expenses to remaining prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_PrepaidExpensesToRemainingPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_SignificantAgreementsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_SignificantAgreementsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a),(b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesAndLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense, excluding income, excise, production and property taxes, and licenses and fees not related to production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesAndLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bwv_OlogyBioservicesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bwv_OlogyBioservicesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583736139976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 17, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 23, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_AggregatePurchaseShares', window );">Aggregate shares</a></td>
<td class="nump">2,222,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Common stock price per share (in Dollars per share)</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongDurationContractsAssumptionsByProductAndGuaranteeDiscountRate', window );">Underwriting discount percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOwnershipInterestsOfferingCosts', window );">Other offering costs (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare', window );">Fair value price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,146,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_ConversionPricePerShares', window );">Conversion price, per shares (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_UnderwrittenPublicOfferingNettingProceeds', window );">Underwritten public offering netting proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_OfferingPricePercentage', window );">Offering price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_CumulativeDividendsPerShare', window );">Cumulative dividends, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeDividends', window );">Cumulative dividends (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,586,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Cumulative dividends per series seed share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendPreferenceOrRestrictions', window );">Description of liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">As of December&#160;31, 2021, and all other prior
historical periods, the Liquidation Preference Amount was equal to two times the Series&#160;Seed Original Issue Price per share, plus
unpaid cumulative dividends.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Reserved shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_CommonStockShareAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNoParValue', window );">Preferred stock par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,048,587<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=bwv_TwoThousandNinteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Reserved shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bwv_SeriesSeedPreferredStockMember', window );">Series Seed Preferred Stock.[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Preferred stock, shares designated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,146,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bwv_OriginalIssuePriceMember', window );">Original Issue Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Original issue price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_AggregatePurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of aggregate purchase shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_AggregatePurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_CommonStockShareAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of excess stock shares permitted to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_CommonStockShareAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_ConversionPricePerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion price, per shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_ConversionPricePerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_CumulativeDividendsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative dividends per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_CumulativeDividendsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_OfferingPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering price percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_OfferingPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_StockholdersEquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_StockholdersEquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_UnderwrittenPublicOfferingNettingProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwritten public offering netting proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_UnderwrittenPublicOfferingNettingProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative cash dividends distributed to shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share amount of a dividend declared, but not paid, as of the financial reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of excess stock shares permitted to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of excess stock held by shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value per share that would be issued upon settlement of forward contract indexed to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongDurationContractsAssumptionsByProductAndGuaranteeDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage discount rate used to calculate present value of an expected stream of future payments, which is included in the calculation of the amount of the specified guaranteed benefit obligation as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124506351&amp;loc=d3e14931-158439<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 80<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124508989&amp;loc=d3e19393-158473<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 55<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124504833&amp;loc=d3e7104-158389<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongDurationContractsAssumptionsByProductAndGuaranteeDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOwnershipInterestsOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of offering costs allocated to the other unit holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB TOPIC 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOwnershipInterestsOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendPreferenceOrRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Priority of payment of dividends and restrictions on the payment of dividends, indicating the source, pertinent provisions and amount of retained earnings or net income restricted or free of restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendPreferenceOrRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=bwv_TwoThousandNinteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=bwv_TwoThousandNinteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bwv_SeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bwv_SeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bwv_OriginalIssuePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bwv_OriginalIssuePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583730924360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 03, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 18, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 20, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 07, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Company leased office space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_RentalDeposits', window );">Rental deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Office lease term, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company is not a party to a lease with a term in excess of 12&#160;months
and has a month-to-month lease as of March&#160;31, 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_LitigationsDescription', window );">Litigations description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">As of March 31, 2022, the Company
is not a party to any material legal proceedings and is not aware of any pending or threatened claims.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bwv_OUIAgreementMember', window );">OUI Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_PercentageOfRoyaltyOnSales', window );">Percentage of royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_MinimumRoyaltyExpense', window );">Minimum Royalty Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_RoyaltyRatePercentage', window );">Royalty rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_RoyaltyOnSumReceivedFromSublicenseePercentage', window );">Royalty on sum received from sublicensee, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_AggregatePayments', window );">Aggregate payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_SpecifiedMilestones', window );">Specified milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_RegulatoryMilestones', window );">Regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_CommercialMilestones', window );">Commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bwv_OxfordResearchMember', window );">Oxford Research [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_PurchaseObligationDueInThirdYearperiod', window );">Agreement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInThirdYear', window );">Total (in Euro) | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_PrepaidAmount', window );">Prepaid amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 554,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bwv_StJudeAgreementMember', window );">St. Jude Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_RoyaltyOnSumReceivedFromSublicenseePercentage', window );">Royalty on sum received from sublicensee, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_AggregatePayments', window );">Aggregate payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_SpecifiedMilestones', window );">Specified milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_RegulatoryMilestones', window );">Regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_CommercialMilestones', window );">Commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_RoyaltyPaymentsPercentage', window );">Royalty payments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_AnnualMaintenanceFee', window );">Annual maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_AccuredExpenses', window );">Accured expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bwv_StJudeResearchAgreementMember', window );">St Jude Research Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_AggregateAmount', window );">Aggregate amount</a></td>
<td class="nump">$ 73,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_AccuredExpenses', window );">Accured expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_OtherResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bwv_CHMCAgreementMember', window );">CHMC Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_PercentageOfRoyaltyOnSales', window );">Percentage of royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_RoyaltyOnSumReceivedFromSublicenseePercentage', window );">Royalty on sum received from sublicensee, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_AggregatePayments', window );">Aggregate payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_SpecifiedMilestones', window );">Specified milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_RegulatoryMilestones', window );">Regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_CommercialMilestones', window );">Commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_AccuredExpenses', window );">Accured expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_RoyaltyRateDecreasePostValidClaimExpiration', window );">Royalty rate decrease, post valid claim expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_OptionFee', window );">Option fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bwv_OlogyAgreementMember', window );">Ology Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_AggregateAmount', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_AccuredExpenses', window );">Accured expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">332,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_OtherResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_CostPlusPercentage', window );">Cost plus percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bwv_UnderwriterTerminationAgreementMember', window );">Underwriter Termination Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_TerminationFee', window );">Termination fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bwv_PrephaseIIIYearMember', window );">Pre-phase III year [Member] | OUI Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFee', window );">Annual maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">$10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bwv_PhaseIIIYearMember', window );">Phase III year [Member] | OUI Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFee', window );">Annual maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">$20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bwv_PhaseIMember', window );">Phase I [Member] | St. Jude Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_AggregateAmount', window );">Aggregate amount</a></td>
<td class="nump">57,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bwv_PhaseIIMember', window );">Phase II [Member] | St. Jude Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_AggregateAmount', window );">Aggregate amount</a></td>
<td class="nump">$ 15,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_AccuredExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accured expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_AccuredExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_AggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_AggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_AggregatePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_AggregatePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_AnnualMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual maintenance fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_AnnualMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_CommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_CommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_CommitmentsandContingenciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_CommitmentsandContingenciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_CostPlusPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost plus, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_CostPlusPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_LitigationsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigations description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_LitigationsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_MinimumRoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents of minimum royalty expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_MinimumRoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_OptionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_OptionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_OtherResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Research and Development Expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_OtherResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_PercentageOfRoyaltyOnSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_PercentageOfRoyaltyOnSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_PrepaidAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>prepaid amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_PrepaidAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_PurchaseObligationDueInThirdYearperiod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_PurchaseObligationDueInThirdYearperiod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_RegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_RegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_RentalDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_RentalDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_RoyaltyOnSumReceivedFromSublicenseePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty on sum received from sublicensee of percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_RoyaltyOnSumReceivedFromSublicenseePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_RoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty payments percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_RoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_RoyaltyRateDecreasePostValidClaimExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty rate decrease post valid claim expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_RoyaltyRateDecreasePostValidClaimExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_RoyaltyRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty rate percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_RoyaltyRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_SpecifiedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents of specified milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_SpecifiedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_TerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Definite liabilities to third parties under a termination loan agreement, whether or not guaranteed in whole or in part by the government.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_TerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of a fee associated with the debt instrument, including a commitment fee on unborrowed portions of a lender's total contractual commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bwv_OUIAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bwv_OUIAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bwv_OxfordResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bwv_OxfordResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bwv_StJudeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bwv_StJudeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bwv_StJudeResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bwv_StJudeResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bwv_CHMCAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bwv_CHMCAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bwv_OlogyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bwv_OlogyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bwv_UnderwriterTerminationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bwv_UnderwriterTerminationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bwv_PrephaseIIIYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bwv_PrephaseIIIYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bwv_PhaseIIIYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bwv_PhaseIIIYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bwv_PhaseIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bwv_PhaseIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bwv_PhaseIIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bwv_PhaseIIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583739877976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty', window );">Fees under consulting agreement</a></td>
<td class="nump">$ 63,000<span></span>
</td>
<td class="nump">$ 105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Receivable from related party</a></td>
<td class="nump">165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transactions amounts</a></td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousCurrent', window );">Remaining balance</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousNoncurrent', window );">Miscellaneous payments</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583737748568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage', window );">Employees compensation percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140583736341656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 04, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Apr. 20, 2022</div></th>
<th class="th"><div>Apr. 19, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_AgentFee', window );">Agent fee, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_ManagementFee', window );">Management fee, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_AggregateSubscriptionAmountPaidPercentage', window );">Aggregate subscription amount paid percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSubsequentEventsTextBlock', window );">Subsequent event, description</a></td>
<td class="text">the Company&#8217;s compensation
committee approved stock option grants <span>under the Company&#8217;s 2022 Equity Incentive Plan</span>
to the Company&#8217;s executive officers, board members, employees and certain consultants. The stock options granted totaled 694,540
options, of which 500,000 were granted to the Company&#8217;s executive officers, and all of which have an exercise price of $6.45.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">License fee (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_RoyaltyRatePercentage', window );">Royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_RoyaltyRatePercentage', window );">Royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">590,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfDebt', window );">Aggregate net proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_AggregateOutofPocketExpensesToPlacementAgent', window );">Aggregate out-of pocket expenses to placement agent (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_AggregatesPurchaseShares', window );">Aggregates purchase shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">590,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_PurchasePricePerShare', window );">Purchase price, per share (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Excerise price, per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Preferred Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_AggregatesPurchaseShares', window );">Aggregates purchase shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,180,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_PurchasePricePerShare', window );">Purchase price, per share (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Excerise price, per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Wainwright Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Excerise price, per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.46875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Issued warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_SharesPercentage', window );">Shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.46875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bwv_OlogyAmendmentMember', window );">Ology Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Subsequent event, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company and Ology entered into
a first amendment to the second Project Addendum (the &#8220;Ology Amendment&#8221;), see Notes 5 and 7. The Ology Amendment provides
for an increase to the Company&#8217;s obligation of $0.3 million, specifically related to regulatory support on the project.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bwv_StJudeAmendmentMember', window );">St. Jude Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bwv_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Subsequent event, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The St. Jude Amendment provides
for a revised development milestone timeline, a one-time license fee of $5,000, and an increase to the royalty rate from 4% to 5%. The
St. Jude Amendment also provides for an increase to the contingent milestone payments, from $1.0 million to $1.9 million in the aggregate;
specifically, development milestones of $0.3&#160;million, regulatory milestones of $0.6&#160;million, and commercial milestones of $1.0&#160;million.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_AgentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agent fee percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_AgentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_AggregateOutofPocketExpensesToPlacementAgent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents of aggregate out-of pocket expenses to placement agent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_AggregateOutofPocketExpensesToPlacementAgent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_AggregateSubscriptionAmountPaidPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate subscription amount paid, percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_AggregateSubscriptionAmountPaidPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_AggregatesPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of aggregates purchase shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_AggregatesPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_ManagementFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Management fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_ManagementFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_PurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_PurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_RoyaltyRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty rate percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_RoyaltyRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_SharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_SharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bwv_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bwv_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bwv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, losses resulting from fire or flood, losses on receivables, significant realized and unrealized gains and losses that result from changes in quoted market prices of securities, declines in market prices of inventory, changes in authorized or issued debt (SEC), significant foreign exchange rate changes, substantial loans to insiders or affiliates, significant long-term investments, and substantial dividends not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bwv_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bwv_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bwv_PreferredInvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bwv_PreferredInvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bwv_WainwrightWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bwv_WainwrightWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bwv_OlogyAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bwv_OlogyAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bwv_StJudeAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bwv_StJudeAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>f10q0322_bluewatervac_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bwv="http://www.bluewatervaccines.com/20220331"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pf0="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bwv-20220331.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <instant>2022-05-12</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-23</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bwv:OlogyBioservicesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bwv:OlogyBioservicesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bwv:OlogyBioservicesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-21</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bwv:OlogyBioservicesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bwv:OlogyBioservicesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bwv:OlogyBioservicesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-20</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bwv:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-17</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
        </entity>
        <period>
            <instant>2022-02-17</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bwv:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bwv:OriginalIssuePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bwv:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bwv:TwoThousandNinteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:OUIAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:OUIAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:OUIAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bwv:PrephaseIIIYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:OUIAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bwv:PhaseIIIYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:OxfordResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-18</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:OxfordResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-18</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:OxfordResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:OxfordResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:OxfordResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:StJudeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:StJudeResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-03</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:StJudeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bwv:PhaseIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-03</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:StJudeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bwv:PhaseIIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-03</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:StJudeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:StJudeResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:CHMCAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:CHMCAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:OlogyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:CHMCAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:CHMCAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:UnderwriterTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-20</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">bwv:UnderwriterTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-07</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bwv:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bwv:PreferredInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bwv:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bwv:PreferredInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bwv:WainwrightWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bwv:WainwrightWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bwv:OlogyAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-20</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-04</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bwv:StJudeAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782107</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:DocumentType contextRef="c0">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c0">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0">001-41294</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0">Blue Water Vaccines Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0">81-2262816</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0">201 E. Fifth Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0">Suite 1900</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0">Cincinnati</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0">OH</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0">45202</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0">(513)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0">620-4101</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0">Common stock, $0.00001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0">BWV</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c0">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c1" decimals="INF" unitRef="shares">11638993</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="0" unitRef="usd">18609249</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="0" unitRef="usd">1928474</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent contextRef="c2" decimals="0" unitRef="usd">90005</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c3" decimals="0" unitRef="usd">234551</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:DeferredCostsCurrent contextRef="c2" decimals="0" unitRef="usd">238804</us-gaap:DeferredCostsCurrent>
    <us-gaap:DeferredCostsCurrent contextRef="c3" decimals="0" unitRef="usd">757646</us-gaap:DeferredCostsCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent contextRef="c2" decimals="0" unitRef="usd">164515</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent contextRef="c3" decimals="0" unitRef="usd">152524</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="0" unitRef="usd">19102573</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="0" unitRef="usd">3073195</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="c2" decimals="0" unitRef="usd">129454</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" unitRef="usd">15399</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" unitRef="usd">11502</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepositsAssetsNoncurrent contextRef="c2" decimals="0" unitRef="usd">87638</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:Assets contextRef="c2" decimals="0" unitRef="usd">19335064</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="0" unitRef="usd">3084697</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c2" decimals="0" unitRef="usd">907538</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="0" unitRef="usd">582605</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c2" decimals="0" unitRef="usd">1893438</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">1055515</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="0" unitRef="usd">2800976</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">1638120</us-gaap:LiabilitiesCurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c2" decimals="5" unitRef="usdPershares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c3" decimals="5" unitRef="usdPershares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c2" decimals="INF" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c3" decimals="INF" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <bwv:PreferredStockSharesDesignated contextRef="c2" decimals="INF" unitRef="shares">0</bwv:PreferredStockSharesDesignated>
    <us-gaap:PreferredStockSharesIssued contextRef="c2" decimals="INF" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c2" decimals="INF" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <bwv:PreferredStockSharesDesignated contextRef="c3" decimals="INF" unitRef="shares">1150000</bwv:PreferredStockSharesDesignated>
    <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="c2" decimals="0" unitRef="usd">0</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockSharesIssued contextRef="c3" decimals="INF" unitRef="shares">1146138</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c3" decimals="INF" unitRef="shares">1146138</us-gaap:PreferredStockSharesOutstanding>
    <bwv:PreferredStockValue1 contextRef="c3" decimals="0" unitRef="usd">11</bwv:PreferredStockValue1>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c2" decimals="5" unitRef="usdPershares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c3" decimals="5" unitRef="usdPershares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="INF" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="INF" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="INF" unitRef="shares">11048587</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="INF" unitRef="shares">3200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="0" unitRef="usd">110</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="0" unitRef="usd">32</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="0" unitRef="usd">24561309</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="0" unitRef="usd">7403204</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="0" unitRef="usd">-8027331</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" unitRef="usd">-5956670</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" unitRef="usd">16534088</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" unitRef="usd">1446577</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="0" unitRef="usd">19335064</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="0" unitRef="usd">3084697</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" unitRef="usd">1615569</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c4" decimals="0" unitRef="usd">237544</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" unitRef="usd">455092</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c4" decimals="0" unitRef="usd">88237</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" unitRef="usd">2070661</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c4" decimals="0" unitRef="usd">325781</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-2070661</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c4" decimals="0" unitRef="usd">-325781</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-2070661</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="0" unitRef="usd">-325781</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments contextRef="c0" decimals="0" unitRef="usd">96359</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments contextRef="c4" decimals="0" unitRef="usd">137687</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c0" decimals="0" unitRef="usd">-2167020</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c4" decimals="0" unitRef="usd">-463468</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <bwv:NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare contextRef="c0" decimals="2" unitRef="usdPershares">-0.34</bwv:NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare>
    <bwv:NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare contextRef="c4" decimals="2" unitRef="usdPershares">-0.14</bwv:NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare>
    <bwv:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares contextRef="c0" decimals="INF" unitRef="shares">6339435</bwv:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares>
    <bwv:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares contextRef="c4" decimals="INF" unitRef="shares">3200000</bwv:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares>
    <us-gaap:SharesOutstanding contextRef="c5" decimals="INF" unitRef="shares">1146138</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="0" unitRef="usd">11</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c6" decimals="INF" unitRef="shares">3200000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c6" decimals="0" unitRef="usd">32</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="0" unitRef="usd">7403204</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="0" unitRef="usd">-5956670</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" unitRef="usd">1446577</us-gaap:StockholdersEquity>
    <bwv:OfferingCostsNet contextRef="c0" decimals="1" unitRef="usd">2.9</bwv:OfferingCostsNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c10" decimals="INF" unitRef="shares">2222222</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c10" decimals="0" unitRef="usd">22</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c11" decimals="0" unitRef="usd">17138818</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c0" decimals="0" unitRef="usd">17138840</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c9" decimals="INF" unitRef="shares">-1146138</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c9" decimals="0" unitRef="usd">-11</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c10" decimals="INF" unitRef="shares">5626365</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c10" decimals="0" unitRef="usd">56</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c11" decimals="0" unitRef="usd">-45</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c11" decimals="0" unitRef="usd">19332</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c0" decimals="0" unitRef="usd">19332</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:ProfitLoss contextRef="c12" decimals="0" unitRef="usd">-2070661</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" unitRef="usd">-2070661</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding contextRef="c14" decimals="INF" unitRef="shares">11048587</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c14" decimals="0" unitRef="usd">110</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="0" unitRef="usd">24561309</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="0" unitRef="usd">-8027331</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" unitRef="usd">16534088</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c17" decimals="INF" unitRef="shares">1146138</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="0" unitRef="usd">11</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c18" decimals="INF" unitRef="shares">3200000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="0" unitRef="usd">32</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="0" unitRef="usd">7273063</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="0" unitRef="usd">-2539336</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="0" unitRef="usd">4733770</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c24" decimals="0" unitRef="usd">41721</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c4" decimals="0" unitRef="usd">41721</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:ProfitLoss contextRef="c25" decimals="0" unitRef="usd">-325781</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c4" decimals="0" unitRef="usd">-325781</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding contextRef="c26" decimals="INF" unitRef="shares">1146138</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="0" unitRef="usd">11</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c27" decimals="INF" unitRef="shares">3200000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="0" unitRef="usd">32</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c28" decimals="0" unitRef="usd">7314784</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c29" decimals="0" unitRef="usd">-2865117</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c30" decimals="0" unitRef="usd">4449710</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-2070661</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="0" unitRef="usd">-325781</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c0" decimals="0" unitRef="usd">1300</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c4" decimals="0" unitRef="usd">1232</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="0" unitRef="usd">19332</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c4" decimals="0" unitRef="usd">41721</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c0" decimals="0" unitRef="usd">-144546</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c4" decimals="0" unitRef="usd">57309</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties contextRef="c0" decimals="0" unitRef="usd">11991</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties contextRef="c4" decimals="0" unitRef="usd">5056</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="0" unitRef="usd">129454</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c4" decimals="0" unitRef="usd">-46233</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets contextRef="c0" decimals="0" unitRef="usd">87638</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c0" decimals="0" unitRef="usd">896659</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c0" decimals="0" unitRef="usd">351816</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c4" decimals="0" unitRef="usd">42412</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" unitRef="usd">-886091</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c4" decimals="0" unitRef="usd">-256548</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="0" unitRef="usd">5197</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" unitRef="usd">-5197</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c0" decimals="0" unitRef="usd">5000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c0" decimals="0" unitRef="usd">18400000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c0" decimals="0" unitRef="usd">822937</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" unitRef="usd">17572063</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="0" unitRef="usd">16680775</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c4" decimals="0" unitRef="usd">-256548</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" unitRef="usd">1928474</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c21" decimals="0" unitRef="usd">4308821</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" unitRef="usd">18609249</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c30" decimals="0" unitRef="usd">4052273</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:DeferredOfferingCosts contextRef="c2" decimals="0" unitRef="usd">233804</us-gaap:DeferredOfferingCosts>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c0" decimals="0" unitRef="usd">45</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering contextRef="c0" decimals="0" unitRef="usd">104035</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note&#160;1 &#x2014;&#160;Organization and Basis of Presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Organization and Nature of Operations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Blue Water Vaccines Inc. (the &#x201c;Company&#x201d;)
was formed on October&#160;26, 2018, to focus on the research and development of transformational vaccines to prevent infectious diseases
worldwide. The Company&#x2019;s lead vaccine candidates, BWV-101 and BWV-102, are being investigated as a universal influenza vaccine with
the potential against all influenza strains and may provide a first-in-class long-term global vaccine that protects millions. The Company&#x2019;s
proprietary, immunogenic, multi-purpose platform enables the Company to bioengineer viral nanoparticles to deliver antigens, enhancing
immunity, in an array of infectious disease agents, including influenza. All of the Company&#x2019;s vaccine candidates are in the pre-clinical
developmental stage.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Initial Public Offering&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt"&gt;On February 23, 2022, the Company completed its
initial public offering (&#x201c;IPO&#x201d;) in which the Company issued and sold 2,222,222 shares of its common stock, at a price to the
public of $9.00 per share. Proceeds from the IPO, net of underwriting discounts, commissions, and offering costs of $2.9 million, were
$17.1 million. In connection with the completion of the IPO, all outstanding shares of convertible preferred stock were converted into
5,626,365 shares of common stock. See Note 6.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;On November&#160;24, 2021, the Company&#x2019;s
board of directors approved a 4-for-1 (4:1) stock split (the &#x201c;Stock Split&#x201d;) of the Company&#x2019;s common stock without any
change to its par value, which became effective on November&#160;24, 2021. All references to share and per share amounts for all periods
presented in these financial statements have been retrospectively restated to reflect the Stock Split and proportional adjustment of the
preferred stock conversion ratio. Par values were not adjusted.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company&#x2019;s unaudited condensed financial
statements have been prepared in conformity with accounting principles generally accepted in the United&#160;States of America (&#x201c;U.S.&#160;GAAP&#x201d;).&lt;/p&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <bwv:InitialPublicOfferingShares contextRef="c31" decimals="0" unitRef="shares">2222222</bwv:InitialPublicOfferingShares>
    <bwv:PricePerShare contextRef="c31" decimals="2" unitRef="usdPershares">9</bwv:PricePerShare>
    <bwv:InitialPublicOffering contextRef="c32">Proceeds from the IPO, net of underwriting discounts, commissions, and offering costs of $2.9 million, were
$17.1 million.</bwv:InitialPublicOffering>
    <us-gaap:ConvertiblePreferredStockSharesReservedForFutureIssuance contextRef="c31" decimals="0" unitRef="shares">5626365</us-gaap:ConvertiblePreferredStockSharesReservedForFutureIssuance>
    <bwv:LiquidityAndFinancialConditionTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note&#160;2 &#x2014;&#160;Liquidity and Financial Condition&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company has had limited operating activities
to date, substantially all of which have been devoted to seeking licenses and engaging in research and development activities. The Company&#x2019;s
product candidates currently under development will require significant additional research and development efforts prior to commercialization.
The Company has financed its operations since inception primarily using proceeds received from seed investors, and proceeds received upon
the completion of its IPO.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company has incurred substantial operating
losses since inception and expects to continue to incur significant operating losses for the foreseeable future. As of March 31, 2022,
the Company had cash of approximately $18.6&#160;million, working capital of approximately $16.3&#160;million and an accumulated deficit
of approximately $8.0 million.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;On April 19, 2022, the Company completed a private
placement in which it received approximately $7.0 million in net proceeds, after deducting placement agent fees and other initial offering
expenses, see Note 11.&#160;The Company believes the existing cash at March&#160;31, 2022, together with the net proceeds received upon
the close of the private placement, will be sufficient to continue operations, satisfy its obligations and fund the future expenditures
that will be required to conduct the clinical and regulatory work to develop its product candidates for at least&#160;one year&#160;after
the date that these financial statements are available to be issued. As such, the Company determined that it is not probable based on
projected cash flows that substantial doubt about the Company&#x2019;s ability to continue as a going concern exists for the one-year period
following the date that the financial statements for the three months ended March 31, 2022 were available to be issued.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company will require significant additional
capital to make the investments it needs to execute its longer-term business plan. The Company expects a significant increase in cash
outflows as compared to its historical spend for its planned pre-clinical development and clinical trial activities, and as such, it will
need to raise additional capital to sustain operations and meet its long-term operating requirements beyond the one year period following
the issuance of these financial statements. The Company expects to seek additional funding through additional debt or equity financings;
however, there are currently no commitments in place for further financing nor is there any assurance that such financing will be available
to the Company on favorable terms, if at all. If the Company is unable to secure additional capital, it may be required to curtail any
clinical trials and development of products and take additional measures to reduce expenses in order to conserve its cash in amounts sufficient
to sustain operations and meet its obligations in the long-term.&lt;/p&gt;</bwv:LiquidityAndFinancialConditionTextBlock>
    <us-gaap:InvestmentsAndCash contextRef="c2" decimals="-5" unitRef="usd">18600000</us-gaap:InvestmentsAndCash>
    <us-gaap:OtherAdditionalCapital contextRef="c2" decimals="-5" unitRef="usd">16300000</us-gaap:OtherAdditionalCapital>
    <us-gaap:RetainedEarningsAppropriated contextRef="c2" decimals="-5" unitRef="usd">8000000</us-gaap:RetainedEarningsAppropriated>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c33" decimals="-5" unitRef="usd">7000000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentTerm contextRef="c0">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LongTermDebtDescription contextRef="c0">long-term operating requirements beyond the one year period</us-gaap:LongTermDebtDescription>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note&#160;3 &#x2014;&#160;Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The preparation of financial statements in conformity
with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the
reporting periods. The most significant estimates in the Company&#x2019;s financial statements relate to the valuation of common stock,
stock-based compensation, accrued research and development expenses and the valuation allowance of deferred tax assets resulting from
net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed
to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets
and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and
adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s
future results of operations will be affected.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Unaudited Interim Financial Statements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The accompanying condensed balance sheet as of March&#160;31, 2022,
and the condensed statements of operations, the condensed statements of changes in stockholders&#x2019; equity, and the condensed
statements of cash flows for the three months ended March&#160;31, 2022 and 2021 are unaudited. These unaudited interim financial
statements have been prepared on the same basis as the audited financial statements, and in management&#x2019;s opinion, include all
adjustments, consisting of only normal recurring adjustments, necessary for the fair statement of the Company&#x2019;s financial
position as of March&#160;31, 2022 and its results of operations and cash flows for the three months ended March&#160;31, 2022 and
2021. The financial data and the other financial information disclosed in the notes to these condensed financial statements related
to the three-month&#160;periods are also unaudited. Operating results for the three months ended March&#160;31, 2022 are not
necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022, &lt;span&gt;any
other interim periods, or any future year or period&lt;/span&gt;. The unaudited condensed financial statements included in this Quarterly
Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the
Company&#x2019;s annual report on Form 10-K for the year&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;ended December 31, 2021, which includes a broader discussion of the Company&#x2019;s
business and the risks inherent therein.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Financial instruments that potentially subject
the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal
Depository Insurance Coverage limit of $250,000. As of March 31, 2022 and December&#160;31, 2021, the Company has not experienced losses
on these accounts and management believes the Company is not exposed to significant risks on such accounts.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Property and equipment consists of computers and
office furniture and fixtures, all of which are recorded at cost. Depreciation is recorded using the straight-line method over the respective
useful lives of the assets ranging from &lt;span style="-sec-ix-hidden: hidden-fact-38"&gt;three&lt;/span&gt; to &lt;span style="-sec-ix-hidden: hidden-fact-39"&gt;seven&lt;/span&gt;&#160;years. Long-lived assets are reviewed for impairment whenever events or circumstances
indicate that the carrying amount of these assets may not be recoverable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Fair value is defined as the price that would
be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement
date. U.S.&#160;GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and
the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In some circumstances, the inputs used to measure
fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is
categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
Financial instruments, including cash, prepaid expenses, deferred offering costs, receivables from related parties, accounts payable and
accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.
&lt;span&gt;None of the Company&#x2019;s non-financial assets or liabilities are recorded at fair value on a
non-recurring basis. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Deferred Offering Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span&gt;The Company
capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings
as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded
in stockholders&#x2019; equity as a reduction of proceeds generated as a result of the offering. Should the in-process equity financing
be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations.
As of March 31, 2022, all previously deferred offering costs related to the IPO, totaling approximately $0.8&#160;million, and of which
$0.3 million were paid during 2021, were netted against the proceeds received upon the closing of the IPO, which occurred on February
23, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company expenses the cost of research and
development as incurred. Research and development expenses include costs incurred in funding research and development activities, license
fees, and other external costs. Advance payments for goods and services that will be used in future research and development activities
are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and
milestone payments due to third parties that perform research and development services on the Company&#x2019;s behalf will be expensed
as services are rendered or when the milestone is achieved. When billing terms under research and development contracts do not coincide
with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of period end to
those third parties. Accrual estimates are based on several factors, including the Company&#x2019;s knowledge of the progress towards completion
of the research and development activities, invoicing to date under the contracts, communication from the research institution or other
companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant
judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ
from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the
actual costs. See Notes 5 and 7.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In accordance with FASB ASC Topic&#160;730-10-25-1,&#160;&lt;i&gt;Research
and Development,&lt;/i&gt; costs incurred in obtaining licenses and patent rights are charged to research and development expense if the technology
licensed has not reached commercial feasibility and has no alternative future use. The licenses purchased by the Company (see Note&#160;5)
require substantial completion of research and development, regulatory and marketing approval efforts to reach commercial feasibility
and have no alternative future use. Accordingly, the total purchase price for the licenses acquired is reflected as research and development
on the Company&#x2019;s statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company expenses stock-based compensation
to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. Stock-based
awards to employees with graded-vesting schedules are recognized, using the accelerated attribution method, on a straight-line basis over
the requisite service period for each separately vesting portion of the award.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company estimates the fair value of stock
option grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards
represent management&#x2019;s best estimates and involve inherent uncertainties and the application of management&#x2019;s judgment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;i&gt;Expected Term&lt;/i&gt;&#160;&#x2014;&#160;The expected term
of options represents the period that the Company&#x2019;s stock-based awards are expected to be outstanding based on the simplified method,
which is the half-life from vesting to the end of its contractual term.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"&gt;&lt;i&gt;Expected Volatility&lt;/i&gt;&#160;&#x2014;Volatility is a measure
of the amount by which the Company&#x2019;s share price has historically fluctuated or is expected to fluctuate (i.e., expected volatility)
during a period. &#160;&lt;span&gt;Due to the lack of an adequate history of a public market for the trading
of the Company&#x2019;s common stock and a lack of adequate company-specific historical and implied volatility data, &lt;/span&gt;the Company
computes stock price volatility over expected terms based on comparable companies&#x2019; historical common stock trading prices. For these
analyses, the Company has selected companies with comparable characteristics, including enterprise value, risk profiles, and position
within the industry, and with historical share price information sufficient to meet the expected term of the stock-based awards.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;i&gt;Common Stock Fair Value&lt;/i&gt;&#160;&#x2014;&#160;&lt;span&gt;Due
to the absence of an active market for the Company&#x2019;s common stock prior to the IPO, t&lt;/span&gt;he fair value of the common stock underlying
the Company&#x2019;s stock options was estimated at each grant date and was determined with the assistance of an independent third-party
valuation expert. The assumptions underlying these valuations represented management&#x2019;s best estimates, which involved inherent uncertainties
and the application of significant levels of management judgment. &lt;span&gt;After the completion of the IPO,
the fair value of each share of common stock is based on the closing price of the Company&#x2019;s common stock as reported by the Nasdaq
Capital Market.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;i&gt;Risk-Free Interest Rate&lt;/i&gt;&#160;&#x2014;&#160;The Company
bases the risk-free interest rate on the implied yield available on U.S.&#160;Treasury securities with a remaining term commensurate with
the estimated expected term.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;i&gt;Expected Dividend&lt;/i&gt;&#160;&#x2014;&#160;The Company has
never declared or paid any cash dividends on its shares of common stock and does not plan to pay cash dividends in the foreseeable future,
and, therefore, uses an expected dividend yield of zero in its valuation models.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company recognizes forfeitures of equity awards
as they occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In order to determine the fair value of shares
of common stock of the Company when issuing stock options prior to the IPO, its board of directors considered with input from third party
valuations, among other things, contemporaneous valuations of the Company&#x2019;s common stock. Given the absence of a public trading
market of the Company&#x2019;s capital stock prior to its IPO, its board of directors has exercised reasonable judgment and considered
a number of objective and subjective factors to determine the best estimate of the fair value of the Company common and preferred stock,
including:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the prices, rights, preferences and privileges of the Company&#x2019;s preferred stock relative to the Company&#x2019;s common stock;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the Company&#x2019;s business, financial condition and results of operations, including related industry trends affecting the Company&#x2019;s operations;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the likelihood of achieving a liquidity event, such as an IPO, or sale of the Company, given prevailing market conditions;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the lack of marketability of the Company&#x2019;s common stock;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the market performance of comparable publicly traded companies;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;U.S.&#160;and global economic and capital market conditions and outlook; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;common stock valuation methodology.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In estimating the fair market value of common
stock of the Company, its board of directors first determined the equity value of its business using accepted valuation methods.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company engaged a third-party valuation specialist
to conduct a valuation, which used its most recent preferred stock financing as a starting point and determined the equity value of the
Company based on the Backsolve method using an Option Pricing Method (OPM) to calculate the implied value based on a market approach.
The Company&#x2019;s equity value was allocated using OPM to estimate the fair market value of the Company&#x2019;s classes of equity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span&gt;After the completion of the IPO,
the fair value of each share of common stock is based on the closing price of the Company&#x2019;s common stock as reported by the Nasdaq
Capital Market.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Income taxes are accounted for under the asset
and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between
the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax
credit carryforwards.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be
recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rate is recognized in operations in the period
that includes the enactment date. Deferred tax assets are reduced to estimated amounts expected to be realized by the use of a valuation
allowance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Comprehensive Income (Loss)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company is required to report all components
of comprehensive income (loss), including net income (loss), in the accompanying condensed financial statements in the period in which
they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events
and circumstances from non-owner sources, including unrealized gains and losses on investments and foreign currency translation adjustments.
Net loss and comprehensive loss were the same for all periods presented.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span&gt;The
Company determines the accounting classification of warrants that are issued, as either liability or equity, by first assessing whether
the warrants meet liability classification in accordance with ASC 480-10, &lt;i&gt;Accounting for Certain Financial Instruments with Characteristics
of both Liabilities and Equity&lt;/i&gt;, (&#x201c;ASC 480-10&#x201d;), and then in accordance with ASC 815-40, &lt;i&gt;Derivatives and Hedging - Contracts
in Entity's Own Equity&lt;/i&gt; (&#x201c;ASC 815-40&#x201d;). Under ASC 480-10, warrants are considered liability-classified if the warrants
are mandatorily redeemable, obligate the issuer to settle the warrants or the underlying shares by paying cash or other assets, or must
or may require settlement by issuing variable number of shares. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15.5pt 0pt 4.5pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span&gt;If
the warrants do not meet liability classification under ASC 480-10, the Company assesses the requirements under ASC 815-40, which states
that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective
of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability
classification under ASC 815-40, in order to conclude equity classification, the Company assesses whether the warrants are indexed to
its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP. After all relevant assessments
are made, the Company concludes whether the warrants are classified as liability or equity. Liability-classified warrants are required
to be accounted for at fair value both on the date of issuance and on subsequent accounting period ending dates, with all changes in fair
value after the issuance date recorded as a component of other income (expense), net in the statements of operations. Equity-classified
warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date. As of
March 31, 2022, all of the Company&#x2019;s outstanding warrants are equity-classified warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15.5pt 0pt 4.5pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Basic loss per share is computed by dividing the
net income or loss applicable to common shares by the weighted average number of common shares outstanding during the period. Diluted
earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding
during the period. Potential common shares consist of the Company&#x2019;s preferred stock, warrants and options. Diluted loss per share
excludes the shares issuable upon the conversion of preferred stock, as well as common stock options and warrants, from the calculation
of net loss per share if their effect would be anti-dilutive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The two-class method is used to determine earnings
per share based on participation rights of participating securities in any undistributed earnings. Each preferred stock that includes
rights to participate in distributed earnings is considered a participating security and the Company uses the two-class method to calculate
net income available to the Company&#x2019;s common stockholders per common share&#160;&#x2014;&#160;basic and diluted.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The following securities were excluded from the
computation of diluted shares outstanding due to the losses incurred in the periods presented, as they would have had an anti-dilutive
impact on the Company&#x2019;s net loss:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended &lt;br/&gt; March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Options to purchase shares of common stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;780,640&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;780,640&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Series&#160;Seed Preferred Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-36"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,584,552&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Warrants to purchase shares of common stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;111,111&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-37"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;891,751&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;5,365,192&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;New Accounting Pronouncement&lt;/i&gt;s&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In April 2012, the Jump-Start Our Business Startups
Act (the &#x201c;JOBS Act&#x201d;) was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting
requirements for an emerging growth company. As an emerging growth company, the Company may elect to adopt new or revised accounting standards
when they become effective for non-public companies, which typically is later than when public companies must adopt the standards. The
Company has elected to take advantage of the extended transition period afforded by the JOBS Act and, as a result, unless the Company
elects early adoption of any standards, will adopt the new or revised accounting standards on the relevant dates on which adoption of
such standards is required for non-public companies.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In August&#160;2020, the FASB issued ASU No.&#160;2020-06,&#160;&lt;i&gt;Debt&#160;&#x2014;&#160;Debt
with Conversion and Other Options (Subtopic&#160;470-20) and Derivatives and Hedging&#160;&#x2014;&#160;Contracts in Entity&#x2019;s Own
Equity (Subtopic&#160;815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/i&gt;, which simplifies
accounting for convertible instruments by removing major separation models required under current GAAP.&#160;The ASU also removes certain&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;settlement conditions that are required for equity contracts to qualify
for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This guidance is
effective for public business entities except for smaller reporting companies for fiscal&#160;years, and interim periods within those
fiscal&#160;years, beginning after December&#160;15, 2021. For all other entities, the standard will be effective for fiscal&#160;years
beginning after December&#160;15, 2023, including interim periods within those fiscal&#160;years. Early adoption is permitted. The Company
adopted ASU&#160;2020-06 on January&#160;1, 2022, using the modified retrospective method, and the adoption of the ASU did not impact
the Company&#x2019;s financial position, results of operations, cash flows or net loss per share.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In October 2020, the FASB issued&#160;ASU 2020-10,&#160;Codification
Improvements, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC&#x2019;s
regulations. The Company&#160;adopted&#160;ASU&#160;2020-10&#160;as of the reporting period beginning January 1, 2022. The adoption of
this update did not have a material effect on the Company&#x2019;s financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In May&#160;2021, the FASB issued ASU&#160;2021-04,
Earnings Per Share (Topic&#160;260), Debt&#160;&#x2014;&#160;Modifications and Extinguishments (Subtopic&#160;470-50), Compensation&#160;&#x2014;&#160;Stock
Compensation (Topic&#160;718), and Derivatives and Hedging&#160;&#x2014;&#160;Contracts in Entity&#x2019;s Own Equity (Subtopic&#160;815-40):
Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of
the FASB Emerging Issues Task Force). The ASU clarifies and reduces diversity in an issuer&#x2019;s accounting for modifications or exchanges
of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange.
The ASU provides guidance that will clarify whether an issuer should account for a modification or an exchange of a freestanding equity-classified
written call option that remains equity classified after modification or exchange as (1)&#160;an adjustment to equity and, if so, the
related earnings per share (EPS) effects, if any, or (2)&#160;an expense and, if so, the manner and pattern of recognition. The new guidance
is effective for all entities for annual and interim periods beginning after December&#160;15, 2021, and early adoption is permitted,
including adoption in an interim period. The Company adopted ASU&#160;2021-04 on January&#160;1, 2022, and the adoption of the ASU did
not impact the Company&#x2019;s financial position, results of operations, cash flows, or net loss per share.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company&#x2019;s management does not believe
that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying
condensed financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The preparation of financial statements in conformity
with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the
reporting periods. The most significant estimates in the Company&#x2019;s financial statements relate to the valuation of common stock,
stock-based compensation, accrued research and development expenses and the valuation allowance of deferred tax assets resulting from
net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed
to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets
and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and
adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s
future results of operations will be affected.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Unaudited Interim Financial Statements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The accompanying condensed balance sheet as of March&#160;31, 2022,
and the condensed statements of operations, the condensed statements of changes in stockholders&#x2019; equity, and the condensed
statements of cash flows for the three months ended March&#160;31, 2022 and 2021 are unaudited. These unaudited interim financial
statements have been prepared on the same basis as the audited financial statements, and in management&#x2019;s opinion, include all
adjustments, consisting of only normal recurring adjustments, necessary for the fair statement of the Company&#x2019;s financial
position as of March&#160;31, 2022 and its results of operations and cash flows for the three months ended March&#160;31, 2022 and
2021. The financial data and the other financial information disclosed in the notes to these condensed financial statements related
to the three-month&#160;periods are also unaudited. Operating results for the three months ended March&#160;31, 2022 are not
necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022, &lt;span&gt;any
other interim periods, or any future year or period&lt;/span&gt;. The unaudited condensed financial statements included in this Quarterly
Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the
Company&#x2019;s annual report on Form 10-K for the year&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;ended December 31, 2021, which includes a broader discussion of the Company&#x2019;s
business and the risks inherent therein.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Financial instruments that potentially subject
the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal
Depository Insurance Coverage limit of $250,000. As of March 31, 2022 and December&#160;31, 2021, the Company has not experienced losses
on these accounts and management believes the Company is not exposed to significant risks on such accounts.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount contextRef="c2" decimals="0" unitRef="usd">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Property and equipment consists of computers and
office furniture and fixtures, all of which are recorded at cost. Depreciation is recorded using the straight-line method over the respective
useful lives of the assets ranging from &lt;span style="-sec-ix-hidden: hidden-fact-38"&gt;three&lt;/span&gt; to &lt;span style="-sec-ix-hidden: hidden-fact-39"&gt;seven&lt;/span&gt;&#160;years. Long-lived assets are reviewed for impairment whenever events or circumstances
indicate that the carrying amount of these assets may not be recoverable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Fair value is defined as the price that would
be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement
date. U.S.&#160;GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and
the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In some circumstances, the inputs used to measure
fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is
categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
Financial instruments, including cash, prepaid expenses, deferred offering costs, receivables from related parties, accounts payable and
accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.
&lt;span&gt;None of the Company&#x2019;s non-financial assets or liabilities are recorded at fair value on a
non-recurring basis. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Deferred Offering Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span&gt;The Company
capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings
as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded
in stockholders&#x2019; equity as a reduction of proceeds generated as a result of the offering. Should the in-process equity financing
be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations.
As of March 31, 2022, all previously deferred offering costs related to the IPO, totaling approximately $0.8&#160;million, and of which
$0.3 million were paid during 2021, were netted against the proceeds received upon the closing of the IPO, which occurred on February
23, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredCostsCurrentAndNoncurrent contextRef="c2" decimals="-5" unitRef="usd">800000</us-gaap:DeferredCostsCurrentAndNoncurrent>
    <us-gaap:DeferredCostsCurrentAndNoncurrent contextRef="c3" decimals="-5" unitRef="usd">300000</us-gaap:DeferredCostsCurrentAndNoncurrent>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company expenses the cost of research and
development as incurred. Research and development expenses include costs incurred in funding research and development activities, license
fees, and other external costs. Advance payments for goods and services that will be used in future research and development activities
are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and
milestone payments due to third parties that perform research and development services on the Company&#x2019;s behalf will be expensed
as services are rendered or when the milestone is achieved. When billing terms under research and development contracts do not coincide
with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of period end to
those third parties. Accrual estimates are based on several factors, including the Company&#x2019;s knowledge of the progress towards completion
of the research and development activities, invoicing to date under the contracts, communication from the research institution or other
companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant
judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ
from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the
actual costs. See Notes 5 and 7.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In accordance with FASB ASC Topic&#160;730-10-25-1,&#160;&lt;i&gt;Research
and Development,&lt;/i&gt; costs incurred in obtaining licenses and patent rights are charged to research and development expense if the technology
licensed has not reached commercial feasibility and has no alternative future use. The licenses purchased by the Company (see Note&#160;5)
require substantial completion of research and development, regulatory and marketing approval efforts to reach commercial feasibility
and have no alternative future use. Accordingly, the total purchase price for the licenses acquired is reflected as research and development
on the Company&#x2019;s statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company expenses stock-based compensation
to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. Stock-based
awards to employees with graded-vesting schedules are recognized, using the accelerated attribution method, on a straight-line basis over
the requisite service period for each separately vesting portion of the award.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company estimates the fair value of stock
option grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards
represent management&#x2019;s best estimates and involve inherent uncertainties and the application of management&#x2019;s judgment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;i&gt;Expected Term&lt;/i&gt;&#160;&#x2014;&#160;The expected term
of options represents the period that the Company&#x2019;s stock-based awards are expected to be outstanding based on the simplified method,
which is the half-life from vesting to the end of its contractual term.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"&gt;&lt;i&gt;Expected Volatility&lt;/i&gt;&#160;&#x2014;Volatility is a measure
of the amount by which the Company&#x2019;s share price has historically fluctuated or is expected to fluctuate (i.e., expected volatility)
during a period. &#160;&lt;span&gt;Due to the lack of an adequate history of a public market for the trading
of the Company&#x2019;s common stock and a lack of adequate company-specific historical and implied volatility data, &lt;/span&gt;the Company
computes stock price volatility over expected terms based on comparable companies&#x2019; historical common stock trading prices. For these
analyses, the Company has selected companies with comparable characteristics, including enterprise value, risk profiles, and position
within the industry, and with historical share price information sufficient to meet the expected term of the stock-based awards.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;i&gt;Common Stock Fair Value&lt;/i&gt;&#160;&#x2014;&#160;&lt;span&gt;Due
to the absence of an active market for the Company&#x2019;s common stock prior to the IPO, t&lt;/span&gt;he fair value of the common stock underlying
the Company&#x2019;s stock options was estimated at each grant date and was determined with the assistance of an independent third-party
valuation expert. The assumptions underlying these valuations represented management&#x2019;s best estimates, which involved inherent uncertainties
and the application of significant levels of management judgment. &lt;span&gt;After the completion of the IPO,
the fair value of each share of common stock is based on the closing price of the Company&#x2019;s common stock as reported by the Nasdaq
Capital Market.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;i&gt;Risk-Free Interest Rate&lt;/i&gt;&#160;&#x2014;&#160;The Company
bases the risk-free interest rate on the implied yield available on U.S.&#160;Treasury securities with a remaining term commensurate with
the estimated expected term.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;i&gt;Expected Dividend&lt;/i&gt;&#160;&#x2014;&#160;The Company has
never declared or paid any cash dividends on its shares of common stock and does not plan to pay cash dividends in the foreseeable future,
and, therefore, uses an expected dividend yield of zero in its valuation models.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company recognizes forfeitures of equity awards
as they occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments contextRef="c0" decimals="0" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <bwv:FairValueOfCommonStockPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In order to determine the fair value of shares
of common stock of the Company when issuing stock options prior to the IPO, its board of directors considered with input from third party
valuations, among other things, contemporaneous valuations of the Company&#x2019;s common stock. Given the absence of a public trading
market of the Company&#x2019;s capital stock prior to its IPO, its board of directors has exercised reasonable judgment and considered
a number of objective and subjective factors to determine the best estimate of the fair value of the Company common and preferred stock,
including:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the prices, rights, preferences and privileges of the Company&#x2019;s preferred stock relative to the Company&#x2019;s common stock;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the Company&#x2019;s business, financial condition and results of operations, including related industry trends affecting the Company&#x2019;s operations;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the likelihood of achieving a liquidity event, such as an IPO, or sale of the Company, given prevailing market conditions;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the lack of marketability of the Company&#x2019;s common stock;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the market performance of comparable publicly traded companies;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;U.S.&#160;and global economic and capital market conditions and outlook; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;common stock valuation methodology.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In estimating the fair market value of common
stock of the Company, its board of directors first determined the equity value of its business using accepted valuation methods.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company engaged a third-party valuation specialist
to conduct a valuation, which used its most recent preferred stock financing as a starting point and determined the equity value of the
Company based on the Backsolve method using an Option Pricing Method (OPM) to calculate the implied value based on a market approach.
The Company&#x2019;s equity value was allocated using OPM to estimate the fair market value of the Company&#x2019;s classes of equity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span&gt;After the completion of the IPO,
the fair value of each share of common stock is based on the closing price of the Company&#x2019;s common stock as reported by the Nasdaq
Capital Market.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</bwv:FairValueOfCommonStockPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Income taxes are accounted for under the asset
and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between
the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax
credit carryforwards.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be
recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rate is recognized in operations in the period
that includes the enactment date. Deferred tax assets are reduced to estimated amounts expected to be realized by the use of a valuation
allowance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Comprehensive Income (Loss)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company is required to report all components
of comprehensive income (loss), including net income (loss), in the accompanying condensed financial statements in the period in which
they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events
and circumstances from non-owner sources, including unrealized gains and losses on investments and foreign currency translation adjustments.
Net loss and comprehensive loss were the same for all periods presented.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span&gt;The
Company determines the accounting classification of warrants that are issued, as either liability or equity, by first assessing whether
the warrants meet liability classification in accordance with ASC 480-10, &lt;i&gt;Accounting for Certain Financial Instruments with Characteristics
of both Liabilities and Equity&lt;/i&gt;, (&#x201c;ASC 480-10&#x201d;), and then in accordance with ASC 815-40, &lt;i&gt;Derivatives and Hedging - Contracts
in Entity's Own Equity&lt;/i&gt; (&#x201c;ASC 815-40&#x201d;). Under ASC 480-10, warrants are considered liability-classified if the warrants
are mandatorily redeemable, obligate the issuer to settle the warrants or the underlying shares by paying cash or other assets, or must
or may require settlement by issuing variable number of shares. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15.5pt 0pt 4.5pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span&gt;If
the warrants do not meet liability classification under ASC 480-10, the Company assesses the requirements under ASC 815-40, which states
that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective
of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability
classification under ASC 815-40, in order to conclude equity classification, the Company assesses whether the warrants are indexed to
its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP. After all relevant assessments
are made, the Company concludes whether the warrants are classified as liability or equity. Liability-classified warrants are required
to be accounted for at fair value both on the date of issuance and on subsequent accounting period ending dates, with all changes in fair
value after the issuance date recorded as a component of other income (expense), net in the statements of operations. Equity-classified
warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date. As of
March 31, 2022, all of the Company&#x2019;s outstanding warrants are equity-classified warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15.5pt 0pt 4.5pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Basic loss per share is computed by dividing the
net income or loss applicable to common shares by the weighted average number of common shares outstanding during the period. Diluted
earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding
during the period. Potential common shares consist of the Company&#x2019;s preferred stock, warrants and options. Diluted loss per share
excludes the shares issuable upon the conversion of preferred stock, as well as common stock options and warrants, from the calculation
of net loss per share if their effect would be anti-dilutive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The two-class method is used to determine earnings
per share based on participation rights of participating securities in any undistributed earnings. Each preferred stock that includes
rights to participate in distributed earnings is considered a participating security and the Company uses the two-class method to calculate
net income available to the Company&#x2019;s common stockholders per common share&#160;&#x2014;&#160;basic and diluted.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The following securities were excluded from the
computation of diluted shares outstanding due to the losses incurred in the periods presented, as they would have had an anti-dilutive
impact on the Company&#x2019;s net loss:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended &lt;br/&gt; March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Options to purchase shares of common stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;780,640&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;780,640&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Series&#160;Seed Preferred Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-36"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,584,552&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Warrants to purchase shares of common stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;111,111&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-37"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;891,751&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;5,365,192&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <bwv:OptionsToPurchaseSharesOfCommonStock contextRef="c0" decimals="INF" unitRef="shares">780640</bwv:OptionsToPurchaseSharesOfCommonStock>
    <bwv:OptionsToPurchaseSharesOfCommonStock contextRef="c4" decimals="INF" unitRef="shares">780640</bwv:OptionsToPurchaseSharesOfCommonStock>
    <bwv:SeriesSeedPreferredStock contextRef="c4" decimals="INF" unitRef="shares">4584552</bwv:SeriesSeedPreferredStock>
    <bwv:WarrantsToPurchaseSharesOfCommonStock contextRef="c0" decimals="INF" unitRef="shares">111111</bwv:WarrantsToPurchaseSharesOfCommonStock>
    <bwv:TotalShares contextRef="c0" decimals="INF" unitRef="shares">891751</bwv:TotalShares>
    <bwv:TotalShares contextRef="c4" decimals="INF" unitRef="shares">5365192</bwv:TotalShares>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;New Accounting Pronouncement&lt;/i&gt;s&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In April 2012, the Jump-Start Our Business Startups
Act (the &#x201c;JOBS Act&#x201d;) was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting
requirements for an emerging growth company. As an emerging growth company, the Company may elect to adopt new or revised accounting standards
when they become effective for non-public companies, which typically is later than when public companies must adopt the standards. The
Company has elected to take advantage of the extended transition period afforded by the JOBS Act and, as a result, unless the Company
elects early adoption of any standards, will adopt the new or revised accounting standards on the relevant dates on which adoption of
such standards is required for non-public companies.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In August&#160;2020, the FASB issued ASU No.&#160;2020-06,&#160;&lt;i&gt;Debt&#160;&#x2014;&#160;Debt
with Conversion and Other Options (Subtopic&#160;470-20) and Derivatives and Hedging&#160;&#x2014;&#160;Contracts in Entity&#x2019;s Own
Equity (Subtopic&#160;815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/i&gt;, which simplifies
accounting for convertible instruments by removing major separation models required under current GAAP.&#160;The ASU also removes certain&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;settlement conditions that are required for equity contracts to qualify
for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This guidance is
effective for public business entities except for smaller reporting companies for fiscal&#160;years, and interim periods within those
fiscal&#160;years, beginning after December&#160;15, 2021. For all other entities, the standard will be effective for fiscal&#160;years
beginning after December&#160;15, 2023, including interim periods within those fiscal&#160;years. Early adoption is permitted. The Company
adopted ASU&#160;2020-06 on January&#160;1, 2022, using the modified retrospective method, and the adoption of the ASU did not impact
the Company&#x2019;s financial position, results of operations, cash flows or net loss per share.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In October 2020, the FASB issued&#160;ASU 2020-10,&#160;Codification
Improvements, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC&#x2019;s
regulations. The Company&#160;adopted&#160;ASU&#160;2020-10&#160;as of the reporting period beginning January 1, 2022. The adoption of
this update did not have a material effect on the Company&#x2019;s financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In May&#160;2021, the FASB issued ASU&#160;2021-04,
Earnings Per Share (Topic&#160;260), Debt&#160;&#x2014;&#160;Modifications and Extinguishments (Subtopic&#160;470-50), Compensation&#160;&#x2014;&#160;Stock
Compensation (Topic&#160;718), and Derivatives and Hedging&#160;&#x2014;&#160;Contracts in Entity&#x2019;s Own Equity (Subtopic&#160;815-40):
Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of
the FASB Emerging Issues Task Force). The ASU clarifies and reduces diversity in an issuer&#x2019;s accounting for modifications or exchanges
of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange.
The ASU provides guidance that will clarify whether an issuer should account for a modification or an exchange of a freestanding equity-classified
written call option that remains equity classified after modification or exchange as (1)&#160;an adjustment to equity and, if so, the
related earnings per share (EPS) effects, if any, or (2)&#160;an expense and, if so, the manner and pattern of recognition. The new guidance
is effective for all entities for annual and interim periods beginning after December&#160;15, 2021, and early adoption is permitted,
including adoption in an interim period. The Company adopted ASU&#160;2021-04 on January&#160;1, 2022, and the adoption of the ASU did
not impact the Company&#x2019;s financial position, results of operations, cash flows, or net loss per share.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company&#x2019;s management does not believe
that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying
condensed financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note&#160;4 &#x2014;&#160;Balance Sheet Details&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Prepaid Expenses&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Prepaid expenses consisted of the following as
of March 31, 2022 and December&#160;31, 2021:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt; March&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt; December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Prepaid research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;69,205&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;203,910&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-40"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,842&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Prepaid other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,800&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,799&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;90,005&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;234,551&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Accrued Expenses&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Accrued expenses consisted of the following as
of March 31, 2022 and December&#160;31, 2021:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt; March&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt; December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accrued license fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;227,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;225,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;564,634&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300,182&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued deferred offering costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;187,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;246,236&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;680,537&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;234,265&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued insurance expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;118,988&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-41"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued board of directors&#x2019; compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-42"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accrued other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;80,529&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;49,832&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,893,438&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,055,515&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt; March&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt; December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Prepaid research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;69,205&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;203,910&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-40"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,842&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Prepaid other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,800&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,799&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;90,005&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;234,551&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c0" decimals="0" unitRef="usd">69205</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c36" decimals="0" unitRef="usd">203910</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:PrepaidInsurance contextRef="c3" decimals="0" unitRef="usd">4842</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c2" decimals="0" unitRef="usd">20800</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c3" decimals="0" unitRef="usd">25799</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c2" decimals="0" unitRef="usd">90005</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c3" decimals="0" unitRef="usd">234551</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt; March&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt; December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accrued license fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;227,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;225,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;564,634&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300,182&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued deferred offering costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;187,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;246,236&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;680,537&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;234,265&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued insurance expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;118,988&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-41"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued board of directors&#x2019; compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-42"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accrued other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;80,529&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;49,832&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,893,438&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,055,515&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:ProceedsFromLicenseFeesReceived contextRef="c0" decimals="0" unitRef="usd">227500</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:ProceedsFromLicenseFeesReceived contextRef="c36" decimals="0" unitRef="usd">225000</us-gaap:ProceedsFromLicenseFeesReceived>
    <bwv:AccruedResearchAndDevelopment contextRef="c0" decimals="0" unitRef="usd">564634</bwv:AccruedResearchAndDevelopment>
    <bwv:AccruedResearchAndDevelopment contextRef="c36" decimals="0" unitRef="usd">300182</bwv:AccruedResearchAndDevelopment>
    <bwv:AccruedDeferredOfferingCosts contextRef="c2" decimals="0" unitRef="usd">187500</bwv:AccruedDeferredOfferingCosts>
    <bwv:AccruedDeferredOfferingCosts contextRef="c3" decimals="0" unitRef="usd">246236</bwv:AccruedDeferredOfferingCosts>
    <us-gaap:CompensatedAbsencesLiability contextRef="c2" decimals="0" unitRef="usd">680537</us-gaap:CompensatedAbsencesLiability>
    <us-gaap:CompensatedAbsencesLiability contextRef="c3" decimals="0" unitRef="usd">234265</us-gaap:CompensatedAbsencesLiability>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesFairValueDisclosure contextRef="c2" decimals="0" unitRef="usd">118988</us-gaap:AccountsPayableAndAccruedLiabilitiesFairValueDisclosure>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits contextRef="c2" decimals="0" unitRef="usd">33750</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="c2" decimals="0" unitRef="usd">80529</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="c3" decimals="0" unitRef="usd">49832</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c2" decimals="0" unitRef="usd">1893438</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">1055515</us-gaap:AccruedLiabilitiesCurrent>
    <bwv:SignificantAgreementsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note&#160;5 &#x2014;&#160;Significant Agreements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Oxford University Innovation Limited&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In December&#160;2018, the Company entered into
an option agreement Oxford University Innovation (&#x201c;OUI&#x201d;), which was a precursor to a license agreement (the &#x201c;OUI Agreement&#x201d;),
dated July&#160;16, 2019. Under the terms of the OUI Agreement, the Company holds an exclusive, worldwide license to certain specified
patent rights and biological materials relating to the use of epitopes of limited variability and virus-like particle products and practice
processes that are covered by the licensed patent rights and biological materials for the purpose of developing and commercializing a
vaccine product candidate for influenza. The Company is obligated to use its best efforts to develop and market Licensed Products, as
defined in the OUI Agreement, in accordance with its development plan, report to OUI on progress, achieve the following milestones and
must pay OUI nonrefundable milestone fees when it achieves them: initiation of first Phase&#160;I study; initiation of first Phase&#160;II
study; initiation of first Phase&#160;III/pivotal registration studies; first submission of application for regulatory approval (BLA/NDA);
marketing authorization in the United&#160;States; marketing authorization in any EU country; marketing authorization in Japan; first
marketing authorization in any other country; first commercial sale in Japan; first commercial sale in any ROW country; first year that
annual sales equal or exceed certain thresholds. See Note&#160;7 for additional information on the milestone payments as well as royalty
obligations required under the OUI Agreement. The OUI Agreement will expire upon ten (10)&#160;years from the expiration of the last patent
contained in the licensed patent rights, unless terminated earlier. During the year ended December&#160;31, 2021, the U.S.&#160;Patent
related to immunogenic composition was issued to OUI.&#160;This patent expires in August&#160;2037. No additional patents have been issued
during the three months ended March 31, 2022. Either party may terminate the OUI Agreement for an uncured material breach. The Company
may terminate the OUI Agreement for any reason at any time upon six&#160;months&#x2019; written notice expiring after the third anniversary
of the OUI Agreement. OUI&#160;may terminate immediately if the Company has a petition presented for its winding-up or passes a resolution
for winding up other than for a bona fide amalgamation or reconstruction or compounds with its creditors or has a receiver or administrator
appointed. OUI may also terminate if the Company opposes or challenges the validity of any of the patents or applications in the Licensed
Technology, as defined in the OUI Agreement; raises the claim that the know-how of the Licensed Technology is not necessary to develop
and market Licensed Products; or in OUI&#x2019;s reasonable opinion, is taking inadequate or insufficient steps to develop or market Licensed
Products and does not take any further steps that OUI&#160;requests by written notice within a reasonable time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;For the&#160;three months ended March 31, 2022
and 2021, the Company did not incur any licensing fee payments for intellectual property licenses. See Note&#160;7.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;St. Jude Children&#x2019;s Hospital&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"&gt;The Company entered into a license agreement (the
&#x201c;St. Jude Agreement&#x201d;), dated January&#160;27, 2020, with St. Jude Children&#x2019;s Research Hospital (&#x201c;St. Jude&#x201d;).
Under the terms of the St. Jude Agreement, the Company holds an exclusive, worldwide license to certain specified patent rights and biological
materials relating to the use of live attenuated streptococcus pneumoniae and practice processes that are covered by the licensed patent
rights and biological materials for the purpose of developing and commercializing a vaccine product candidate for streptococcus pneumoniae.
The St. Jude Agreement will expire upon the expiration of the last valid claim contained in the licensed patent rights, unless terminated
earlier. The Company is obligated to use commercially reasonable efforts to develop and commercialize the licensed product(s). The milestones
include the following events: (i)&#160;complete IND enabling study; (ii)&#160;initiate animal toxicology study; (iii)&#160;file IND; (iv)&#160;complete
Phase&#160;I Clinical Trial; (v)&#160;commence Phase&#160;II Clinical Trial; (vi)&#160;commence Phase&#160;III Clinical Trial; and, (vii)&#160;regulatory
approval, U.S.&#160;or foreign equivalent. If the Company fails to achieve the development milestones contained in the St. Jude Agreement,
and if the Company and St. Jude fail to agree upon a mutually satisfactory revised timeline, St. Jude will have the right to terminate
the St. Jude Agreement. Either party may terminate the St. Jude Agreement in the event the other party (a)&#160;files or has filed against
it a petition under the Bankruptcy Act (among other things) or (b)&#160;fails to perform or otherwise breaches its obligations under the
St. Jude Agreement, and has not cured such failure or breach within sixty (60)&#160;days. The Company may terminate for any reason on
thirty (30)&#160;days written notice. On May 11, 2022, the Company entered into an amendment to the St.
Jude Agreement, whereby the royalty terms, milestones payments and licensing fees were amended. See Note 11 for more information on this
amendment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;For the&#160;three months ended March&#160;31,
2022, the Company recognized approximately $3,000 for intellectual property licenses, which is recorded as research and development expenses.
For the three months ended March 31, 2021, the Company did not incur any licensing fee payments for intellectual property licenses. See
Note&#160;7 for additional information on the milestone payments as well as royalty obligations required under the St. Jude Agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Cincinnati Children&#x2019;s Hospital Medical Center&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company entered into a license agreement (the
&#x201c;CHMC Agreement&#x201d;), dated June&#160;1, 2021, with Children&#x2019;s Hospital Medical Center, d/b/a Cincinnati Children&#x2019;s
Hospital Medical Center (&#x201c;CHMC&#x201d;). Under the terms of the CHMC Agreement, the Company holds an exclusive, worldwide license
(other than the excluded field of immunization against, and prevention, control, or reduction in the severity of gastroenteritis caused
by rotavirus and norovirus in China and Hong&#160;Kong) to certain specified patent and biological materials relating to the use of norovirus
nanoparticles and practice processes that are covered by the licensed patent rights and biological materials for the purpose of developing
and commercializing CHMC patents and related technology directed to a virus-like particle vaccine platform that utilizes nanoparticle
delivery technology that may have potential broad application to develop vaccines for multiple infectious diseases. The term of the CHMC
Agreement begins on the effective date and extends on a jurisdiction by jurisdiction and product by product basis until the later of:
(i)&#160;the last to expire licensed patent; (ii)&#160;ten (10)&#160;years after the first commercial sale; or, (iii)&#160;entrance onto
the market of a biosimilar or interchangeable product. The Company is obligated to use commercially reasonable efforts to bring licensed
products to market through diligent research and development, testing, manufacturing and commercialization, to use best efforts to make
all necessary regulatory filings and obtain all necessary regulatory approvals, to achieve milestones relating to development and sales,
and report to CHMC on progress. The Company will also be obligated to pay the agreed upon development milestone payments to CHMC, as well
as royalty payments, see Note&#160;7 for additional information. The Company may terminate the CHMC Agreement for convenience, at any
time prior to first commercial sale of a product or process by providing one hundred and eighty (180)&#160;days&#x2019; written notice
to CHMC.&#160;It may also terminate for a CHMC uncured material breach. CHMC may terminate the CHMC Agreement for an uncured Company material
breach or insolvency or bankruptcy. Pursuant to the terms of the CHMC Agreement, if the Company fails to achieve the milestones, and cannot
mutually agree with CHMC on an amendment to the milestones, then CHMC will have the option of converting any and all of such exclusive
licenses to nonexclusive licenses, to continue developing indications that have already entered development at any stage or in which the
Company has invested in developing. CHMC may also terminate the CHMC Agreement to the fullest extent permitted by law in the countries
of the worldwide territory, in the event the Company or its affiliates challenge or induce others set up challenges to the validity or
enforceability of any of the Licensed Patents, as defined in the CHMC Agreement, and the Company will be obligated reimburse CHMC for
its costs, including reasonable attorneys&#x2019; fees.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;For the&#160;three months ended March 31, 2022
and 2021, the Company did not incur any licensing fee payments for intellectual property licenses. See Note 7.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Ology Bioservices, Inc. (which was later acquired by National Resilience,
Inc.)&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"&gt;The Company entered into a Master Services Agreement
(&#x201c;Ology MSA&#x201d;), dated July&#160;19, 2019, with Ology, Inc. (&#x201c;Ology&#x201d;) to provide services from time to time, including
but not limited to technology transfer, process development, analytical method optimization, cGMP manufacture, regulatory affairs, and
stability studies of biologic products. Pursuant to the Ology MSA, the Company and Ology&#160;shall&#160;enter into a&#160;Project Addendum
for&#160;each&#160;project&#160;to be governed by the terms and conditions of the Ology MSA.&#160;The Company has entered into two Project
Addendums as of March 31, 2022 and December&#160;31, 2021.&#160;The initial Project Addendum&#160;was executed on October&#160;18, 2019&#160;and&#160;the
Company&#160;was&#160;required to pay Ology an aggregate of approximately $4&#160;million.&#160;Due to unforeseen delays associated with
COVID-19, the Company and Ology entered into a letter agreement dated January&#160;9, 2020 to stop work on the project. The Company paid
Ology $100,000 for services, of which $48,600 remained as a prepaid expense as of December&#160;31, 2020.&#160;The second Project Addendum&#160;was
executed on May&#160;21, 2021&#160;and&#160;the Company is obligated to pay Ology an aggregate amount of approximately $2.8&#160;million,
plus reimbursement for materials and outsourced testing, which will be billed at cost plus 15%. This project began during
2021, and the Company recorded approximately $164,000 and $115,000 as related accounts payable and accrued expenses, respectively, at
December 31, 2021. During the three months ended March 31, 2022, the Company incurred related research and development expenses of approximately
$217,000, and had approximately $332,000 recorded as related accrued expenses at March&#160;31, 2022. See Note&#160;4. There were no such
expenses incurred during the three months ended March 31, 2021. On April 20, 2022, the Company entered into an amendment to the Ology
MSA, whereby the Company&#x2019;s obligations increased by $0.3 million, specifically related to regulatory support on the project. See
Note 11.&lt;/p&gt;</bwv:SignificantAgreementsTextBlock>
    <bwv:OUIAgreementExpiration contextRef="c0">P10Y</bwv:OUIAgreementExpiration>
    <us-gaap:TaxesAndLicenses contextRef="c0" decimals="0" unitRef="usd">3000</us-gaap:TaxesAndLicenses>
    <bwv:AggregateAgreementAmountInitialAgreement contextRef="c37" decimals="-6" unitRef="usd">4000000</bwv:AggregateAgreementAmountInitialAgreement>
    <bwv:PrepaidExpensesToRemainingPrepaidExpenses contextRef="c38" decimals="0" unitRef="usd">100000</bwv:PrepaidExpensesToRemainingPrepaidExpenses>
    <bwv:PrepaidExpenseRemaining contextRef="c38" decimals="0" unitRef="usd">48600</bwv:PrepaidExpenseRemaining>
    <bwv:AggregateAmount contextRef="c39" decimals="-5" unitRef="usd">2800000</bwv:AggregateAmount>
    <bwv:CostPlusPercentage contextRef="c39" decimals="2" unitRef="pure">0.15</bwv:CostPlusPercentage>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c40" decimals="0" unitRef="usd">164000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <bwv:AccuredExpenses contextRef="c41" decimals="0" unitRef="usd">115000</bwv:AccuredExpenses>
    <bwv:AccuredExpenses contextRef="c37" decimals="0" unitRef="usd">332000</bwv:AccuredExpenses>
    <us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities contextRef="c42" decimals="-5" unitRef="usd">300000</us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note&#160;6 &#x2014;&#160;Stockholders&#x2019; Equity&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Authorized Capital and Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;On February&#160;23, 2022, the Company filed with
the Secretary of State of the State of Delaware an amended and restated certificate of incorporation (the &#x201c;A&amp;amp;R COI&#x201d;),
which became effective immediately. The Company&#x2019;s board of directors and stockholders approved the A&amp;amp;R COI to be effective upon
the closing of the IPO.&#160;There was no change to the Company&#x2019;s authorized shares of common stock and preferred stock of 250,000,000
shares and 10,000,000 shares, respectively, or the par value, which is $0.00001 for both common and preferred stock. Prior to this amendment,
the Company had designated 1,150,000 shares of preferred stock, with par value $0.00001 per share. In addition, on February&#160;23, 2022
and in connection with the closing of the IPO, the Company&#x2019;s board of directors adopted Amended and Restated Bylaws.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;As of March 31, 2022 and December&#160;31, 2021,
there were 11,048,587 and 3,200,000 shares of common stock issued and outstanding, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Holders of the Company&#x2019;s common stock are
entitled to one vote for each share held of record, and are entitled upon liquidation of the Company to share ratably in the net assets
of the Company available for distribution after payment of all obligations of the Company and after provision has been made with respect
to each class of stock, if any, having preference over the common stock, currently including the Company&#x2019;s preferred stock. The
shares of common stock are not redeemable and have no preemptive or similar rights.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;On February&#160;17, 2022, the Company entered
into an underwriting agreement (the &#x201c;Underwriting Agreement&#x201d;) with Boustead Securities, LLC, acting as representative of the
underwriters (&#x201c;Boustead&#x201d;), in relation to the Company&#x2019;s IPO, pursuant to which the Company agreed to sell to the underwriters
an aggregate of 2,222,222 shares of the Company&#x2019;s common stock, at a price of $9.00 per share. The IPO closed on February&#160;23,
2022, and resulted in net proceeds to the Company, after deducting the 8% underwriting discount, and other offering costs, of approximately
$17.1&#160;million. Pursuant to the Underwriting Agreement, the Company issued to Boustead warrants to purchase 111,111 shares of common
stock. The warrants are exercisable, at the option of the holder, at a per share exercise price equal to $10.35 and are exercisable at
any time and from time to time, in whole or in part, starting on February 23, 2022 and terminating on February&#160;11, 2027.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company evaluated the terms of the warrants
issued at the IPO and determined that they should be classified as equity instruments based upon accounting guidance provided in ASC 480
and ASC 815-40. Since the Company determined that the warrants were equity-classified, the Company recorded the proceeds from the IPO,
net of issuance costs, within common stock at par value and the balance of the net proceeds to additional paid in capital. As of March
31, 2022, the outstanding warrants are exercisable into&#160;111,111&#160;shares of common stock whose fair value was $56.50&#160;per
share, based on the closing trading price on that day.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Prior to the close of the IPO, the Company had
designated 1,150,000 shares of preferred stock as Series&#160;Seed Preferred Stock (&#x201c;Series&#160;Seed&#x201d;), with an original
issue price of $6.09 per share (the &#x201c;Original Issue Price&#x201d;). As of March 31, 2022 and December&#160;31, 2021, there were 0
and 1,146,138 shares issued and outstanding, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Conversion&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Each share of the Series&#160;Seed was convertible,
at the option of the holder, at any time and from time to time, and without the payment of additional consideration by the holder, at
a conversion price of $1.52 per share, subject to certain adjustments for stock splits, stock dividends, recapitalizations, and similar
corporate transactions, into fully paid and non-assessable shares of the Company&#x2019;s common stock. Each Series&#160;Seed share was
automatically convertible into common stock of the Company, at the then-effective conversion price, upon the closing of a firmly underwritten
public offering netting proceeds of at least $50&#160;million with an offering price of at least three hundred percent (300%) of the Original
Issue Price of the Series&#160;Seed. On October&#160;7, 2021, the majority of the holders of the Series&#160;Seed approved the automatic
conversion of the outstanding shares of the Series&#160;Seed and all related accrued and unpaid dividends, upon the close of the IPO.&#160;The
number of conversion shares to be issued upon the close of the IPO were to be calculated in accordance with the original conversion terms
provided by the Company&#x2019;s Amended and Restated Certificate of Incorporation (&#x201c;COI&#x201d;) dated July&#160;1, 2019. This conversion
occurred on February&#160;23, 2022, upon the close of the Company&#x2019;s IPO.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Dividends&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Holders of the Series&#160;Seed were entitled
to receive cumulative dividends at a per share rate of 8% per annum, compounded annually, on the initial investment amount commencing
on the date of issue. Dividends were payable only when, as, and if declared by the Board of Directors or upon a Liquidation Event, as
described below. Dividends on Series&#160;Seed were in preference to any dividend on the Company&#x2019;s common stock. Upon the close
of the IPO, aggregate cumulative dividends of $1,586,162 or $1.38 per Series&#160;Seed share were automatically converted into shares
of common stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Liquidation Preference&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In the event of certain voluntary or involuntary
acquisition or sale transactions or upon the liquidation, dissolution or winding up of the Company (each, a &#x201c;Liquidation Event&#x201d;),
the holders of Series&#160;Seed were entitled to receive out of the proceeds or assets of the Company legally available for distribution
to its stockholders (the&#160;&#x201c;Proceeds&#x201d;), prior and in preference to any distribution of the Proceeds of such Liquidation
Event to the holders of shares of common stock by reason of their ownership thereof, an amount (&#x201c;the Liquidation Preference Amount&#x201d;)
determined based on the provisions of the Company&#x2019;s COI.&#160;The COI provided that the Liquidation Preference Amount be calculated
upon the occurrence of a Liquidation Event, based on the Company&#x2019;s achievement of a Pre-Clinical Milestone and a Qualified Financing,
both as defined in the COI.&#160;Per the provisions of the COI, if a Liquidation Event occurred before a Pre-Clinical Milestone was achieved,
the Liquidation Preference Amount would be equal to two times the Series&#160;Seed Original Issue price per share, plus unpaid cumulative
dividends. If a Liquidation Event occurred after a Pre-Clinical Milestone was achieved, and after a Qualified Financing was completed,
then the Liquidation Preference Amount would be equal to one times the Series&#160;Seed Original Issue price, plus unpaid cumulative dividends.
If a Liquidation Event occurred after a Pre-Clinical Milestone was achieved and before a Qualified Financing was completed, the Liquidation
Preference Amount would be equal to the greater of (a)&#160;such amount per share as such holder would have been entitled to receive after
a Qualified Financing or (b)&#160;two times the Series&#160;Seed Original Issue price, plus unpaid cumulative dividends.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;As of December&#160;31, 2021, and all other prior
historical periods, the Liquidation Preference Amount was equal to two times the Series&#160;Seed Original Issue Price per share, plus
unpaid cumulative dividends. In the event that the Proceeds were insufficient to enable the distribution in full of the Liquidation Preference
Amount to the holders of the Series&#160;Seed for all of the preferred shares held by them, all of the Proceeds were to be distributed
among the&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;holders of Series&#160;Seed on a pro rata basis. Upon completion of
the distribution required to the holders of Series&#160;Seed, all of the remaining Proceeds available for distribution to stockholders
were to be distributed among the holders of common shares and preferred shares, on an as-converted basis, pro rata based on the number
of common shares held by each such holder. However, if upon the occurrence of a Liquidation Event, the Liquidation Preference Amount the
Series&#160;Seed stockholders were entitled to receive is two times the Original Issue Price per share, plus unpaid cumulative dividends,
after such distribution is made, then the remaining Proceeds available for distribution to stockholders were to be distributed among the
holders of common shares, pro rata based on the number of common shares held by each such holder.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Voting&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;On any matter presented to the stockholders of
the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in
lieu of meeting), each holder of outstanding shares of Series&#160;Seed were entitled to cast the number of votes equal to the number
of whole shares of common stock into which the shares of Series&#160;Seed held by such holder were convertible as of the record date for
determining stockholders entitled to vote on such matter. Holders of Series&#160;Seed were entitled to vote together with the holder of
common stock as a single class. Holders of Series&#160;Seed were entitled to nominate two out of five of the Company&#x2019;s directors.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Equity Incentive Plans&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;The Company&#x2019;s 2019 Equity Incentive
Plan (the &#x201c;2019 Plan&#x201d;) was adopted by its board of directors and by its stockholders on July&#160;1, 2019. The Company has
reserved 1,400,000 shares of common stock for issuance pursuant to the 2019 Plan. There were no share-based awards granted under the 2019
Plan during the three months ended March 31, 2022 and 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In addition, on February&#160;23, 2022 and in
connection with the closing of the IPO, the Company&#x2019;s board of directors adopted the Company&#x2019;s 2022 Equity Incentive Plan
(the &#x201c;2022 Plan&#x201d;), which is the successor and continuation of the Company&#x2019;s 2019 Plan. Under the 2022 Plan, the Company
may grant stock options, restricted stock, restricted stock units, stock appreciation rights, and other forms of awards to&#160;employees,
directors and consultants of the Company. Upon its effectiveness, a total of 1,600,000 shares of common stock were reserved for issuance
under the 2022 Plan. As of March 31, 2022, there were no share-based awards granted under the 2022 Plan.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <bwv:CommonStockShareAuthorized contextRef="c43" decimals="0" unitRef="shares">250000000</bwv:CommonStockShareAuthorized>
    <us-gaap:ExcessStockSharesAuthorized contextRef="c44" decimals="0" unitRef="shares">10000000</us-gaap:ExcessStockSharesAuthorized>
    <us-gaap:PreferredStockNoParValue contextRef="c43" decimals="5" unitRef="usdPershares">0.00001</us-gaap:PreferredStockNoParValue>
    <us-gaap:CommonStockNoParValue contextRef="c44" decimals="5" unitRef="usdPershares">0.00001</us-gaap:CommonStockNoParValue>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="c45" decimals="0" unitRef="shares">1150000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:CommonStockNoParValue contextRef="c31" decimals="5" unitRef="usdPershares">0.00001</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesIssued contextRef="c14" decimals="0" unitRef="shares">11048587</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c6" decimals="0" unitRef="shares">3200000</us-gaap:CommonStockSharesIssued>
    <bwv:AggregatePurchaseShares contextRef="c46" decimals="0" unitRef="shares">2222222</bwv:AggregatePurchaseShares>
    <us-gaap:PreferredStockConvertibleConversionPrice contextRef="c47" decimals="2" unitRef="usdPershares">9</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:LongDurationContractsAssumptionsByProductAndGuaranteeDiscountRate contextRef="c31" decimals="2" unitRef="pure">0.08</us-gaap:LongDurationContractsAssumptionsByProductAndGuaranteeDiscountRate>
    <us-gaap:OtherOwnershipInterestsOfferingCosts contextRef="c31" decimals="-5" unitRef="usd">17100000</us-gaap:OtherOwnershipInterestsOfferingCosts>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased contextRef="c31" decimals="0" unitRef="shares">111111</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased contextRef="c31" decimals="2" unitRef="usdPershares">10.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c2" decimals="0" unitRef="shares">111111</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ForwardContractIndexedToEquitySettlementShareFairValuePerShare contextRef="c2" decimals="2" unitRef="usdPershares">56.5</us-gaap:ForwardContractIndexedToEquitySettlementShareFairValuePerShare>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="c48" decimals="0" unitRef="shares">1150000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockRedemptionPricePerShare contextRef="c49" decimals="2" unitRef="usdPershares">6.09</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:ExcessStockSharesIssued contextRef="c48" decimals="0" unitRef="shares">0</us-gaap:ExcessStockSharesIssued>
    <us-gaap:ExcessStockSharesOutstanding contextRef="c2" decimals="0" unitRef="shares">0</us-gaap:ExcessStockSharesOutstanding>
    <us-gaap:ExcessStockSharesIssued contextRef="c50" decimals="0" unitRef="shares">1146138</us-gaap:ExcessStockSharesIssued>
    <us-gaap:ExcessStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">1146138</us-gaap:ExcessStockSharesOutstanding>
    <bwv:ConversionPricePerShares contextRef="c0" decimals="2" unitRef="usdPershares">1.52</bwv:ConversionPricePerShares>
    <bwv:UnderwrittenPublicOfferingNettingProceeds contextRef="c0" decimals="-6" unitRef="usd">50000000</bwv:UnderwrittenPublicOfferingNettingProceeds>
    <bwv:OfferingPricePercentage contextRef="c0" decimals="2" unitRef="pure">3</bwv:OfferingPricePercentage>
    <bwv:CumulativeDividendsPerShare contextRef="c0" decimals="2" unitRef="pure">0.08</bwv:CumulativeDividendsPerShare>
    <us-gaap:CumulativeDividends contextRef="c2" decimals="0" unitRef="usd">1586162</us-gaap:CumulativeDividends>
    <us-gaap:DividendsPayableAmountPerShare contextRef="c2" decimals="2" unitRef="usdPershares">1.38</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:PreferredStockDividendPreferenceOrRestrictions contextRef="c36">As of December&#160;31, 2021, and all other prior
historical periods, the Liquidation Preference Amount was equal to two times the Series&#160;Seed Original Issue Price per share, plus
unpaid cumulative dividends.</us-gaap:PreferredStockDividendPreferenceOrRestrictions>
    <us-gaap:SharesIssued contextRef="c51" decimals="0" unitRef="shares">1400000</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="c2" decimals="0" unitRef="shares">1600000</us-gaap:SharesIssued>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note&#160;7 &#x2014;&#160;Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Office lease&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"&gt;The Company leased office space for approximately
$5,500 a month from a related party. The Company paid a $15,000 rental deposit and rent expense for the&#160;three months ended March
31, 2022 and 2021 was approximately $0 and $20,000, respectively. The Company terminated the related party lease in May&#160;2021 and
entered into a new lease with an unrelated party in April&#160;2021. The Company is not a party to a lease with a term in excess of 12&#160;months
and has a month-to-month lease as of March&#160;31, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Litigation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;From time to time, the Company may be subject
to various legal proceedings and claims that arise in the ordinary course of its business activities. As of March 31, 2022, the Company
is not a party to any material legal proceedings and is not aware of any pending or threatened claims. See Note 11.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Significant agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Oxford University Innovation Limited&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Pursuant to the OUI Agreement, as disclosed in
Note&#160;5, the Company is obligated to pay certain milestone and royalty payments in the future, as the related contingent events occur.
Specifically, the Company is obligated to pay a 6% royalty on all net sales of licensed products, as defined in the OUI Agreement, with
an annual minimum royalty payment of $250,000 starting post-product launch, until the expiration of the OUI Agreement or revocation of
the last valid claim covering a licensed product, at which point a royalty rate of 3% will apply. An annual maintenance fee of $10,000
and $20,000 is required in the pre-phase&#160;III year and Phase&#160;III year, respectively, and as defined in the OUI Agreement. The
Company is also obligated to pay a 25% royalty on any sums received by the Company&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;from any sublicensee (including all up-front, milestone and other one-off
payments received by the Company from any sub-licenses or other contracts granted by the Company with respect to the licensed technology).
In addition, the Company is required to pay OUI milestone payments of up to an aggregate of $51.25&#160;million; specifically, upon the
achievement of specified development milestones of approximately $2.25&#160;million, regulatory milestones of approximately $9.5&#160;million,
and commercial milestones of approximately $39.5&#160;million. The annual maintenance fee and milestone fees are indexed to the RPI (Retail
Prices index for all items which is published in the United Kingdom by the Office for National Statistics, or any replacement of it) and
will be increased or decreased as appropriate as set forth in the OUI Agreement. As of March&#160;31, 2022, the Company evaluated the
likelihood of the Company achieving the specified milestones and generating product sales, and determined the likelihood is not yet probable
and as such no accrual of these payments is required as of March&#160;31, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Oxford University Research Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Pursuant to the terms of the OUI Agreement, as
disclosed in Note&#160;5, the Company entered into a sponsored research agreement dated December&#160;18, 2019 with Oxford University
for research related to the OUI Agreement for a period of &lt;span style="-sec-ix-hidden: hidden-fact-43"&gt;three&lt;/span&gt;&#160;years for a total of &#xa3;420,000. The Company prepaid the full
amount to Oxford of $554,802 for the services in January&#160;2020, of which approximately $0.2&#160;million remains as a prepaid expense
as of March 31, 2022 and December&#160;31, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;St. Jude Children&#x2019;s Hospital&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Pursuant to the St. Jude Agreement, as disclosed
in Note&#160;5, the Company is obligated to pay certain milestone and royalty payments in the future, as the related contingent events
occur. Specifically, the Company is obligated to make 4% royalty payments for each licensed product(s)&#160;sold by the Company or its
affiliates, based on the net sales for the duration of the St. Jude Agreement, and also pay 15% of consideration received for any sublicenses.
The Company is required to pay an annual maintenance fee of $10,000 beginning on the first anniversary of the Effective Date (which is
waived if all of the developmental milestones scheduled for completion before such annual fee is due have been achieved). In addition,
the Company is required to pay St. Jude milestone payments of up to an aggregate of $1&#160;million; specifically, upon the achievement
of specified development milestones of approximately $0.2&#160;million, regulatory milestones of approximately $0.3&#160;million, and
commercial milestones of approximately $0.5&#160;million. On May 11, 2022, the Company entered into an amendment to the St. Jude Agreement,
whereby the royalty terms, milestones payments and licensing fees were amended. See Note 11 for more information on this amendment. As
of March&#160;31, 2022, the Company evaluated the likelihood of the Company achieving the specified milestones and generating product
sales, and determined the likelihood is not yet probable and as such no accrual of these payments is required as of March&#160;31, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;St. Jude Children&#x2019;s Sponsored Research Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In addition to the St. Jude Agreement, the Company
also entered into a sponsored research agreement dated May&#160;3, 2021 with St. Jude for research related to the St. Jude Agreement.
Pursuant to this research agreement, the Company is obligated to pay St. Jude an aggregate amount of $73,073 in two parts, Phase&#160;I
for $57,624 and Phase&#160;II for $15,449. This sponsored research project began during 2021, and the Company recorded approximately $8,000
in related accrued expenses at December 31, 2021. During the three months ended March 31, 2022, the Company incurred related research
and development expenses of approximately $8,000, and had approximately $15,000 recorded as related accrued expenses at March&#160;31,
2022. There were no such expenses incurred during the three months ended March 31, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Cincinnati Children&#x2019;s Hospital Medical Center&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Pursuant to the CHMC Agreement, as disclosed in
Note&#160;5, the Company is obligated to pay certain milestone and royalty payments in the future, as the related contingent events occur.
Specifically, the Company is obligated to pay CHMC a single-digit royalty on net sales, being 5%, 4% or 2% depending on the product, until
the last valid claim covering a licensed product exists, at which point the royalty rates decrease by 50%. The Company is also&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;obligated to pay up to a 25% royalty on any non-royalty sublicense
revenue paid to the Company by any sublicensee. The CHMC Agreement also provides the Company with an option to license any CHMC or jointly
patented modification, alteration or improvement of any invention claimed in a Licensed Patent (&#x201c;CHMC Improvement&#x201d; and &#x201c;Joint
Improvement, respectively&#x201d;), with a $50,000 option fee for each Improvement that the Company elects to include in the license grant
of the CHMC Agreement. In addition, the Company is required to pay CHMC milestone payments of up to an aggregate of $59.75&#160;million;
specifically, upon the achievement of specified development milestones of approximately $0.5&#160;million, regulatory milestones of approximately
$1.25&#160;million, and commercial milestones of approximately $58&#160;million. As of March&#160;31, 2022, the Company evaluated the
likelihood of the Company achieving the specified milestones and generating product sales, and determined the likelihood is not yet probable
and as such no accrual of these payments is required as of March&#160;31, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Ology Bioservices, Inc. (which was later acquired by National Resilience,
Inc.)&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Pursuant to the Ology MSA and the second Project
Addendum, as disclosed in Note&#160;5, the Company is obligated to pay Ology an aggregate amount of approximately $2.8&#160;million,
plus reimbursement for materials and outsourced testing which will be billed at cost plus 15%. This project began during 2021, and the
Company recorded approximately $164,000 and $115,000 as related accounts payable and accrued expenses, respectively, at December 31,
2021. During the three months ended March 31, 2022, the Company incurred related research and development expenses of approximately $217,000,
and had approximately $332,000 recorded as related accrued expenses at March&#160;31, 2022. See Note&#160;4. There were no such expenses
incurred during the three months ended March 31, 2021. This project is currently expected to be performed through the fourth quarter
of 2023. On April 20, 2022, the Company entered into an amendment to the Ology MSA, whereby the Company&#x2019;s obligations increased
by $0.3 million, specifically related to regulatory support on the project. See Note 11.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&#160;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Underwriter Termination Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;On February&#160;7, 2022, the Company and its
former underwriter, Maxim Group (&#x201c;Maxim&#x201d;), entered into a termination agreement, whereby the parties agreed to terminate their
engagement of Maxim as the Company&#x2019;s lead managing underwriter and book runner in connection with the Company&#x2019;s IPO.&#160;Per
the terms of the termination agreement, the Company agreed to pay Maxim a termination fee of $300,000, due upon the close of the Company&#x2019;s
IPO. The termination fee was recorded as general and administrative expense during the three months ended March 31, 2022, and is included
in accounts payable in the accompanying condensed balance sheet at March 31, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Indemnification&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In the normal course of business, the Company
enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications.
The Company&#x2019;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the
future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification
obligations. However, the Company may incur charges in the future as a result of these indemnification obligations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Risks and Uncertainties&#160;&#x2014;&#160;COVID-19&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Management continues to evaluate the impact of
the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect
on the Company&#x2019;s financial position, results of its operations and/or search for drug candidates, the specific impact is not readily
determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from
the outcome of this uncertainty.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LeaseCost contextRef="c0" decimals="0" unitRef="usd">5500</us-gaap:LeaseCost>
    <bwv:RentalDeposits contextRef="c4" decimals="0" unitRef="usd">15000</bwv:RentalDeposits>
    <us-gaap:PaymentsForRent contextRef="c0" decimals="0" unitRef="usd">0</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="c4" decimals="0" unitRef="usd">20000</us-gaap:PaymentsForRent>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="c0">The Company is not a party to a lease with a term in excess of 12&#160;months
and has a month-to-month lease as of March&#160;31, 2022.</us-gaap:LesseeOperatingLeaseDescription>
    <bwv:LitigationsDescription contextRef="c0">As of March 31, 2022, the Company
is not a party to any material legal proceedings and is not aware of any pending or threatened claims.</bwv:LitigationsDescription>
    <bwv:PercentageOfRoyaltyOnSales contextRef="c52" decimals="2" unitRef="pure">0.06</bwv:PercentageOfRoyaltyOnSales>
    <bwv:MinimumRoyaltyExpense contextRef="c53" decimals="0" unitRef="usd">250000</bwv:MinimumRoyaltyExpense>
    <bwv:RoyaltyRatePercentage contextRef="c53" decimals="2" unitRef="pure">0.03</bwv:RoyaltyRatePercentage>
    <us-gaap:DebtInstrumentFee contextRef="c54">$10,000</us-gaap:DebtInstrumentFee>
    <us-gaap:DebtInstrumentFee contextRef="c55">$20,000</us-gaap:DebtInstrumentFee>
    <bwv:RoyaltyOnSumReceivedFromSublicenseePercentage contextRef="c53" decimals="2" unitRef="pure">0.25</bwv:RoyaltyOnSumReceivedFromSublicenseePercentage>
    <bwv:AggregatePayments contextRef="c53" decimals="-4" unitRef="usd">51250000</bwv:AggregatePayments>
    <bwv:SpecifiedMilestones contextRef="c53" decimals="-4" unitRef="usd">2250000</bwv:SpecifiedMilestones>
    <bwv:RegulatoryMilestones contextRef="c53" decimals="-5" unitRef="usd">9500000</bwv:RegulatoryMilestones>
    <bwv:CommercialMilestones contextRef="c53" decimals="-5" unitRef="usd">39500000</bwv:CommercialMilestones>
    <us-gaap:PurchaseObligationDueInThirdYear contextRef="c57" decimals="0" unitRef="eur">420000</us-gaap:PurchaseObligationDueInThirdYear>
    <bwv:PrepaidAmount contextRef="c58" decimals="0" unitRef="usd">554802</bwv:PrepaidAmount>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="c59" decimals="-5" unitRef="usd">200000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="c60" decimals="-5" unitRef="usd">200000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <bwv:RoyaltyPaymentsPercentage contextRef="c61" decimals="2" unitRef="pure">0.04</bwv:RoyaltyPaymentsPercentage>
    <bwv:RoyaltyOnSumReceivedFromSublicenseePercentage contextRef="c61" decimals="2" unitRef="pure">0.15</bwv:RoyaltyOnSumReceivedFromSublicenseePercentage>
    <bwv:AnnualMaintenanceFee contextRef="c61" decimals="0" unitRef="usd">10000</bwv:AnnualMaintenanceFee>
    <bwv:AggregatePayments contextRef="c61" decimals="-6" unitRef="usd">1000000</bwv:AggregatePayments>
    <bwv:SpecifiedMilestones contextRef="c61" decimals="-5" unitRef="usd">200000</bwv:SpecifiedMilestones>
    <bwv:RegulatoryMilestones contextRef="c61" decimals="-5" unitRef="usd">300000</bwv:RegulatoryMilestones>
    <bwv:CommercialMilestones contextRef="c61" decimals="-5" unitRef="usd">500000</bwv:CommercialMilestones>
    <bwv:AggregateAmount contextRef="c62" decimals="0" unitRef="usd">73073</bwv:AggregateAmount>
    <bwv:AggregateAmount contextRef="c63" decimals="0" unitRef="usd">57624</bwv:AggregateAmount>
    <bwv:AggregateAmount contextRef="c64" decimals="0" unitRef="usd">15449</bwv:AggregateAmount>
    <bwv:AccuredExpenses contextRef="c65" decimals="0" unitRef="usd">8000</bwv:AccuredExpenses>
    <bwv:OtherResearchAndDevelopmentExpenses contextRef="c66" decimals="0" unitRef="usd">8000</bwv:OtherResearchAndDevelopmentExpenses>
    <bwv:AccuredExpenses contextRef="c66" decimals="0" unitRef="usd">15000</bwv:AccuredExpenses>
    <bwv:PercentageOfRoyaltyOnSales contextRef="c67" decimals="2" unitRef="pure">0.05</bwv:PercentageOfRoyaltyOnSales>
    <bwv:RoyaltyRateDecreasePostValidClaimExpiration contextRef="c68" decimals="2" unitRef="pure">0.50</bwv:RoyaltyRateDecreasePostValidClaimExpiration>
    <bwv:RoyaltyOnSumReceivedFromSublicenseePercentage contextRef="c68" decimals="2" unitRef="pure">0.25</bwv:RoyaltyOnSumReceivedFromSublicenseePercentage>
    <bwv:OptionFee contextRef="c68" decimals="0" unitRef="usd">50000</bwv:OptionFee>
    <bwv:AggregatePayments contextRef="c68" decimals="-4" unitRef="usd">59750000</bwv:AggregatePayments>
    <bwv:SpecifiedMilestones contextRef="c68" decimals="-5" unitRef="usd">500000</bwv:SpecifiedMilestones>
    <bwv:RegulatoryMilestones contextRef="c68" decimals="-4" unitRef="usd">1250000</bwv:RegulatoryMilestones>
    <bwv:CommercialMilestones contextRef="c68" decimals="-6" unitRef="usd">58000000</bwv:CommercialMilestones>
    <bwv:AggregateAmount contextRef="c69" decimals="-5" unitRef="usd">2800000</bwv:AggregateAmount>
    <bwv:CostPlusPercentage contextRef="c69" decimals="2" unitRef="pure">0.15</bwv:CostPlusPercentage>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c70" decimals="0" unitRef="usd">164000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <bwv:AccuredExpenses contextRef="c71" decimals="0" unitRef="usd">115000</bwv:AccuredExpenses>
    <bwv:OtherResearchAndDevelopmentExpenses contextRef="c69" decimals="0" unitRef="usd">217000</bwv:OtherResearchAndDevelopmentExpenses>
    <bwv:AccuredExpenses contextRef="c69" decimals="0" unitRef="usd">332000</bwv:AccuredExpenses>
    <bwv:TerminationFee contextRef="c72" decimals="-5" unitRef="usd">300000</bwv:TerminationFee>
    <bwv:TerminationFee contextRef="c73" decimals="0" unitRef="usd">300000</bwv:TerminationFee>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note&#160;8 &#x2014;&#160;Related Party Transactions&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company originally engaged the Chief Executive
Officer, who is also the Board Chairman and prior to the close of the IPO, sole common stockholder of the Company, pursuant to a consulting
agreement commencing October&#160;22, 2018, which calls for the Company to pay for consulting services performed on a monthly basis. During
the&#160;three months ended March&#160;31, 2022 and 2021, the Company incurred approximately $63,000 and $105,000 in fees under the consulting
agreement, respectively, which are recognized in general and administrative expenses in the accompanying statements of operations. Upon
the close of the Company&#x2019;s IPO, the consulting agreement was terminated and the CEO&#x2019;s employment agreement became effective.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company also leased office space from a related
party, through common ownership. The lease is further described in Note&#160;7 of these financial statements. The lease was terminated
in May&#160;2021, and the related deposit was reclassified to the receivable from related parties balance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;As of March 31, 2022 and December&#160;31, 2021,
the Company has a receivable from related parties of approximately $165,000 and $153,000, respectively. The balance consists primarily
of consulting fee prepayments to the Company&#x2019;s CEO, in the amount of $140,000 as of March 31, 2022 and December&#160;31, 2021. These
consulting fee prepayments were repaid to the Company in lieu of a bonus payout due to the CEO during May 2022. The remaining balance
as of March 31, 2022 consists of approximately $18,000 and $7,000 of miscellaneous payments made by the Company on the behalf of the CEO
and Chief Business Officer, respectively.&#160; The balance due from the Chief Business Officer was repaid to the Company in April 2022.
The remaining balance as of December&#160;31, 2021 consists of miscellaneous payments made by the Company on the behalf of the CEO.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;One of the Company&#x2019;s directors serves on
the Advisory Board for the Cincinnati Children&#x2019;s Hospital Medical Center Innovation Fund, which is affiliated with CHMC.&#160;The
Company has an exclusive license agreement with CHMC as disclosed in Note&#160;5. This director resigned from the Company&#x2019;s board
upon the close of its IPO.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty contextRef="c0" decimals="0" unitRef="usd">63000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty contextRef="c4" decimals="0" unitRef="usd">105000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:DueFromRelatedParties contextRef="c2" decimals="0" unitRef="usd">165000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties contextRef="c3" decimals="0" unitRef="usd">153000</us-gaap:DueFromRelatedParties>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c0" decimals="0" unitRef="usd">140000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:OtherAssetsMiscellaneousCurrent contextRef="c2" decimals="0" unitRef="usd">18000</us-gaap:OtherAssetsMiscellaneousCurrent>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent contextRef="c2" decimals="0" unitRef="usd">7000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note&#160;9 &#x2014;&#160;Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"&gt;No provision for federal, state or foreign income
taxes has been recorded for the three months ended March 31, 2022 and 2021. The Company has incurred net operating losses for all of the
periods presented and has not reflected any benefit of such net operating loss carryforwards in the accompanying financial statements
due to uncertainty around utilizing these tax attributes within their respective carryforward periods. The Company has recorded a full
valuation allowance against all of its deferred tax assets as it is not more likely than not that such assets will be realized in the
near future. The Company&#x2019;s policy is to recognize interest expense and penalties related to income tax matters as income tax expense.
For the three months ended March 31, 2022 and 2021, the Company has not recognized any interest or penalties related to income taxes.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note&#160;10 &#x2014;&#160;Retirement Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Effective January&#160;1, 2022, the Company adopted
a defined contribution savings plan pursuant to Section&#160;401(k)&#160;of the Internal Revenue Code (&#x201c;the 401(k) Plan&#x201d;).
The 401(k) Plan is for the benefit of all qualifying employees and permits voluntary contributions by employees of up to 100% of eligible
compensation, subject to the maximum limits imposed by the Internal Revenue Service. The terms of the 401(k) Plan allow for discretionary
employer contributions. Enrollment in the 401(k) Plan will become available during the second quarter of 2022. No expenses were incurred
related to the 401(k) Plan during the three months ended March 31, 2022.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage contextRef="c0" decimals="2" unitRef="pure">1</us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Note&#160;11
&#x2014;&#160;Subsequent Events&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;On April 19, 2022, the Company consummated
the closing of a private placement (the &#x201c;Private Placement&#x201d;), pursuant to the terms and conditions of a securities purchase
agreement, dated as of April 13, 2022. At the closing of the Private Placement, the Company issued 590,406 shares of common stock (the
&#x201c;Shares&#x201d;), pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;) to purchase an aggregate of 590,406 shares of common
stock and preferred investment options (the &#x201c;Preferred Investment Options&#x201d;) to purchase up to an aggregate of 1,180,812 shares
of common stock. The purchase price of each Share together with the associated Preferred Investment Option was $6.775, and the purchase
price of each Pre-Funded Warrant together with the associated Preferred Investment Option was $6.774. The aggregate net proceeds to the
Company from the Private Placement were approximately $7.0 million, after deducting placement agent fees and other initial offering expenses.
H.C. Wainwright &amp;amp; Co., LLC (&#x201c;Wainwright&#x201d;) acted as the exclusive placement agent for the Private Placement. The Pre-Funded
Warrants have an exercise price of $0.001 per share, are exercisable on or after April 19, 2022, and are exercisable until the Pre-Funded
Warrants are exercised in full. The Preferred Investment Options are exercisable at any time on or after April 19, 2022 at an exercise
price of $6.65 per share, subject to certain adjustments as defined in the agreement. The Company agreed to pay Wainwright a placement
agent fee and management fee equal to 7.5% and 1.0%, respectively, of the aggregate gross proceeds from the Private Placement and reimburse
certain out-of-pocket expenses up to an aggregate of $85,000. In addition, the Company issued warrants to Wainwright (the &#x201c;Wainwright
Warrants&#x201d;) to purchase up to 70,849 shares of common stock. The Wainwright Warrants are in substantially the same form as the Preferred
Investment Options, except that the exercise price is $8.46875. Further, upon any exercise for cash of any Preferred Investment Options,
the Company agreed to issue to Wainwright warrants to purchase the number of Shares equal to 6.0% of the aggregate number of Shares underlying
the Preferred Investment Options that have been exercised, also with an exercise price of $8.46875.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In connection with the Private Placement, the
Company entered into a Registration Rights Agreement with the purchasers, dated as of April 13, 2022 (the &#x201c;Registration Rights Agreement&#x201d;).
The Registration Rights Agreement provides that the Company shall file a registration statement covering the resale of all of the registrable
securities (as defined in the Registration Rights Agreement) with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) no later
than the 20th calendar day following the date of the Registration Rights Agreement and have the registration statement declared effective
by the SEC as promptly as possible after the filing thereof, but in any event no later than the 45th calendar day following April 13,
2022 or, in the event of a full review by the SEC, the 75th day following April 13, 2022. The registration statement on Form S-1 required
under the Registration Rights Agreement was filed with the SEC on May 3, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Upon the occurrence of any Event (as defined in
the Registration Rights Agreement), which, among others, prohibits the Purchasers from reselling the securities for more than ten consecutive
calendar days or more than an aggregate of fifteen calendar days during any 12-month period, the Company is obligated to pay to each purchaser,
on each monthly anniversary of each such Event, an amount in cash, as partial liquidated damages and not as a penalty, equal to the product
of 2.0% multiplied by the aggregate subscription amount paid by such purchaser in the Private Placement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;On April 15, 2022, the Company received a demand
letter (the &#x201c;Demand Letter&#x201d;) from Boustead. The Demand Letter alleges that the Company breached the Underwriting Agreement
entered into between Boustead and the Company, dated February 17, 2022 in connection with the Company&#x2019;s initial public offering.
The Demand Letter alleges that, by engaging Wainwright as placement agent in the Private Placement, the Company breached the right of
first refusal to act as placement agent granted to Boustead under the Underwriting Agreement and, as a result of selling securities in
the Private Placement, breached the 12-month lock-up obligation following the consummation of the initial public offering under the Underwriting
Agreement. The Demand Letter requested that the Company rescind the Private Placement. The Company has not responded to the Demand Letter
and no legal action has been brought by Boustead to date. There can be no assurance as to whether any litigation will be commenced against
the Company with respect to the demand letter or that, if any such litigation is commenced, the Company will not incur material losses
due to damages, penalties, costs and/or expenses as a result of such litigation or that any such losses will not have a material impact
on the Company&#x2019;s financial condition or results of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"&gt;On April 20, 2022, the Company and Ology entered into
a first amendment to the second Project Addendum (the &#x201c;Ology Amendment&#x201d;), see Notes 5 and 7. The Ology Amendment provides
for an increase to the Company&#x2019;s obligation of $0.3 million, specifically related to regulatory support on the project.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;On May 4, 2022, the Company&#x2019;s compensation
committee approved stock option grants &lt;span&gt;under the Company&#x2019;s 2022 Equity Incentive Plan&lt;/span&gt;
to the Company&#x2019;s executive officers, board members, employees and certain consultants. The stock options granted totaled 694,540
options, of which 500,000 were granted to the Company&#x2019;s executive officers, and all of which have an exercise price of $6.45.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;On May 11, 2022, the Company and St. Jude entered
into a first amendment to the St. Jude Agreement (the &#x201c;St. Jude Amendment&#x201d;), see Notes 5 and 7. The St. Jude Amendment provides
for a revised development milestone timeline, a one-time license fee of $5,000, and an increase to the royalty rate from 4% to 5%. The
St. Jude Amendment also provides for an increase to the contingent milestone payments, from $1.0 million to $1.9 million in the aggregate;
specifically, development milestones of $0.3&#160;million, regulatory milestones of $0.6&#160;million, and commercial milestones of $1.0&#160;million.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="c74" decimals="0" unitRef="shares">590406</us-gaap:ConversionOfStockSharesConverted1>
    <bwv:AggregatesPurchaseShares contextRef="c75" decimals="0" unitRef="shares">590406</bwv:AggregatesPurchaseShares>
    <bwv:AggregatesPurchaseShares contextRef="c76" decimals="0" unitRef="shares">1180812</bwv:AggregatesPurchaseShares>
    <bwv:PurchasePricePerShare contextRef="c76" decimals="3" unitRef="usd">6.775</bwv:PurchasePricePerShare>
    <bwv:PurchasePricePerShare contextRef="c75" decimals="3" unitRef="usd">6.774</bwv:PurchasePricePerShare>
    <us-gaap:ProceedsFromRepaymentsOfDebt contextRef="c74" decimals="-5" unitRef="usd">7000000</us-gaap:ProceedsFromRepaymentsOfDebt>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c77" decimals="3" unitRef="usdPershares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c78" decimals="2" unitRef="usdPershares">6.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <bwv:AgentFee contextRef="c33" decimals="3" unitRef="pure">0.075</bwv:AgentFee>
    <bwv:ManagementFee contextRef="c33" decimals="3" unitRef="pure">0.01</bwv:ManagementFee>
    <bwv:AggregateOutofPocketExpensesToPlacementAgent contextRef="c74" decimals="0" unitRef="usd">85000</bwv:AggregateOutofPocketExpensesToPlacementAgent>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c79" decimals="0" unitRef="shares">70849</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c79" decimals="5" unitRef="usdPershares">8.46875</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <bwv:SharesPercentage contextRef="c80" decimals="3" unitRef="pure">0.06</bwv:SharesPercentage>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c80" decimals="5" unitRef="usdPershares">8.46875</us-gaap:StockOptionExercisePriceIncrease>
    <bwv:AggregateSubscriptionAmountPaidPercentage contextRef="c33" decimals="3" unitRef="pure">0.02</bwv:AggregateSubscriptionAmountPaidPercentage>
    <us-gaap:SubsequentEventDescription contextRef="c81">the Company and Ology entered into
a first amendment to the second Project Addendum (the &#x201c;Ology Amendment&#x201d;), see Notes 5 and 7. The Ology Amendment provides
for an increase to the Company&#x2019;s obligation of $0.3 million, specifically related to regulatory support on the project.</us-gaap:SubsequentEventDescription>
    <us-gaap:ScheduleOfSubsequentEventsTextBlock contextRef="c82">the Company&#x2019;s compensation
committee approved stock option grants &lt;span&gt;under the Company&#x2019;s 2022 Equity Incentive Plan&lt;/span&gt;
to the Company&#x2019;s executive officers, board members, employees and certain consultants. The stock options granted totaled 694,540
options, of which 500,000 were granted to the Company&#x2019;s executive officers, and all of which have an exercise price of $6.45.</us-gaap:ScheduleOfSubsequentEventsTextBlock>
    <us-gaap:SubsequentEventDescription contextRef="c83">The St. Jude Amendment provides
for a revised development milestone timeline, a one-time license fee of $5,000, and an increase to the royalty rate from 4% to 5%. The
St. Jude Amendment also provides for an increase to the contingent milestone payments, from $1.0 million to $1.9 million in the aggregate;
specifically, development milestones of $0.3&#160;million, regulatory milestones of $0.6&#160;million, and commercial milestones of $1.0&#160;million.</us-gaap:SubsequentEventDescription>
    <us-gaap:ProceedsFromLicenseFeesReceived contextRef="c84" decimals="0" unitRef="usd">5000</us-gaap:ProceedsFromLicenseFeesReceived>
    <bwv:RoyaltyRatePercentage contextRef="c85" decimals="2" unitRef="pure">0.04</bwv:RoyaltyRatePercentage>
    <bwv:RoyaltyRatePercentage contextRef="c86" decimals="2" unitRef="pure">0.05</bwv:RoyaltyRatePercentage>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="c3"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="c3"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c2"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c3"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <bwv:PreferredStockValue1
      contextRef="c2"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="c3"
      decimals="0"
      id="hidden-fact-7"
      unitRef="usd">15400000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c9"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c12"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c12"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c0"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c9"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c10"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c12"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c9"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c10"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c11"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c13"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c22"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c23"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c25"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c22"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c23"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c24"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="c4"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="c4"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c4"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c4"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="c4"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="c4"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c4"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c4"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredOfferingCosts
      contextRef="c30"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="c4"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering
      contextRef="c4"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <bwv:SeriesSeedPreferredStock
      contextRef="c0"
      id="hidden-fact-36"
      unitRef="shares"
      xsi:nil="true"/>
    <bwv:WarrantsToPurchaseSharesOfCommonStock
      contextRef="c4"
      id="hidden-fact-37"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c34" id="hidden-fact-38">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c35" id="hidden-fact-39">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PrepaidInsurance
      contextRef="c2"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesFairValueDisclosure
      contextRef="c3"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
      contextRef="c3"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <bwv:PurchaseObligationDueInThirdYearperiod contextRef="c56" id="hidden-fact-43">P3Y</bwv:PurchaseObligationDueInThirdYearperiod>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0">0001782107</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>49
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M(2.H\JBTO#%R4YPV/DMC9%I<K@6/A+(?P/NEE&9_8P>H#ZPG_P%02P,$%
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M3&?7I(B;%'$9SQE*<5<4+%. 2JD3&PGH- &=,J [%)#*K:TJE9=7>IGM<[]
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M?F6H,[.Y%!E."F3DBG(J4B!+ZTN3LP55($P!AJ64Z_?D([E;7I.S=^\GOL'
M5NZG39"K.DBT)\A7JLY)''X@41!%/?+Y8?DUI*T\W);[F&Z;<]3F'#E_\1Y_
M2T,-8"D:(E?DA@E,FU%.%E(S5UH_+N^U45A@/P\$B]M@L0LVV!-L@64)2N$
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M6I6&)R94Q?4F%%O[N='J=?RK$)O2<Q@6P]TD)HJ#"D$@<0:C%0Q6Z\U3$H>
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M@:*37)N2(X5F$]J= 9YY4"G#J-__%)9<J"")_=[")+&N4 H%"\-L59;<O,U
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M?G<;)"LVNL'1Z!A]:79\])V-.P8SNF&FU&&/\9SLW-1&1Q' ![?A*K6VPR2
MZ>@A"0X63GEA!:1Y!.@\)%A+@4LZZ?  %78PI>>'KZ<O.J0A>=AOL7N>>YD\
MHOA]^(E),(6\W X*U-TJZ4!T@BI%<:""1IW8%ERHBHF7J?8V+-WY7H1MK25B
MV19MB2?F4N9[+9&JDCKD&DC9PA?M2ND\Z0I*] MZ5/926^D';<E%EO(+M%8;
MZ;@L<U[T+M0M)G,KET5,S1>>@4.&N43#?FX2%O0XY[M+0Y5_87+J[Q0I@W^)
MH]5%.UG*58-JV!$46N58%SL[7&:/7*H/W32-56A8@A@^2K1 //4Q#QZ,&>"0
MGI8D')(6C#;9EH6Z&U-0US!22Z=%=\2=;< /OG-]1S!]M,GW34R]#X O*^2B
M4'WG^9C=9/3+Y>5\)ZSLH5EGO#=1PL JS<TB-F!IA\M^M1_-+]N)]&Y[.]=C
M<%O)76=XB:.3[.71D'P[*[<OT=5I/EVXB&DW/:YQ7;.7#?B^=*C'[D4<]'^P
M7/P#4$L#!!0    ( !>&K50R>/=!>@8  /$/   8    >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&ULK5==;]LV%'WWKR"\84^I'3MIF[5)@*1;T0+K&K3[>!CV
M0$M7$A>*5$G*CO?K=RXIR7+B9,6PASCZX/TZ]]Q#ZGQCW:VOB(*XJ[7Q%],J
MA.;5?.ZSBFKI9[8A@S>%=;4,N'7EW#>.9!Z-:CU?'A^_F-=2F>GE>7QVXR[/
M;1NT,G3CA&_K6KKM-6F[N9@NIOV#3ZJL C^87YXWLJ3/%'YM;ASNYH.77-5D
MO+)&."HNIE>+5]>GO#XN^$W1QH^N!5>RLO:6;][G%]-C3H@T98$]2/Q;TQO2
MFATAC2^=S^D0D@W'U[WWM[%VU+*2GMY8_;O*0W4Q/9N*G K9ZO#);MY15\]S
M]I=9[>.OV*2UI\^G(FM]L'5GC QJ9=)_>=?A,#(X.W[$8-D9+&/>*5#,\@<9
MY.6YLQOA>#6\\44L-5HC.66X*9^#PUL%NW#YD_K2JER%K9 F%V^5D2934HLW
MUN I<#N?!X3AQ?.L<WF=7"X?<7DB/E@3*B]^-#GE^_9SI#?DN.QSO%X^Z?"#
M=#-QLC@2R^/E\@E_)T/-)]'?R7^M6?QQM?+!@3%_/A'N= AW&L.=_I\0/^WR
M9QM(+,5WWYPM%\O7XM\+^J4BW-6--%M128^_7&A5JT"YP( [&90ITXC @/PD
M6)'+0$>85D A38 _#?]:"UN(3:6R"D[6)%9$!F.PMNP*5I[HEGUIE6%TR<>4
MR)2RY*>*)]F3=##G%S"$+C28\C"*/AOG&XM\^=I/&F?S-@LB@Z'BY#P&Q#F8
M(K$67'-[[C8*N3H",HZ$5Z51A8(IXN0)%*D?SX4*Z%WPHG'*.BXKLW5-CE%5
M?TNVGDWN8UI$W(&"@F$'JC4>L?%4\$\3>P&?T#_%27O&!'5E1+E'-AE!HG)1
M.%LSD'!EU@0-</XHIOAP:=M8,PG(! DVFF( -(A3>'_S<?:@\4B#,<O'?=TQ
M8**MYY[=3SGV\*Z!DOH$!NQ,2WP='>[AN^-3YZU@")$'_@-ODBN-ZS:TCF;B
MRG.Z'V(3^A$_B@7MLL[1<E_Q.MD @3O %PCP?;LXF[V *&J-'(^B_'/43#8J
M2'UH_8O92;\^UB1Y6\C:NM62Z0LU5YD*DX>69[/CWG F/AIQA29JL?B^2UB,
M$^XZ 7^2>[V&BTFC94:169B -#TJ[+IX+]K+731>;[ W]YT'#XH0F<ZS$.DS
MN,8FBM^"NJ&S2,K!7J4>%P4Y;C'WD0?SB!DFHI(L%OM$69%6& 8?RZ([Y4/"
M%4V0X7ZS0(*28JB-"E4T&2=\B*K@!7%[^*9#:%?&49K<%8:V+;@?7-28=+O1
M0@FX\,4VC=Q*J[*;.:Z_@"8DWD6N10*S'N(:^E;), 3J5"+OPD2528D"O0S@
ML3M')=/$NFUD&J_M%"-&/Z!.S'M$T20]IL*0V$)L4O\B#KQ*Q$1P!T2*0;@Q
MF2&"@4J0N5Q+I>/8("CR5=ZWE,?A\6U6[=,O!_4<3@I<#OL&SY07QL:6K*(7
M/L: 'X8E]2\,-7435N"(YI/56!YRVZ[ KA7.=.-(O3#CC=*\^8R;!*F1HK21
M-Q8ZXDPBTDX- ,BS" C:J6P^*:Q&>#9X@,UA9'I'H7(@<IW.',1GCGL4%1MZ
M L0Q\;]BSYCT\@(OM;REF$*2Z906\#:1^%A =Y2U*(0)HJTIR3WCYH@5*S]Y
MSZPW^RGT,BOWXD-E<>3V'"FV:H)>I&X!:!8<V=&7(U6*MXQ(7,^4CTA%CB(:
M\P+']V<#M_>V8"P>7@3'@.]VY;0%R9YS*LW/A(OER$XJY#?:7$= >1QD\8$P
MWA795\U?'3TV"9G=YM&U(8&ZHJWMIGD8I,0;,? FSA1WE7?A3EX>F:K#D'>G
MEW$-K"&)DLZV935^E1.& L!RFB!_%\:4_O6DLAN ZN)<,O/PMSNIF'284#U=
M3)*^V*2B=5%)!V=8[7A\.T=(5J) %ROLYA1$WRWO%6T@.Q_DQNJ ':60:^O2
M( !QM%45+%,XVLW$^V)O-2*WII\9#RZ[0QV.7*CE]H&4HAJDP6E/]EGE'QRX
MT*Y.0=.[P*,U"E6#_2S<D6F\]W5ZSN<+)I;CXU\2($]NG48NBAK>RMJVC/5N
M0YE\!2G'^PF6,2X#3V>'O@OFH\\P'!;+^+')XXG@Z8ML>#I\SUZES[C=\O0Q
M# '#>1F#005,CV<O\?GHT@=FN@FVB1]U*QOPB1@O*WR3D^,%>%]8;.S=#0<8
MOO(O_P%02P,$%     @ %X:M5&*Q*TZ)&P  =E(  !D   !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&ULU3Q9<]M&FN_X%5V>J5FKBJ)U6+83)ZF297O&J=A6
M14[RL+4/3:!)]AA$TVA %//K][OZ  G2SM;NPSXD%@ET]W??S1\VKOWLE\9T
MZF%5-_['1\NN6W__Y(DOEV:E_=2M30-/YJY=Z0X^MHLG?MT:7=&B5?WDXNSL
MV9.5MLVCGWZ@[V[;GWYP?5?;QMRVRO>KE6ZWKTSM-C\^.G\4OOC5+I8=?O'D
MIQ_6>F'N3/?;^K:%3T_B+I5=F<9;UZC6S']\='W^_:NG^#Z]\+LU&Y_]K1"3
MF7.?\<.[ZL='9PB0J4W9X0X:_KDW-Z:N<2, XXOL^2@>B0OSO\/N;PEWP&6F
MO;EQ]1^VZI8_/GKQ2%5FKONZ^]5M_F4$GRO<KW2UI_^K#;_[]/*1*GO?N94L
M!@A6MN%_]8/0(5OPXNS @@M9<$%P\T$$Y6O=Z9]^:-U&M?@V[(9_$*JT&H"S
M#3+EKFOAJ85UW4]WS SEYNK.+AH[MZ5N.G5=EJYO.MLLU*VK;6F-_^%)!^?A
MJB>E[/V*][XXL/>E>N^:;NG5FZ8RU7#]$X S GL1@'UU<73#][J=JLOSB;HX
MN[@XLM]E1/Z2]KL\L-\(ENH_KV>^:T%8_NO( 4_C 4_I@*?_)]0]OO<'UQEU
MJ?[QMQ<7YQ<OU;<?I7[S!E][XSL+8@U??%H:!2J]UJTF58&'<]OHIK2Z5KZ#
M=T -.Z]LHTK7H"6PW;;8V&ZI?IO>3=4_KZ]O04._]+:%W5:Z 77&%:IS\.FS
M428>I9M*:0\F8(TG>=4M=:?T? Y*"G\;V&7MVL[ 2RN$VR,L\+[I>&EM]<S6
MMK.\55%97];.]RUA!, AIGCRH35\2@6PX +\>Q137'<('/, %M'#9E7?(EWA
MO8+?PT]KTUI7^2D1=>5\IWS&CD0(H"4><.-6:]ULB8O/7_IQ:%I3(\! 35QR
MK^L^\JETJQ7\!7:B_#PIZ)]3M%(5/D$XZ<T)6+^R[>%;8)#1;;DD#"MS#U9Y
M3:R*6 74TS&Z!M,-4!')P.*9MH6=.OT0J R;@A%$[.>M6Q4-^!+P&BA,\!6P
M![8E>OACDJ"!APPY'%GV< 9 -0=%]!.UM(!9"R2L"<[6&H0&=[C70.X>^ (@
MM_2Z:[V:F=H";E4!))LA%[5WC9[51O5@BEK"K[1MV:^ RK 5','<1CR(R9NE
M!2*AJ-,3 ,QZ_(CRC%C]NZ\6(BHS\'6\HV[;+3Y$TIE,=(L1T94#2]=6N"27
M*]8)($?C.H2]LO56Z36H)Y$$2"SH>M>W)=+VNNQZH$V ?Z6WJK*@5 AN!^0"
M#FY)7W1U;UKPB5O>IAOR!)C$(F8>.E)?.,00)&$;V1;)CU3N-L:P'._P=0#/
M9$S2BWG?H=IF-!>906'8V+I&SK%E,-54_=;HOK*HBN\:A&6EWD95N4NJ@EH'
MLLYG(6'!)E1(U@IX6),0<["CZ<CWI O!I4R*P)BT*E/# 8B3H^^52PUVB+2<
M='+I:I [+\@K-)7==J+VCBMVMM$>A!"TCV4/7^V6K4'#0H[5H&/=08(VA3_.
MB7%](%M0P/@%P,9TC"8G/WRI[T'JD;OL&%@M$0"O5T$?M*=OPH9CMHMQ!#(D
MKQ!MG5O;AHR3;<JZKPP:&I#0?T/4(VN!+G!.)PKB&I#;!F,Q%"TT$?A@L* Q
M()@>_6"@UUS;-L$3C/Y!LUNLG;=L]48$A)&)%F]7:O'I_Y1E!;*,O4:B(_@I
M'85$3%Q\:!N.R1%8\8/$57H93 =:$B<JGN3TB(,A<QD!/B6 @S\C8=*U=[E$
M?8Q&/M#C+Z#,]JT('$,;9YL*;#R&Z8%/85\RB6C69H;L9$GR)H=MP:/A(0C(
M:]AN-0,Z19T&^FT+IEV0>,%IHF #>*K$%-$^\!4_%K!W-X3_LV\0H07*J%GK
M-+H5Y$+OO;CF,:,WZSV$<3[S -9_1C.!EC987-M,82&8JJ9+ =D-J*#MU*_P
M?F;Y; /!:L],)!JM'5IN-OB^G_T;*%5D@*!$E/G6;&9X;X0EJ%RT/IH#2#)E
M>B!]H)==S]$%461"T15D;$!89)5Y*(UA+-\:( \HUVM#ZN5 /]\U$+61/;YQ
MX)/ -H"'A+@2#_[[Q=79Y.SL#!S;(24<84N.YA*T%[UGBA8J"40*-F/>),QP
MORQHE>#!#S:T<3_2,B!C'M8Q%S$.Z\M$LJFZ;=$Z=.1[U1LP^AQK#;XV\6LA
MO9>X;MV#M'*8Z^9P$!B&OFTLB2HNG-L'_!M-+#C+&+/H-L05&+;BKKZ; KW
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M-4#540A9.A L"$"Y@T3E(@A 66'B\=C,Q9,C2X8)/J6PU'"J1KI,:&H@M()
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M*:B)XV[AFZJ\TD -B 2&#0#[R:X*/>;'(7\PE<J0QA3JO5X,2WC %(AQ-A[
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MZ@R$BD1=#WW/"]?0302VA,5]&W:,9=JSDEVYFRQ"W%)Y#%#9U2@0=!:>Z(A
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MA_?6H4.>CN1J@:V3\9-'!V$.U3P@E?'[UW,#6%7PQQ6PM+*T +\O#!B-#W1
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M#O6_W%DT<RGE8E '"47YE#,5R4=[.Y=L=1.U>:1N4R.?DRIW$F]UOVV@#],
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M6H#?EP;HZ[_0 =T+TF__"U!+ P04    "  7AJU4VJP2G L.  #"*P  &0
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MP;J_:"0A"%Y!YYHVDI&AQ_M/E^*\H3$@+V6ARG!()<SSM.\)2&]F.;F-PM1
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MQ-W^I+RW5:*FR[QNL$V2Z\\JUTMCLJ;J->M"O%#&T=--N'1\1H9'GU!4-JG
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MU1MY[PZ_\Y#/L\A7.Q/2?SIDW\6BH+H/XKH!# 6=MOE7W0]U. %<S+X#J 9
ME73G0$GE*R5JO?3N0#YZ@RTN4JH)#7':QD/Y(!Y?-7"R?F-KUS%]5/<<EJ6
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M7*+'*$L">#\W %K[A3:(OWG>_A=02P,$%     @ %X:M5%!V&4D^'   D5D
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MNNE]RUI=XNZ-D\PJ8CZ'0"%W=C-8!4DU'0MXK E98BPVZ# PM(7@5Z] H?Z
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MEB L\:LDS3P\;1;2?MP^%8!LLB*%UE3!NV57^.T)(5VZ?*5KS/;9["O)S#T
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M9AS#0!\[W"E<Z+6JED?F!NUV6,J6%%M>!UA'4+$L7JRI6S;/?\?G"U1LK Z
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MZW@@CO<!G:ST2H_RYN DKLD@5B)04[Q\T8/E*"64:8U9,E& DS0R(%27PW-
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M%^#YTMK6?\ #PJ\P__@?4$L#!!0    ( !>&K51#L@^TD@(  '8%   9
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MT*\ _4M KP,05H#0Q+X,EHGT@B@R&0E^1$*_#6SZQ*3+H"' +-.5M58"GC+
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M1,K@:H 94=6<J#9&;ESG7$B#?=@MUSA:05D#O%]*:0X;ZZ 9UMD+4$L#!!0
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MTY:> ' A@?8;:_$8A +3HU+^ 5!+ P04    "  7AJU4?\)P.5,&   >&P
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M>. \)*NV@_)A569%0I*'[=G17CV;^\T1D0]SX.TK/':.JHE02_AG=<=/ZNI
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ %X:M5*K;'0E9 P  HQ8
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M4$L! A0#%     @ %X:M5+,W6&SO    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ %X:M5)E<G",0!@  G"<
M !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    "  7AJU4B)QRJFL%  "\%@  &               @($."   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ %X:M5%I#6S*1!0  V10
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M965T-BYX;6Q02P$"% ,4    "  7AJU4W)- ;\P%  #0%P  &
M    @($'(@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
M%X:M5&KR4&G2!0  O P  !@              ("!"2@  'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    ( !>&K50R>/=!>@8  /$/   8
M          " @1$N  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    "  7AJU48K$K3HD;  !V4@  &0              @('!-   >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( !>&K52+W0$]+P,  %4'
M   9              " @8%0  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @ %X:M5)7!'H<:$   G"\  !D              ("!YU,
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  7AJU4R<..
MG)<.   L+0  &0              @($X9   >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    ( !>&K53:K!*<"PX  ,(K   9
M  " @09S  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
M%X:M5/?*X[]F!0  %0T  !D              ("!2($  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    "  7AJU48Z(DSG(#  "T!P  &0
M            @('EA@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    ( !>&K53?7C(3-P,  .X&   9              " @8Z*  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ %X:M5/X2<0QU"@
M_QP  !D              ("!_(T  'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    "  7AJU44'8923X<  "160  &0              @(&H
MF   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( !>&K51#
ML@^TD@(  '8%   9              " @1VU  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @ %X:M5/IP+F 9 P  % <  !D
M     ("!YK<  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !>&K50!\4&_KP(  $X'   9              "
M@97'  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ %X:M
M5,V=5%]- P  /@H  !D              ("!>\H  'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"% ,4    "  7AJU4VU;_1=T#  "W#0  &0
M        @('_S0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0
M   ( !>&K50@6@]%% 8  !D;   9              " @1/2  !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ %X:M5 I4[&WI!P  Z"H
M !D              ("!7M@  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"% ,4    "  7AJU4&BS5++L"  "X!P  &0              @(%^X
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( !>&K52A'VJ
M_@$  & $   9              " @7#C  !X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL4$L! A0#%     @ %X:M5'_"<#E3!@  'AL  !D
M ("!I>4  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  7
MAJU4M98JUTD#  !L%   #0              @ $O[   >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( !>&K527BKL<P    !,"   +              "  :/O
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( !>&K52JVQT)60,  *,6   /
M          "  8SP  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  7AJU4
MX#T)5V@!  !*%   &@              @ $2]   >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    "  7AJU4')H)78P!  #G%   $P
M        @ &R]0  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     *0 I !8+
(  !O]P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>87</ContextCount>
  <ElementCount>232</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>28</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Condensed Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Condensed Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Statements of Stockholders??? Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Condensed Statements of Stockholders??? Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Statements of Stockholders??? Equity (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3_Parentheticals</Role>
      <ShortName>Condensed Statements of Stockholders??? Equity (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Liquidity and Financial Condition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/LiquidityandFinancialCondition</Role>
      <ShortName>Liquidity and Financial Condition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/BalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Significant Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/SignificantAgreements</Role>
      <ShortName>Significant Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/RetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/BalanceSheetDetails</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Organization and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails</Role>
      <ShortName>Organization and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Liquidity and Financial Condition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/LiquidityandFinancialConditionDetails</Role>
      <ShortName>Liquidity and Financial Condition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/LiquidityandFinancialCondition</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of computation of diluted shares outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofcomputationofdilutedsharesoutstandingTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of computation of diluted shares outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Balance Sheet Details (Details) - Schedule of prepaid expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofprepaidexpensesTable</Role>
      <ShortName>Balance Sheet Details (Details) - Schedule of prepaid expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Balance Sheet Details (Details) - Schedule of accrued expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/ScheduleofaccruedexpensesTable</Role>
      <ShortName>Balance Sheet Details (Details) - Schedule of accrued expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Significant Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/SignificantAgreementsDetails</Role>
      <ShortName>Significant Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/SignificantAgreements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Stockholders??? Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders??? Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/StockholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/CommitmentsandContingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/RelatedPartyTransactions</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Retirement Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/RetirementPlanDetails</Role>
      <ShortName>Retirement Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/RetirementPlan</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="f10q0322_bluewatervac.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bluewatervaccines.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bluewatervaccines.com/role/SubsequentEvents</ParentRole>
      <Position>33</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="f10q0322_bluewatervac.htm">f10q0322_bluewatervac.htm</File>
    <File>bwv-20220331.xsd</File>
    <File>bwv-20220331_cal.xml</File>
    <File>bwv-20220331_def.xml</File>
    <File>bwv-20220331_lab.xml</File>
    <File>bwv-20220331_pre.xml</File>
    <File>f10q0322ex10-1_bluewater.htm</File>
    <File>f10q0322ex10-2_bluewater.htm</File>
    <File>f10q0322ex31-1_bluewater.htm</File>
    <File>f10q0322ex31-2_bluewater.htm</File>
    <File>f10q0322ex32-1_bluewater.htm</File>
    <File>f10q0322ex32-2_bluewater.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="287">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>55
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "f10q0322_bluewatervac.htm": {
   "axisCustom": 0,
   "axisStandard": 8,
   "contextCount": 87,
   "dts": {
    "calculationLink": {
     "local": [
      "bwv-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bwv-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "f10q0322_bluewatervac.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bwv-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bwv-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bwv-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd"
     ]
    }
   },
   "elementCount": 320,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 40,
    "http://www.bluewatervaccines.com/20220331": 4,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 48
   },
   "keyCustom": 55,
   "keyStandard": 177,
   "memberCustom": 20,
   "memberStandard": 8,
   "nsprefix": "bwv",
   "nsuri": "http://www.bluewatervaccines.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Balance Sheet Details",
     "role": "http://www.bluewatervaccines.com/role/BalanceSheetDetails",
     "shortName": "Balance Sheet Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bwv:SignificantAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Significant Agreements",
     "role": "http://www.bluewatervaccines.com/role/SignificantAgreements",
     "shortName": "Significant Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bwv:SignificantAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Stockholders\u2019 Equity",
     "role": "http://www.bluewatervaccines.com/role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Commitments and Contingencies",
     "role": "http://www.bluewatervaccines.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Related Party Transactions",
     "role": "http://www.bluewatervaccines.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Income Taxes",
     "role": "http://www.bluewatervaccines.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Retirement Plan",
     "role": "http://www.bluewatervaccines.com/role/RetirementPlan",
     "shortName": "Retirement Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Subsequent Events",
     "role": "http://www.bluewatervaccines.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Accounting Policies, by Policy (Policies)",
     "role": "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Condensed Balance Sheets",
     "role": "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet",
     "shortName": "Condensed Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Balance Sheet Details (Tables)",
     "role": "http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables",
     "shortName": "Balance Sheet Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "bwv:InitialPublicOfferingShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Organization and Basis of Presentation (Details)",
     "role": "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails",
     "shortName": "Organization and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "bwv:InitialPublicOfferingShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentsAndCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Liquidity and Financial Condition (Details)",
     "role": "http://www.bluewatervaccines.com/role/LiquidityandFinancialConditionDetails",
     "shortName": "Liquidity and Financial Condition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentsAndCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "bwv:OptionsToPurchaseSharesOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of computation of diluted shares outstanding",
     "role": "http://www.bluewatervaccines.com/role/ScheduleofcomputationofdilutedsharesoutstandingTable",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of computation of diluted shares outstanding",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "bwv:OptionsToPurchaseSharesOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Balance Sheet Details (Details) - Schedule of prepaid expenses",
     "role": "http://www.bluewatervaccines.com/role/ScheduleofprepaidexpensesTable",
     "shortName": "Balance Sheet Details (Details) - Schedule of prepaid expenses",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromLicenseFeesReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Balance Sheet Details (Details) - Schedule of accrued expenses",
     "role": "http://www.bluewatervaccines.com/role/ScheduleofaccruedexpensesTable",
     "shortName": "Balance Sheet Details (Details) - Schedule of accrued expenses",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromLicenseFeesReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bwv:OUIAgreementExpiration",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Significant Agreements (Details)",
     "role": "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails",
     "shortName": "Significant Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bwv:OUIAgreementExpiration",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c31",
      "decimals": "5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Stockholders\u2019 Equity (Details)",
     "role": "http://www.bluewatervaccines.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders\u2019 Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c31",
      "decimals": "5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c2",
      "decimals": "5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Condensed Balance Sheets (Parentheticals)",
     "role": "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "Condensed Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c2",
      "decimals": "5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Related Party Transactions (Details)",
     "role": "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Retirement Plan (Details)",
     "role": "http://www.bluewatervaccines.com/role/RetirementPlanDetails",
     "shortName": "Retirement Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c33",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "bwv:AgentFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.bluewatervaccines.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c33",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "bwv:AgentFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Condensed Statements of Operations (Unaudited)",
     "role": "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement",
     "shortName": "Condensed Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c17",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Condensed Statements of Stockholders\u2019 Equity (Unaudited)",
     "role": "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3",
     "shortName": "Condensed Statements of Stockholders\u2019 Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c17",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": "1",
      "first": true,
      "lang": null,
      "name": "bwv:OfferingCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Condensed Statements of Stockholders\u2019 Equity (Unaudited) (Parentheticals)",
     "role": "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3_Parentheticals",
     "shortName": "Condensed Statements of Stockholders\u2019 Equity (Unaudited) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": "1",
      "first": true,
      "lang": null,
      "name": "bwv:OfferingCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "006 - Statement - Statements of Cash Flows (Unaudited)",
     "role": "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow",
     "shortName": "Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bwv:LiquidityAndFinancialConditionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Liquidity and Financial Condition",
     "role": "http://www.bluewatervaccines.com/role/LiquidityandFinancialCondition",
     "shortName": "Liquidity and Financial Condition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_bluewatervac.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bwv:LiquidityAndFinancialConditionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 28,
   "tag": {
    "bwv_AccruedDeferredOfferingCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued deferred offering costs.",
        "label": "AccruedDeferredOfferingCosts",
        "terseLabel": "Accrued deferred offering costs"
       }
      }
     },
     "localname": "AccruedDeferredOfferingCosts",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofaccruedexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bwv_AccruedResearchAndDevelopment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development.",
        "label": "AccruedResearchAndDevelopment",
        "terseLabel": "Accrued research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopment",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofaccruedexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bwv_AccuredExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accured expenses.",
        "label": "AccuredExpenses",
        "terseLabel": "Accrued expenses",
        "verboseLabel": "Accured expenses"
       }
      }
     },
     "localname": "AccuredExpenses",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails",
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bwv_AgentFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agent fee percentage.",
        "label": "AgentFee",
        "terseLabel": "Agent fee, percentage"
       }
      }
     },
     "localname": "AgentFee",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bwv_AggregateAgreementAmountInitialAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of aggregate Agreement amount initial agreement.",
        "label": "AggregateAgreementAmountInitialAgreement",
        "terseLabel": "Aggregate agreement amount initial agreement"
       }
      }
     },
     "localname": "AggregateAgreementAmountInitialAgreement",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bwv_AggregateAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount.",
        "label": "AggregateAmount",
        "terseLabel": "Aggregate amount"
       }
      }
     },
     "localname": "AggregateAmount",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails",
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bwv_AggregateOutofPocketExpensesToPlacementAgent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents of aggregate out-of pocket expenses to placement agent.",
        "label": "AggregateOutofPocketExpensesToPlacementAgent",
        "terseLabel": "Aggregate out-of pocket expenses to placement agent (in Dollars)"
       }
      }
     },
     "localname": "AggregateOutofPocketExpensesToPlacementAgent",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bwv_AggregatePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate payments.",
        "label": "AggregatePayments",
        "terseLabel": "Aggregate payments"
       }
      }
     },
     "localname": "AggregatePayments",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bwv_AggregatePurchaseShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of aggregate purchase shares.",
        "label": "AggregatePurchaseShares",
        "terseLabel": "Aggregate shares"
       }
      }
     },
     "localname": "AggregatePurchaseShares",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bwv_AggregateSubscriptionAmountPaidPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate subscription amount paid, percentage",
        "label": "AggregateSubscriptionAmountPaidPercentage",
        "terseLabel": "Aggregate subscription amount paid percentage"
       }
      }
     },
     "localname": "AggregateSubscriptionAmountPaidPercentage",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bwv_AggregatesPurchaseShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of aggregates purchase shares.",
        "label": "AggregatesPurchaseShares",
        "terseLabel": "Aggregates purchase shares (in Shares)"
       }
      }
     },
     "localname": "AggregatesPurchaseShares",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bwv_AnnualMaintenanceFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual maintenance fee.",
        "label": "AnnualMaintenanceFee",
        "terseLabel": "Annual maintenance fee"
       }
      }
     },
     "localname": "AnnualMaintenanceFee",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bwv_CHMCAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHMCAgreementMember",
        "terseLabel": "CHMC Agreement [Member]"
       }
      }
     },
     "localname": "CHMCAgreementMember",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bwv_CashFlowsFromOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CashFlowsFromOperatingActivitiesAbstract",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "CashFlowsFromOperatingActivitiesAbstract",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "bwv_CommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "CommercialMilestones",
        "terseLabel": "Commercial milestones"
       }
      }
     },
     "localname": "CommercialMilestones",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bwv_CommitmentsandContingenciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Line Items]"
       }
      }
     },
     "localname": "CommitmentsandContingenciesDetailsLineItems",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bwv_CommitmentsandContingenciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Table]"
       }
      }
     },
     "localname": "CommitmentsandContingenciesDetailsTable",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bwv_CommonStockShareAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of excess stock shares permitted to be issued.",
        "label": "CommonStockShareAuthorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockShareAuthorized",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bwv_ConversionPricePerShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion price, per shares.",
        "label": "ConversionPricePerShares",
        "terseLabel": "Conversion price, per shares (in Dollars per share)"
       }
      }
     },
     "localname": "ConversionPricePerShares",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bwv_CostPlusPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost plus, percentage.",
        "label": "CostPlusPercentage",
        "terseLabel": "Cost plus, percentage",
        "verboseLabel": "Cost plus percentage"
       }
      }
     },
     "localname": "CostPlusPercentage",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails",
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bwv_CumulativeDividendsPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative dividends per share.",
        "label": "CumulativeDividendsPerShare",
        "terseLabel": "Cumulative dividends, per share"
       }
      }
     },
     "localname": "CumulativeDividendsPerShare",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bwv_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bwv_FairValueOfCommonStockPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FairValueOfCommonStockPolicyTextBlock",
        "terseLabel": "Fair Value of Common Stock"
       }
      }
     },
     "localname": "FairValueOfCommonStockPolicyTextBlock",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bwv_InitialPublicOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial public offering description.",
        "label": "InitialPublicOffering",
        "terseLabel": "Initial public offering, description"
       }
      }
     },
     "localname": "InitialPublicOffering",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bwv_InitialPublicOfferingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued initial public offering of shares.",
        "label": "InitialPublicOfferingShares",
        "terseLabel": "Initial public offering"
       }
      }
     },
     "localname": "InitialPublicOfferingShares",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bwv_LiquidityAndFinancialConditionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity and Financial Condition [Abstract]"
       }
      }
     },
     "localname": "LiquidityAndFinancialConditionAbstract",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bwv_LiquidityAndFinancialConditionTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LiquidityAndFinancialConditionTextBlock",
        "terseLabel": "Liquidity and Financial Condition"
       }
      }
     },
     "localname": "LiquidityAndFinancialConditionTextBlock",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/LiquidityandFinancialCondition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bwv_LiquidityandFinancialConditionDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity and Financial Condition (Details) [Line Items]"
       }
      }
     },
     "localname": "LiquidityandFinancialConditionDetailsLineItems",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/LiquidityandFinancialConditionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bwv_LiquidityandFinancialConditionDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity and Financial Condition (Details) [Table]"
       }
      }
     },
     "localname": "LiquidityandFinancialConditionDetailsTable",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/LiquidityandFinancialConditionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bwv_LitigationsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigations description.",
        "label": "LitigationsDescription",
        "terseLabel": "Litigations description"
       }
      }
     },
     "localname": "LitigationsDescription",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bwv_ManagementFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Management fee.",
        "label": "ManagementFee",
        "terseLabel": "Management fee, percentage"
       }
      }
     },
     "localname": "ManagementFee",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bwv_MinimumRoyaltyExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents of minimum royalty expense.",
        "label": "MinimumRoyaltyExpense",
        "terseLabel": "Minimum Royalty Expense"
       }
      }
     },
     "localname": "MinimumRoyaltyExpense",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bwv_NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net loss per share attributable to common stockholder, basic and diluted (in Dollars per share).",
        "label": "NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare",
        "terseLabel": "Net loss per share attributable to common stockholders, basic and diluted (in Dollars per share)"
       }
      }
     },
     "localname": "NetLossPerShareAttributableToCommonStockholderBasicAndDilutedinDollarsPerShare",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "perShareItemType"
    },
    "bwv_OUIAgreementExpiration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OUIAgreementExpiration",
        "terseLabel": "OUI Agreement Expiration"
       }
      }
     },
     "localname": "OUIAgreementExpiration",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bwv_OUIAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OUIAgreementMember",
        "terseLabel": "OUI Agreement [Member]"
       }
      }
     },
     "localname": "OUIAgreementMember",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bwv_OfferingCostsNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "OfferingCostsNet",
        "terseLabel": "Offering costs, net"
       }
      }
     },
     "localname": "OfferingCostsNet",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3_Parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bwv_OfferingPricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering price percentage.",
        "label": "OfferingPricePercentage",
        "terseLabel": "Offering price percentage"
       }
      }
     },
     "localname": "OfferingPricePercentage",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bwv_OlogyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OlogyAgreementMember",
        "terseLabel": "Ology Agreement [Member]"
       }
      }
     },
     "localname": "OlogyAgreementMember",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bwv_OlogyAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OlogyAmendmentMember",
        "terseLabel": "Ology Amendment [Member]"
       }
      }
     },
     "localname": "OlogyAmendmentMember",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bwv_OlogyBioservicesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OlogyBioservicesIncMember",
        "terseLabel": "Ology Bioservices, Inc [Member]"
       }
      }
     },
     "localname": "OlogyBioservicesIncMember",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bwv_OptionFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option fee.",
        "label": "OptionFee",
        "terseLabel": "Option fee"
       }
      }
     },
     "localname": "OptionFee",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bwv_OptionsToPurchaseSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase shares of common stock.",
        "label": "OptionsToPurchaseSharesOfCommonStock",
        "terseLabel": "Options to purchase shares of common stock"
       }
      }
     },
     "localname": "OptionsToPurchaseSharesOfCommonStock",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofcomputationofdilutedsharesoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "bwv_OriginalIssuePriceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OriginalIssuePriceMember",
        "terseLabel": "Original Issue Price [Member]"
       }
      }
     },
     "localname": "OriginalIssuePriceMember",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bwv_OtherResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Research and Development Expense.",
        "label": "OtherResearchAndDevelopmentExpenses",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "OtherResearchAndDevelopmentExpenses",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bwv_OxfordResearchMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OxfordResearchMember",
        "terseLabel": "Oxford Research [Member]"
       }
      }
     },
     "localname": "OxfordResearchMember",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bwv_PercentageOfRoyaltyOnSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PercentageOfRoyaltyOnSales",
        "terseLabel": "Percentage of royalty on net sales"
       }
      }
     },
     "localname": "PercentageOfRoyaltyOnSales",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bwv_PhaseIIIYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PhaseIIIYearMember",
        "terseLabel": "Phase III year [Member]"
       }
      }
     },
     "localname": "PhaseIIIYearMember",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bwv_PhaseIIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PhaseIIMember",
        "terseLabel": "Phase II [Member]"
       }
      }
     },
     "localname": "PhaseIIMember",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bwv_PhaseIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PhaseIMember",
        "terseLabel": "Phase I [Member]"
       }
      }
     },
     "localname": "PhaseIMember",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bwv_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PreFundedWarrantsMember",
        "terseLabel": "Pre-Funded Warrants [Member]"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bwv_PreferredInvestmentOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PreferredInvestmentOptionsMember",
        "terseLabel": "Preferred Investment Option [Member]",
        "verboseLabel": "Preferred Investment Options [Member]"
       }
      }
     },
     "localname": "PreferredInvestmentOptionsMember",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bwv_PreferredStockSharesDesignated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock, shares designated.",
        "label": "PreferredStockSharesDesignated",
        "terseLabel": "Preferred stock, shares designated"
       }
      }
     },
     "localname": "PreferredStockSharesDesignated",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "bwv_PreferredStockValue1": {
     "auth_ref": [],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "PreferredStockValue1",
        "terseLabel": "Series Seed: 0 and 1,150,000 shares designated at March 31, 2022 and December 31, 2021, respectively; 0 and 1,146,138 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively; $0 and $15.4 million aggregate liquidation preference at March 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "PreferredStockValue1",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bwv_PrepaidAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "prepaid amount.",
        "label": "PrepaidAmount",
        "terseLabel": "Prepaid amount"
       }
      }
     },
     "localname": "PrepaidAmount",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bwv_PrepaidExpenseRemaining": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prepaid expense remaining.",
        "label": "PrepaidExpenseRemaining",
        "terseLabel": "Prepaid expense remaining"
       }
      }
     },
     "localname": "PrepaidExpenseRemaining",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bwv_PrepaidExpensesToRemainingPrepaidExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents of prepaid expenses to remaining prepaid expenses.",
        "label": "PrepaidExpensesToRemainingPrepaidExpenses",
        "terseLabel": "Prepaid expenses to remaining prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpensesToRemainingPrepaidExpenses",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bwv_PrephaseIIIYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PrephaseIIIYearMember",
        "terseLabel": "Pre-phase III year [Member]"
       }
      }
     },
     "localname": "PrephaseIIIYearMember",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bwv_PricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price per share",
        "label": "PricePerShare",
        "terseLabel": "Initial public offering price per share (in Dollars per share)"
       }
      }
     },
     "localname": "PricePerShare",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bwv_PurchaseObligationDueInThirdYearperiod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PurchaseObligationDueInThirdYearperiod",
        "terseLabel": "Agreement period"
       }
      }
     },
     "localname": "PurchaseObligationDueInThirdYearperiod",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bwv_PurchasePricePerShare": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price per share.",
        "label": "PurchasePricePerShare",
        "terseLabel": "Purchase price, per share (in Dollars)"
       }
      }
     },
     "localname": "PurchasePricePerShare",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bwv_RegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "RegulatoryMilestones",
        "terseLabel": "Regulatory milestones"
       }
      }
     },
     "localname": "RegulatoryMilestones",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bwv_RentalDeposits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "RentalDeposits",
        "terseLabel": "Rental deposit"
       }
      }
     },
     "localname": "RentalDeposits",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bwv_RoyaltyOnSumReceivedFromSublicenseePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty on sum received from sublicensee of percentage.",
        "label": "RoyaltyOnSumReceivedFromSublicenseePercentage",
        "terseLabel": "Royalty on sum received from sublicensee, percentage"
       }
      }
     },
     "localname": "RoyaltyOnSumReceivedFromSublicenseePercentage",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bwv_RoyaltyPaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty payments percentage.",
        "label": "RoyaltyPaymentsPercentage",
        "terseLabel": "Royalty payments percentage"
       }
      }
     },
     "localname": "RoyaltyPaymentsPercentage",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bwv_RoyaltyRateDecreasePostValidClaimExpiration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty rate decrease post valid claim expiration.",
        "label": "RoyaltyRateDecreasePostValidClaimExpiration",
        "terseLabel": "Royalty rate decrease, post valid claim expiration"
       }
      }
     },
     "localname": "RoyaltyRateDecreasePostValidClaimExpiration",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bwv_RoyaltyRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty rate percentage.",
        "label": "RoyaltyRatePercentage",
        "terseLabel": "Royalty rate, percentage",
        "verboseLabel": "Royalty rate"
       }
      }
     },
     "localname": "RoyaltyRatePercentage",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails",
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bwv_ScheduleOfAccruedExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of accrued expenses [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfAccruedExpensesAbstract",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bwv_ScheduleOfComputationOfDilutedSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of computation of diluted shares outstanding [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfComputationOfDilutedSharesOutstandingAbstract",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bwv_ScheduleOfPrepaidExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of prepaid expenses [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfPrepaidExpensesAbstract",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bwv_SeriesSeedPreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series Seed Preferred Stock.",
        "label": "SeriesSeedPreferredStock",
        "terseLabel": "Series Seed Preferred Stock"
       }
      }
     },
     "localname": "SeriesSeedPreferredStock",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofcomputationofdilutedsharesoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "bwv_SeriesSeedPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SeriesSeedPreferredStockMember",
        "terseLabel": "Preferred Stock Series Seed",
        "verboseLabel": "Series Seed Preferred Stock.[Member]"
       }
      }
     },
     "localname": "SeriesSeedPreferredStockMember",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bwv_SharesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares percentage.",
        "label": "SharesPercentage",
        "terseLabel": "Shares percentage"
       }
      }
     },
     "localname": "SharesPercentage",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bwv_SignificantAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Agreements [Abstract]"
       }
      }
     },
     "localname": "SignificantAgreementsAbstract",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bwv_SignificantAgreementsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Agreements (Details) [Line Items]"
       }
      }
     },
     "localname": "SignificantAgreementsDetailsLineItems",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bwv_SignificantAgreementsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Agreements (Details) [Table]"
       }
      }
     },
     "localname": "SignificantAgreementsDetailsTable",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bwv_SignificantAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SignificantAgreementsTextBlock",
        "terseLabel": "Significant Agreements"
       }
      }
     },
     "localname": "SignificantAgreementsTextBlock",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bwv_SpecifiedMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents of specified milestones.",
        "label": "SpecifiedMilestones",
        "terseLabel": "Specified milestones"
       }
      }
     },
     "localname": "SpecifiedMilestones",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bwv_StJudeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "StJudeAgreementMember",
        "terseLabel": "St. Jude Agreement [Member]"
       }
      }
     },
     "localname": "StJudeAgreementMember",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bwv_StJudeAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "StJudeAmendmentMember",
        "terseLabel": "St. Jude Amendment [Member]"
       }
      }
     },
     "localname": "StJudeAmendmentMember",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bwv_StJudeResearchAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "StJudeResearchAgreementMember",
        "terseLabel": "St. Jude Agreement [Member]",
        "verboseLabel": "St Jude Research Agreement [Member]"
       }
      }
     },
     "localname": "StJudeResearchAgreementMember",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bwv_StockholdersEquityDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) [Line Items]"
       }
      }
     },
     "localname": "StockholdersEquityDetailsLineItems",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bwv_StockholdersEquityDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) [Table]"
       }
      }
     },
     "localname": "StockholdersEquityDetailsTable",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bwv_SubsequentEventsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsLineItems",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bwv_SubsequentEventsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsTable",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bwv_SummaryofSignificantAccountingPoliciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Line Items]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bwv_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bwv_TerminationFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Definite liabilities to third parties under a termination loan agreement, whether or not guaranteed in whole or in part by the government.",
        "label": "TerminationFee",
        "terseLabel": "Termination fee"
       }
      }
     },
     "localname": "TerminationFee",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bwv_TotalShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total shares.",
        "label": "TotalShares",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "TotalShares",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofcomputationofdilutedsharesoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "bwv_TwoThousandNinteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwoThousandNinteenEquityIncentivePlanMember",
        "terseLabel": "2019 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandNinteenEquityIncentivePlanMember",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bwv_UnderwriterTerminationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UnderwriterTerminationAgreementMember",
        "terseLabel": "Underwriter Termination Agreement [Member]"
       }
      }
     },
     "localname": "UnderwriterTerminationAgreementMember",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bwv_UnderwrittenPublicOfferingNettingProceeds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten public offering netting proceeds.",
        "label": "UnderwrittenPublicOfferingNettingProceeds",
        "terseLabel": "Underwritten public offering netting proceeds (in Dollars)"
       }
      }
     },
     "localname": "UnderwrittenPublicOfferingNettingProceeds",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bwv_WainwrightWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WainwrightWarrantsMember",
        "terseLabel": "Wainwright Warrants [Member]"
       }
      }
     },
     "localname": "WainwrightWarrantsMember",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bwv_WarrantsToPurchaseSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to purchase shares of common stock.",
        "label": "WarrantsToPurchaseSharesOfCommonStock",
        "terseLabel": "Warrants to purchase shares of common stock"
       }
      }
     },
     "localname": "WarrantsToPurchaseSharesOfCommonStock",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofcomputationofdilutedsharesoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "bwv_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average number of common shares outstanding, basic and diluted (in Shares).",
        "label": "WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares",
        "terseLabel": "Weighted average number of common shares outstanding, basic and diluted (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfCommonSharesOutstandingBasicAndDilutedinShares",
     "nsuri": "http://www.bluewatervaccines.com/20220331",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r141",
      "r159",
      "r183",
      "r220",
      "r221",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r350",
      "r352",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails",
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r141",
      "r159",
      "r183",
      "r220",
      "r221",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r350",
      "r352",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails",
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r124",
      "r139",
      "r140",
      "r203",
      "r204",
      "r310",
      "r348",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r124",
      "r139",
      "r140",
      "r203",
      "r204",
      "r310",
      "r348",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r134",
      "r138",
      "r139",
      "r140",
      "r141",
      "r159",
      "r183",
      "r206",
      "r220",
      "r221",
      "r228",
      "r229",
      "r230",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r350",
      "r352",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails",
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r134",
      "r138",
      "r139",
      "r140",
      "r141",
      "r159",
      "r183",
      "r206",
      "r220",
      "r221",
      "r228",
      "r229",
      "r230",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r350",
      "r352",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails",
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of trade and related party payables and accrued expenses.",
        "label": "Accounts Payable and Accrued Liabilities, Fair Value Disclosure",
        "terseLabel": "Accrued insurance expense"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofaccruedexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r27",
      "r298"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r329",
      "r345"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails",
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet",
      "http://www.bluewatervaccines.com/role/ScheduleofaccruedexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r19",
      "r298"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r233",
      "r234",
      "r235",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r10",
      "r73",
      "r117",
      "r119",
      "r122",
      "r126",
      "r143",
      "r144",
      "r145",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r154",
      "r155",
      "r257",
      "r261",
      "r275",
      "r296",
      "r298",
      "r323",
      "r338"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r26",
      "r73",
      "r126",
      "r143",
      "r144",
      "r145",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r154",
      "r155",
      "r257",
      "r261",
      "r275",
      "r296",
      "r298"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Unaudited Interim Financial Statements"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r8",
      "r63"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r56",
      "r63",
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, end of period",
        "periodStartLabel": "Cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r56",
      "r276"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, FDIC Insured Amount",
        "terseLabel": "Federal depository insurance coverage limit"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r14",
      "r16",
      "r17",
      "r69",
      "r73",
      "r94",
      "r95",
      "r96",
      "r99",
      "r100",
      "r105",
      "r106",
      "r107",
      "r126",
      "r143",
      "r148",
      "r149",
      "r150",
      "r154",
      "r155",
      "r180",
      "r181",
      "r185",
      "r189",
      "r196",
      "r275",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Excerise price, per share (in Dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Issued warrants (in Shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants exercisable"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r32",
      "r330",
      "r342"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (see Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r142",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r79",
      "r80",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3",
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value",
        "terseLabel": "Common stock par value (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17",
      "r298"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.00001 par value, 250,000,000 shares authorized at March 31, 2022 and December 31, 2021; 11,048,587 and 3,200,000 shares outstanding at March 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensatedAbsencesLiability": {
     "auth_ref": [
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability accrued for the employer's obligation related to an employee's right to receive compensation for future absences that have been earned by employee.",
        "label": "Compensated Absences Liability",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "CompensatedAbsencesLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofaccruedexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r110",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r64",
      "r65",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Shares issued (in Shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r15",
      "r16",
      "r192",
      "r197",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Preferred stock, shares designated"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of nonredeemable convertible preferred shares reserved for future issuance.",
        "label": "Convertible Preferred Stock, Shares Reserved for Future Issuance",
        "terseLabel": "Convertible preferred stock shares"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CumulativeDividends": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative cash dividends distributed to shareholders.",
        "label": "Cumulative Dividends",
        "terseLabel": "Cumulative dividends (in Dollars)"
       }
      }
     },
     "localname": "CumulativeDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r64",
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Conversion of convertible preferred stock to common stock upon initial public offering"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r72",
      "r77",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r284",
      "r324",
      "r325",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFee": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of a fee associated with the debt instrument, including a commitment fee on unborrowed portions of a lender's total contractual commitment.",
        "label": "Debt Instrument, Fee",
        "terseLabel": "Annual maintenance fee"
       }
      }
     },
     "localname": "DebtInstrumentFee",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r31",
      "r72",
      "r77",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Least term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/LiquidityandFinancialConditionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary.",
        "label": "Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage",
        "terseLabel": "Employees compensation percentage"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RetirementPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of prepaid expenses"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCostsCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.",
        "label": "Deferred Costs, Current",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCurrentAndNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of deferred costs.",
        "label": "Deferred Costs",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredCostsCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r131"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred offering costs included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": {
     "auth_ref": [
      "r246",
      "r247"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits",
        "terseLabel": "Accrued board of directors\u2019 compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofaccruedexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
        "label": "Deposits Assets, Noncurrent",
        "terseLabel": "Deposit"
       }
      }
     },
     "localname": "DepositsAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r61",
      "r132"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsPayableAmountPerShare": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.",
        "label": "Dividends Payable, Amount Per Share",
        "terseLabel": "Cumulative dividends per series seed share (in Dollars per share)"
       }
      }
     },
     "localname": "DividendsPayableAmountPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r18",
      "r75",
      "r146",
      "r148",
      "r149",
      "r153",
      "r154",
      "r155",
      "r292",
      "r327",
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from Related Parties",
        "terseLabel": "Receivable from related party"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r3",
      "r18",
      "r75",
      "r146",
      "r148",
      "r149",
      "r153",
      "r154",
      "r155",
      "r292"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due from Related Parties, Current",
        "terseLabel": "Receivable from related parties"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r102",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r42",
      "r43",
      "r44",
      "r79",
      "r80",
      "r81",
      "r83",
      "r88",
      "r90",
      "r104",
      "r127",
      "r196",
      "r200",
      "r233",
      "r234",
      "r235",
      "r249",
      "r250",
      "r273",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r288",
      "r353",
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3",
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExcessStockSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of excess stock shares permitted to be issued.",
        "label": "Excess Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "ExcessStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ExcessStockSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.",
        "label": "Excess Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "ExcessStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ExcessStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of excess stock held by shareholders.",
        "label": "Excess Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "ExcessStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value per share that would be issued upon settlement of forward contract indexed to equity.",
        "label": "Forward Contract Indexed to Equity, Settlement, Share, Fair Value Per Share",
        "terseLabel": "Fair value price per share (in Dollars per share)"
       }
      }
     },
     "localname": "ForwardContractIndexedToEquitySettlementShareFairValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r74",
      "r241",
      "r242",
      "r245",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r41",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Accounts Receivable, Related Parties",
        "negatedLabel": "Receivable from related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDepositOtherAssets": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.",
        "label": "Increase (Decrease) in Deposit Assets",
        "negatedLabel": "Deposit"
       }
      }
     },
     "localname": "IncreaseDecreaseInDepositOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses, long-term"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsAndCash": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date.",
        "label": "Investments and Cash",
        "terseLabel": "Company cash"
       }
      }
     },
     "localname": "InvestmentsAndCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/LiquidityandFinancialConditionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Company leased office space"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Lessee, Operating Lease, Description",
        "terseLabel": "Office lease term, description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r73",
      "r126",
      "r275",
      "r298",
      "r326",
      "r340"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r29",
      "r73",
      "r126",
      "r143",
      "r144",
      "r145",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r154",
      "r155",
      "r258",
      "r261",
      "r262",
      "r275",
      "r296",
      "r297",
      "r298"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongDurationContractsAssumptionsByProductAndGuaranteeDiscountRate": {
     "auth_ref": [
      "r335",
      "r349",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage discount rate used to calculate present value of an expected stream of future payments, which is included in the calculation of the amount of the specified guaranteed benefit obligation as of the balance sheet date.",
        "label": "Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate",
        "terseLabel": "Underwriting discount percentage"
       }
      }
     },
     "localname": "LongDurationContractsAssumptionsByProductAndGuaranteeDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongTermDebtDescription": {
     "auth_ref": [
      "r31",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of long-term debt arrangements, which are debt arrangements that originally require full repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer, and disclosures pertaining to the underlying arrangements, including repayment terms, conversion features, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements. Types of long-term debt arrangements include borrowing under notes payable, bonds payable, debentures, term loans, and other contractual obligations for payment.",
        "label": "Long-Term Debt, Description",
        "terseLabel": "Long-term operating description"
       }
      }
     },
     "localname": "LongTermDebtDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/LiquidityandFinancialConditionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r56",
      "r59",
      "r62"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r39",
      "r40",
      "r44",
      "r45",
      "r62",
      "r73",
      "r82",
      "r84",
      "r85",
      "r86",
      "r87",
      "r89",
      "r90",
      "r97",
      "r117",
      "r118",
      "r120",
      "r121",
      "r123",
      "r126",
      "r143",
      "r144",
      "r145",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r154",
      "r155",
      "r274",
      "r275",
      "r331",
      "r347"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow",
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r84",
      "r85",
      "r86",
      "r87",
      "r92",
      "r93",
      "r98",
      "r100",
      "r117",
      "r118",
      "r120",
      "r121",
      "r123"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss applicable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Noncash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses [Abstract]",
        "terseLabel": "Operating costs and expenses"
       }
      }
     },
     "localname": "OperatingCostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r117",
      "r118",
      "r120",
      "r121",
      "r123"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r78",
      "r91",
      "r116",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.",
        "label": "Other Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofaccruedexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAdditionalCapital": {
     "auth_ref": [
      "r36",
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of additional paid-in capital (APIC) classified as other.",
        "label": "Other Additional Capital",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "OtherAdditionalCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/LiquidityandFinancialConditionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.",
        "label": "Other Assets, Miscellaneous, Current",
        "terseLabel": "Remaining balance"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.",
        "label": "Other Assets, Miscellaneous, Noncurrent",
        "terseLabel": "Miscellaneous payments"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOwnershipInterestsOfferingCosts": {
     "auth_ref": [
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of offering costs allocated to the other unit holders.",
        "label": "Other Ownership Interests, Offering Costs",
        "terseLabel": "Other offering costs (in Dollars)"
       }
      }
     },
     "localname": "OtherOwnershipInterestsOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r24",
      "r130"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Prepaid other"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofprepaidexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r238"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other research and development expense.",
        "label": "Other Research and Development Expense",
        "terseLabel": "Prepaid research and development"
       }
      }
     },
     "localname": "OtherResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofprepaidexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRent": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to lessor's for use of assets under operating leases.",
        "label": "Payments for Rent",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "PaymentsForRent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfInitialPublicOffering": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.",
        "label": "Payments for Repurchase of Initial Public Offering",
        "terseLabel": "Initial public offering costs included in accounts payable"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payment of deferred offering costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payments of initial public offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Retirement Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RetirementPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share conversion price of preferred stock.",
        "label": "Preferred Stock, Convertible, Conversion Price",
        "terseLabel": "Common stock price per share (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionPrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockDividendPreferenceOrRestrictions": {
     "auth_ref": [
      "r15",
      "r16",
      "r71",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Priority of payment of dividends and restrictions on the payment of dividends, indicating the source, pertinent provisions and amount of retained earnings or net income restricted or free of restrictions.",
        "label": "Preferred Stock, Dividend Preference or Restrictions",
        "terseLabel": "Description of liquidation preference"
       }
      }
     },
     "localname": "PreferredStockDividendPreferenceOrRestrictions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustments": {
     "auth_ref": [
      "r93",
      "r101"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends and Other Adjustments",
        "terseLabel": "Cumulative preferred stock dividends"
       }
      }
     },
     "localname": "PreferredStockDividendsAndOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "auth_ref": [
      "r69",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.",
        "label": "Preferred Stock, Liquidation Preference, Value",
        "terseLabel": "Aggregate liquidation preference shares (in Dollars)"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreferenceValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock",
        "verboseLabel": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3",
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNoParValue": {
     "auth_ref": [
      "r16",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, No Par Value",
        "terseLabel": "Preferred stock par value (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockRedemptionPricePerShare": {
     "auth_ref": [
      "r179",
      "r197",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.",
        "label": "Preferred Stock, Redemption Price Per Share",
        "terseLabel": "Original issue price per share (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockRedemptionPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r16",
      "r298"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.00001 par value, 10,000,000 shares authorized at March 31, 2022 and December 31, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r24",
      "r129",
      "r130"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet",
      "http://www.bluewatervaccines.com/role/ScheduleofprepaidexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrentAndNoncurrent": {
     "auth_ref": [
      "r24",
      "r328",
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.",
        "label": "Prepaid Expense",
        "terseLabel": "Prepaid expense"
       }
      }
     },
     "localname": "PrepaidExpenseCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.",
        "label": "Prepaid Expense, Noncurrent",
        "terseLabel": "Prepaid expenses, long-term"
       }
      }
     },
     "localname": "PrepaidExpenseNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r5",
      "r128",
      "r130"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofprepaidexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/LiquidityandFinancialConditionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from issuance of common stock in initial public offering, net of underwriting discount"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from licensees for license fees during the current period.",
        "label": "Proceeds from License Fees Received",
        "terseLabel": "Accrued license fees",
        "verboseLabel": "License fee (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromLicenseFeesReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ScheduleofaccruedexpensesTable",
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfDebt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.",
        "label": "Proceeds from (Repayments of) Debt",
        "terseLabel": "Aggregate net proceeds (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r39",
      "r40",
      "r44",
      "r55",
      "r73",
      "r82",
      "r89",
      "r90",
      "r117",
      "r118",
      "r120",
      "r121",
      "r123",
      "r126",
      "r143",
      "r144",
      "r145",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r154",
      "r155",
      "r256",
      "r259",
      "r260",
      "r263",
      "r264",
      "r274",
      "r275",
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r133",
      "r298",
      "r333",
      "r341"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r133",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, Plant and Equipment, Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseObligationDueInThirdYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year Three",
        "terseLabel": "Total (in Euro)"
       }
      }
     },
     "localname": "PurchaseObligationDueInThirdYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r210",
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails",
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r291",
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Related party transactions amounts"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.",
        "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party",
        "terseLabel": "Fees under consulting agreement"
       }
      }
     },
     "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r210",
      "r291",
      "r293",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails",
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r289",
      "r290",
      "r292",
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation.",
        "label": "Repayment of Long-Term Debt, Long-Term Lease Obligation, and Capital Security",
        "terseLabel": "Increased in obligation"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebtAndCapitalSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r238",
      "r309",
      "r364"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r200",
      "r298",
      "r339",
      "r356",
      "r357"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAppropriated": {
     "auth_ref": [
      "r37",
      "r70",
      "r177",
      "r178",
      "r337"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A segregation of retained earnings which is unavailable for dividend distribution. Includes also retained earnings appropriated for loss contingencies.",
        "label": "Retained Earnings, Appropriated",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAppropriated",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/LiquidityandFinancialConditionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r79",
      "r80",
      "r81",
      "r83",
      "r88",
      "r90",
      "r127",
      "r233",
      "r234",
      "r235",
      "r249",
      "r250",
      "r273",
      "r353",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/BalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of computation of diluted shares outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSubsequentEventsTextBlock": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, losses resulting from fire or flood, losses on receivables, significant realized and unrealized gains and losses that result from changes in quoted market prices of securities, declines in market prices of inventory, changes in authorized or issued debt (SEC), significant foreign exchange rate changes, substantial loans to insiders or affiliates, significant long-term investments, and substantial dividends not in the ordinary course of business.",
        "label": "Schedule of Subsequent Events [Table Text Block]",
        "terseLabel": "Subsequent event, description"
       }
      }
     },
     "localname": "ScheduleOfSubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased",
        "terseLabel": "Exercise price per share (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r223",
      "r225",
      "r226",
      "r227",
      "r228",
      "r231",
      "r236",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Reserved shares of common stock"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r68",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r14",
      "r16",
      "r17",
      "r69",
      "r73",
      "r94",
      "r95",
      "r96",
      "r99",
      "r100",
      "r105",
      "r106",
      "r107",
      "r126",
      "r143",
      "r148",
      "r149",
      "r150",
      "r154",
      "r155",
      "r180",
      "r181",
      "r185",
      "r189",
      "r196",
      "r275",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r35",
      "r42",
      "r43",
      "r44",
      "r79",
      "r80",
      "r81",
      "r83",
      "r88",
      "r90",
      "r104",
      "r127",
      "r196",
      "r200",
      "r233",
      "r234",
      "r235",
      "r249",
      "r250",
      "r273",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r288",
      "r353",
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3",
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r104",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r34",
      "r167",
      "r196",
      "r197",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock to common stock upon initial public offering (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r196",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock in initial public offering, net of $2.9 million of offering costs (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r35",
      "r196",
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock to common stock upon initial public offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r196",
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock in initial public offering, net of $2.9 million of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r16",
      "r17",
      "r200",
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionExercisePriceIncrease": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.",
        "label": "Stock Option, Exercise Price, Increase",
        "terseLabel": "Exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "StockOptionExercisePriceIncrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
        "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased",
        "terseLabel": "Warrants to purchase shares of common stock"
       }
      }
     },
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r21",
      "r22",
      "r73",
      "r125",
      "r126",
      "r275",
      "r298"
     ],
     "calculation": {
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet",
      "http://www.bluewatervaccines.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r70",
      "r181",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r193",
      "r194",
      "r195",
      "r200",
      "r202",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventDescription": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.",
        "label": "Subsequent Event, Description",
        "terseLabel": "Subsequent event, description"
       }
      }
     },
     "localname": "SubsequentEventDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r283",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/LiquidityandFinancialConditionDetails",
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails",
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r283",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/LiquidityandFinancialConditionDetails",
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails",
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r283",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/LiquidityandFinancialConditionDetails",
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r299",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Details"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/BalanceSheetDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxesAndLicenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense, excluding income, excise, production and property taxes, and licenses and fees not related to production.",
        "label": "Taxes and Licenses",
        "terseLabel": "Intellectual property licenses is recorded as research and development expenses"
       }
      }
     },
     "localname": "TaxesAndLicenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r108",
      "r109",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bluewatervaccines.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21332-112643"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21346-112643"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21564-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.F)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19366-108361"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124504833&loc=d3e7104-158389"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(23)(a)(4)(i))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1,2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.10)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r365": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r366": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r367": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r368": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r369": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(30)(a)(3)(ii))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r371": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r372": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.T)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868742-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>56
<FILENAME>0001213900-22-026516-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-22-026516-xbrl.zip
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M3Z0Q/";7W_O7U&[O@\LW(]3^L _.WHY:G9V]SW?@X_7@#%GGJ/JP5QV4J4F
M>?SEX0O]V/O<:GPI7Y_9G>_?)J9U:Y_=#HYN>K>]\]G^[M'W>_#Q+>W?/31^
M[NU6^G?.W>[7.[/L/=R<UH;HO/)MM/U';[K7?OOF^FRZ/?YC?UK]"6X_3:Z^
MG<Z^@Z'E7.R=#3Z63S[;V'Y;GU1GW=K=S?U/YPMZ<(_/=J\OFGM=_/.X>K1W
M,MJKW[,9\=#J'M?)[*A<W?]>:X'VSM7A7T:]<\G?D%CSI&/V,P;(@M,Q/_A#
M---+VC++D::*:8K45C%I@C&-<-"-2UV.778+>S /N]*66>RF"G3+L1N,N6%W
M]:U864:D:Y>U\5=-%_JD^[*;;&?5'5H9<\I&61,R5?/3G=S4,[<A+N_&K83!
M'*VUI;UJJK2GW<75<[EA,M=^KH3&K*:99:!:JK2GWN'=3,@5]ABEY,D:9%.6
MJMPE=ATS>-K0I-U_E)9NY$VR<I1:^G!2<C-RDYXLQU;#-3UNZ$>.=<+B"YTU
M'?[2?^1PN[9%UH%HX0V##J(_66>&WYL1Z>YO$,O>E6-OK_.+_J78>^[B,KN*
M1F,74\.1?L! \?J\X7]+X<PU17<:$?[75BBWQ2]M5:I;M<KK*;'"=[:71,&5
M]E]$7@Y%*/<8%*KO)L@0D/##!E&A 0!C(5.&-B7S;L3KV8][%M+/(*CP9$F*
MO\D<2 [KD'^Z(2<CH0"G8F<Q:FX6DM_@R$<#DXI0,.\CSD%>U0DT7P_<29D@
M,P^(9'/^(S9P,&CP=1(QZF%IO@MT)-M;.NH1BEF>5S+\3P"(KU\<L&LLA6]2
M..).H62 H-5AB6*/O[TO6HTA1J[5%7*6AP-?["#;YC6:L"UAH8\Y4(_?_8!=
M;QP.@ECWBVB;$V8YZG;BBH8%G%:_OJAHM_H-OYXMWDXDK44UNS":/Q9WU-Q5
M3Z+MERE/@CI6 756(<Q%])%?IRNP>BJ$.O5DY;'BJ*9%IW)"X2NBY!2[H^!M
M>V;*;'TY0?S+((51+S=0]>QC%MV'&+.IRTM<UX EM96X7B/78<D_GLDTZP.;
M2%7S$R :WNKY!>W#DLE&0O31"DO1YE7.=TX-2)A1\.)!@CYQ]W%*KD6;%#RU
M7A>0GKF$M"$60D>4F5Z/^6(&H>OR$I?K1"J6_(2,R0)5X*.1TW 97#P7#Y\#
MRY*X>N+:4L]A93M>LS[QK";^Z+Y"-!@RJ:,)FRT#>.&->A"+8,8'28:OU%!^
MBY4M9^4GMAXU(BEX_"FU^LPPF6#=)91<0+H&C[!0.>$2+-A;P2.DD.K(UZ=M
M73BEQS8SL^B$H.'%Y^4W+U)-6B4+?452,0.@CL=3@+!P_G.+Y][!/X!=)!7S
MX=1D5ZVQJ&EWW;:'S2%;R@=3.]K=RSNC7"A5R5:'(8&D Z$5#X<OKY82F=)M
M?@48 V[%Q>8K'TRU:^FZ%-A%B811,"H;"]8UEY! P!3FD1!.H.V._:]W/5UL
M6S'=U>-6FF$@U@B,-A8BBYO;:U%K?&23EYR!W?9ZS*V&4FNRSE4S?!TV)7UM
MC$RXMN1\]45*%,VR/.1=(C^=?Y##RJP_ZLZV!^>_GGGQ;]&#(9/$IM<3%B!)
M%K-!*XTN5Q]GR!%#)R?6"Q9@\\'5)9-+'7DO&O6/ *]9,BS367%LX9&PE0FI
MYL!?X>C/Q+ILZ;9X[.9"J:YD7#7G8B?3,0K11+4*,3[SJDF.3.>JC@9,8  H
MG L>C;B9!S%N?K7(*6U>%32&F]B%Z;J7< 20PR=[_,X3)KNK5:WR:Y#[,<Q[
M^$647N!5!Z2%L0@;^27,VD>JH8TO:-JVQ\O5)C]H,TCF^/SJ\[HB"22- BRV
M>ABN<Y(]X?HYAE07#%6'Q0L7\O5 -=F=2K! L3X;HG+/=E&Y\O>0/#IT,7HH
MP#:?!EJN8!\OTKU\Q4T%3*<,6YH%_SLI5D\@+[_WJ$2F3"FO'&:?]QA1"IUX
M6>$"4K'DP*X)H55DSYA?!]6$"]N'3ZTHL4R%2Q>1O9$X>CJ!#31!%G0LU=[X
M"X1F#3:EA6:_-U.TJ)87L<[]Z^6+$^66P:JQVDMNV'8#CEV"UE+7?Z(=^@1.
M=>65HH$8GY^!,3$:IQ?J+U$_5N#2'#J:^YQ6_]*= 9O.6DX'V*E@M[0S6;F4
MKT:FL;-SMDH;>:- (,BEBVMN<KBZW"1H>LDSFN+$,3FJ''HP2IGZT(0L9EC\
M8&!'Q'?^& JH7TZT.6H$;3 +/J==V*PKC56S7!M#4_R'SG/$)BAE:A38Q\O
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M6QJ"(CR<2 CN(BOVF:/'V7:B'%@*'4_Z TL801H.@T\=1J1-H2*U,XQ8"1^
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MW4F#7H&,YC?4+>GESZ@:J8J6KL2 7E:2,1HU(5+'MHZ5'+FIOR[J<E"G0EW
M8%('8!#W"*M:S7!D]+QU?NGAI#*KCQ]5JE@(C9#':72'W"AT_0"U6$\C,@M\
MAI-H2>]\\RXA65/@K:3@J4'#$(T6X(+M4;TBTMAG:!4CU]=Q6VF1-EH$2N.N
MZ;0<:&"IZ]EV/S?-GMOD%RY%SI53^8L*'GZ,,+M+5/Q_8\#E(Z>^W%0HXP.Q
M_4$*6 1/3<\TNT-H]_71+L@..Y/B$U_>_<+L(JG'T-KE6S5?P)H'^6L2AMAN
MLZ%=IMP!&'4MJ18S'VYM)A%SS55M!LNU5^<AZ6C[(SD(LXG".C8Z!W1=A>AW
MQU,VE-JGR"DLS3DK5,N7AJ>6L"&J<NE4A=V']NZR_')$2<-32U,B]CE1]D3:
MVRE<\3->^T3+J5NC":B<)NE,!-[4U'L:H8SM-9I%T.4_E2N4[TVX1LE>O) 2
M SB,EUG@)5<&8"V'*]84I4MFY'[*_!@Q&Z.J?E.',S:<%B^Y$UI/\@(H0_R.
MFC>UL<W\!8A:!&5M5V#&(,I2@^;T=]\ O@3]W0NP%HNZTBSCV25Z2$D4%ND=
MD8=,:%+8-$X'N&T!:YVFH:DX:E/)>- N0E[^7EWQO"'H.<$D>PA\MXJ!41_0
M!N1K[I*K2*YPA+7ES-9+JXZ4U+]'*:S,7G55;U,:EEQGHMZSU-@9^@7H7Q&4
MM35H(",@_R/6^-H)4/Y^@<?LNV5H'[;4VS]H_&41]=R]^5\]N4'FY<4;W843
MSM$=-C2NL,Y1;G+M>?!6F6O[%BS7[;;WU7E(B\V"B$U%F&ORSD6ABSEMKY2A
M5^O)/"M UZ4.S-<> 0M@R<U9D0S@*]Y'6]'NRB/Y:#P,FO:B"[@=I4<%3-L=
MC=P'MSEK9<8:L4WP$+.\I/:2O+D\5RXS(%NSA0:'21**K.ZKV744WZ%5%N.3
M/$'CV5ZNX"*L3=8-'2)A,7QAT7Q[S^\9QW,G]#_G8:1.Z)&"F$DTF\0HP5,K
M@DMETP&*YUJ2,AEA)#0&];,921JC35"V"5#X/W)XQBUXSK.$($KZ(;JQO\H7
M;^CMCFF*I72.V7Y4/'N]8S7K5N$OH5;U>KU2.\S\O**SG)]NG%IU.0&>?5&0
M2CA3CR0:U21'-)("26Y 0J+&)9\T8Z])#+*[$PSD?8F)H\K( P-TF,OZ/ELN
MG7@3S>[]>>C/?)>\)._LSF/)XG;VGDR]<.@Z8H!,;3HKH#@>YNXX=P+R,'"_
M0"B])$7NBFH",@NJ2:H,8K_T$S+++-:V+X!,A]0)SU:KHOZU$[30VK+1MEM$
M6!N\^XA)OK5YA,"%^B[V?\8T=, \1JAHUB+5+IY*2L!2ZO]>W 7 I"EB&7$(
M[-_#!D:Z,H)X$ "S8/>_,G=K9JHJ2OHV2I&VDAN]S :6M]LAO-4VVC0YF*_)
M)P&(A/L+LC+1/-3]0:I@^T6V-;[VXEL-L=Y06%X)I!_(MU1'':I;=#3M'3'>
MP\JJ<_GHVD^"S,UM*JF5T"W3+@+SH6ZT1EKK9AH[88+GBWE(WS98]#3M*BZ[
M ;77Z93U;R(1SJ9[7\*$W2[9+H KK*WBWC=-4?)CZCRA 37^:B+:CYX^3D.*
M3'2)ZMH0O:R,9T#RA-A)>>P![4!7^QU*_3B_69%T']F#H5G-)H\ZJHCNP_("
M<QX2#%^T2*HJ!$PB3+)F=8Y"+)QT#Z>']#",&F.B2Z/U2B\-_&'Z?N^SAP1]
MRD@?K;6<PVKKQFM3TN468+&1+G?>(:C/D<OB8S8\F".VMJ>6"=5AKN[=QYCS
M3?ZOC?PZM_BY[QT)*+I*4G^)X5(=.-DA;O I0NSMK@N*IN[J9=1(9VSE:M2E
M<X!,;7IJA>+(#X.4,RQ#%VN^.#<?[OSDXT6,/#\E_U)N2+(Y&2U-*22M7KRT
MI* QJP7HW6E@MD8/>S'AP:&$9)G)"//:\>.\-\8;Y!!S>LM<KS3A?,U=9,1D
M*8 DI*W4H/2-BX43SU&B5X0<9A9M0QYL@+I5DD[I!.%)D;2M2[1&093O_;(V
M86E%JW9&\SE:)#@0@(#^30I+9X^KV.2;_%SVUX@H]T2+-&5&8(LZE4*7GQ0G
M*&L2E%(K=M(AK.[FW*M;J>$Y,#HVW!0$4.&V?!KV6J'WA&.RL>;JS0:J%,PK
MQ9=PLEECM" ^W#4JN._#G 2SM>AP@T-9W<1UI)O&_MHA>E:[,<ED9,N)U8=5
M)2&VLT1&.E6?] F*\^-2KXAXW&R1$Q>U2EBJ*_<\-L891R'^IUM$N.Y#0PJS
MM\$0D<>VDC&G,_>!YE%-23UEZ: NB]]7[MT%\K( &YTC3-?S@XSHVVVWWJ(.
M#O)(@35R?F9%]NAXUMWTVMX@U0_0'E^T#NEP'XL.))]KNR7_2NNB>-9(692R
MV+C_&7EE.XYV_PW]T32#AV-E^M=P(6@K9]/0&#M='_(=M0<]S6-L4O\.R/D3
M0!90T,:(+51.(9JYV\,BFN7G"O(2<E D498FJ1.2TG?YK"322?+$LQJMUKET
M6;#*SZ1DO&4EDBDH25G00,I;5.?.T60:3<K:-B7UIH,.,&(0&1.;0H&@ZF[>
M(*@@MH?8,D,QWG[W*->]A5*&2H7YJ;$Z%XI$P<9$=9TMPNV#$\=.WOM@V":!
MT3'7?%J1<(!P\6MEB<II&F$CI> %D$;SKTUI)J&55>';FN:!)@QLC^%583"B
MXGTUV1ZX\L=MNP&G4 H^EX;LZU)N#?<^+2LV1@$,#5P\A 35JNL%P$_IT;H-
MI\K'>!-BZYB8S<HCT#KD#554D)')+C0PHU]N\[0'=I'A0UUYRZ8>1A;)I0\N
M3?VD]R$<Z^72+Y*#>S6HCVBGN.RK/*)+_\&@(YI%0_:(;C92N?5=0O0:H;*_
M\Q9##0UJ:-Q,KVN.A%@=:*C *4[.( ,MAT>W" #+J/_[ [C_ O 'X* VGZ+!
M$%#4O0]W9KUVFT#OK].N]J6_#EA$'AX5PM964CE?54> ]K(Z!.^#@&KJATU;
MFYU.E^*BJG#'85X'.VZ=[WJ>RH5'88?V&XPU/V-BR.ODU'DJ'K](*8?R9Y7E
MUTYFK_+/KY:K(-H@5/VWIG=*!0.S04_KD(>6ID?%.RE@$>NXZX+X6F2*"H )
M2.&05/T=5GINPVP^UJEO%EZ@=D0'V"RC48WY_TTP'9$_M>D)^+VE[VL;XD:Y
M"("*;0@!/HGQ;;N*;P- W/[[@T\XH4Q1L8.9*3/9]6I!8&7/G#7=7/.N5SX^
MB=N/\<6^()Z+>(V\ZRB^SE)LF%<=;Y7?:B6'84L*@CS.T&OP@?6U:1VSPML>
M1!O/!N4MP #Z0)"@E*X"\2C\\XH&7!#3>/XZ0;!K2<H)9Z?M#0"EW4,Y"E.\
M9J^*W@:OCQ,T+UW*BJ-4VU6YIOB3T9.O^I+'XJ)1H O\9>QF#^@$_[2HNR<I
MX-9"[JEHML5.7TSQ+L?+7('KEU?)1^.MKA+3B=>:4F_%N>YZY8BG @M8XUJ=
M?/YXMD\):18/FCE9D.J3#P%+3P6N#LLW+:M'CV1*'@:[,O!T1H],*H!T[9>B
MV6E=F]Y)%HJ%06%@[NE(WISHPTMGL-/(*\:&AUGDUFAQ_NXP,17G.EQ +-34
M1A%7W.[(B$+D53F&H]4JCE:Q3]X9%4NJEY7-6ZH?0UA0U* 8']*<^RU*Q[/J
M)JRC,3V H:'7M.$2A( )*4LG]\SZD&[;J$]1O%3^7+K#P.;=1L,+4(+N;]__
M_>3DZ-\?WKS_^C___M5=94^_A5^_\CZ_7,]_VX3O+K/''U[&KU[^?/;GN^DF
M"5ZNW<_/@I_2T_0>_?3YY8N/3\_=V_39[]?79_<_GZZ?SB]^>[;V[N/?'N-7
MZ*?D<G&>O/]]]CX-)J^<NW\N_<D/KYS;;Y;C^Z^__?F3\^/[^:WOO?'//G][
M-C]-W<1QSW_Y_$OZX\//X\M?3M_?!O>__[IVO8_![<?YZ+>'CP]O-J]>CGY_
M='[\)IU]^GSYY[<OG\\^A9]>?OCDGF:??[M^L?#?//]U^>P?#T_?3K[YY_O;
MIV>K?[QZ.OO3^?C3^MVOUYO?G847OOWV=O[CZ=7/01Q\<[$^VTQ??/KM\<_P
M%_]S='[[\OW;FV]_>?KI'S]F;X/54_QY?H_&-S^ZHQ\_!--7/WWSZI_>/WY^
M]OH_1Q?W=R<G<B[3VRB<$Q$1H36:4RM>X2PN-B]S)G*PU]X#+<W1]'0*Q]R*
M<!#Q=TH2ENQC*<(,Z@"5(*KI-DEU@@Z37)T**8'<8*>HB'B3./WCS@GG8/<G
M_J"AWO!_;55;FY8F88$<G/(+E@BN@XERMV9-'^Z(@:"^=;F8\552EU(+3P&_
MR@ \84Y'040-^!:A>(+\AJ)XOL'S7&9+92NT3<](D!1CVU6(=F:LVO>7LW">
MU(+:HG>0H+9GK#K_OWY]=Y+%]>7-19X,B;S1DFAZU2$,5!Z&HC,'&R<<Y'0)
MBMD>X5V"9EEPZ\_4I_CR.9J+V50F1Q"PFM)/V]6HBOA1/(2W4>AJ";[E\S.8
M)Z-,H@!4N6Y:=47P1Z04QKSHV+?9_LG$V9 ?C1Z=V*O3/$9)DBV+<CPD!MG-
M2URM?0_?T\N_5QYHL9<QVZ[K]R19H--Y_]Z>!G[S&!7%9+?.'6&G2 \Y(4\.
MB(YDIX,^XF!'#9>&K@L2W3$C@GOMA^'C,#P63>XMD]YM^WS3_(V&V#0!QMK>
MI6&^'.@2AC0QI\&J+6RMR4I+O!J%@3'OC_R"9LD-'+6F1C;*8]48TC$8I:9:
M-K"(M;\B=/>D]'B!N6I;5?P5E/M74.Y?0;ERJ8/C()IOSOV() 7Y+DIN0I?F
M%*87\V5^:R[8EFWIU.5YV3-6FYGY5\SS8<4\Y\)_=U.?8E=/*[]H;0Q9Z_0/
M#;KW9"Z?K.GK,IVFSA,B@=)E-3#5-M,.>4-^,5%1L.%17^QX-,=#FF.=6 ^M
M>%DI4W_KGP+V )B4)6(0@X<?B2R>MM\J&3F-[A"98-YFJO4;@&S@M(Q5UY<1
MCP!$ &?O, '5K(7%L?W25,6DX=@W9@]I63U 3U&>S#GJR.@#^#"MTW[E[@E+
M%<63/-9-@HRTO2+=C)TYQ,%.^<BF%4N;L_*VS9VJ#%5UJ3V\-D,XF@L@D#6"
M0#AR6SU+E"_-MI7?@!5+6U_8I&ZZD^4W:);S9*_*I]?QK!F GV=*YGEXVW9]
MRCW< JQM46ERN/(;-AMY\B85:!91@,>6D(B@=#,HF8%%;0?'OM=D/A')) 46
M8? [=S^!O28?@)&N'[@YL]]K4D'M8DKQLB14+P(GP=LH'Z2.5QPF'WT',^P9
M![0F6UXY-F3:WJF;K+0\X5 8&'^GYJ[-5I0L!2%=[S:[O)0_V##D8?*I9I@T
M-)9.J096;%\2.!>%>2$*C6J,RDN7A'0K,CIPNGS?'6Y:U!F=A_ZW3H@VZUNF
M3?$P<-(2:T/EI5RI,:5R&(IMD&!T!MHT>AEJ>23=I6^R2FNO?NCTKNC"HJO#
M7:-:J!8)4%D8<5D)2X&.CHXVLM/':+J(LL0)O;=X1@B%Q2!O0N+4]->(9-:
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M^6NJ70MQ03(_M<23T3_]"NL^QY4PVN_P 1@_QGZ:HK#=R?LM/@OS5.FB/Q,
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MMSME0/$$"6 M;4(^!%A&*_+>,@CB,8VDTFP=FAIZEVB-@FB5=[^#@PVA8IT
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M'QFE3W5;=M=^@.(+?+K,HUC%\F_3LTFY=Y#@/X3)FI&3O(N<"D.'3M$*C<,
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M":/_'9>1J/#]*>'TX"2(_-G_ 5!+ P04    "  7AJU4&O_KIZ]F  !!]P0
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M,1)-*YYE5*A[\51M/!OQ5 !G$L]UN03D#RSE=+6(SD="-=RWD%",2B,E%+:
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M4/;.AE&E'T4CVJC8UI&00<S@$Y<&\I4IZZ/8KN2XPK0E6(@@5[.Y%%?S2;6
MOXK0 SDGJZ,,H<?HJL[10Q*Q*P\\S\Y.;LM-O13'M0(-2][?K%9!MH7#L[$.
MJ1<B<B7?NNDPMK=2_.T)--KI<+MXI.$FIE?+([8\+^X>/34JX+U_$8%QD+L
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M 1S._'+JL-RQVJ0D.S"YC]+80P#3VH^WS;_LX5P8L/'DP:ZZ@\(>+BO[KBM
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MZ#PYR@P3(E=L(#0DYI/G4KA"ST6L1((&[9UJ+#:]AG<T6^W5^\LW\'$D]<'
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M_EBPL7G<F+ ?W;RPF?!TF5X'XN%S8DE"M_$0\:V&Q.X88N9%1IY@O"DEUT\
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MKKM2('!@IW<YG/#QA$]07M>N3V\#)ZK#6X?NJ*86S^G=8[K)@R2\A!9,-($
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MSVH=A\X&*X!&2]$L3+Q!O+.1IO[M-*Y<J^A7S4L1[.5Z4FS@^'KJ0X %U,)
MKA[QXA]S\)'C[%$T'>]B..YN@D4>TSBD62X<[T,O)OT"KNP[+12ZVO/EI-_^
MYLMWAU]\(VL%:&\E]Z]J-CRJG]>,I!C[M(HL/.@R,B_BT-XR K.3Y""VU%RD
M![^'[,@RU$0"S]5UEH:;19$?)>%M6<G*_AHR.!GQM9TXM+4@X%W/8#SW7)<3
MYN!Z-')).B+U^.[23.J^.$_R(MN #G09K/;S6HMNX\*6,@&!]HRZ+T@]_H#
M#-]"8\NW=E%O#=YCT\#2U2KBL8-0&.<DY7X>FHQP9=NNY.ZRLH0([RH@9_/3
MIC5?I^ZX3BH;QL$JT6P <<:$ )C7'Z($#5G-E5MG $R[BIA*+YJ=F*':T5!"
M[=!<Y3;@_>U!'8/S\6IYEP5)'BSX0^]>PI?,&[J\&LW@8/HYFS@OR]Z>E:U8
M)CL"C'4PMB.EAK_V:J8[\T9K@+",=9N9#]J"*?7[E@'Y:05CD)UO6L*EO]D
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M:1'$^M U/F0&.48-4'ND[&+A^B2JNKP7-&F'P%W2@A?ES](%DUB4R,T%>L&
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M@CK/2M'Y/I4^3R<!9,_IW6.ZR8,DO(2RM31Y__,F*K;G"7Q$T1.]9L34"_*
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M4:Y RB4X&\M%2&.5&9B+-LBB-J,]I1P;CHW'7*W!*,9):[$T2H0Z[_^L;&&
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MYOI*R B 1@1L?F]ZMWQ0G9<^),&M*S]Z2*)EM B28H1/MS%[YBY9.SR5ZLH
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M3;4'R]&$#R=LO+=ZVDKHU5Y[)8I.%<=:AY5=&0VG46-&E?$]F^K,.#I*A=.
MO.OWD]K 8,(11O&FB)YHG;XBRM'1$$IG0<W*C>@2<;641J4LIC',<&OLU4PA
MDKN)VF.-_7@G+&FA5Y5)#/EHGLV]B>AI, LGY9K+4\#0P?V&YC1[8BBDV=FF
MV&04?$LZOW)C/8(%YLA%^8.46);(=?WG"@RGA4HV=J/K3"J"F N_:XN"J(K
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M&'@ R?_M:66JDN^'5@0=-1NTN#OQ:=2P'(4A6S2_9H=>$/\S6NLZ-)1,**?
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M^O\D>9_<?EW25VE-7Q]_$GSCV TE"TQ"XN B1U-" ]6_MR&3M39"4^=]B5:
M\B9OQ]NLWGOS:=:;85TD"?4>JOD@V41D8:)PC=WK(+Q.8GHT&451TL,]F[88
MQ[_,=4<:*EA@9--O[N96:LZC8KWV='1K&G5V::(@9#LQ1?=#BC(U!YSV(X42
M=4?0T+K=H0N=A#Y+6VJG]DR5(HSW])/!$X$^&(NX&.\/*#UO&@I7[C#3]W*\
M3KGZ^_(,@R4B?O]:S/D<5]71NA&WZ*[ JG06Z-#BIDK_+5X^X+!?/>0\C+:N
MT59  1!T.<2C7TQ4]\22_]ZAGC[K ;[M48*B!;!E<A@<]1*_YW-42YCLHV4J
MHZ :CG6S0=#Q9,_*>@EC[S')S.Z;OY^>GOSGP]OW7_[W/S\[J^3I%__+-^[G
M5^OY+QO_W3!Y_.Y5^.;5C^>_O[O?1-ZKM?/YN?=#?!9/\0^?7[W\^/3"N8F?
M_WI]?3[]\6S]=''YR_.U.PU_>0S?X!^BX>(B>O_K['WL3=Z@NW\NR>2[-^CF
MJ^5X^N7K'S^A[]_/;XC[EIQ_?GT^/XN="#D7/WW^*?[^X<?Q\*>S]S?>]->?
MUX[[T;OY.!_\\O#QX>WFS:O!KX_H^Z_BV:?/P]]?OWHQ^^1_>O7ADW.6?/[E
M^N6"O'WQ\_+Y/QZ>7D^^^N?[FZ?GJW^\>3K_'7W\8?WNY^O-KVCA^K>O;^;?
MGUW]Z(7>5Y?K\\W]RT^_//[N_T0^!Q<WK][?CEY/)Q?#L\'/T_?G;\;A]=4/
M__SAJ]_=A??ZIY]^_<I9+ :OO_WOR>7T[O34P"+=?2:(K [V<9I&U3PJNH_=
MXM'S8+4*@U5(V&4X\)1H9&7O$M>,H/D$T%U^UQ _Q+<X'L^*> 4G90<T,T[
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MS_5R7H(K'N''QW;V%ESTB =OMOGQU9.#HZA41%RDE^Z^40.G(YL=C2'G1L3
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M#O_,?OL@?M&TWR8\-)CIN2%W 9]#_BO\(";"T1O\S\@&+G NOF_<PT&^8Q^
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MYYQ#<&OAR3,!Y+)YV[QKLHO)U/%FW!<0R.(/N_*:F6W+$_U [$ZRP*U;[?:
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M'@JXY!9P.51PR<.LY:@[5[2E4T_1EA4-_PI(3)05)FFG#:)(W$Y&RU3TK94
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M.U26R4 L/!!Q8//\UM90AK*Z=:$24U[86&^D;9-7Q+\!O&X%N&X$M%9B4'L
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MPY_IS)Y,(M=[X*YMZFP2.:'= $5UZH%:,76,$&'/N(MZ5T"G)0=#^ ]MC[N
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MC_)+,RV@X?$2-,1MH3] W:]PVXY"DB=0XJ!+.H8 >;+9B$O1QD-BCQ,VE)-
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M3AK,L8FCA(&\G^,0:2O\ C?)[&FA8=9>TO/VR;EB]%N[NP5R[E4FY^Z!G/>
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M E& &SU]:FED7$B<M+2CYVMI]7QD6S$?H+,Z'V 3DNO60+8[ZD>;F([FPL\
MLXB2-4^TGR4J"U*83S:(QITY]I!"O+B5,5D.)Y[%G=@FER[DK6SMIN&8*+:I
MX7*FEDQ$D"L644=9R0WS"H4.,<8N6V4:38,.-B)25>TB5P9J9(IL@Y#H*",F
M3)PSMC(2UD-?XJ>**\E*6GM&7!4CX#NK(^ W(8Q>#<151S/5^8.\4 5&L>,:
MGJ=J1I*R"=R/4X5(T::LD0PO*"-&\&#!\)VO",R3"%-.*5/&C0QYQFF1N3\#
M&^X^.%5NJ;M*DQ4E92JLX8S@OAIQ&1<N+QX9C2(MW=3D2YK6T6Z<M.9Z0V12
M,7J[DQ>]71^9]&L@DTU[28K_YY#(/SWD_*AS+Q!*\A5Y">.8<"7IB$I%PYF,
MC\FE#-RR5,317I%X3+"S@1,AKH;"-PE3I DF_I(=V4W>U),O'^-EO=>D=\J(
M73L2.2D6YVL2Q4Q&>IEC;X&4A^.*M<Q$9OTT&@*\599'7 H9I%",8RN(:$[W
M]!#M%)*)U"RRSGD#JUXA2F:<1G@W(NUG=D4Y)KJ*:D[-J\EB7I+A2+"F7B2Y
M/</4@E2G#FJX*?*/E.M/Q06FUI39D]R_S'%K8FUA$7.HP=WLS (5N)\NBQAP
M:5%)'(PDT:?G!ZP -@5'!IS,S+A7R4P-TP6BKPG714E+#.1$E[5P+JJRWYK,
M/A!AB%8$PKTLUDXSIEN*IO P78 [VU:9^AV&\Q>#DNP7N?R;XZ\5P\X[@ZWR
MUT$-_+6.I)OY@SP7I$3Z+DN*RA0()#'/4N7<C6' 92\?8R[_-&902SD25:[(
M!JU*IK(@Y O'?.I=BC-PL"*=5BCQQ.+2$Y!]8@0 (8ET95)31-0"D22%1L>-
ML9-ZZ $6*S22G:*.A!V 1?GK.#Q;2_+AJ.IJ*$S<&84F7K2,C$ZEUL4B';=6
M:RU)26]27*P"S44KT%S2V41)/E0J 2?68V19>Q'S+0\A96E7!Z<MJF7"'$%L
M;:Z[%-ZD&?E2A;0*]E?J+@N2AEK287!E!);QIW8N^R/_3GA8:]1K77QP^VRP
M8EI%)R^MHCXV>%P#&QQL@0U22>UOV%."&@ AH=T"D2W1RY2\@U@<Q%7Q&R,<
MPU9C^-0:3E[^4HB:831!JLT\?)T4-KKW27Z=B>[-(M^,N!"F.4RDEX\N?/))
M47'K4/@7M:R9,R,>O#DAH&+8=^=DJ]A_4@/V'V_3%O'5?L3Z$-9JO$<Q6A,%
M9"UN.H8,WJ3T!OR:BKI;<CB*#T7EG^Z"8.$R(%^FQX57>0J;1H%@:BR,HK)H
M/;PE.5&/\+52LZ54KCN:W,EHEY"!&D72'RQA:0)):TGU]Y']BUN-?W/?*^>E
M._.Q5##=JE]FR2,W(@#W#,7T. /[+!$5U*FH0Y'/!\6%Y'%)B_DG,A<Y$4W(
MVEJ38O"B[/_=BK']G<)*VYMQ@YV8[&-'% 6WCS@5U1:]1V6FG3"8BU* ,Y%"
M]);" [H58Y"ZE0N/7H^$VD5:UYKYRL.GQX^E!MI.L5%L]))2&=]J $"W8DA)
M=XUZHZ6P9*'6:$G<VF;@&P4?B](R4I7.<]F1**#-BP)9S4]D8]AP)Y*#/:/0
M+UH.\)8;>L#,J+4PI49C_UX36PV(]!*9&XU5-60,N\JX2*GN:,"#!3TDV=?N
M@V@=&/()*)R&R[%)<$IO+Z&N-MG?X1IP%XPFRJBKK+C2=E(THM1LYVPGN/%E
M$$"3)_^%$6P!=6V.&Q@K'5_T&(SAI!G,C:A_&/J;J+L/VG4H(RJ*_U3]D1<.
M.F.GR*FR,G?&$DQD-/55=K/L01T;7=]T6=)NQ7"C[AIE24OQC862I"5YU*&H
MV',6%0M5A6>LXT/1P+JD--%Z6U >:!D.?^"%W&R.-D7! >0#D@4OXWZ'XJ0Y
MM%2U-?<:Q4E+D>="8=*2K.! U,]-U OIMK)1IYYJH >'9<G^PZZ5WV$X[=M4
M9424JQ($$S*]&*,17OL%R:7)6-NE]+*Y4AM1^3XD!+;?2D+@R2$A\) 0>$@(
M/"0$*K&B8A1I=XTZRJ7DFX4:RB5EJ8-4]-Q2D6/_Y(X]]CQ178$*AX@ /,?^
M,[(MM'E3T\.DO#',3O:35*>;E)BCLP>RW6 5-L.FNB/23!,+5X?V"WDT63'4
MM;LZU'4]JAQ4HN7^@9:?GY9EJ*J@-]E8JHR]]4"/.715,32RNSHT<CW*.JY$
MCX,#/3X[/:I^;:(FE@J(3(5-"W>&Z/9FI0.L#P290U@5@_2ZJX/TUB.MDTH$
M>7P@R&<ER"1L$$U[#XXWQ.(5<#3>Q#:%2T_Z"Q?$55$2,0H=S_MY:.E30&45
M@PB[JX,(UZ.STTK4>7*@SF>ESDQ80RKXCK(GJ:+.H:5-;#:I&)C775UT=\W
MF%8E6CO=:CR-#*7(I+Y+CAX'5 ALT_*": K#0D:V'X3I?)=4 ?]X8'I7^I5D
M.C\6L9A2EN,<5K_%F-)>Q>C!7EX%LXU0MUTM%*RUH\H1[H.!M<>,3#N+!(,H
M]Q0NC2#$W#*45"(SA*?C)U2^DZ@( 5@YP=+36 K9#1>"$^+V#J(O0Q :LKJJ
M9\MHIQ5HC]5-U=(SB4I?#/-G0)4B!,XKFG"9B/IE-[*FQ>_BZZ/KF]_?H^-"
M5;#@F6P0,6$\@Z$(FXJ1&>:XJ=WG6#HRJ\6D-<.!0R7'K5@.3$H%:U005B'?
MR+6C.-CX*!4B_):B@7L5(SM[>9&=5>AQZWUI#HE\A(Q[>IU4#/7K==8,1K]T
MX1#XO?&K8K^LHO=K##L74S"8@[_9]EB]BE%BO=518BLQ0''"$JBR1?&7<"!$
M'*""-;)#%A<%SY)2\]2KCY*=5:^^F;RAFRQNN0;#J*9^Z2?37?U$S38:7-;Q
MQ)<P-EK&I@1QX392KC'Z619&Q^^&/'SBW!4\- Y5B*MP4N-#2OX6E4G$)8NM
M6H6LDK\TD<%M4XN#J8R^QE6)W%,RY<3MIH#]RC>,7YH)F[;EI+"C&@M"O"P9
MO6)002\OJ* <26RQ'EM9;):E<"Q-B(3<-40^,+SE4]FS="D;K Y [8#A:]EH
MF A/I%R*8YUQPT]U]Y5-*T1.A#_+D,%B:2D-B>M1-?F 18<.=O.@$E<46X@"
MA%5B:Y0U88XQHY)6)[<C*N7&](MED>.@1)4X*@KP:**AJFCY$,CZ5  ;HD\L
M!5' ,(A!@%8B=I2J)2$I>:Z4EL^IWU\LTX#>(M8>:S0:2NU/Z$1Y4P)VQ:B
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M4S(Y?=#^]#[N&%>XV)-VO]$3BTUA KWV#VX]X,H;<"7*QG+8_?H"]A/._M^
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M3<NVM3@!AA-G%$J;CFYBAZ&J0Z@44'I$2. 9Z1L5Q?\P@+C\F5R52M9-<L5
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MWK2Y;>Q:&_V.7X%*TN=UWX)H4;/2N5TERW:BG.Z6CMV=KO?>>NL62((2VB#
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MV-V#!]3NU #C!/OI+!W]DJ%_,0<(ZNB@74'@M.:,N;\R:G5E@#EG*:]^.\<
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MI%3]H!+#TSQ&A8)@$5&)[P+=UNX\G77E[&K,P3;YG)?$7Z(DOLFR48,(FS2
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M%&W:<@P&2\YFK=?XHR0)5A&R@P<(Z :3 VUTRS,0DEUHQ1N)(\_>YB4+NE9
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MH<>$ 0S3*W$=Z8!)Q8G4[ZGS/K<L3^<C7-0??*+.22  E(2'X?J -2F$.L#
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M/+[_9MKQ8&'MN,'6L-]4;30QA^:4J!93AD93.]_>_/,M]>$!-A-A @-EO,#
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M"S#UB$B"EL<2E,8N.[#W,+H1^L_A% ]06GKD\/#,A+Z@AT&+BBH,>83H1"%
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M!D]RA+XD 9H$W&D3%AQ CA$86IG,&?;I$']LEK/Y*]S.EH$Y)4[H:S*]P2S
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M PD=GCV_WVXS B%JV(WCN@*T"6Y=#J=(0  ^&[V;2DJW;3KFI).';TKE6&U
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M+&25?8Y ^O4=Z/D ZQG]X,[%-N,+G4J0BUCFA-MT;:*B RO!Q?'[6C7-&^J
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M@"LFD.-P[;?;?#OSU#)P1&CZ.DH27'%);0S0 KQQ]]L8I^;DZW'M:7!I&T[
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MEZ]=Y:$/6*-P+J@BL)M(*3SI<Y%E?C,\CPN%9[MKKCBC%<X?5B!&H_J0IO/
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MK[DG_]MRS0'_WUW0M??^'U!+ P04    "  7AJU4.0QG[\@.  !/:0  '
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M3Z=@DP[^C9KEIVZ3ML.-EKV=Z,RP;0PX.<LCVCN%^#WYM>MJLZEM->VHZS-
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MO6-1L!$PX%HI85GA**AQ881!RB7T5'0%"#W!PQFQ81:)'2Y[X&#K((@YTRN
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ML9^'-^W._/-7NE7-U,2ZMF@8J2Q32=DVE4$6D;W:#[C[WF ^S3UMCL_C>8#
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M+2Q%@$*.8F$32 %T1[$T$76G;@F4EM26/@?2^+$R.<:1!FL5%S1-M/)%@&;
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M23>EPO3W!,4?&-#?(?P74$L#!!0    ( !>&K53B8$01A@<  &,P   <
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M_2JZ'QC=-R_C*XGWZDO$^Q'5+%Q?@WA.)N0BE6/!PB%S;-@K&^RA!).IS$@
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MZ_(OXA?L8J*+_R1@_VL _[G@'U!+ P04    "  7AJU4&=CJM5L#  "J#
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M)Y J4!!O <@W$%!O(, _ 4( @'@!\?L"_KP@(*&@7\# PL&_?/7$4/T:@(2
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M'_VJNMA)3KC $2_\+5_ D$Q]N*-MLYTFW0-9*H$FT9ZM5H,ZZ=+'09T(K&P
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M'\YYO?PGU0LE2/.98L$3<)8.G1EO>L$;BRN=\9 /0?'4__.>T=F4MFS<'N3
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M7%0ZN[A\DR907E,7?"\["A%CC1X&1WH-A>#1,Y5>(Y^O+O'!.6J-FX8.A:I
M:P:9)IE>3,#WFDW']35#EVR X*E'2PY!%D9X4<F&+3R*K,DM H=C-W>#?E S
M>EFP#J[.2=7I1V-,1)3=L\\N +&*[^-",I)7:JP'C:T$X6Q#_ .I1,;2WO6;
M/:E:1.LBR)8E'+Z<'^?'4(X<B!V%R_.::GR)N1F%2T*HGR*[$2L#/P9E"O=O
M *BV%US;07%,IX72AIPWCF?FP6P$2^PYY9$ID;Z0>&   XH>>S<Q#R9ZK>ZS
M9$@J7DM]U?G' ;0K6WIE*,NG<)8>;H>/(,:]VUS=65FNIB;QU]XQ$.:2::P"
MX8?9AQ)@^B%61!F_CBS7'&6@TUI;,+-0FT/3['X*VOF+4*2VCI+%;#OWZ7+B
MI*J[<R4V4H#[&7/G B=/ZO8@K3<VEOZ+EUZ--B$0,IVP(19^@;4G0X/2NJT'
MI0WN?IFT$B@?(B.DH2\R6!>H0ZU\OHT^B,$-!*B+Q<9<$>6_;8G]W1G-M\M\
MYS!^Y-T\TM)=%.V;M R0,XY D??-=XON:U6?(KXG0#,]W&X(,K&T2/@R0D+\
M>3!(T&*/7AJ?*K6Q*93BP,'M'QW4A2Q$6PN3]S7OCT3DRF!<SP]#C"Z^UY*@
M(BML4'6Q R<\#Q$UQEW)4*/:?*\#\;N)I'>#&B(XJ"&YK^)D&$)LQ;K?!V0>
M_=5#J[=24:?T$\6.JA9-L\9+F;'>^HP=]-F1:Q;CDJ:,)L ML.(!]408;=*X
M^VIKBS<!GRJ;$FQRFJ;,]=*;/@5A-W6&]O?P4LC[<'<!KO\<$UKF="%T*Z<P
MH<:&;LP;C-S%\E7E;XMWR7F;/R'VX!F<I)\.R8]56[W17KJADY]P</NFTY*X
M^3Z(TSK20$<$-\3!HL3'+3I$!K:0W9.F1:JG&>W)]RHM"PH!MM)_9M-/0_WW
M?-#\HF*;NZ/0C'4W=S8I :T25H&-K7L-QA-ALJ'$4Y\@P_S*1=7'2GF=L,,N
M[$O,NOG>IS*+EW+./HLTQ[0DH=M!4XHA3=18+'R</U*3UTHU]U@<<7DF.;J:
M4.IA(S@N[B903*;.U)<[L"/I-#B_ A9M4)L/!8EQ"32/FS^*#Q%D>ZAM&?5M
M$("V7I**HFMUDF71\KN:U"@N"P<L>YE!]A4\_?WD$/GA#),:X9,%LEFOONAR
M[)[S0EL3C"A!+O5L>+K8$/V-LVY,@F;.":<&-#F3RCGU;&T3A@,Q5<A4=;+T
M]6:, )LEC^  Y?&NBKI[.1?B&LSVE3L"MAR<$E_-QQA-D>UM7%Z$R]WQQ!S6
M *(ZOSCU)/_(A:8H_%8&JMK($&L.&VD"@NK%N"@YKLF8,'K1<".>[YD3]T&7
MG$C!VI6):PZJRKV!;YJ.K+L"L:"PN3D=AD3OMKZ'!$U70.YANYXAV3R$*H"!
MKWJSF13OAGY^I38+N9=J2Y@/HW>-'!)O>%%961[9O4R^*N#]?:9\!6GC7+)0
M3RJ#?NKS@#]JUY4=1-+0X@S+TO?+HO(A_)]4U)+U>(92<",KYA1-[";]BCE)
M60 _4,#HDH#G %.M)R(:JZ44V[8Y ZCOAU$:#EQ)A+/.$0JA*: 9W&2!A#3E
M0<TCY^CKZ <@<C 0J?S4KC*[AR[G+B=='HR/=SAJ4J&T95>^>*<"$="T8S"\
M+C5>D#ZNB0U+KR>FAV]+YOMJXE:O6H1);$/2U^-ZU^?2?SF,9^(V"7UXS)"Q
M]+=[13NUP*.##(O%G&6UKIK!E]O]%O%>BS'+0BX$:<>KYZ78L.G0U)9[(Q)7
MW$0AZ'6K1*.$#?</[I]#4.CZWS1EV)%[L)1&L'?,&3LED^3NE6>SOSXFOD^H
M[46KS.^;XXCV3E:*(:"H#T/4Q4%WFDA(,5CTA:*G[/I2V&664O.#21F9J3<J
MVO1=H5?A=V6Y^A6[D$DZ<V//_;L90C(!X9/-,[5..ZJY+KPD5I=H0!?I%7&$
M)YP.$F5J1MY(KN9CZDKWH*R!<N@U519"$=3"&[6GN3^JG>EUEU,.]=XG0O/'
M4UEK8KE\AO#X,FZ[L,FDXCVJPKVHI6+IUQ'(D1O(M5!86    V"MH^TVQ%_7
MH,589 C\3^G35)I)JA\.>68^OQ":S(OF#[)U8\P2%@*C%=R- =J">\@5V.@7
M<>&%ZONNDC59GV>#[!%@';C;KV'?MIB/%],R:PHO=4PZ25NOHLYSCY3OWRB/
M);+$6V6:LLPYE/^4(=*XUE](L[4U[Q]T\5@" QFS?BW-H3@Z8$ %#/CQ?.>=
MXEW5TIWA^=L*".3W+V<>GCD\?]R ?R$])515 1GIT+_737+S%K33\V0@GIK]
M5X'Z8]ED-_#:$_5A]^(?R=ASZ=YKU=[50.!]DW,O%41;K!\V]U@:YQ+;]QIK
M^TR?[#%.+SVUR\]IZ'F-A2HAN*V!RQH.:X3Z[=+63'8(G$&J+-5V6$8 ;#6@
M.W.SKC6Q\F'6- ZAW-3:#/.-&&<1;\*6X>L5+Y$X%Y[,VB-WPUPU4QS'#,H%
MQCUZCTRXK'![/Q98/9%T:.,]8$A6.X#CLTPQ1;Y9Y'P2>3%9X'M%S#<BC1"]
MF@O'.HZ1R9.AYIUJ,(UV^GF?=A&74C#NG==FU-C4-^[#BEE2TFTYRM" B],M
M/]H"Q" )SD!#_W=U*NI]R]1ZHOZ@-'H2@@=%1+>>2)7=N^\_@E0N<5&AJI3I
MTQ)9$_2ITPE<4]G8>]#3E^#&<1PCQ*QSRFBL6(K((584%0"(CE5AD<V@K0LK
MN!MYQ9I4*MQ#R3$3!%42786@G51<G0%X$A+2.)(3)@@GI1O?C8$WE>']8>3'
M+?/X&]2D?BM^!H"7Z^NVTV0?!G7ZFVF):"5)=K_^_K%@.X:OWS[F$I-+/C+*
M;)\4VKESCY7J)A@WM,2I=K4E.D8Z]1N'?/SY4+>*+K ","@'^-J/TL</UI%J
MYUR]0L#&("1%2G.RLE(#+&/7:>@T6M2I/C8HQ\V6KKCHDD<+8"N[1D^@=!*F
MH$>NAL-JF^*LM#8D693D^,ZHSGMDCU0RKC;$: #H?+!D$R?DZ:_^6KH-4T]_
M;[.)A 4&WESF/A9[CA"# 0^<LL.7KR1:Z\(/#@2G!H[?9V;</_715$'0'9/'
M7RR\529.GM:>1FN<=$V)00&'^B 7Y/N=T:LGL5P!CQ<FH-&,Q<?VQZ1O!RUG
M9I2$U>&W&[S'62)S/0]GA->C6??" 4[7L%>6))7W??GY7Z9XMR.>XN900G/"
M\U[/9>'P0QS\Y07"V;JP_^WJ!\' WU>'FW\H.I=6N?4:!C TD=(C\9/L:Q!>
M\82# 1YYSY6GQ./E7)R#7V8)R^49+3L+96F%A/2'\,Q&Y ,/0I![[E-R$PU"
M\]3? 0/GFZP@Z+23$MXI/$RG:^1[6.Q9CYWUG=+.>T(1,)!&T7KRE''XD?V+
MZ#]X8:^0/E3>C_;*:GK^"U7[7W04L]$>'R$?X!D;7F>%%\U-/P30M>XW>G+L
M>%9<>-Z>)8$!2.D;Q1)!L3'#B5+-@TWJ,092C3?1:3F$\S><YYI/[R8@>&[@
M6 11R $,S-SQ/MQ*@@%OL@>*O]>7!96O-+;6\9;;I,0OA?$$[8.!OU%E["WP
MPF_^6]:\5;H %B&Z;[3R6^Y=YI&CGH&MJ#TKYI,V6J:FZ^I)N*(6%L4T^CYH
M<$&OK(&V@M95G3W"\VVKVVH7Q1]JZ$8;RRN.X_T,]*'%+1>N=&IZSQ%11Z4]
MHO:]^2?UM%A2Z.)O['.=8*#$5RT(=] J;;S: KZ@2YSS0YAU#.DJS2@SVE#9
M4VH[%OH;%D=>R+.T/L59XG] P.-?R%Z$GWA=>%K_?$I4/&OE]90V ^*"C*9!
M8&!7^#?D0\Y,J 8#K7>ROZ$,U$ZNA><Q*.8W .X$?XT[_I;]L@5YY$X&\K<_
M5C IJ_CR92FF4?LII7]VW_^YP#^6OB=L'H<]I,\+R/_+VO?S8I)T+B^GM<V0
M$-?HO,"X-$<7"D)CXPM%@NS4& C!GXXT!3>.H"Z,E:I3M*ZF3'9VT#X!Q-WI
M7-/E WS) O68A*XN^N:4UQ6!/<)K?GHGJC;06:6/LA?_8=!%56MUU!J5?=.W
M 6IAYU\<4:<^,*=[36$>72(P%;D+N+I(>>;$]9(G+V+%8CT4G C%@?/[<$3G
M<)G)[4DZIF^I<V*'!)+TRU#;U#:B7S%VSQJI5DYL]A4.W>'7S#V0U-FX&DT1
M0R+RU4,'HMW'T4;N9?'K>>J8]V2TYC2&F%BNRX>HR5"R;:D8"86A\M:5'&NO
M1S;(H88^-Y$5SXMEC* WA;ZKWHCB4I83VE#_>93CDXGJ#R$FD!<2X<R\6XT@
M]>-C91=]% NVD@ <R<R8V-N/:'WT?(-H&$0&J<!=(A +!B9K?XU^<K"B:;'[
M=97IQ>;2NKXF?3URGO\^D=/YNG]>F0W/F.R7PKEG6?SC^<->S@;,VO* 8F@8
M/VX?UC6T+:*S_&+J XOR>Q$D[^FCR,C(($>1_$(?JJ]5SBD_ZP(L#_ '9YB%
ME\4CNMY$"&<QQ'TSAB9G'ZD?$EK6&],<2F3D%C+HR>XOLU23Z2""812F_WDJ
MB?/I_B539"R<K$WRNK.EJ>85(;5;$MHLJ<HZ(XMX^%'(E/:5(.TQK5"X=82A
MW6C+S@.E],$N3Y<#G,FOH=#"A)GO/>==G"WM)M=,A4R)[.^BF#]7.2/>A 0-
M6U *DC3TY@\;#-#:^6-!G3!%[D8+Y\2TE9*&"2G"6O4SB!^7JW$/?0[7J@II
M5ZC@@H@RIZ6A5>F /*TAH:CSC2&-KO>XS:6-I.PH:GA/7*D82/E%PWCF.O.X
MW+:G/M.*2)W??N2;*#0#?G@U:?S5K\-E<MQXZS:RS4NV'<KZ\LCB$IJ0C(\J
M2VW&;'CZ/)=HK@X3# VDHX2,=!3!OFW8[83>NT(;&.&VYUKS6;VAY(@X5E:&
MEP7ZD>\##01C=",\A(QJHCX5?O35F<MV,G@)@[SV0O.'7\G!JE\O=7!5Y*]Q
MR6599EP3S.4SI(:G0$ZXGG+?JG4#_\F7:83:*@X%+N+7T?EKM:;+JG%()28&
MUBV-(9-30+STL9W9ZT&W KW9-(S)/F@GB:&8#QW+>HV)7PECSK:Z)VDGA".-
M+H5B$SW3F5D3%O F04"#/8Q=C3. Z,NQF16IYWIGFGB>85YP4?A;HSAX?(GW
M.Y4L*RF#MO1L^X(93&,X/\=-JZY K65O0]%S:&/*Y^&U-HZDR0>A7>!(L;&V
MT[[$RMW-J"X-61(ZA];XDV _4!I*R2H;"C2]/\3@5Z(# QO$-D^1**)R$288
M.'M=]V29?_S,;0R(>?<N=B<SR)?O3R< E75B67"%J,-/_!.333#5^RF/ 0/2
MW<T,(L/+?LY>[T0-2>G9H1V9]U,))OR+LKML/:=T2'T?*Z8?/'&N&1NN@[/O
MS,)3ANFOHHH;=H:"R#.;[;J>]PQ^%]W[ODM0S-T?-^#N+_1S$?PU-D;@[_6&
M9^WQ!4?B[YV[?V[H/14$Z<:;M&WIW#_\UR\8CZNRW-U0E.5E]7EL*1)444R;
MJR$M:,8-O* 3WJ!O=WD_/U;6>/+8(<A0?_1[N4UF*=;##GM:ICM:G/N+B\S<
MD/30AKL8XE.8:^3\#H?'"ZH4YO*]%'*INX&,1B%#3Y,%%UE1&HDX.56T,_;U
MU!1*YHFCT'H7BSAL1=6@BA&HC!X=#X_\^B%]HZ N3:4C$5+3C5*;E)F'#Y?H
M-#F/0XO]V7$M']TD+*EQ/3\C#\I:5V0ONW@N@6)CU\R1#WD1S.($%FE)$Z>$
MPM[+"/*,UY9A#U,I7&J7790Q3CD<OZ'-<$**=U1S;N(C\H=Y52,:-RBNN]NF
MA\S-S]16#>O/G.!@A=B@H;D;;+IZ;L']$Y+EK4;G?246/0C%%O;DLKB94W@B
M:YR+)'/)V7&#)E%]R,D-S>9'5O>MJ*_E"SZN'PBG$1S)8CDW86#@9_R<7D_Q
MXKS*TK(9 @'1MS6VCN\31_*A]42@Z@+S=?,!7ICW&?9*=\H3R](U#2J]$G[G
MJBAZ^?#M4)EAHNOYZ2_7^L_.-:>L1@(N-;FC)DLL>#HW!<Z)(U73!A>O9T*\
M7(&%S2+]GRQJ.3U!52X6;YM2QTV#]@B9>B!)'*)MZWAT\'3\H0GH78K=6K\U
M5%=)DEV1FEA<;$_09J6*!%Z),(360-;?>BTT>NT/298ZKRFT-HV5^##)S2_V
MH$^\Z.3GDL&&(PW-#A<B@R7T@N5\]%U+X6S'D8K-W66=NHZ+&S,R.0I\NZEJ
M#9P+'.C 0_M?S'U02USV<] 4IA'8VEJZ.\PZA6:EGP_._&#B!W_FOP*Q>>_;
M,Y85W-50W543D+<@6C&RM6N7%*SN _HLSR 7A8?\/88T["N.1?A/"RE$E"7#
M\K!=W;$DV7J7(]&(3*G1<FC:5SH&QI!>W#*G$,!KE@M><:J @.[I>+6A8GC#
MS]2TE^SV$_KLYQ/=8:K]^ECOV+!77KN-\L&SWMWR+O,.)T@G/;JW'J=M?RI[
MJ?YC.:R7/#-(\.5P0YU]O6Y]>:6 -W_/$AG9PYU2**N>%5V5)0GV5?9D=TI(
M_,11XI228BAN/R,)0C(P+V4F,I&CF% !KV HI)O\X37R"I4\U*\O"M\)?,]R
MC!=*#6?Z<*J&-LN#N/WTC;#9;\/8LNZU!*]"*[K=*V+?540VPI)PFZL_U]!Q
M1>X/YED=(NC^U%#$Y$\*92[\Q5+1>[:1K0C'OI)M[DC#A8%'[$B$=X#9\YE_
M4DB@2P&RAS3L0G7I&C6J.@I?"$T1!4U6".!_RH.)]LON-LRC2FON0?S3VI>]
MT^\TOJ>,+OO<&.[?8=!8D5:AP$V]5P40*HETK&W9>"X9]S%[^5$- D&C<3)B
M[OID\W/YHRJ%/X(JC3_FCT<W"GT_/M(/.D0'J9==UA.Z)8/P)3GFY5*GV/6%
M J=DT!\FEB,X[>;G"F7%%!*=ZCB8YDQ+!CZ886)B#%B1% C-C_+1U/KU'7LY
MYV^G'!E'F<(QL@^\9A@2$B)CEW!D&P]Q_)_<9MK,K>_-=-Z><F80)>)?63,L
MJ15U()YY_:)//G[?KE9[UNYNKFGY;"FO8Y8-_GP!;XIU*MP8:+:(>2'X>XF_
M2&-J6D3?0]&8\J,^"/UH,X9=9X^G-?+<I9LDT2QJM[7@'9JL5L6ZW__"TP[Y
MVRZRO ZO'7E*JI +"E S[IZ<:3HRXR0(6]L<9W(I]ZY?K7DBD#@(UV-5W MV
M4)0LUTU9-G-G^DXS>6IZFBZ_NA,C<3-79U :CWA5F).B-!K-)HC:G.,\6<&P
MDK%UE6!\Y.''EZ^>Q=Q[0J.?(Z)(+!7REKGAVA_V)9B,8B-C!Q.X>'6.\(3Y
M%U0>?FZ3D7YA-IJ6J*Z,'O16E5ILJB!!=PRBAL)]WG)0E#YHYCTD-+G'([!*
MNPH%J8PDU1H]@ $WJX$T*<IYC\VGOW?RN]ZA=JLI,&NOXSFXOT:2AK,I>XL'
M6&HV.'"/N [4G;)^-<9Q##F;6YC?>Y=1&TB"##\#T9..SZ#YL6^KD]19OEY\
M-9XD<L$)O6OW"TSC^,;8!D>RQ=6K @,)&U07V7927039(]M^&$9&46P2K"[
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MTT@1@!PH BSR">D'EVYA"<O<@]O2I_'ISC/? ^EE_$K%M(MS GWM"<'F.1&
MD"T(_,LP4XS[NO=/VN17W3 Y4(1012%4&%\L C1U"BT(+7K/1(#>*L+:.IQ.
M_%-G^^?C&]9=J*+[6<\60J&,1&@R938'7'QT ?$-/@-N6XYQSYO$?/0$+U40
M;T:V/N:XV+<>O[]L) )$1@LN[(YCO4=%4[ MOJ"@?7C:\-FZG$;4?MW'MGN%
MW]?!(? &N.W*\]NT>]"QP@QMLB%T+,O5:5EMLVN]?_;(&F.94EPD!B\(O+&)
M!+Q,B"?8 J(DOP+RNIT7R^<<O<2X&,4=W^9%B;Q8TFRO^&5SYPG-0=)6JJ4&
M6BX/"-BN:0G-)T\$]! EJVTSYY?,S!6+0HE#I_51 LYZW^>JEB#]X !27-R;
MAC;AAC!RFU0E(MC_8^Y4(ZZJ(NXF;*S:;;&%GS?\E_U_T?Q6\NFS;#!$_VI"
M%(=S07R48N=DHFF/=0^<J1O<-X MWH7CH_PJ\7NFS;/G%?": <JFX/*%623(
M(=UD]+2_^W5-9$%^99H,778]?)0Q'+T6AIQ PM0J8T/3YF\7AT6T'I-.D*G(
M:RD$RN_W_V8W@NO;?;3GC?RUHZW6Z"QGF^GL\9_-*0+<9<9T?\A*32U-]:2.
M08^LH=D9_C\-B;>_IL?CP_V&4GF*"P/-)M!DPYQ"+3GZJ'ILTD>$JX,4'0 H
MS'>+A3+*?H%!=,#:;)8T\4#>,CF!U2S;O(:3EC$XM&+-=COR:X.50E/6G>!=
MID?;U$^@O;K->+U[8HUEIX&WI<A!S&'3*P-]/A;8>%BFQ8##+=?^7[A>=!TJ
MOCB]=2)EGJ/1 '^(H"8;.YN]?1YSAF%V/DFA=M^[E^%[,I'67.3GDRP)*0D:
MP7<'!X.?.39TH)/=8]=>S*94\8_D3MBNV+&*E$1O_PU02P$"% ,4    "  7
MAJU4-%%91P4/   #E@  $               @ $     8G=V+3(P,C(P,S,Q
M+GAS9%!+ 0(4 Q0    ( !>&K53\(CZB)P@  $Y,   4              "
M 3,/  !B=W8M,C R,C S,S%?8V%L+GAM;%!+ 0(4 Q0    ( !>&K53#RVP@
MQRH  &=G @ 4              "  8P7  !B=W8M,C R,C S,S%?9&5F+GAM
M;%!+ 0(4 Q0    ( !>&K50:_^NGKV8  $'W!  4              "  85"
M  !B=W8M,C R,C S,S%?;&%B+GAM;%!+ 0(4 Q0    ( !>&K53=0>UMG"H
M /J( @ 4              "  6:I  !B=W8M,C R,C S,S%?<')E+GAM;%!+
M 0(4 Q0    ( !>&K53<.HKV1 ,! !=="  9              "  334  !F
M,3!Q,#,R,E]B;'5E=V%T97)V86,N:'1M4$L! A0#%     @ %X:M5#D,9^_(
M#@  3VD  !P              ( !K]<! &8Q,'$P,S(R97@Q,"TQ7V)L=65W
M871E<BYH=&U02P$"% ,4    "  7AJU4:]R,F<,,   \1   '
M    @ &QY@$ 9C$P<3 S,C)E>#$P+3)?8FQU97=A=&5R+FAT;5!+ 0(4 Q0
M   ( !>&K52[5CT%H@<  (XP   <              "  :[S 0!F,3!Q,#,R
M,F5X,S$M,5]B;'5E=V%T97(N:'1M4$L! A0#%     @ %X:M5.)@1!&&!P
M8S   !P              ( !BOL! &8Q,'$P,S(R97@S,2TR7V)L=65W871E
M<BYH=&U02P$"% ,4    "  7AJU4&=CJM5L#  "J#   '
M@ %* P( 9C$P<3 S,C)E>#,R+3%?8FQU97=A=&5R+FAT;5!+ 0(4 Q0    (
M !>&K51*\;BC4 ,  %X,   <              "  =\& @!F,3!Q,#,R,F5X
M,S(M,E]B;'5E=V%T97(N:'1M4$L! A0#%     @ %X:M5'=IG4U%20  ,%(
M  T              ( !:0H" &EM86=E7S P,2YJ<&=02P4&      T #0"$
) P  V5,"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
